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Chapter 1: Introduction 
The Human Genome Project revealed that the human organism contains far fewer 
genes than proteins. The fact that approximately 33,000 genes encode more than 
200,000 proteins invalidated the long-held assumption that one gene encodes a sin-
gle protein.1 In addition, the discrepancy between the number of genes and the num-
ber of proteins refocused attention on the latter.2 The pharmaceutical and economic 
interest in protein analysis was further stimulated when studies demonstrated that 
even small structural variations  such as posttranslational or interactive modifica-
tions  could have an enormous impact on the physiology of the entire cell.3 
 The importance of these modifications can be illustrated using as an example the 
family of brain diseases known as “transmissible spongiform encephalopathies”, or 
TSEs.4 Among these, the Creutzfeld-Jakob Disease (CJD) and the Bovine Spongi-
form Encephalopathies (BSE) have alarmed scientists, politicians and the public 
worldwide, after an unusually large number of cases arose in Great Britain. CJD and 
its most important variant, vCJD, lead to strong personality changes, problems with 
balance and coordination and finally coma and death, just months after patients have 
developed the first symptoms. Until the early 1980s, there was no clear understand-
ing of the causes of the disease. Consequently, medical treatments could not be de-
veloped. Most scientists conjectured that a virus was the most probable cause of the 
infection. This changed when Stanley Prusiner, a researcher at the University of 
California at San Francisco, suggested that JCD was not caused by a known patho-
gen, but by a protein characterized by a peculiar three-dimensional structure. While 
the hypothesis was harshly criticized initially, the idea that misfolded proteins 
 
1   The number of different protein molecules expressed by the human genome is probably 
closer to a million than to the 200,000 generally estimated by genome scientists. The actual 
amount of proteins in the human organism is still unknown, but some researchers believe 
that there exist as many as two million, see Service, Robert F., Gene and Protein Patents Get 
Ready to Go Head to Head, 294 Science 2001, 2082, 2082. The number of genes of the hu-
man organism is barely higher than the number of genes characterizing the roundworm Cae-
norhabditis elegans. The fact that the human genome is able to produce such a high degree of 
complexity with only a few genes is generally attributed to the phenomenon of alternative 
splicing. Alternative splicing is explained in Pennisi, Elizabeth, Why Do Humans Have So 
Few Genes?, 309 Science 2005, 80 and Jollès, Pierre/Jörnvall, Hans, Proteomics in Func-
tional Genomics, Protein Structure Analysis, Basel et al. 2002, XI. See also Straus, Joseph, 
Produktpatente auf DNA-Sequenzen – eine aktuelle Herausforderung des Patentrechts, 
GRUR 2001, 1016, 1019f. 
2   Bohrer, Robert A., Proteomics: The Next Phase in the Biotechnology Revolution and the 
Next Challenge for Biotechnology Law, 22 Biotechnology Law Report 2003, 263, states that 
“[t]he massive trove of genetic information has produced more questions than answers”. 
3   Straus, Joseph, Produktpatente auf DNA-Sequenzen – eine aktuelle Herausforderung des 
Patentrechts, GRUR 2001, 1016, 1019f. 
4   The term TSE is derived from the spongy holes that are present in infected brains. 
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(called prions, or proteinaceous infectious parts) were responsible for CJD is now 
widely accepted.5 Prusiner received the Nobel Prize6 in 1997, and prions can be con-
sidered the first 3-D proteomic structures that penetrated the consciousness of the 
wider public.7  
The human genome project and subsequent “post-genomic”8 studies clearly de-
monstrated that these 3-D structures are of prime importance.9 More importantly, 
they revealed that molecular biology could only be understood as a dynamic system, 
which uses a wide range of regulatory mechanisms to control its activities.10 The 
dynamic changes in proteins, such as their seemingly endless modifications and in-
teractions, their binding activity or self-regulatory adjustments, can be considered 
their crucial element. This acknowledgement was the starting point for the so-called 
“post-genomic” era, where proteomics – the science of the proteome as defined be-
low – begins.11  
 
5   See Prusiner, Stanley B./Scott, Michael R., Genetics of Prions, 31 Annual Revue of Genetics 
1997, 139. A major advancement in the study of prions and prion-based diseases was the 
discovery and purification of a protein characterized as prion protein (“PrP”). A leading 
theory is that prion diseases are caused by the modification of PrP from PrP.sup.C into 
PrP.sup.Sc. The precise biological function of PrP.sup.C is still unknown.  
6   Prusiner, Stanley B., Nobel Lecture, 95 PNAS 1998, 13363. 
7   Neurodegenerative diseases like Alzheimer’s provide another example of the importance of 
protein folding, with even larger social and economic implications, see Whitford, David, 
Proteins: Structure and Function, Hoboken, NJ 2005, 468-470.  
8   The term “post-genomic” refers to research techniques that became relevant after the disclo-
sure of genetic sequences; see Barton, John H., United States Law of Genomic and Post-
Genomic Patents, 33 IIC 779, 786 (2002). 
9   Thus, life science research moved from a genome-based level that emphasized the study of 
the gene to a ‘post-genomic’ level focusing on information regarding proteins; Masuoka, 
Kunihisa, Study on the Ways of Protection of Post-Genome Research Products, IIP Bulletin 
2002, 84-95, 84. Many scientist hold the view that proteomics involves complexities that 
scholars of genomics do not encounter. “If genomics resembles the Matterhorn, proteomics 
is like the Mount Everest”, see Gwynne, Peter/Heebner, Gary, Drug Discovery and Biotech-
nology Trends – Proteomics I: In Pursuit of Proteins, Science 2003, 665, 665.  
10   Straus, Joseph, Produktpatente auf DNA-Sequenzen – eine aktuelle Herausforderung des 
Patentrechts, GRUR 2001, 1016, 1019f. The disclosure of the human genome also showed 
that systems of DNA regulation have a much stronger impact than expected. 
11   Barton, John H., United States Law of Genomic and Post-Genomic Patens, 33 IIC 779 
(2002); Peltonen, Leena/McKusick, Victor A., Dissecting Human Disease in the Postgenom-
ic Era, 291 Science 2001, 1224. In many cases, a better picture of the molecular biology of a 
cell is only achieved by the study of proteins, as emphasized in Russell, Robert B., Genom-
ics, Proteomics and Bioinformatics: All in the Same Boat, 3 Genome Biology 2002, RE-
PORTS 4034. Nevertheless, the Human Genome Project provides powerful insights into 
human diseases. It thus has been “worth the effort”, as stated by Daiger, Stephen P., Was the 
Human Genome Project Worth the Effort? 308 Science 2005, 362, 364. The new proteomic 
view of a dynamic molecular biology inspired the further development of “genomic tools”, 
such as ‘Genome Fingerprint Scanning’, which is usually combined with the proteomics 
technology of mass spectrometry, see Sender, Aaron J., Decoding Recorders for Protein ID, 
Genome Technology 2003, 26, 27.   
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One of the key promises of proteomics is that of drug design, because most drugs 
act through the modification of a specific protein. Proteomic technologies may speed 
up the screening of new pharmaceutical compounds and thus lower time and money 
consuming investments.12 If a pharmaceutical company is able to market a drug only 
one year earlier, this could amount to $500 million additional profits.13 Another 
promising and accelerating field is biomarker development. The term ‘biomarker’ 
refers to biochemical molecules that are used to measure the progression of disease 
or the effects of pharmaceutical treatment. Biomarkers are increasingly important in 
the progress of drug design, because they provide novel and specific means for early 
detection and diagnosis of diseases such as cancer, HIV or hepatitis.14  
The era of proteomics thus offers a wide range of opportunities and challenges for 
research and development. At the same time, however, it creates new challenges for 
the individuals and institutions constituting the biotechnological research complex, 
including patent law as its central legal institution. Here, the main question is 
whether and how traditional standards must be readjusted in order to cope with the 
nature of this dynamic scenario envisioned by many. To answer this question, how-
ever, it is of paramount importance to answer yet another question: How do patent 
law institutions, in particular patent offices, currently treat proteomic inventions, and 
how would they treat the range of inventions that can be expected to materialize in 
the not so distant future? Due to the novelty and broad scope of the subject, a sys-
tematic description of current practices is still lacking, and the analysis below at-
tempts to provide first steps towards a comprehensive summary of existing prac-
tices.  
More generally, this study provides a comparative analysis of patentability issues 
related to proteomics inventions with the following two main objectives: to clarify 
current views and practices and to derive legal policy conclusions related to proteo-
mic patents. It aims at identifying the issues that the major players in the field (re-
search units, companies, lawyers, patent offices, courts and legislature) will be con-
 
12   The scientific community frequently emphasizes that the efficiency of drug design is signifi-
cantly enhanced by proteomics. It is held that genomic information had little effect on drug 
discovery. In the long run, however, the advanced understanding of the roles genes and pro-
teins play in the organism does promise new approaches to the comprehension of diseases; 
Hall, Stephan S., Revitalizing drug discovery, Technology Review October 2003, 39, 39  
13   Vorndran, Charles/Florence, Robert L., Bioinformatics: Patenting the Bridge between In-
formation Technology and the Life Science, 93 IDEA  The Journal of Law and Technology 
2003, 93, 104. Bioinformatics may also speed up discovery by screening precise drug targets 
at an early stage. See also Howard, Ken, The Bioinformatics Gold Rush, Scientific Am. 58, 
58 (July 2000).  
14   Kleist, Peter, Biomarker und Surrogat-Endpunkte: Garanten für eine schnellere Zulassung 
von neuen Arzneimitteln? 83 Schweizerische Ärztezeitung 2002, 2347, 2347; as for recent 
discoveries in the field of biomarkers, see Zucht, Hans-Dieter, Biomarker Discovery, Trans-
kript 2004, 48; Deutsche Gesellschaft für Proteomforschung, Biomarker Discovery and Im-
aging Proteomics,Transkript 2004, 57; the search for disease biomarkers using proteomics is 
also referred to as “disease proteomics”; Hanash, Sam, Disease proteomics, 422 Nature 
2003, 226, 229. 
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fronted with in the years to come. By discussing alternative approaches to deal with 
these problems, the study also contributes to the further development of legal stan-
dards. In the course of this analysis, it will become clear that proteomics touches yet 
another important policy issue. When the first DNA patents were granted, many ob-
servers expressed the concern that they would constitute the basis for permanent and 
harmful monopoly positions, with adverse effects on price setting behavior and re-
search dynamics. In particular, it was hypothesized that gene patents would provide 
disincentives to invest in research and development activities that would lead to the 
pharmaceutical innovations originally envisioned. As will become clear below, pro-
teomics is an important test field in this regard. It can provide some first indications 
as to whether the original fears were legitimate. 
To summarize, the proteomic era confronts legal experts with a set of important 
and exciting questions. To answer these questions, chapter II introduces the reader to 
the scientific background of proteomics. This includes a discussion of different pro-
tein structural folding levels. Moreover, the relative importance of primary, second-
ary and tertiary protein structure is discussed with regard to biological functions, 
demonstrating why the tertiary stage is typically the major focus of pharmaceutical 
research. Furthermore, an overview of basic proteomic analysis techniques, as well 
as an illustration of major proteomic organizations and networks, will be provided. 
Chapter III looks at the patentability of proteomic inventions, and starts with an 
overview of general patentability requirements in both the European and the U.S. 
patent law system. The statutory background and the decisive case law are pre-
sented, with the focus set on applications related to proteomics. In a next step, the 
second part of Chapter III will go through a case study that illustrates how claims 
directed to typical proteomic features such as complex protein structures or bioin-
formatics research tools are likely going to be approached from the legal point of 
view. Among other things, the discussion will emphasize differences in the legal cri-
teria and practices being applied in the U.S. and Europe in the course of the exami-
nation process. 
The remainder of the study is devoted to the question of adequate scope of protec-
tion for proteomic inventions (chapter IV). Chapter IV first discusses claim con-
struction issues related to the scope of protection. With patent infringement being 
treated under German law, particularly the German perspective will be taken into 
account. In a second step, a concrete claim analysis under both German and U.S. law 
will be carried out. Using a broad spectrum of claims from the field of 3-D protein 
structure, the scope of protection of DNA and protein patents is analyzed. Chapter V 
summarizes the major findings of the study regarding patentability and scope of pro-
tection and derives a set of core conclusions with respect to the broader policy im-
plications of these findings.  
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Chapter 2: Scientific background  
In order to understand the legal treatment of 3-D protein structure-related claims, a 
thorough understanding of basic proteomic concepts is necessary. This chapter 
therefore provides a brief introduction into the scientific background of the subject. 
Since proteomics is a rapidly growing and dynamically changing field, it is of course 
unrealistic to provide a complete and exhaustive treatment. Instead, the focus will be 
on issues that are indispensable as a background and relevant from the point of view 
of intellectual property rights. 
After defining the term “proteomics”, the role of proteins in biological organisms 
will be reviewed, with special emphasis on theories of amino acid structure and pro-
tein folding. Since many pharmaceutical applications of proteomics deal with specif-
ic folding details, the concepts of “structurally similar, sequence dissimilar proteins” 
as well as the basic idea of “posttranslational modifications” have to be introduced. 
In section C, the role played by genetic information in the shaping of proteomic 
structures will be assessed. This subject is of prime importance for two reasons. 
First, from a biological point of view, recent proteomic research has significantly 
changed the conceptual treatment of protein encoding. In particular, the close asso-
ciation of genetic code and protein functionality has become increasingly blurred. 
Second (and closely related), this may have important implications for the legal 
treatment of proteomics, since questions of patent dependency have to be evaluated 
in light of the relative importance of genetic information. The chapter closes with a 
description of the most important proteomic research techniques. The diversity of 
active research areas shows how dynamic the field of proteomics is, and provides a 
sense of the types of issues confronting the patent system.  
A. Definition of the Term  
 “Proteomics” is derived from the term “proteome”, which was first used in 1994 
during a scientific conference in Siena, Italy. At that time, following rapid advances 
in analytical techniques, it had become possible for biochemists to identify and to 
examine many new proteins. Consequently, the possibility for large-scale protein 
studies seemed attainable.15 The proteome was defined as the total set of proteins 
expressed in a given cell at a given time, the study of which is termed ‘proteo-
mics’16.  
 
15   See Patterson, Scott D./Aebersold, Ruedi H., Proteomics: The First Decade and Beyond, 33 
Nature Genetics Supplement 2003, 311, 314. 
16   See Dove, Alan, Proteomics: Translating Genomics into Products? 17 Nature Biotechnology 
1999, 233. A comprehensive glossary of biotechnological terms and definitions is provided 
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‘Proteomics’ conjures up two distinct but interdependent associations. First, it re-
fers to the general analysis of proteins. Here, the objective is to gain insights into the 
composition, function and further development of protein structures. This analysis is 
carried out against the backdrop of the effects that protein structural changes can 
have on biological organisms.17 Second, the term was coined to make an analogy 
with genomics, to indicate proteomics’ potential to become the major “next step” of 
biotechnological analysis.18 ‘Proteomics’ particularly focuses on the complex rela-
tions between proteins and gene sequences, taking into account that the specific 
function of the genome can only be determined with knowledge of the genome’s 
product, the protein. Starting from the encoding of proteins by the genome, proteo-
mics can therefore also be defined as the systematic study of proteins, with the aim 
of understanding the whole and detailed function of gene sequences.19 Proteomics 
aims to provide information about (a) the conditions under which predicted gene 
products are translated, (b) the timing of the translation, and (c) the extent of ‘post-
translational’ modifications, i.e. changes to the structure of proteins not directly re-
lated to the genetic code and the process of translation. It is worth noting that none 
of these elements is necessarily predicted by the nucleotide acid sequence alone.20 
Consequently, one of the major aims of proteomics is to identify the forces that de-
termine the exact structure of gene products apart from the genetic code.21 
It is worth mentioning that the term ‘proteomics’ is sometimes used differently, 
depending on the context. In the scientific community, it is used very broadly, en-
compassing everything from protein characterization techniques (such as mass spec-
trometry and two-dimensional gel electrophoresis) to anything remotely related to 
the quantitative determination of proteins. At the same time, biotechnology firms 
engaged in any kind of protein analyses often describe themselves as “proteomic 
firms”, using the term as a cachet to signal attractiveness for potential investors.22 
 
on the website of the “Human Genome Project Information”, at http://www.ornl.gov/. See 
also Patterson, Scott D./Aebersold, Ruedi H., Proteomics: The First Decade and Beyond, 33 
Nature Genetics Supplement, 311, 314. Hall provides a slightly modified definition of “pro-
teomics”, as “the science and technology of cataloguing and describing the behavior of all 
the proteins encoded in a particular organism’s genome”, see: Hall, Stephan S., Revitalizing 
Drug Discovery, Technology Review October 2003, 39, 44. 
17   Patterson, Scott D./Aebersold, Ruedi H., Proteomics: The First Decade and Beyond, 33 Na-
ture Genetics Supplement, 311, 314.  
18   http://www.wikipedia.org/wiki/Protemics, last checked on January 22, 2008.     
19   Patterson, Scott D./Aebersold, Ruedi H., Proteomics: The First Decade and Beyond, 33 Na-
ture Genetics Supplement, 311, 314; Mullner, S/Neumann, T./Lottspeich, F., Proteomics–A 
new Way for Drug Target Discovery, 48 Arzneimittelforschung 1998, 93. 
20   Humphery-Smith, I., Blackstock, W., Proteome Analysis: Genomics via the Output rather 
than the Input Code, 16 Journal of Protein Chemistry 1997, 537. 
21   The proteomic analysis of complete complements of proteins encompasses not only the iden-
tification and quantification of proteins, but also the determination of their localization, mod-
ifications, interactions, activities, and function, see Fields, Stanley, Proteomics in Genomel-
and, 291 Science 2001, 122f, 122.  
22   Dove, Alan, Proteomics: Translating Genomics into Products?, 17 Nature Biotechnology 
1999, 233. 
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Finally, the term ‘functional proteomics’ should be introduced, as it refers to the 
3-D structure determination of all proteins encoded by the genome of key organ-
isms, a major focus of this study. The major goal of functional proteomics is the 
analysis of protein structures by an integrated approach combining computer-based 
technologies of bioinformatics and the in-depth analysis of 3-D protein structures 
through physical methods, such as nuclear magnetic resonance (NMR) spectroscopy 
or x-ray crystallography (see below). 
B. Proteins and the biological organism 
Proteins23 support every aspect of biological activity.24 Through their structural sta-
bility, diversity, and chemical reactivity, proteins influence and enable most of the 
key processes associated with life. They operate as catalysts25, provide mechanical 
support and immune protection, transport and store other molecules such as oxygen, 
cause movement26, transmit nerve impulses, and direct growth and differentiation.27 
I. Amino acid sequences 
In order to understand the functioning of proteins one must be aware that the term 
“protein structure” refers to three distinct levels of organization: primary, secondary, 
and tertiary. The primary structure refers to the amino acid sequence as such. The 
secondary structure describes the conformation or spatial relationship adopted by 
local regions of the polypeptide chain. Finally, “tertiary structure” expresses the en-
tire folding of the polypeptide chain.28  
 
23   The origin of the word “protein” is usually attributed to Jöns Jakob Berzelius (1779-1848) 
and has been ascribed to derivation from the Latin word primarius, or from the Greek word 
for “first thing” (in Greek πρωτεϊνη = first element), see Whitford, David, Proteins – 
Structure and Function, Chichester, West Sussex, England, 2005, 1. 
24   Whitford, David, Proteins: Structure and Function, Chichester, West Sussex, U.K., 2005, 9.  
25   The term catalyst refers to substances that accelerate chemical reactions.  
26   Schwaiger, Ingo/Sattler, Clara/Hostetter, Daniel R./Rief, Matthias, The Myosin coiled-coil is 
a truly elastic Protein Structure, 1 Nature Materials 2002, 232. 
27   Berg, Jeremy M./Tymoczko, John L./Stryer Lubert, Biochemistry, New York, NY, 2005, 41.  
28   Whitford, David, Proteins: Structure and Function, Chichester, West Sussex, U.K., 2005, 81. 
The term “quaternary structure” further refers to a certain association of multiple 3-D folded 
proteins to form multi-subunit complexes.  
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1. Primary structure 
All natural proteins are composed of the same set of 20 amino acids.29 Each amino 
acid is constructed with a central tetrahedral carbon atom connected to an amino 
group, a carboxylic acid group, a distinctive side chain, and a hydrogen atom. The 
side chains of the 20 amino acid building blocks vary tremendously in size, shape, 
and the presence of functional groups. Amino acids can be grouped as follows: (1) 
aliphatic side chains: glycine, alanine, valine, leucine, isoleucine, methionine, and 
proline; (2) aromatic side chains: phenylalanine, tyrosine, and tryptophan; (3) hy-
droxyl-containing aliphatic side chains: serine and threonine; (4) sulfhydryl-
containing cysteine; (5) basic side chains: lysine, arginine, and histidine; (6) acidic 
side chains: aspartic acid and glutamic acid; and (7) carboxamide-containing side 
chains: asparagine and glutamine. These groups are somewhat arbitrary and many 
other assemblies are possible.30 
Overall, the bonds between amino acids are described as the primary structure of 
the protein. These bonds have several important characteristics. First, they are resis-
tant to hydrolysis31, so that proteins are kinetically remarkably stable. Second, the 
peptide group is planar because the C-N bond has a significant double-bond charac-
ter. Third, each peptide bond has both a hydrogen-bond donor (the NH group) and a 
hydrogen-bond acceptor (the CO group). Hydrogen bonding between these back-
bone groups is a distinctive feature of protein structure. Ultimately, the peptide bond 
is uncharged, which allows proteins to form tightly packed globular structures hav-
ing significant amounts of the backbone buried within the protein interior. Because 
they are linear polymers, proteins can be described as sequences of amino acids. 
Such sequences are written from the amino to the carboxyl terminus.32 The complete 
amino acid sequences of more than 100,000 proteins are now known and docu-
mented. The primary structure can be illustrated as follows:33  
 
29   Berg, Jeremy M./Tymoczko, John L./Stryer Lubert, Biochemistry, New York, NY, 2005, 53.  
30   Berg, Jeremy M./Tymoczko, John L./Stryer Lubert, Biochemistry, New York, NY, 2005, 71-
72. 
31   Hydrolysis is a chemical process by which water reacts with a compound to produce other 
compounds. Specifically, a bond is split, and the hydrogen cation and the hydroxide anion of 
the water are added.  
32   Berg, Jeremy M./Tymoczko, John L./Stryer Lubert, Biochemistry, New York, NY, 2005, 72. 
33   Based on figure provided by National Human Genome Research Institute, Talking Glossary 
of Genetic Terms, available at:  
  http://www.genome.gov/Pages/Hyperion//DIR/VIP/Glossary/Illustration/ amino_acid .shtml, 
last checked on October 16, 2005.  
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Figure 1: Primary protein structure 
Figure 1: Primary protein structure 
2. Secondary structure 
As to the secondary structure, a spatial arrangement of amino acid residues exists in 
proximity to the sequence. Parts of the amino acid sequence are linked through hy-
drogen bonds. Polypeptide chains can fold into regular structures such as the α-
helix, the beta sheet, and turns and loops. Two major forms of secondary structure 
are the α- and the β-strand. In the α-helix, the polypeptide chain is stabilized as a 
tightly packed rod. Within the helix, the CO group of each amino acid is hydrogen 
bonded to the NH group of the amino acid’s four residues along the polypeptide 
chain. In the β-strand, the polypeptide chain is almost fully extended rather than be-
ing tightly wound as in the α-helix. Two or more β-strands linked by NH-to-CO hy-
drogen bonds unite to form β-sheets. 
Most proteins have compact, globular shapes, requiring reversals in the direction 
of their polypeptide chains. Many of these reversals consist of a common structural 
element called the reverse turn. In many reverse turns, the CO group of residue i of a 
polypeptide is hydrogen bonded to the NH group of residue i + 3. This interaction 
adjusts to abrupt changes in the direction of the polypeptide chain. In other cases, 
structures that are more elaborate are responsible for chain reversals.  
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These structures are called loops, reflecting their overall shape. Unlike α-helices 
and β-strands, loops do not consist of regular, periodic structures. However, loop 
structures are often rigid and well defined. Turns and loops are consistently found on 
the surfaces of proteins and thus often play an important role in interactions between 
proteins and other molecules. The protein compound complex is typically the major 
focus of research related to drug development. Drug design only succeeds if the ad-
ministered pharmaceuticals efficiently bind to the targeted protein. The commonly 













Figure 2: Secondary Structure of a -sheet 
3. Tertiary structure 
The tertiary structure is the single most important determinant of the protein’s bio-
logical function.35 It refers to the folding of the basic protein, which is stabilized by 
interactions between the amino acid side chains on a single polypeptide forming the 
three dimensional molecule. Water-soluble proteins fold into compact structures 
with a nonpolar interior. Their asymmetric structures have two properties in com-
mon: (1) a core built of amino acids with hydrophobic side chains and (2) a surface 
formed largely of hydrophilic amino acids that interact with the aqueous36 environ-
ment. The leading force behind the formation of the tertiary structure of water-
soluble proteins is the hydrophobic interaction between the interior residues. Some 
proteins that exist in a hydrophobic environment in membranes display the inverse 
distribution of hydrophobic and hydrophilic amino acids. Within those proteins, the 
hydrophobic amino acids are on the surface to interact with the environment, whe-
reas the hydrophilic groups are shielded from the environment in the interior of the 
protein. 
 
34   Based on a figure provided by Wikipedia, available at: http://en.wikipedia.org/  
  wiki/Beta_sheet, last checked on January 21, 2008.  
35   Whitford, David, Proteins: Structure and Function, Chichester, West Sussex, U.K., 2005, 39.  
36   A solution in which the solvent is water. 
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The folding of most proteins is complex and devoid of symmetry. A unifying 
principle becomes apparent from the distribution of side chains. The physical analy-
sis of myoglobin37 provided the first 3-D picture of a protein. Many of the basic 
rules governing tertiary structure rely on this discovery. In myoglobin, approximate-
ly 70% of the main chain is folded into eight α-helices and much of the remaining 
amino acids form turns and loops between helices. The interior consists almost en-
tirely of nonpolar residues such as leucine, valine, methionine, and phenylalanine. 
Charged residues such as aspartate, glutamate, lysine, and arginine are absent from 
the inside of myoglobin. Only two polar residues reside inside the protein. Both are 
histidine residues and play critical roles in binding iron and oxygen. The outside of 
myoglobin consists of both polar and nonpolar residues.38 There are approximately 
200 different structures, including mutants of myoglobin.39 Meanwhile, physical 
proteomics technologies, such as hX-ray crystallography and NMR approaches de-
scribed below, have revealed the detailed three-dimensional structures of thousands 
of proteins.40 To understand the protein’s function, it is of fundamental importance 
to define the 3-D folding type.41 An illustration of the 3-D folding structure of 
myoglobin is shown in Figure 342: 
 
37   The protein myoglobin is the oxygen carrier in muscles.  
38   Polypeptides containing more than one polypeptide chain exhibit a fourth level of structural 
organization (“Quaternary structure”). Each polypeptide chain in such a protein is called a 
subunit. Quaternary structure describes the spatial arrangement of subunits and the nature of 
their interaction and can be as simple as two identical subunits or as complex as dozens of 
different subunits. In most cases, the subunits are held together by noncovalent bonds. One 
identical subunit organization is present in the DNA-binding protein CRo found in a bacteri-
al virus called λ. A more complicated quaternary structure is human hemoglobin, the oxy-
gen-carrying protein in blood, which consists of two subunits of one type and two subunits 
of another type. See Berg, Jeremy M./Tymoczko, John L./Stryer Lubert, Biochemistry, New 
York 2002, 63-64. 
39   Whitford, David, Proteins: Structure and Function, Chichester, West Sussex, U.K., 2005, 68.  
40   Whitford, David, Proteins: Structure and Function, Chichester, West Sussex, U.K., 2005, 
346.  
41   Matthias Mann, director of the Center for Experimental BioInformatics (CEBI) at the Uni-
versity of Southern Denmark, in his opening remarks at the HUPO 4th Annual World Con-
gress, “From defining the proteome to understanding the function”, held from August 29 to 
September 1, 2005 in Munich.  
42   The figure is based on the represenatation provided by Wikipedia, available at 
http://en.wikipedia.org/wiki/Protein, last checked on January 21, 2008. Myoglobin was the 
the first protein structure revealed by X-ray crystallography. Max Perutz and Sir John 
Cowdery Kendrew discovered its structure in 1958; both men later received the Nobel Prize 
in Chemistry.  
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Figure 3: 3-D folding structure of myoglobin 
 
 
III. Protein folding 
1. Folding funnel theory of protein folding 
How is a protein able to fold reliably into a predictable conformation? How can the 
mechanism be described in which the protein is carried from its unfolded random 
coil to a uniquely folded metastable state? Biochemical studies found that denatured 
proteins have all of their native three-dimensional structure disrupted. Yet, many of 
them refold efficiently and completely recover their biological activity when placed 
under conditions in which the folded form of the protein is stable.43 Therefore, it is 
assumed that a native protein exists in some kind of thermodynamic configurational 
equilibrium. The biologically active state is the one with the lowest configurational 
energy.44 The sequence of events guiding the protein folding is called the “protein 
folding pathway”.45 A random search among the entire conformation space for con-
formers would require an enormously long time.46 Proteins, however, are able to 
 
43   Berg, Jeremy M./Tymoczko, John L./Stryer Lubert, Biochemistry, New York, NY, 2005, 72-
73. 
44   Levinthal, Cyrus, Are there Pathways for Protein Folding? 65 Journal de Chimie Physique 
1968, 44, 44. 
45   Levinthal, Cyrus, Are there Pathways for Protein Folding?, 65 Journal de Chimie Physique 
1968, 44, 44. 
46   Although the protein is able to sample new configurations very fast, it will take at least 1027 
years to try them all, see Zwanzig, R./Szabo, A./Bagchi, B., Levinthal's paradox, 89 Proceed-
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fold within milliseconds to seconds. This implies that only a small amount of con-
formation space is sampled during the folding process. The problem of how proteins 
fold rapidly into their three-dimensional conformation despite the infinite number of 
possible configurations is described as the Levinthal-Paradox.47 Each bond connect-
ing amino acids can occur in several possible states.48  
Several models attempt to explain the phenomenon of protein folding. A more re-
cent model approaches the issue through a so-called “folding funnel” theory.49 The 
conformational energy surface of a protein folding pathway is graphically displayed 
as a funnel. Convergent kinetic pathways guide the folding to a unique, stable, na-
tive conformation.50 It is assumed that the random polypeptide chain first collapses 
in a dense structure. Native bonds emerge when fluctuation of the peptide chain ran-
domly associates distant polypeptide sequences. Each native conformation stabilizes 
the chain and simultaneously narrows the conformational space. Thus, the random 
search for all further native conformations occurs more rapidly. Through the gradual 
native configuration, the peptide chain is efficiently transformed into its three-
dimensional structure. 
As already mentioned, the collapse of the primary amino acid structure into the 
tertiary folding state can be illustrated through an energy landscape that has the im-
age of a folding funnel. The wide rim demonstrates the multitude of accessible con-
formation pathways that exist initially. The narrow bottom shows the minimum of 
configuration flexibility, which mirrors the final state.51 Each protein follows a dif-
ferent folding path as it approaches its specific native structure. The exact nature of 
 
ings of the National Academy of Science of the United States of America 1992, 20-22; 
Nienhaus, Ulrich, Physik der Proteine, 3 Physik Journal 2004, 37, 39. 
47   Nienhaus, Ulrich, Physik der Proteine, 3 Physik Journal 2004, 37, 39; Zwanzig, R./Szabo, 
A./Bagchi, B., Levinthal's paradox, 89 Proceedings of the National Academy of Science of 
the United States of America 1992, 20-22; Levinthal, Cyrus, Are there Pathways for Protein 
Folding?, 65 Journal de Chimie Physique 1968, 44-45. 
48   Whitford, David, Proteins: Structure and Function, Chichester, West Sussex, U.K., 2005, 
403-404. 
49   Onuchic, J. N./Luthey-Schulten, Z./Wolynes, P. G., Theory of Protein Folding: The Energy 
Landscape Perspective, 48 Annual Revue of Physical Chemistry 1997, 545; Leopold, E. Pe-
ter/Montal, Mauricio/Nelson ONuchic, José Nelson, Protein Folding Funnels: A Kinetic Ap-
proach to the Sequence-structure Relationship, 89 Proceedings of the National Acadamy of 
Science of the United States of America 1992, 8721; Nienhaus, Ulrich, Physik der Proteine, 
3 Physik Journal 2004, 37, 39. 
50   Leopold, E. Peter/Montal, Mauricio/Nelson ONuchic, José Nelson, Protein Folding Funnels: 
A Kinetic Approach to the Sequence-structure Relationship, Proceedings of the National 
Acadamy of Science of the United States of America 1992, 8721, 8721.  
51   Nienhaus, Ulrich, Physik der Proteine, 3 Physik Journal 2004, 37, 39-40. 
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these differences depends on the protein’s size, stability, and structure.52 Figure 4 


































Figure 4: Energy landscape of a protein 
 
52  For a statistical energy landscape approach that explains when and why certain processes 
such as specific folding pathways occur in some proteins, see Bryngelson, J. D./Onuchic, J. 
N./Socci, N. D./Wolynes, P. G., Funnels, Pathways, and the Energy Landscape of Protein 
Folding: A Synthesis, 21 Proteins 1995, 167-195. 
53  Based on a figure from Kavraki, Lydia E., Protein folding, available at 
  http://cnx.org/content/m11467/latest/.  
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2. Protein misfolding and diseases arising from ‘folding’ defects 
With a better understanding of folding, scientists realized that diseases arise because 
of misfolding.54 Already small structural defects can give rise to a wide range of 
folding diseases. Genetic diseases, such as cystic fibrosis and sickle cell anemia, are 
typically caused by mutations within coding regions.55 Protein misfolding also plays 
a crucial role in the pathogenesis of prion diseases.56 A prion is a protein part that 
lacks nucleic acid.57 Normally, it occurs in a harmless form, but its misfiled varia-
tion has been identified as the cause of various neurodegenerative disorders such as 
scrapie, bovine spongiform encephalopathy (BSE, its human equivalent, the Creutz-
feld-Jakob disease (CJD), and Kuru. The progression of these diseases is accompa-
nied by the appearance of insoluble protein plaques in the brain (amyloid plaques).58 
The specific protein that has been isolated from the protein plaque is the PrP protein, 
which has the ability to exist in two stable forms, PrP-C and PrP-Sc. The sequences 
of PrP-C and PrP-Sc are found to be identical. Biochemical researchers discovered 
that the brain plaques contain PrP-Sc. All experiments showed that the Prp-Sc was 
not from an external source, but expressed by the host cell itself. This form of the 
protein was the only cause of infection in the prion diseases. The disease-specific 
feature is consequently not the expression of the prion protein, but rather its bio-
physical and biochemical characteristics. A purely structural change is assumed to 
cause its aggregation in the brain.59 The ability of PrP to exist in two stable forms 
and the fact that the disease-specific feature does not depend on the genetic coding 
 
54   Whitford, David, Proteins: Structure and Function, Chichester, West Sussex, U.K., 2005, 
426.  
55   Whitford, David, Proteins: Structure and Function, Chichester, West Sussex, U.K., 2005, 
426. 
56   Tatzelt, Jorg/Winklhofer, Konstanze F., Folding and Misfolding of the Prion Protein in the 
Secretory Pathway, 11 Amyloid 2004, 162-172. 
 57   The term ‘prion’ is derived from ‘proteinaceous infectious particle, see Whitford, David, 
Proteins: Structure and Function, Chichester, West Sussex, U.K., 2005, 431. For a definition, 
see Medline Plus, Medical Dictionary,  available at:  
  http://www.nlm.nih.gov/medlineplus/mplusdictionary.html, last checked on January 21, 
2008.  
58   Scarpie occurs in sheep and leads to a progressive loss of motoric coordination, finally end-
ing in an inability to stand unsupported. It was first identified in the 17th century in the Unit-
ed Kingdom, with similar forms discovered more recently in other animals, such as mink, 
deer and elk. CJD typically occurs in humans above 50 years of age. Infected persons exhibit 
dementia and loss of motoric coordination. CDJ was first described in the 1920s. Kuru or 
‘the laughing dead’ occurred in the 1960 in the Highlands of Papua New Guinea, where the 
conduct of cannibalism was held to be responsible for the progression of the disease. A de-
cline in cannibalism resulted in a decline in Kuru, although the precise agent has yet not 
been identified, as described in Whitford, David, Proteins: Structure and Function, Chiche-
ster, West Sussex, U.K., 2005, 433. For the potential causes of scarpie, see also Prusiner, 
Stanley B., Novel Proteinaceous Infectious particles cause scrapie, 216 Science 1982, 136.  
59   Tatzelt, Jorg/Winklhofer, Konstanze F., Folding and Misfolding of the Prion Protein in the 
Secretory Pathway, 11 Amyloid 2004, 162, 162.  
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seems contrary to the long-held hypothesis that an amino acid codes for a single 
unique 3-D structure.60 Amyloid plaques or protein aggregations in the brain are also 
associated with Alzheimer’s disease and Parkinson’s disease, conditions not consi-
dered prion-based but also dependent on aberrant protein folding.61 The primary 
structure does not absolutely determine the tertiary folding structure. It is now wide-
ly believed that gene expression alone largely, but not exclusively, controls the pro-
tein’s 3-D properties.  
III. Structurally similar, sequence dissimilar proteins 
With the discovery of increasingly more protein structures, it has further become 
evident that many proteins that possess similar structures share only a very small 
number of identical residues in structurally associated positions.62 Various structu-
rally similar protein pairs have only a minimal amount of sequence identity. This 
suggests that many sequence positions do not play a significant role in structure de-
termination, and folding determinants are restricted to a limited number of sequence 
residues.63 Structurally similar proteins do therefore not necessarily reflect se-
quence-similar proteins.64 Some proteins bearing diverse sequences with essentially 
no sequence homology, do fold into the same structure. With the protein’s effect de-
pending on the structure, large numbers of different proteins are able to perform the 
same functions.65  
IV. Posttranslational modifications (PTM)  
An important component of protein regulation and function is the modification of 
protein structures, which occur either co- or posttranslationally. Translation refers to 
 
60   Tatzelt, Jorg/Winklhofer, Konstanze F., Folding and Misfolding of the Prion Protein in the 
Secretory Pathway, 11 Amyloid 2004, 162, 166. 
61   Tatzelt, Jorg/Winklhofer, Konstanze F., Folding and Misfolding of the Prion Protein in the 
Secretory Pathway, 11 Amyloid 2004, 162, 162.  
62   Jaenichen, Hans-Rainer/Mcdonell, Leslie A./Haley, James F., Jr., From Clones to Claims, 
Cologne, Berlin, Bonn, Munich 2002, 167; molecular biologists thus attempted to identify 
the common hidden information within these sequences that directs them to assume similar 
folds. 
63   Kleist, Peter, Biomarker und Surrogat-Endpunkte: Garanten für eine schnellere Zulassung 
von neuen Arzneimitteln?, 83 Schweizerische Ärztezeitung 2022, 2347, 2350. 
64   Wachenfeld, Joachim, The Patenting of Protein Structures, 
  http://www.vossiusandpartner.com/eng/publication/mip-yearbook.html 2002. 
65   Structural protein families are also called ‘protein superfamilies’; see: Hultquist, Steven 
J./Robert Harrison, and Yongzhi Yang, Patenting Bioinformatic Inventions: Emerging 
Trends in the United States, 20 Nature Biotechnology 2002, 743; 771. A list of protein su-
perfamilies with structure-based-sequence-alignment is available at:  
  http://www-cryst.bioc.cam.ac.uk/~campass/superfamily.html, last checked on May 06, 2005. 
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the process in which the genetic code carried by mRNA directs the synthesis of pro-
teins from amino acids.66 Through constant modification of the protein, organisms 
accommodate radically different protein expression in different parts of the body 
and in different stages of the life cycle. Although amino acids can be predicted from 
nucleotide sequences, posttranslational modifications to proteins, in general, cannot.  
Once synthesized on the ribosomes, proteins are subject to a multitude of modifi-
cation steps. Because they are cleaved (thus eliminating signal sequences, transit or 
pro-peptides and initiator methionines), many simple chemical groups (for example 
acetyl, methyl, phosphoryl) as well as more complex molecules (such as sugars and 
lipids) can associate with them. Moreover, they can be internally or externally cross-
linked (example: disulfide bonds). So far, over 200 different modifications have 
been described. The complexity due to all these modifications is compounded by the 
high level of diversity that alternative splicing67 can produce at the level of the se-
quence. Many PTM have well described roles in signal transduction and the regula-
tion of cellular processes. In contrast, other modifications are much less well docu-
mented but are also likely to play very important roles within the cell. Identifying 
the type and location of these proteins is a first step in understanding their regulatory 
potential. The complex study of posttranslational modifications is one major objec-
tive of proteomics and is referred to as ‘PTM proteomics’. 68  
V. Role of Enzymes and their chemical activity 
One important function performed by proteins is the ability to catalyze chemical 
reactions.69 The biological catalysts were named enzymes.70 Enzymes are usually 
specific to the reaction they catalyze and the chemical substances involved in the 
reaction. Many enzymes are composed of several proteins acting together as a unit. 
 
66   Human Genome Project Information, Glossary of the Human Genome Project, available at  
  http://www.ornl.gov/TechResources/Human_Genome/glossary/. Recent advances in mim-
icking PTMs are helping to elucidate the role of the modifications and are the subject of high 
expectations for future pharmaceuticals, Davis, Benjamin G., Mimicking Posttranslational 
Modifications of Proteins, 303 Science 2004, 480.  
67  Alternative splicing of mRNA permits that many gene products with different functions are 
produced from a single coding sequence, see Brett, David/Pospisil, Heike et al., Alternative 
splicing and genome complexity, Nature Genetics 30, 2 (2001).  
68   MacCoss, Michael J./Hayes McDonald; Saraf,/Saraf, Anita/Sadygov, Rovshan/Clark, Judy 
M./Tasto, Joseph J./Gould, Kathleen L./Wolters, Dirk/Washburn, Michael/Weiss, 
Avery/Clark, John I./Yates, John R., Shotgun Identification of Protein Modifications from 
Protein Complexes and Lens Tissue, 99 Proceedings of the National Academy of Science of 
the United States of America 2002, 7900, 7901. 
69   Catalytic function was amongst the first biological roles recoginzed in proteins through the 
work of Eduard Buchner and Emil Fischer., Whitford, David, Proteins: Structure and Func-
tion, Chichester, West Sussex, U.K., 2005, 189.  
70   The name derived from the Greek for ‘in yeast’ - ‘en’ ‘zyme’, Whitford, David, Proteins: 
Structure and Function, Chichester, West Sussex, U.K., 2005, 189.  
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Most parts of an enzyme have regulatory or structural functions. The catalyzed reac-
tion takes place in only a small part of the enzyme called the active site. It is deter-
mined by a 3-D cleft formed by groups originating from different parts of the amino 
acid sequence. The active site, also described as a “binding pocket”, takes up a rela-
tively small part of the total volume of the enzyme. 
Enzyme-substrate binding was historically described through the “lock-and-key 
model”. The binding depends on the precisely defined arrangements of atoms in an 
active site. Complementary structural properties of the enzyme and substrate are 
responsible for this specificity. Most enzymes are highly selective with respect to 
the substrates that they bind, since their catalytic specificity depends partly on the 
specificity of binding. The active site contains the residues directly involved in the 
breaking and formation of bonds. These residues are referred to as catalytic groups. 
The catalytic power of enzymes originates from their ability to unite substrates in 
favorable orientations so as to promote the formation of the transitional states in en-
zyme-substrate complexes.71 In 1958, Daniel Koshland introduced the “induced fit 
model”, a modification of the lock and key model. It is based on the understanding 
that enzymes are flexible structures, in which the active side is continuously re-
shaped by its interaction with the substrate. Consequently, the amino acid side 
chains constituting the active side are molded into the exact position to start the cata-
lytic function of the enzyme.72 The enzyme-substrate complex according to the “in-

















71   Berg, Jeremy M./Tymoczko, John L./Stryer Lubert, Biochemistry, New York, NY, 2005, 
200; Wikipedia, Enzymes, available at 
  http://en.wikipedia.org/wiki/Image:Two_substrates_b.png, last checked on January 22, 2008. 
72   Koshland D. E., Application of a Theory of Enzyme Specificity to Protein Synthesis, 
Proceedings of the National Academy of Science 44 (2), (1958), 98. 
73   Based on Figure 5 provided by Wikipedia, Enzymes, available at: 
  http://en.wikipedia.org/wiki/Imag e: Two_substrates_b.png, last checked on January  
  22, 2008.  
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Figure 5: Enzyme-substrate complex 
 
The primary function of enzymes is to enhance rates of reaction. Thereby they are 
compatible with the needs of the organism. Chemical reactions require a certain 
amount of activation energy to take place. Enzymes can increase the reaction speed 
by favoring or enabling a different reaction path with lower activation energy, mak-
ing it easier for the reaction to occur. They can also serve to associate two or more 
reactions together, such that a thermodynamically favorable reaction can be used to 
“drive” a thermodynamically unfavorable one. The most common examples are en-
zymes that use the dephosphorylation of ATP to drive some otherwise unrelated 
chemical reactions.74 Enzymes conduct up to several million catalytic reactions per 
second. In order to understand how enzymes work, a kinetic description of their ac-
tivity is used. The maximum speed of an enzymatic reaction is determined by the so 
called “Michaelis-Menten equation”. Here, the substrate concentration is increased 
until a constant rate of product formation is achieved. This is the maximum velocity 
(Vmax) of the reaction catalyzed by the enzyme. In this state, all enzyme active sites 
are saturated with substrate. Since the substrate concentration at Vmax cannot be pre-
cisely determined, enzymes are characterized by the substrate concentration at which 
 
74   Figure available at http://lc.brooklyn.cuny.edu/smarttutor/core3_21/energy.html, last 
checked on January 22, 2008. 
 
https://doi.org/10.5771/9783845221441, am 02.12.2021, 20:19:12
Open Access -  - http://www.nomos-elibrary.de/agb
 38
the rate of reaction is half its maximum. This substrate concentration is called the 
Michaelis-Menten constant (KM).
75 
The activities of many enzymes can be anticipated by the binding of specific 
small molecules and ions. Inhibitor activity serves as a major control mechanism in 
biological systems. Many drugs act in this fashion. Inhibition by specific substrates 
can give a valuable insight into the mechanism of enzyme action. Enzyme inhibition 
occurs either reversibly or irreversibly. An irreversible inhibitor disconnects slowly 
from its target enzyme, because it binds tightly to it. Some important drugs are irre-
versible inhibitors. Penicillin acts by modifying the enzyme and thereby inhibiting 
the synthesis of bacterial cell walls, thus killing the bacteria. Aspirin has the ability 
to suppress the production of prostaglandins and thromboxanes by enzyme 
modification.76 
Reversible inhibition, in contrast, describes the rapid dissociation of the enzyme-
inhibitor complex. By competitive inhibition, an enzyme is not only bound by its 
natural substrate, but also by a further substrate (“inhibitor”) which does not trigger 
the catalytic reaction. In this way, further binding of the natural substrate and its 
subsequent reaction are inhibited. The competitive inhibitor is similar to the sub- 
strate and associates to the active center of the protein. Thus, it prevents the sub-
strate from binding to the same active site and diminishes the rate of catalysis by re-
ducing the proportion of enzyme molecules bound to a substrate. Increasing sub-
strate concentration leads to a decrease of competitive inhibitions.77 Competitive in-











75   Berg, Jeremy M./Tymoczko, John L./Stryer Lubert, Biochemistry, New York, NY 2005, 
200-203. 
76   Prostaglandins are hormone-like substances, which are produced in the body and have 
various effects, including the transmission of pain information to the brain, modulation of 
the hypothalamic thermostat, and inflammation. Thromboxanes act to promote the 
aggregation of platelets that form blood clots. The effects of aspirin were discovered in 1971 
by the British pharmacologist, John R. Vane. He was awarded a Nobel Prize in Physiology 
and Medicine for his research in 1982. Berg, Jeremy M./Tymoczko, John L./Stryer Lubert, 
Biochemistry, New York, NY 2005, 209. 
77   For a detailed overview of the specific chemical procedures see Berg, Jeremy M./Tymoczko, 
John L./Stryer Lubert, Biochemistry, New York, NY, 2005, 209-219.  
78   See: http://en.wikipedia.org/wiki/Enzyme, last checked on January 22, 2008. 
79   The diagram showing the mechanism of non-competitive inhibition is taken from Wikipedia 
http://en.wikipedia.org/wiki/Enzyme, last checked on January 21, 2008. 
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C. Genetic coding of proteins80 
In order to produce a protein, a cell requires information about the sequence in 
which the amino acid must be assembled.81 The cell utilizes a long polymeric mole-
cule, DNA (deoxyribonucleic acid), to store this information. The amino acid se-
quence of a protein is genetically determined by the sequences of bases in a DNA 
molecule. The subunits of the DNA are called nucleotides.82 DNA encompasses four 
nucleotides that are distinguishable from the base regions of the molecule. The four 
bases are adenine, guanine, cytosine, and thymine (referred to as A, G, C and T). 
The sequence of these bases along the DNA molecule determines which amino acids 
will be inserted in sequence into the polypeptide chain of a protein. DNA is synthe-
sized in extremely long strands (called chromosomes) encompassing information 
encoding for the sequence of many proteins. The region of DNA on the chromosome 
that determines the sequence of a single protein is called a gene.83 The process in 
which the data in a gene is utilized to synthesize a new protein is called gene expres-
sion. To express a gene, a copy of the gene as a molecule of RNA (ribonucleic acid) 
is made. RNA is a molecule very similar to DNA. One difference, however, is that 
RNA contains a different sugar (ribose instead of deoxyribose). Furthermore, the 
base thymine (T) of DNA is replaced in RNA by the structurally similar base, uracil 
(U).84 The process of making an RNA copy of DNA is called transcription.85 The 
transcribed RNA copy contains sequences of A, U, C, and G having the same infor-
mation as the sequence of A, T, C and G in the DNA. The RNA molecule, referred 
to as messenger RNA (mRNA), then progresses to a location in the cell where pro-
teins are synthesized. The information encoding the sequence of amino acids in a 
protein (the “genetic code”) is composed of serially reaching groups of three conti-
guous nucleotides. Each combination of three contiguous nucleotides, called a co-
don, determines one amino acid. The four bases A, G, C and U can be specified as 
triplets in 64 different ways, but there are only 20 amino acids to be translated. Thus, 
 
80   Alberts, Bruce/Johnson, Alexander/Lewis, Julian, Molecular Biology of the Cell (4th ed.), 
New York 2002, 111-112. 
81   CAFC decisions often provide a useful and clear illustration of the scientific background. 
The process of genetic coding and translation is explained in: In re O’Farrell 853 F.2d 894, 
895-899 (Fed. Cir. 1988); for a detailed overview of the genetic coding of proteins see 
Vossius, Volker/Jaenichen, Hans-Rainer, Zur Patentierung biologischer Erfindungen nach 
Europäischem Patentübereinkommen und Deutschem Patentgesetz - Formulierung und Aus-
legung von Patentansprüchen, GRUR 1985, 821. 
82    Alberts, Bruce/Johnson, Alexander./Lewis, Julian, Molecular Biology of the Cell, New York 
2002, 98. 
83   For a brief overview of the basics of genetics, see also Kraßer, Rudolf, Patentrecht: ein Lehr- 
und Handbuch zum deutschen Patent- und Gebrauchsmusterrecht, europäischen und interna-
tionalen Patentrecht, 5. Aufl., München 2004, 222. 
84   Alberts, Bruce/Johnson, Alexander./Lewis, Julian, Molecular Biology of the Cell, New York 
2002, 104-105. 
85   Alberts, Bruce/Johnson, Alexander./Lewis, Julian,Molecular Biology of the Cell, New York 
2002, 104. 
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most amino acids are encoded by more than one codon. In addition, three codons 
exist which do not encode any amino acid. They are called ‘stop codons’.86 Compli-
cated cellular machinery is involved in the synthesis of proteins. Complexes of more 
than fifty different proteins associated with several structural RNA molecules 
(rRNAs), are called ribosomes.87 These molecules ‘read’ the necessary information 
in the messenger RNA molecule, shift three nucleotides along the strand of RNA at 
a time, and add the amino acid determined by the codon to a growing polypeptide 
chain. When it arrives at a stop codon, the polypeptide chain is complete and de-
taches from the ribosome. This process of synthesizing a new polypeptide chain 
from the genetic information contained on the messenger RNA molecule with the 
aid of ribosomes is referred to as translation.88 The messenger RNA can be used to 
synthesize many copies of the same protein. The translation of messenger RNA 
starts at the particular sequence of nucleotide that binds the RNA to the ribosome. 
The translation then continues by reading nucleotides, three at a time, until a stop 
codon is read. Reading errors might lead to entirely different peptides, most likely 
useless ones. 89 
D. Recombinant Protein Synthesis 
If a human gene is transferred into a bacterium, this bacterium is able to synthesize 
the human protein.90 The method of producing large quantities of identical copies of 
a gene by integrating it into prokaryotic cells and then replicating those cells is re-
ferred to as “DNA-cloning”.91 After having produced a significant amount of the 
 
86   Alberts, Bruce/Johnson, Alexander./Lewis, Julian, Molecular Biology of the Cell, New York 
2002, 106. 
87   Alberts, Bruce/Johnson, Alexander./Lewis, Julian, Molecular Biology of the Cell, New York 
2002, 107. 
88   Alberts, Bruce/Johnson, Alexander./Lewis, Julian, Molecular Biology of the Cell , New 
York 2002, 106. 
89   Alberts, Bruce/Johnson, Alexander./Lewis, Julian, Molecular Biology of the Cell, New York 
2002, 107.  
90   Human beings, animals, and plants are classified as eukaryotic organisms: their DNA is en-
closed in chromosomes in a special part of the cell, the nucleus. In contrast, Bacteria (proka-
ryotic organisms) have a different organization. Their DNA is not included in a separate nuc-
leus. Irrespective of the large differences between them, all organisms, whether eukaryotic or 
prokaryotic, encode proteins pursuant to the same rules that govern genes. While most com-
mercially valuable proteins come from human beings or other eukaryotes, bacteria can be 
grown in huge amounts. Therefore, one strategy for producing a preferable protein is to shift 
the gene carrying the protein’s information from the eukaryotic cell, where the gene normal-
ly occurs, into a bacterium. Bacteria bearing genes from a foreign source (heterologous 
genes) integrated into their own genetic machinery are said to be transformed. When trans-
formed bacteria grow and divide, the integrated heterologous genes are replicated. It is poss-
ible to synthesize large amounts of transformed bacteria that encompass transplanted hetero-
logous genes, see In re O’Farell, 853 F.2d 894, 898 (Fed. Cir. 1988). 
91   Brown, Terence A., Gentechnologie für Einsteiger, Berlin 2002, 4-5. 
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transformed bacteria, it is stimulated to express the cloned gene and to make useful 
quantities of the protein. To make a particular protein by expressing its cloned gene 
in bacteria (referred to as ‘a recombinant process’)92 several steps must be per-
formed.93 First, the gene coding for the particular protein has to be isolated. Next, 
the isolated genes must be transferred to the host bacterium. This is typically per-
formed by incorporating the gene into a cloning vector. A cloning vector is a portion 
of DNA that can be integrated into bacteria and that replicates itself each time the 
bacteria divide. A frequently used type of cloning vector is referred to as plasmid. A 
plasmid is a small circular loop of DNA originating in bacteria, which exists sepa-
rately from the chromosome. Due to their small size, they can easily be isolated. Re-
combinant DNA technology can be used to modify plasmids. Such a modified plas-
mid can then be introduced into bacteria, where it replicates as the bacteria grows.94 
Even after a cloned heterologous gene has been introduced into a bacteria and repli-
cated, it is not guaranteed that the gene will be expressed and encode for a protein. 
E. coli, for example, consists of genetic information for several thousand proteins. 
Often, a great number of those genes are not expressed at all. Thus, methods that 
‘turn on’ the cloned gene are necessary. Many biotechnological inventions are di-
rected to this field of research.95  
E. Proteomic research  
The determination of the genome changed the entire emphasis of protein studies of 
the past. It is now possible to comprehend the concrete impact that genetic informa-
tion has on protein composition and structure. Moreover, it was discovered that dif-
ferent genes neither generate the same amount of proteins nor reveal the precise de-
termination of circumstances under which protein synthesis is initiated. This specifi-
cation of the total cellular protein output is therefore an important focus of current 
research efforts.96  
 
92   Jollès, Pierre/Jörnvall, Hans, Proteomics in Functional Genomics, Protein Structure Analy-
sis, Basel et al. 2002, XI.  
93   Watson, James D., Molecular Biology of the Gene, Menlo Park, California 1987, 208. As for 
inventions in the field of recombinant technologies see Vossius, Volker/Jaenichen, Hans-
Rainer, Zur Patentierung biologischer Erfindungen nach Europäischem Patentübereinkom-
men und Deutschem Patentgesetz  -  Formulierung und Auslegung von Patentansprüchen, 
GRUR 1985, 821, 821.  
94   Whitford, David, Proteins: Structure and Function, Chichester, West Sussex, U.K., 315-316. 
95   Fernandez, Dennis/Chow, Mary, Intellectual Property Strategy in Bioinformatics and Bio-
chips, Journal of Patent and Trademark Office Society June 2003, 465, 470; Biochip compa-
nies, such as Affymetrix and Hyseq, are involved in developing assays, tools, and computa-
tional techniques for the disclosure and modification of gene expression profiles; In re 
O’Farell, 853 F.2d 894, 898. 
96   Jollès, Pierre/Jörnvall, Hans, Proteomics in Functional Genomics, Protein Structure Analy-
sis, Basel et al. 2002,  XI. 
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Advances in proteomic science now allow for analyses of known protein forms 
with regard to their binding regions, the results of which are used for screening 
against database entries. An important challenge is the need for a simultaneous eval-
uation of many proteins in highly complex mixtures. Not only must single proteins 
be identified in order to understand their functional interactions, but also the global 
output of gene products from essentially all tissues must be determined. This deter-
mination has to be carried out under healthy as well as pathogenic conditions, and in 
developmental and other special states. With the 3-D geometry of proteins being 
critical to their function, it is important and challenging to preserve this geometry 
through all research steps. Furthermore, one must take into account that the prote-
ome is constantly changing. One organism will have radically different protein ex-
pression in different parts of its body and in different stages of its life cycle.97  
I. Proteome initiatives  
Proteome research is already highly organized on an international level. The “Hu-
man Proteome Project” (HPP) has been founded as an analogue to the “Human Ge-
nome Project” (HGP).98 It aims to consolidate national and regional proteome organ-
izations into a worldwide network. Moreover, it engages in scientific and education-
al activities to encourage the spread of proteomic technologies and to disseminate 
knowledge pertaining to the human proteome and that of model organisms. Finally, 
it assists in the coordination of public proteome initiatives. In 2001, the “Human 
Proteome Organization” (HUPO)99, again an analogue to the complementary ge-
nome initiative, the “Human Genome Organization” (HUGO),100 was founded.101 
Among other things, its goals are to promote the analysis of particular proteins or 
protein complexes, as well as their relationship to certain diseases. Moreover, it 
seeks to advance: the disclosure of biomarker proteins, which allow a diagnosis of 
disease shortly after its outbreak, the development of diagnostic tools that enable 
predictions about the course of diseases or its cure, and the disclosure of proteins 
 
97   Jollès, Pierre/Jörnvall, Hans, Proteomics in functional Genomics, Protein Structure Analysis, 
Functional Genomics, Protein Structure Analysis, Basel et al. 2002,  XI.  
98   The Human Genome Project started in 1990 and was coordinated by the U.S. Department of 
Energy (DOE) and the National Institutes of Health (NIH). The project was finished in 2003, 
when the disclosure of the human genome was completed, see Krefft, Alexander Richard, 
Patente auf human-genomische Erfindungen: Rechtslage in Deutschland, Europa und den 
USA, München 2003, 6. For further information see Straus, Joseph, Genpatente: rechtliche, 
ethische, wissenschafts- und entwicklungspolitische Fragen, Basel, Frankfurt/Main 1997, 16. 
99   Human Proteome Organization, available at http://www.hupo.org/, last checked on January 
21, 2008.  
100   Human Genome Organization, available at http://www.hugo-international.org/, last checked 
on January 21, 2008.  
101   Hanash, Sam, Building a Foundation for the Human Proteome: The Role of the Human 
Proteome Organization, 3 Journal of Proteome Research 2004, 197.  
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that can be used as new drugs targets. HUPO encompasses five major initiatives102, 
including projects on plasma103, the liver104, bioinformatics, and the brain105.  One of 
them, the “Human Brain Proteome Project” is carried out under the supervision of 
the German government. Furthermore, the “Deutsche Gesellschaft für Proteome 
Forschung e.V.” represents the German proteome research in EU, HUPO, and other 
international proteome organizations.106 Protein research involves immense invest-
ments. The U.S. government, for instance, is supporting a wide range of initiatives 
in order to cope with challenges in the proteomics field. For example, the National 
Heart, Lung, and Blood Institute (NHLBI) is supporting 10 proteomic centers with 
more than U.S. $ 150 million for a period of seven years, and the National Institute 
of Neurological Disorders and Stroke (NINDS) has detailed plans for other pro-
jects.107 
 
102   In addition, several sub-initiatives exist, such as for Pan-Asian proteomics, see Mason, Ka-
therine A., As Pan-Asian Proteomics Powerhouse Emerges, Focus is on Liver Cancer, 
SARS, Genome Technology 2003, 47. All data obtained by the (non-profit) HUPO initia-
tives are available for public access.  
103   Human Plasma Proteome Project, available at http://psidev.sourceforge.net/ppp/pilotPhase/, 
last checked on September 28, 2005.  
104   Human Liver Proteome Project, available at http://www.hlpp.org/hlpp/, last checked on Sep-
tember 28, 2005.  
105   Human Brain Proteome Project, available at http://www.hbpp.org/, last checked on January 
21, 2008. 
106   Deutsche Gesellschaft für Proteome Forschung, available at http://www.dgpf.org/dgpf-
set.htm, last checked on January 21, 2005. The Federal Ministry of Education and Research 
founded the proteomics-based initiative “New efficient procedures for functional proteome 
analysis” in June 2000. Since then, over 75 million Euro were made available for the 
development of proteomics-based technologies. For further information see 
http://www.bmbf.de/en/1756.php, last checked on January 21, 2008. One of the projects that 
has been sponsored by the ministerial program is “Fighting Mycobacterium tuberculosis 
with structural proteomics” conducted by the European Molecular Biology Laboratory 
(EMBL) and several partners (Max-Planck Groups for Molecular Structural Biology, 
Hamburg; Max-Planck-Institute for Infectious Biology, Berlin; Technical University of 
Munich, Research Center Weihenstefan, Biomax, Martinsried; Combinature, Berlin; 
MarResearch, Norderstedt). The project aims to combat tuberculosis under a proteomics 
approach and has received from the ministry a 3.5 million Euro grant in support of its efforts. 
For a detailed description, see EMBL Hamburg, MTB-Strukturproteomik Konsortium Ge-
samtdarstellung, Hamburg, Berlin, München 2003, 1.  
107   Lottspeich, Friedrich, Humanproteomorganisation - HUPO, in: Fäden des Lebens, Tagungs-
band der Münchener Wissenschaftstage im Jubiläumsjahr 2003; München, 2003; 98, 100. 
The “beat of the proteomic drum” also encouraged many researchers to create private re-
search organizations for the analysis of disease-related proteins, such as the Plasma Prote-
ome Institute, see MacNeil, John S., Like Father, like Son, Genome Technology 2003, 50, 
51. 
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II. Proteomics Technologies 
1. Protein expression, purification and characterization 
As defined earlier, the major objective of methods employed in proteomics is the 
total characterization of the protein. A thorough examination of the protein profile 
requires several steps, ranging from the proteins’ identification and structural deter-
mination to the study of its post-translational modifications and from its quantifica-
tion to the handling of the resulting proteomic data. In order to study any protein it is 
necessary to obtain it in a purified form. This is often a challenging task, particularly 
if proteins are present within the cell in low concentration. Frequently, this involves 
the purification of one single protein from a cell paste encompassing over 10.0000 
different proteins. Two major alternatives are employed for isolating proteins. First, 
proteins can be isolated conventionally by obtaining the desired protein directly 
from the used source, such as a cell or tissue. Second, proteins can be expressed re-
combinantly, e.g. by introducing the DNA-sequence into a bacterial host.108 In re-
cent years, there have been numerous technical advances for proteomic technolo-
gies. Most commonly used methods for protein separation and identification are 2-D 
gel electrophoresis for protein separation and the proteome’s analysis by mass spec-
trometry.109 With the study of some proteins still being difficult to accomplish, fur-
ther development of these tools is needed. 
a) Gel electrophoresis  
2D electrophoresis aims to separate proteins according to mass and overall charge. 
The technology is classified as the most common method for analyzing the purity of 
an isolated protein.110 The principle of electrophoresis is the separation of proteins 
according to molecular mass by their movement through a polyacrylamide gel of 
closely defined composition under the influence of an electric field. The mobility of 
a protein through polyacrylamide gels is determined by a combination of overall 
charge, molecular shape, and molecular weight. The method is conducted by intro-
ducing a protein mixture to the top of a gel that proceeds through the matrix because 
of the electric field, with lighter components migrating faster than ‘heavier’ mole-
cules. Over time, the component proteins are separated and the resolving power of 
 
108   Whitford, David, Proteins: Structure and Function, Chichester, West Sussex, U.K., 313.  
109   Another frequently employed method fort the purification of proteins is chromatography, see 
Whitford, David, Proteins: Structure and Function, Chichester, West Sussex, U.K., 326. 
There exist a number of different chromatographic methods.  
110   See Gorg, Angelika/Weiss, Walter/Dunn, Michael J., Current two-dimensional electrophore-
sis technology for proteomics, 4 Proteomics 2004, 3665, 3665. The author considers two-
dimensional gel electrophoresis (2-DE) with immobilized pH gradients (IPGs) combined 
with protein identification by mass spectrometry (MS) ‘the workhorse’ of proteomics. 
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the technique is sufficiently high that heterogeneous mixtures of proteins can be se-
parated and distinguished from each other. The movement of proteins through the 
gel depends on the voltage/current conditions used as well as the temperature. 
Commonly, the mobility of an unknown protein or mixture of proteins is compared 
to that of a pure component of known molecular mass. Using this method for indi-
vidual cell types or organisms makes it possible to identify large numbers of differ-
ent proteins within proteomes of single-celled organism or individual cells. The 
technique allows the monomeric molecular mass to be determined with reasonable 
accuracy. 111  
b) Mass spectrometry 
Mass spectrometry has emerged as the central analytical technique in proteomic 
analysis.112 Like gel electrophoresis, the method is based on the discovery that the 
mass of a protein is one of the most useful characteristics for its identification.113 Its 
observed parameter is the mass-to- charge ratio of gas phase ions, e.g. of electrically 
charged proteins in vapor state. Typically, mass spectrometers involve three basic 
components: an ion source, a mass analyzer and a detector. Ions are produced from 
samples generating charged states, which the mass analyzer separates according to 
their charge ratio. Simultaneously, a detector produces quantifiable signals. 114 Final-
ly, the magnitude of these signals is recorded and converted into a mass spectrum. 
Early mass spectrometers required the sample to be a gas. Modern instrumentation, 
specifically the popular methods of “matrix assisted laser desorption time of flight 
(MALDI-TOF)” and “electrospray spectrometry”, enable the analysis of ions em-
bedded in a matrix or liquid solution samples. Over the last 20 years mass spectro-
metry has advanced rapidly and specifically in the area of proteomics. The impor-
tance of mass spectrometry for protein characterization was demonstrated by the 
award of the Nobel Prize for Chemistry in 2002.115 The introduction of the tech-
niques116 described above enables accurate mass determination for primary se-
quences. Moreover, they allow for the detection of post-translational modifications 
 
111   Whitford, David, Proteins: Structure and Function, Chichester, West Sussex, U.K., 333.  
112   Recent successes demonstrate the role of mass spectrometry-based proteomics as an decisive 
tool in molecular and cellular biology, Aebersold, Ruedi/Mann, Matthias, Mass Spectrome-
try-based Proteomics, 422 Nature 2003, 198, 198. 
113   After a protein has been isolated by gel electrophoresis, it is typically analyzed further by 
mass spectrometry. 
114   The development of MALDI-TOF, where a matrix assists in the formation of a gas phase 
protein ion enabled to overcome existing practical difficulties, such as the non-volatility of 
proteins.  
115   The prize was given to John Fenn and Koichi Tanaka, two pioneers in the field of mass spec-
trometry, for their research related to the development of ‘soft’ desorption-ionization me-
thods in mass spectrometry.  
116   Such as MALDI-TOF and electrospray methods.  
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and single residue mutations in genetically engineered proteins. Large numbers of 
inventions focus on the improvement of mass spectrometry tools. 117 
2. Physical methods of determining the three-dimensional structure of proteins 
a) Protein Crystallization  
Another core element of proteomics is the development of methods leading to pro-
tein structure determination.118 One of the most common methods of structure de-
termination is protein crystallization. Protein crystals are characterized by a high de-
gree of internal three-dimensional order and a definite overall chemical composi-
tion.119 The crystallization process of molecules of any substance from its solution is 
characterized by a reversible equilibrium phenomenon, determined by the minimiza-
tion of the free energy of the system. A solution in which the molecules are fully 
solvated120 corresponds to the system at equilibrium; its free energy is minimized. If 
the amount of molecules in the solution is increased, the system goes through inter-
nal changes until the point is reached where there is insufficient liquid to maintain 
full hydration of the molecules. These conditions are called “the supersaturation 
state”.121 Crystallizing purified proteins is not only a time consuming process, but 
also requires a significant amount of protein sample. There are a number of tech-
niques, which have been developed for bringing a protein solution into a supersatu-
ration state. Among them, the most common methods are micro-batch, vapor-
 
117   Whitford, David, Proteins: Structure and Function, Chichester, West Sussex, U.K., 345. The 
development of “surface enhanced laser desorption” (SELDI) a technology that facilitates 
the fast monitoring of biomarkers for cancer diagnosis, is one example of a new mass spec-
trometry system, see Langbein, William, Mass Spec meets Oncology - A prolific pair of 
governments researchers developed a Proteomic Bar Code for detecting cancer, Genome 
Technology 2003, 42, 43. Another recently developed mass spectrometry tool is “Fourier 
transform mass spectrometry” (FT/MS). It is particularly used for the identification of post-
translational modifications; see MacNeil, John S., Making things happen, Genome Technol-
ogy 2003, 34, 34. 
118   Whitford, David, Proteins: Structure and Function, Chichester, West Sussex, U.K., 347. 
119   The term crystal comes from the Greek word “krustallos” (clear ice). Like clear ice, crystals 
are homogeneous solids, many of them having a transparant sparkling appearance and a 
well-defined geometrical shape, with regular faces and sharp edges, see Chirgadze, Dima, 
Protein Crystallization in Action, 3, available at 
  http://daffy.bioc.cam.ac.uk/~dima/whitepapers/xtal-in-action/, last checked on July 5, 2005.  
120   A liquid substance is considered as solvent if it is capable of dissolving other substances. 
One characteristic of a solvent is that the substance does not change its state in forming a so-
lution. Solvation is a chemical process in which solvent molecules and molecules or ions of 
the solute combine to form a compound, see http://www.wordreference.com, last checked on 
January 21, 2008.  
121   See Chirgadze, Dima, Protein Crystallization in Action, 3, available at 
  http://daffy.bioc.cam.ac.uk/ ~dima/whitepapers/xtal-in-action/, last checked on  
  July 5, 2005. 
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diffusion and dialysis.122 Although supersaturation of a protein solution can be at-
tained by means of each of these procedures, the underlying principles of these me-
thods differ.  
Micro-Batch crystallization123 involves the direct mixing of the undersaturated 
protein solution with a precipitant solution. The method aims to produce a final su-
persaturated concentration, which may eventually lead to crystallization. This is 
achieved with large amounts of solutions, and typically results in larger crystals ow-
ing to the larger volumes of solute present and the lower chance of impurities diffus-
ing onto the face of the crystal. The main disadvantage of the micro-batch technique 
is that equilibration takes place very rapidly and therefore affects the rate of crystal 
growth and consequently the quality of the obtained crystals. Nevertheless, since the 
use of very small volumes of protein solution can be made, the method is quite use-
ful as an early screening method.124   
Vapor diffusion is the standard method utilized for protein crystallization.125 It is 
the favored technique when screening large numbers of conditions.126 Vapor diffu-
sion is based on evaporation and diffusion of water between solutions of different 
concentrations as a means of approaching supersaturation of proteins. Typically, the 
protein solution is mixed in a 1:1 ratio with a solution containing the precipitant 
agent at the concentration required after vapor equilibration has occurred. A drop is 
then suspended and sealed over the well solution, which contains the precipitant so-
lution at the target concentration. The difference in precipitant concentration be-
tween the drop and the well solution acts as the driving force. It leads to the vapori-
zation of the drop until the concentration of the precipitant in the drop equals that of 
the well solution.  
 
 
122   Chirgadze, Dima, Protein Crystallization in Action, 7, available at,  
  http://daffy.bioc.cam.ac.uk/ ~dima/whitepapers/xtal-in-action/, last checked on July 5, 2005; 
as well as Ng, Joseph D./Gavira, Jose A./Garcia-Ruiz, Juan M., Protein crystallization by ca-
pillary counterdiffusion for applied crystallographic structure determination, 142 Journal of 
Structural Biology 2003, 218 who do not explicitly refer to the method of dialysis. 
123   Ng, Joseph D./Gavira, Jose A./Garcia-Ruiz, Juan M., Protein crystallization by capillary 
counterdiffusion for applied crystallographic structure determination, 142 Journal of Struc-
tural Biology 2003, 218, 220. Micro-Batch is a variation of the simple batch crystallization 
technique.  
124   Chirgadze, Dima, Protein Crystallization in Action, 7, available at  
  http://daffy.bioc.cam.ac.uk/ ~dima/whitepapers/xtal-in-action/, last checked on July 5, 2005. 
This method was successfully conducted in order to obtain the initial NK1 protein crystalli-
zation conditions.  
125   Ng, Joseph D./Gavira, Jose A./Garcia-Ruiz, Juan M., Protein crystallization by capillary 
counterdiffusion for applied crystallographic structure determination, 142 Journal of Struc-
tural Biology 2003, 218, 220; Whitford, David, Proteins: Structure and Function, Chichester, 
West Sussex, U.K., 359. 
126   Chirgadze, Dima, Protein Crystallization in Action, 10, available at  
  http://daffy.bioc.cam.ac.uk/ ~dima/whitepapers/xtal-in-action/, last checked on July 5, 2005. 
This technique can also be conducted to increase or decrease the concentration of proteins in 
the equilibrated state, relative to its initial concentration.  
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Dialysis techniques are typically conducted for proteins at low and high ionic 
strength.127 They employ diffusion and equilibration of small precipitant molecules 
through a semipermeable membrane as a way of slowly approaching the concentra-
tion at which the macromolecule solute crystallizes. In a preliminary step, the pro-
tein solution is contained within the dialysis membrane, which is then equilibrated 
against a precipitant solution. Equilibration against the precipitant in the surrounding 
solvent slowly reaches supersaturation for the solute within the dialysis membrane, 
eventually resulting in crystallization. The improvement of dialysis over other me-
thods is in the ease with which the precipitating solution can be varied, simply by 
shifting the entire dialysis button from one condition to another. Hence, the protein 
solution can be continuously recycled until the correct conditions for crystallization 
are obtained.128 
b) X-ray crystallography  
X-ray crystallography is a technique in which the pattern produced by the diffraction 
of x-rays through the closely spaced lattice of atoms in a crystal is recorded and then 
analyzed to reveal the nature of that lattice. It can provide an astonishingly fine vi-
sualization of protein structure, since it reveals the precise three-dimensional posi-
tions of most atoms in a protein molecule.129 
The material and molecular structure of a substance can often be inferred by 
quantitative study of this pattern. It is widely used in chemistry and biochemistry to 
determine the structures of molecules, including DNA and proteins. The first protein 
structure of myoglobin was disclosed by Max Perutz and Sir John Cowdery 
Kendrew in 1958 and led to a Nobel Prize in Chemistry.130 To determine a structure, 
one must obtain crystals of the protein of interest. This can be a painstaking proce-
dure for macromolecules. Many proteins, such as hydrophobic or membrane-
associated proteins, might not crystallize at all. Actually, it is generally possible to 
achieve crystalline forms of only 5-10 % of proteins, even though increasingly large 
and complex polypeptides are being crystallized.131 Some proteins crystallize readi-
 
127   Whitford, David, Proteins: Structure and Function, Chichester, West Sussex, U.K., 359.  
128   Chirgadze, Dima, Protein Crystallization in Action, 10, available at 
  http://daffy.bioc.cam.ac.uk/~dima/whitepapers/xtal-in-action/, last checked on July 5, 2005. 
Under these conditions, the protein solution can be continiously recycled until the correct 
conditions for crystallization are obtained.  
129   Pusey, Marc L./Liu, Zhi-Jie/Tempel, Wolfram/Praissman, Jeremy/Lin, Dawei/Wang, Bi-
Cheng/Gavira, Jose A./Ng, Joseph D., Life in the Fast Lane for Protein Crystallization and 
X-ray Crystallography, 88 Progress in Biophysics & Molecular Biology 2005, 359 describes 
X-ray crystallography as the “foremost method” to acquire data relating to the three-
dimensional structures for a multitude of proteins.  
130   Today, X-ray crystallography is often used to determine how drugs, such as anti-cancer me-
dications, can be improved to better influence their protein targets. 
131   See Maggio, Edward T./Ramnarayan, Kal, Recent Developments in Computational Pro-
teomics, 19 Trends in Biotechnology 2001, 266, 266. 
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ly, whereas others do so only after considerable effort has been spent in determining 
the optimal conditions. After the crystallization of the substance, the crystals are 
harvested and often frozen with liquid nitrogen. Freezing the crystals both reduces 
radiation damage incurred during data collection and decreases thermal motion with-
in the crystal. Crystals are placed on a diffractometer, a machine that emits a beam 
of x-rays. The x-rays diffract off the electrons in the crystal. The crystal is rotated 
such that the beam can strike the crystal from many directions. This rotational mo-
tion results in an x-ray photograph consisting of a regular array of spots called ref-
lections. The intensity of each spot is measured. These intensities and their positions 
are the basic experimental data of an x-ray crystallographic analysis. The observed 
intensities are then used to reconstruct an image of the protein. Furthermore, an elec-
tron density map is calculated, which serves for the determination of the density of 
electrons at a large number of regularly spaced points in the crystal.132 In the next 
step, this density map is interpreted. The resolution of the x-ray analysis is deter-
mined by the number of scattered intensities. Once a model of a protein's structure 
has been determined, it is deposited in the Protein Data Bank (PDB).133 The devel-
opment of new methods for solving x-ray crystal structures is considered an impor-
tant field of research.134  
c) NMR structure determination 
Structure Determination of Proteins with NMR Spectroscopy is another classic pro-
tein analysis technique. It is accomplished by the determination of the biological 
macromolecular structure at atomic resolution, but it is only possible with water-
soluble proteins. The technique is based on the fact that energy levels of atomic nuc-
lei are split by a magnetic field. Transitions between these energy levels can be 
achieved by exciting the sample with radiation whose frequency is equivalent to the 
energy difference between the two levels. The field of NMR spectroscopy has re-
cently experienced an explosive growth, which started with the development of 
pulsed Fourier-transform NMR and multidimensional NMR spectroscopy and con-
tinues today. Progress in the theoretical and practical capabilities of NMR spectros-
copy leads to an increasingly efficient utilization of the information content related 
 
132   The term “electron density map” refers to the distribution of electron density in a crystal that 
is measured by the X-ray diffraction template. 
133   Berg, Jeremy M./Tymoczko, John L./Stryer Lubert, Biochemistry, New York, NY, 2002, 
110-112. Peters, Linde, http://www.boa-muenchen.org/linde.peters/postgen0.htm#top, Part 
IV, 1-14.  
134   For a method relying on the introduction of iodine into proteins, see Dauter, Zbigniew, Phas-
ing in Iodine for Structure Determination, 22 Nature Biotechnology 2004, 1239. 
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to it. Parallel developments in the biochemical methods (such as recombinant pro-
tein expression) allow simple and rapid preparation of protein samples.135  
d) Protein modeling (homologous-comparison) 
In addition to protein crystallization or synchronization that is not possible with all 
existing proteins, new computational methodologies have recently yielded modeled 
structures that are, in many cases, quantitatively comparable to crystal structures.136 
The method of homology modeling of proteins relies on the structural knowledge of 
proteins for which 3-D structures have been determined, in order to infer the struc-
ture of other proteins for which only the sequence is known. The sequence of a 
polypeptide of unknown structure is combined with the template of another polypep-
tide in an attempt to predict the unknown structure. Obtained data helps to determine 
the structure of homologous proteins. For comparative protein modeling, at least one 
sequence of known 3-D structure with significant similarity to the target sequence is 
required. Accordingly, protein modeling is only limited by the need for at least one 
crystal structure within each fold-class to be modeled. In order to determine whether 
a modeling request can be carried out, one compares the target sequence with a da-
tabase of sequences derived from a sequence-related protein database using the cor-
responding bioinformatics program. This method might lead to the selection of sev-
eral suitable templates for a given target sequence. Commonly, up to ten templates 
are used in the modeling process. The best template structure, which is the one with 
the highest sequence similarity to the target, will be chosen as the reference. As a 
next step, the target sequence needs to be aligned with the template sequence. Resi-
dues that are unimportant for the model building will be ignored during the model-
ing process. Thus, the common core of the target protein and the loops defined by at 
least one supplied template structure are simulated. Further, the position of each 
atom in the target sequence is averaged with the help of the location of the corres-
ponding atoms in the template. Those loops for which no structural information is 
available in the template structure are not defined and thus must be simulated. Most 
of the known 3-D structures available do not share complete similarity with the tem-
plate. However, there may be similarities in the loop regions, which can be simu-
lated as loop structure of the new protein. The loop fragments are extracted from the 
searched protein database. Since each loop is defined by its length and particular 
atom co-ordinates of its residues, they can be indicated by using particular algo-
 
135   For a detailed description see Griesinger, Christian, Proteinstruktur-Aufklärung durch 3D-
NMR-Spektroskopie, Laborwelt 2003, 10, 10ff; another description is provided by the Max-
Planck-Institute for biochemistry, available at:  
  http://www.cryst.bbk.ac.uk/PPS2/projects/schirra/ html/ home.htm, last checked October 12, 
2004. 
136   Maggio, Edward T./Ramnarayan, Kal, Recent developments in computational proteomics, 
19 Trends in Biotechnology 2001, 266-272, providing a general review about computational 
proteomics. 
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rithms. Since the templates fail to provide the structural information of many protein 
side chains, these can therefore not be assimilated in a first attempt and must be add-
ed later by further simulation. The amount of side chains required to be constructed 
depends on the degree of sequence identity between target and template protein. The 
method has its major weakness regarding protein divergences, which are not con-
nected to any typical homologous family. 137  
III. Data and Bioinformatics for proteomics 
1. Databases 
To catalogue all human proteins and reveal their function and interaction is an im-
mense challenge for scientists. The number of databases providing biological infor-
mation is steadily increasing.138 A new discipline, bioinformatics, has emerged to 
utilize the information in these databases for a better understanding of biological 
processes. Bioinformatics scientists work to interpret experimental data. Several se-
quence and sequence-related databases are available for public use. Additionally, a 
number of specialized databases exist which focus on a single enzyme, protein fami-
ly or disease.139 For amino acid sequences, the databases differ in their content. 
SWISS-Prot, established in 1986, strives to provide a high level of protein annota-
tion with several cross-links to other databases.140 Since 2003, it has been carried out 
by the UniProt Consortium, a collaboration between the Swiss Institute of Bioinfor-
matics (SIB) and the Department of Bioinformatics and Structural Biology of the 
Geneva University, the European Bioinformatics Institute (EBI) and the Georgetown 
 
137   Maggio, Edward T./Ramnarayan, Kal, Recent Developments in Computational Proteomics, 
19 Trends in Biotechnology 2001, 266, 271.  
138   Detailed overview of bioinformatics techniques of importance in protein analysis is provided 
by: Persson, Bengt, Bioinformatics in protein analysis, In: Proteomics in Functional Genom-
ics - Protein Structure Analysis; Jollès, P./Jörnvall, H. Ed. Basel, Boston, Berlin, 2000; 215. 
Access to most protein databases is free. Recently, however, many providers stopped grant-
ing open access and started requiring licenses from commercial users. In the future, even 
academic users might have to register and pay. Goodman, Phillip, Access Ability, Genome 
Technology 2004, 21. Carugo, Oliviero/Pongor, Sàndor, The Evolution of Structural Data-
bases, 20 Trends in Biotechnology 2002, 498 emphasize that the evolution of structural da-
tabases has been driven by the practical application of structural knowledge.   
139   Links to biologically relevant databases are available at the web pages of EBI (European 
Bioinformatics Institute, Hinxton, England; http://www.ebi.ac.uk), the University of Geneva, 
Switzerland (http://www.expasy.ch), and NCBI (National Center for Biological Information, 
Bethesda, MD, USA; http://ncbi.nlm.nih.gov).  
140   An annotation gives a narrative description to the formal structure of a protein, Carugo, Oliv-
iero/Pongor, Sàndor, The Evolution of Structural Databases, 20 Trends in Biotechnology 
2002, 498, 498. 
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University Medical Center's Protein Information Resource (PIR).141 TrEMBL, which 
stands for Translated EMBL, is another large protein database, carried out by 
EBI/EMBL142. It is constituted in the same format as Swiss-Prot. It consists of 
computer translations of genetic information contained in the EMBL Nucleotide 
Sequence Database,143 which are not yet integrated in SWISS-PROT. PIR (Protein 
Information Resource),144a U.S. protein related organization, has established the 
Protein Sequence Database (PSD) that contains functionally annotated protein se-
quences, which grew out of the “Atlas of Protein Sequence and Structure” (1965-
1978) edited by Margaret Dayhoff. 145Apart from that, GenPept is a database, which 
contains translated protein-coding sequences, which were produced by translating 
open reading frames from GenBank, the NIH genetic sequence database.146 Fur-
thermore, 3-D structures of biological macromolecules are collected in the Protein 
Data Bank (PDB) maintained by the Research Collaboratory for Structural Bioin-
formatics (RCSB).147 More recently, another data resource has been initiated in In-
 
141   Available at http://www.expasy.org/sprot/sprot_details.html, last checked on January 21, 
2008.  
142   The European Molecular Biology Laboratory is a non-profit organization and a basic re-
search institute funded by public research monies from 20 member states. Research at 
EMBL is carried out by approximately 80 independent groups covering the whole spectrum 
of molecular biology. The Laboratory is divided into five units: the main Laboratory in Hei-
delberg, and Outstations in Hinxton (the European Bioinformatics Institute), Grenoble, 
Hamburg, and Monterotondo in the Rome region. The key issues of EMBL's work are: to 
perform basic research in molecular biology, to train scientists, students and visitors at all le-
vels, to provide crucial services to scientists in the member states, and to develop new in-
struments and methods in the life sciences, and technology transfer. The European Bioin-
formatics Institute (EBI) is associated with EMBL.  
  See http://www.embl-heidelberg.de/aboutus/index.html, last checked on January 20, 2008.  
143   The EMBL Nucleotide Sequence Database (also referred to as EMBL-Bank) is Europe’s 
primary nucleotide sequence collection. The DNA and RNA sequences are mainly obtained 
from submissions of individual researchers, genome sequencing projects, and patent applica-
tions. The database is maintained in an international collaboration with GenBank (USA) and 
the DNA Database of Japan (DDBJ), available at http://www.ebi.ac.uk/embl/, last checked 
on January 21, 2008.  
144   Further information on the Protein Information Resource center is available at: 
http://pir.georgetown.edu/, last checked on January 21, 2008. 
145   Dayhoff, M. O., Eck, R. V. and Park, C. M. Atlas of Protein Sequence and Structure, Vol. 5, 
75, London 1979, published by National Biomedical Research Foundation (NBRF).  
146   GenBank contains a collection of all publicly available DNA sequences, which are released 
at the NCBI ftp site, available at ftp://ftp.ncbi.nih.gov/genbank/gbrel.txt, last checked on 
January 21, 2008. Open Reading Frames (ORFs) are DNA protein-coding sequences, which 
devoid of stop codons and are therefore suitable for RNA polymerase, see Alberts, 
Bruce/Johnson, Alexander.Lewis, Julian, Molecular Biology of the Cell (4th ed.), New York 
2002, 110-111. 
147   Available at http://www.pdb.bnl.gov.; the PDB is common ancestor of all structural data-
bases. It was established in 1971. Over the years, the quantity, phenotype and quality of the 
deposited structures have changed due to new experimental techniques. A good description 
is provided by Carugo, Oliviero/Pongor, Sàndor, The Evolution of Structural Databases, 20 
Trends in Biotechnology 2002, 498, 499. 
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dia, where the “Institute of Bioinformatics” (founded in 2002) works to establish the 
“Human Protein Reference Database” (HPRD)148 – “a centralized platform to visual-
ly depict and integrate information pertaining to domain architecture, post-
translational modifications, interaction networks, and disease association for each 
protein in the human proteome.” Most of the protein annotation data it contains is 
more or less redundant with SWISS-Prot; the interaction data, however, goes far 
beyond. It is set apart by manual curation, which means a reliable way to control 
quality compared to other databases that are created by automatic processes. So far, 
none of the existing databases can be considered an established standard, in fact all 
are still in their early stages. Hence, the existing variety offers scientists the possibil-
ity of choosing instead of imposing one database by default. The latest accomplish-
ment of a ‘Human Proteome Atlas for Normal and Disease Tissue, established by 
the Swedish Human Proteome Resource (HPR) program, funded by the Knut and 
Alice Wallenberg Foundation, however, represents a highlight of proteomics endea-
vor that might set new standards for proteomic research.149  
2. Cross-linking of database information 
In 2000, the Swiss Institute of Bioinformatics (SIB) and the European Bioinformat-
ics Institute (EBI) founded the Human Proteomic Initiative (HPI) with the major 
goal to annotate, describe and distribute a large amount of information concerning 
human protein sequences to the life science community. Being aware of the huge 
complexity of the proteome, the initiative aims to annotate all known human se-
quences according to the quality standards of SWISS-Prot. These standards include 
more than 9000 annotated human sequences associated with about 23200 literature 
references; 22600 experimental or predicted PTM's, 2800 splice variants and 15100 
polymorphisms. The interpretation of all known human sequences for each known 
protein includes a wealth of information. It refers to the description of its function, 
domain structure, subcellular location, post-translational modifications, and variants 
or similarities to other proteins. The HPI project contains a number of sub-
components, such as  
 
 Analysis of all known human proteins, 
 analysis of mammalian orthologs150 of human proteins,  
 analysis of all known human polymorphisms at the amino acid level,  
 
148   Genome Technology 10, 2003, 16. 
149  The protein atlas aims to demonstrate the expression and localization of proteins in large va-
riety of normal tissue and cancer cells. The basic concept of the resource centre is to produce 
antibodies to human target proteins. The antibodies are subsequently used for functional 
analysis of the corresponding proteins in numerous further platforms.  
  See http://proteinatlas.org/, last checked on January 21, 2008.  
150   Proteins orthologs are proteins that have evolved from the same inherited region. 
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 analysis of all known post-translational modifications in human proteins, 
 tight links to structural information, and the 
 classification of all known vertebrate proteins.151 
3. Database screening and drug design  
The structure-based screening approach aims to identify a subset of an existing or a 
virtual library of compounds with an enhanced probability of binding. Typically, the 
first step of drug development is the selection of an adequate target. When a high-
quality structure is available for investigation, it can be used to screen databases or 
libraries of existing chemical substances. The screening process will then select 
those substances containing an array of chemical groups compatible with binding to 
the targeted binding pocket of the protein. 
Compounds possessing the desired binding characteristics are analyzed in further 
tests. If the tested effect is confirmed, it is examined to determine whether the com-
pound is pharmaceutically acceptable and toxicologically safe. If the drug succeeds, 
auxiliary substances are added for the final stage of the pharmaceutical process.152 
Drug development research using 3-D structure information can be illustrated using 


















151   The web-page of HPI is available at http://www.expasy.org/sprot/hpi/hpi_desc.html, last 
checked on January 21, 2008.  
152   Maggio, Edward T./Ramnarayan, Kal, Recent Developments in Computational Proteomics, 
19 Trends in Biotechnology 2001, 266, 271. The process of drug discovery involves im-
mense labors. For views from inside the pharmaceutical industry, see Mervis, Jeffrey, The 
Hunt for a New Drug: Five Views from the Inside, 309 Science 2005, 722, 722.  
153   The figure was adopted from Masuoka, Kunihisa, Study on the Ways of Protection of Post-
Genome Research Products, IIP Bulletin 2002, 84, 87.  
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Figure 8: Stylized illustration of proteomic drug design 
4. In-silico screening of binding pockets 
In-silico154 screening methods are methods that aim to scan chemical/ pharmaceuti-
cal compounds for new drug design. They involve the computerized simulation of 
the three-dimensional structure of a polypeptide. The simulated protein is then used 
to screen several pharmaceutical compound-related databases. In order to determine 
the pharmaceutical/chemical response of binding pocket properties the screening 
methods comprise several steps. These include the application of 3-D molecular 
modeling algorithm to the atomic coordinates of a protein, the determination of the 
spatial coordinates of binding pockets, and the electronic screening of candidate 
compounds against the spatial coordinates of the protein. The major goal is to identi-
fy compounds that can bind to the computerized protein. More precisely, the mole-
cular model simulates the positions of heteroatoms in the amino acids, which form 
the binding pockets of the protein. It also includes information about hydrogen 
 
154   From literally: ‘in the computer’. 
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bonds. The coordinate data of the computerized protein is then incorporated in the 
database such that the interatomic distances between the atoms of the simulated pro-
tein is retrieved. In a further step, the distances between the bonding of different 
candidate compounds and the atoms that bind in the computerized protein model are 
compared. Thereby, it is possible to identify those candidate compounds that would 
theoretically form the most stable complex with computerized 3-D model.155 The 
obtained ligands can efficiently be used for the development of new drugs.156 
In-silico screening methods replace the traditionally used in vitro157 methods, 
which were generally based on a ‘trial and error’ approach. The Human Genome 
Project and the improvement of protein analysis techniques has lead to a dramatic 
increase in the information to be interpreted. The method of in vitro research thus 
became too expensive and time consuming. However, since an in-silico screening is 
only hypothetical and based on simulated structures, it always requires in vitro test-
ing of useful identified compounds in order to verify that the underlying technical 
problem of finding an appropriate agent has indeed been solved. Consequently, a 
biological evaluation of the obtained compounds is necessary.158 
 
155   A good overview is provided by Gnanakaran, S./Nymeyer, Hugh/Portman, John/ Sanbon-
matsu, Kevin Y./Garcia, Angel E., Peptide Folding Simulations, 13 Current Opinion in 
Structural Biology 2003, 168.  
156   See note: Innovatives in-silico Verfahren beschleunigt Wirkstoffsuche, Transkript 2004, 28, 
emphasizing that most recent in-silico methods rely upon protein structure homology for the 
search of new compounds.  
157   In an artificial environment outside a living organism or body, for example, testing con-
ducted in the laboratory. 
158   Lonati, Milena, Patentability of Receptors and Screening Methods: Does in silico Screening 
Pose New Legal Problems? Bioscience Law Report 2000/2001, 144, 145. 
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Chapter 3: Patentability Requirements 
A. Statutory Background and Fundamental Case Law in Europe and the U.S. 
I. Introduction 
As outlined in chapter II above, the tertiary structure is the single most important 
determinant of a protein’s biological function.159 Research related to drug design 
that is conducted on grounds of the tertiary folding type has a more reliable basis 
than studies that solely involve the knowledge of primary structures. The goal of this 
chapter is to provide an overview of the legal terrain faced by those seeking to pa-
tent protein 3-D structure related claims. The requirements of the patentability of 
proteomic claims depend on statutory background on the one hand and existing case 
law related to chemical, biotechnology and software inventions on the other. Thus, 
as a first step, the applicable law will be presented regarding the patentable subject 
matter, industrial application/utility, specification/written description, enablement 
and novelty and/or inventive step. 
Next, the major case law will be examined. Cases related to biotechnological ma-
terial will be used to exemplify how patent law systems have coped with the new 
genomic technologies. Since proteins are considered chemical compounds, the legal 
treatment of molecular structures will also be reviewed. One particular focus will be 
the patenting of primary structure-related protein inventions, where problems have 
mainly occurred regarding the novelty and inventive step requirement. Patent ex-
aminers have resolved these issues by applying certain principles, which will be de-
veloped in detail below. Such a comprehensive description will form the basis of 
subsequent chapters, which discuss the applicability of traditional patent law stan-
dards to 3-D, or proteomic, structures. 
II. Applicable law in the U.S. and Europe 
In order to be granted a patent in compliance with American patent law, at least the 
following criteria must be met: subject matter eligibility and utility (35 U.S.C. § 
101), written description (35 U.S.C. § 112 1), enablement (35 U.S.C. § 112 1), clari-
ty (35 U.S.C. § 112 2) novelty, no loss of rights (35 U.S.C. § 102), and non-
obviousness (35 U.S.C. § 103). European patents are granted for any invention that 
is susceptible to industrial application, is new and involves an inventive step (Art. 52 
I EPC). According to the practice of the EPO, an invention as understood in patent 
 
159   See at Chapter 1 B II 2.  
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law is a “practical teaching, which requires the claimed subject-matter or activity to 
have a technical character, and which is capable of being realized and repeatable and 
provides a solution to a problem based on technical consideration.”160 
1. Patentable Subject Matter 
a) U.S. 
The fundamental principle of U.S. patent law is that one may patent that which is 
new. According to § 101, a patentable subject matter is determined as “any useful 
process, machine, manufacture, or composition of matter, or any new and useful im-
provement thereof”.161 As for the patenting of genes or proteins in the human organ-
ism, the intuitively appealing objection is that they themselves are not new. The hu-
man genome and the encoded proteins have existed in humans apart from any inven-
tive effort of anyone who might seek to patent them.162 The reasoning in Funk 
Brothers Seed Co. v. Kalo Inoculant Co. in 1948 was based on this argument.163 The 
Supreme Court found the patent claims that were directed to a mixed culture of dif-
ferent strains of bacteria invalid and argued that patents cannot be issued for the dis-
covery of a phenomenon of nature 
“The qualities of these bacteria, like the heat of the sun, electricity, or the qualities of metals, 
are part of the storehouse of knowledge of all men. They are manifestations of law of nature, 
free to all men and reversed exclusively to none.”164 
In light of a broad reading of Funk Brothers, DNA sequences and human proteins 
could not be considered as patentable subject matters. Although the Funk Brother 
decision never has been officially overruled, subsequent patent law does not deny 
the patentability of all inventions consisting of naturally occurring products or laws 
of nature. In the 1980 decision of Diamond v. Chakrabarty165, the Supreme Court 
again touched the question of patentability of biotechnological inventions. The pa-
tent claim referred to living microorganisms into which the inventor had introduced 
multiple naturally occurring plasmids. These rings of bacterial DNA encompassed 
genetic information that resulted in the organism’s ability to break down multiple 
components of crude oil. The USPTO found the plasmids not to be “products of na-
ture”, since bacteria containing the introduced plasmids did not occur in nature. 
Nevertheless, it rejected the claims on the ground that living organisms as such 
 
160   Schulte/Moufang, PatG mit EPÜ, § 1, No. 19. 
161   Chisum, Donald/Nard, Craig Allen/Schwartz, Herbert F./Newman, Pauline/Kieff, F. Scott, 
Principles of Patent Law, New York 2001, Chapter 3. 
162   Eisenberg, Rebecca, Patenting the Human Genome, 39 Emory Law Journal 1990, 721, 723. 
163   Funk Brothers Seed Co. V. Kalo Inoculat Co., 333 U.S. 127 (1948). 
164   Funk Brothers Seed Co. V. Kalo Inoculat Co., 333 U.S. 127, 130.  
165    Diamond v. Chakrabarty, 447 U.S. 303 (1980).  
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would not be patentable subject matter.166 The Supreme Court concluded that a liv-
ing, genetically modified organism may be patentable as a new “manufacture” or 
“composition of matter” under section 101. The Court distinguished Funk Brothers 
on the grounds set forth as follows: while the patent holder in Funk Brothers had not 
modified the function of any of the species of root-nodule bacteria in the mixed-
culture inoculant, Chakrabarty had formed “a new bacterium with markedly differ-
ent characteristics from any found in nature”. The discovery thus was “not nature’s 
handiwork, but his own; accordingly it is patentable subject matter ….” In order to 
support this wide range of the categories of patentable subject matter, the Court re-
lied on the language from committee reports accompanying the 1952 Patent Act, to 
the effect that Congress intended statutory subject matter to “include anything under 
the sun that is made by man.” The question of distinguishing patentable subject mat-
ter and products of nature depends on whether the claimed invention is the result of 
human invention. With regard to human DNA sequences, one might still reason that 
they should not be patentable as such, although they might be a patentable subject 
matter in the creation of recombinant material that incorporates human genes. Nev-
ertheless, a substantial amount of case law concludes that newly isolated or purified 
materials may be patented even though those materials exist in nature in an impure 
state. As long as the purified material offers some advantages, it is sufficient that a 
patent applicant has made the sequences available in an isolated or purified form 
that does not exist in nature.167 In Merck & Co. v. Olin Mathieson Chemical Corp., a 
patent was granted on purified vitamin B12 isolated from fermentation materials. 
The Court upheld the validity of the patent, arguing that the patent product was ad-
vantageous to the previously available vitamin B12 from cattle due to its relatively 
abundant supply, cheap price, freedom from toxic substances, and amenability to 
control potency and dosage. As a whole, the Courts’ reasoning suggested that there 
should be no bar to patenting a “product of nature” assuming the invention is new, 
useful, falls within the categories of patentable subject matter under section 101, and 
complies with all further statutory patent requirements.168 
In sum, Diamond v. Chakrabarty opened the door for the patenting of biological 
material. It thus can be considered as a decisive step in the rise of the biotechnologi-
cal industry. Its economic implications have indeed been much further reaching than 
those of the German Red Dove decision, which will be discussed next.169  
 
166   Eisenberg, Rebecca, Patenting the Human Genome, Emory Law Journal, 39 Emory Law 
Journal 1990, 721, 725. 
167   Eisenberg, Rebecca, Patenting the Human Genome, 39 Emory Law Journal 1990, 721, 726-
727. 
168   Merck & Co. V. Olin Mathieson Chemical Corp. 253 F.2d 156 (4th Cir. 1958). 
169   Straus, Joseph, Biotechnology and Patents, 54 Chimia 2000, 293, 293.  
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b) Europe 
aa) Patentability of biological material 
In Europe, for many decades, inventions involving biological material were not con-
sidered patentable on grounds that they were not ‘technical’ but ‘a product of na-
ture’. This approach has been radically changed by the landmark decision of Red 
Dove170, where the patent application was directed to a method for breeding a dove 
with red plumage.171 The German Federal Supreme Court clearly extended the field 
of technology so as to cover biological phenomena and forces, defining them as  
“… [a] teaching to methodically utilize controllable natural forces to achieve a causal, per-
ceivable result, …, provided that teaching meets the general prerequisites of industrial applica-
tion, novelty, [etc.].”172 
The court reasoned that there generally are three possibilities of biological inven-
tions that have been considered patentable in theory and practice: 
-If the course of biological events is affected with means other than animate matter; 
- if inanimate matter is influenced by biological means and 
- if the means as well as the final result lie within the field of biology. 
The patent application at issue belonged to the third category of possibilities in 
which a biological result is obtained either solely by or primarily as the result of bio-
logical means. Thus, patentability would in principal be possible. Nevertheless, it 
was necessary that the method of breeding be recurrent. Lacking such requirement, a 
patent could not be granted. Although a patent was not granted for the claim at issue, 
the decision clearly approved the patentability of biological inventions as eligible 
subject matters. 173 
With the goal of providing high and harmonized standards of protection for bio-
technology comparable to those in the U.S. and Japan, the European Commission 
adopted the Directive on the Legal protection of Biotechnology Inventions 
(98/44/EC) (‘the Directive’) in 1998.174 The Directive, which became effective on 
 
170   BGH, 1 IIC 136 (1970) - Red Dove (Rote Taube); see also Herrlinger, Karolina A., Die Pa-
tentierung von Krankheitsgenen: dargestellt am Beispiel der Patentierung der 
  Brustkrebsgene BRCA 1 und BRCA 2, München 2005, 115.  
171   Straus, Joseph, Biotechnology and Patents, 54 Chimia 2000, 293, 293; the “Red Dove case” 
also is the starting point for the modern jurisdiction on the patentablility of biological inven-
tions in Germany, Straus, Joseph, Patenting Human Genes in Europe - Past Developments 
and Prospects for the Future, 26 IIC 920, 920 (1995); Benkart/Melullis, EPÜ, Art. 53, No. 
44.  
172   BGH 1 IIC 136, 137 (1970) - Red Dove (Rote Taube); see also Busse/Keukenschrijver, 
PatG, § 1, No. 24.  
173   BGH 1 IIC, 137ff (1970) - Red Dove (Rote Taube). 
174   Benkard/Schäfers, PatG, § 34 No. 37e; Jaenichen, Hans-Rainer/Mcdonell, Leslie A./Haley, 
James F., Jr., From Clones to Claims, Cologne, Berlin, Bonn, Munich 2002, 2; Straus, Jo-
seph, Biotechnology and Patents, 54 Chimia 2000, 293, 295. 
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July 6, 1998, strikes a balance between the commercial needs of scientists and in-
dustry and the ethical concerns of some of the public that strongly opposed the idea 
of patenting living material.175 The contracting states of the EU were supposed to 
put the Directive into practice within two years of the date of publication by chang-
ing the national practice and law where necessary. Irrespectively, the process of im-
plementation in each of the member states took much longer than expected. After 
three years, only four member states, United Kingdom, Finland, Denmark and Irel-
and, had actually put the rule into practice. The European Court of Justice rejected 
an action of annulment against the Directive that was filed by the Netherlands and 
supported by Italy and Norway.176 In 2004, Germany was convicted by the European 
Court of Justice for having failed to implement the Directive into national law. Con-
sequently, the German legislature reacted and implemented the Directive in Febru-
ary 2005 by amending the German Patent Act.177  
With the EPO not being linked to the European Union, the Directive does not 
have any direct influence on the EPC.178 However, in order to harmonize the EPO’s 
practice with the EU Directive, the Implementing Regulations to the EPC were 
amended by a decision of the Administrative Council of the European Patent Organ-
ization on June 16, 1999. For this amendment, the EPO introduced several new 
rules. On December 13, 2007, a revised version of these rules entered into force.179 
To incorporate the Directive into the EPC, the EPO introduced Rule 26 (former 23b) 
(General and definitions), Rule 27 (former 23c) (Patentable biotechnological inven-
 
175   As for the concerns of the different groups of interest in Germany, see particularly ‘Entwurf 
eines Gesetzes zur Umsetzung  der Richtlinie über den rechtlichen Schutz biotechnologisch-
er Erfindungen’, Bundestagsdrucksache 14/5642 (November 23, 2001), 1-24 (reasons and 
statements provided by the German Federal Council and the German Federal Government; 
see also Straus, Joseph, Biotechnology and Patents, 54 Chimia 2000, 293, 295. 
176   EuGH C-377/98 in: GRUR Int 01, 1043 = BIPMZ 01, 357 Biotechnology Directive; see also 
Schulte/Moufang, PatG mit EPÜ, § 1 No. 79. According to the French view, the patenting of 
human genes is violating human dignity. Consequently, France rejected the implemenation 
of the rule into its national law and asked the Commission to reconsider the Directive. In a 
statement that strongly supported this policy, the French National Committee on Ethics in 
the Life and Health Sciences summarized the underlying considerations. For example, it 
stated: “L'exigence qui porte à exclure cette connaissance du gène de la brevetabilité rejoint 
deux autres préoccupations éthiques le souci de maintenir le corps humain, ses éléments et 
ses produits hors des circuits marchands, l'apparition d'une aspiration au partage des bienfaits 
attendus de la connaissance du genome,” Comité Consultatif National d'Ethique pour les 
sciences de la vie et  de la santé, "Avis sur l'avant-projet de loi portant transposition, dans le 
code de la propriété intellectuelle de la directive 98/44/CE du Parlement européen et du Con-
seil, en date du 6 juillet 1998, relative à la protection juridique des inventions biotechnologi-
ques," 8 Juin 2000, para 6), available at http://www.ccne-ethique.fr/francais/start.htm, last 
checked on December 10, 2006. 
177   The details of the European Court of Justice’s verdict and of the German Patent Act amend-
ment will be discussed in Chapter IV D below. 
178   Benkard/Melullis, EPÜ, Art. 53, No. 39; Straus, Joseph, Biotechnology and Patents, 54 
Chimia 2000, 293, 295.  
179   Decision of the Administrative Council, Act revising the European Patent Convention of 29 
November 2000.  
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tions), Rule 28 (former 23d) (Exceptions to patentability) and Rule 29 (former 23e) 
(The human body and its elements).180 Rule 26(1), second sentence (former 23 b (1)) 
establishes the general principle that the Directive “shall be used as a supplementary 
means of interpretation” of the EPC.181 The basic principles of the Directive are 
listed in Recitals 35-46. These include the exclusion from patentability for processes 
for treatment of the human or animal body by surgery or therapy and diagnostic me-
thods (Recital 35) and the guarantee of ordre public or morality (Recitals 37 and 
39). The Directive also contains a commitment to the special importance of the “eth-
ical clause”, where it is indicated that all ethical aspects of biotechnology must be 
interpreted in light of the specified principles of patent law and specifically eva-
luated by the Commission’s European Group on Ethics in Science and new Tech-
nologies (Recital 44).182 With regard to biological material, the Directive confirms 
the practices that were approved in the German Red Dove decision by introducing 
the patentability of biological material or processes.183 The principle applies also to 
biological material, provided it is isolated from the natural environment or produced 
by means of a technical process (Art. 2(1)(a)(Rule 23b (3) EPC; Art. 3(1) (2); Rule 
27(a) EPC (former Rule 23c (a)).184 
bb) Exclusions from patentability  
The approach to what constitutes patentable subject matter can be considered a ma-
jor difference between the European and the U.S. patent law system. As illustrated 
in Diamond v. Chakrabarty, the U.S. Patent Act does not contain any specific exclu-
sions or exceptions from patentability.185 Rather, the courts are responsible for set-
ting the limits inherent in the principles of the patent system. In contrast, European 
patent law is characterized by several of such exclusions and exceptions and many 
are specifically directed to the field of biotechnology.186  
Section 52 EPC excludes certain matters from patentability. Items on this list in-
clude, in particular, discoveries, scientific theories, mathematical methods, aesthetic 
 
180   Jaenichen, Hans-Rainer/Mcdonell, Leslie A./Haley, James F., Jr., From Clones to Claims, 
Cologne, Berlin, Bonn, Munich 2002, 3. 
181   Schulte/Moufang, PatG mit EPÜ, § 1, No. 6, citing Rule 23b(1) Second Sentence; see also 
Straus, Joseph, Biotechnology and Patents, 54 Chimia 2000, 293, 295.  
182   For the “ethical dimension of the patent law system” as expressed in Art. 53(a) EPC see 
Moufang, Rainer, Patentierung menschlicher Gene, Zellen, und Körperteile? - Zur ethischen 
Dimension des Patentrechts, GRUR 1993, 439, 442. Despite Art. 53(a) EPC the European 
Patent Office issued large numbers of gene patents without raising any ethical issues; Straus, 
Joseph, Patenting Human Genes in Europe - Past Developments and Prospects for the Fu-
ture, 26 IIC 920, 926 (1995).  
183   Schulte/Moufang, PatG mit EPÜ, § 1 No. 86.  
184   Straus, Joseph, Biotechnology and Patents, 54 Chimia 2000, 293, 295.  
185   Diamond v. Chakrabarty, 447 U.S. 303 (1980), see Chapter 3 A II 1 a).  
186   Schulte/Moufang, PatG mit EPÜ, § 1 Nos. 86ff, see also Straus, Joseph, Biotechnology and 
Patents, 54 Chimia 2000, 293, 294.  
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creations, schemes, rules and methods for performing mental acts, playing games or 
doing business, programs for computers and presentations of information.187 Lack-
ing a technical character, a discovery does not provide a practical teaching and is 
therefore not patentable. 188 This is particularly relevant for inventions involving 
biotechnological substances. Under the foregoing definition, the revealing of a pre-
viously unrecognized substance occurring in nature is a mere discovery. If the patent 
applicant, however, shows in which way the substance was isolated from its natural 
environment or how a technical process had produced it, patentability is established. 
Thus, the mere description of biological material is not sufficient. If a repeated suc-
cess in isolating a biological substance, like a protein or a gene, is not guaranteed, 
the invention does not establish a technical teaching and lacks patentability.189 The 
disclosed technical teaching, i.e. the isolation of the biological substance, must be 
repeatable.190  
The House of Lords’ decision in the case of Asahi Kasei Kogyo’s Application can 
be considered decisive for determining the threshold for genetic sequences disclo-
sures.191 Here, the application in suit [the ‘Asahi-Application’] disclosed and 
claimed a physiologically active polypeptide produced by genetic engineering and 
useful in treating human tumors. The Asahi-Application was rejected by the Patent 
Office on the grounds that they lacked novelty in view of a co-pending application. 
The co-pending application was filed after the priority date of the application in suit 
but claimed priority from an earlier application, which disclosed and claimed the po-
lypeptide but failed to explain how to obtain and how to use the genetic sequences 
coding for it. The applicant appealed to the English House of Lords asserting that 
the co-pending application was not an effective anticipation because the only docu-
ment of earlier priority did not contain an enabling disclosure.192 The House of 
Lords concluded that, for anticipation “published information is required to contain 
an enabling disclosure.” An invention is “not made available to the public merely by 
a published statement of its existence, unless the method of working is so self-
evident as to require no explanation.”193 As for the description of the polypeptide, 
 
187   Guidelines for Examination in the EPO, Part C-IV, § 2, available at 
   http://www.epo.org/patents/law/legal-texts/guidelines.html, last checked on 
   January 21, 2008. The list established in Art. 52 EPC is not complete, but is seen to provide 
a number of examples, see Busse/Keukenschrijver, PatG, § 1, No. 39. 
188   Singer/Stauder, EPC, Vol 1, Art. 52, No. 24.  
189   Schulte/Moufang, PatG mit EPÜ, § 1 No. 93. A patent applicant establishes patentability for 
natural substances if he provides “the discovery of a technical application of the discovery.” 
The patent is granted, because the substance was “previously not available.” Therefore, the 
public is not being denied access to something previously accessible; see Singer/Stauder, 
EPC, Vol 1, Art. 52, No. 25. 
190   Schulte/Moufang, PatG mit EPÜ, § 1 No. 98.   
191   Asahi Kasei Kogyo’s Application, [1991] R.P.C. 485 (House of Lords). See also Cornish, 
William/Llewelyn, David, Intellectual Property: Patents, Copyright, Trade Marks and Allied 
Rights, 6th ed., London 2007, 190.  
192   Asahi Kasei Kogyo’s  Application, [19 91], R.P.C. 485, 486.  
193   Asahi Kasei Kogyo’s Application, [1991], R.P.C. 485, 486. 
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the court stated “[f]or a chemical product (as what the polypeptide was treated) the 
invention does not consist in the formula itself, but in a description of a method”, 
because a person skilled in the art will need to know “a method by which it can be 
produced.”194 In light of these principles, the co-pending application did not destroy 
the novelty of the Asahi-application, since it failed to provide any methods for pre-
paring the claimed polypeptide.195 
Further, Directive 98/44/EC implements the principle of non-commercialization 
of the human body.  Art. 5(1) states that “[t]he human body, at various stages of its 
formation and development, and the simple discovery of one of its elements, includ-
ing the sequence or partial sequence of a gene” are excluded from patentability. The 
Implementing Regulations to the EPC, Rule 29 EPC (former 23e (1) EPC) follows 
this standard.196 However, an element isolated from the human body or otherwise 
produced in the course of a technical process, which is industrially applicable, may 
be eligible as a patentable subject matter, even if the structure of that element is 
identical to that of a natural element. As set forth above, biological material that is 
isolated from its natural environment or produced in the course of a technical 
process may be patentable.197 Non-isolated genes in their natural environment, by 
contrast, are considered mere discoveries.198  
With regard to computerized methods of protein analysis, the exclusion of com-
puter programs plays an important role. The question will be addressed in the course 
of the following case study. At this point, it has already been stressed that exclusions 
are only made if the listed subject matters are claimed “as such”.199 The former ver-
sion of Art. 52(4) EPC stated that methods for treatment of the human or animal 
body by surgery or therapy and diagnostic methods practiced on the human or ani-
mal body are not susceptible to industrial application and therefore excluded from 
patentability.200 The exclusion does not apply to certain products, e.g., pharmaceuti-
cals, which are considered industrially applicable even if used for medical treat-
ment.201 In light of the fact that the provision was found to be systematically incor-
 
194   Asahi Kasei Kogyo’s Application, [1991], R.P.C. 485, 486. 
195   See Tumour Necrosis Factor, 2 IIC 247 (1993), particularly the comment by Rainer Mou-
fang in the same issue who notes that in the light of the House of Lords’ decision, a patent 
application referring to biological material anticipates later filed applications if others “under 
no obligation of confidentiality had access to the said material at the critical date,” at 258. 
196   Ahrens, Claus, Genpatente - Rechte auf Leben? Dogmatische Aspekte der Patentierbarkeit 
von Erbgut, GRUR 2003, 89, 91. 
197   Guidelines for Substantive Examination, Part C-IV, § 2a.2 available at 
   http://www.epo.org/patents/law/legal-texts/guidelines.html, last checked on January 21, 
2008  
198   Krefft, Alexander Richard, Patente auf human-genomische Erfindungen: Rechtslage in 
Deutschland, Europa und den USA, München 2003, 266.   
199   As for the difficulties that exist with the interpretation of the term “as such”, see 
Busse/Keukenschrijver, PatG, § 1, No. 41. 
200   Busse/Keukenschrijver, PatG, § 5, No. 19. 
201   Methods which are employed outside the human body (ex vivo), on a blood or other sample 
also do not fall under the definition of diagnostic methods practised on the human body, 
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rect - since methods are excluded on public interest grounds and not due to the lack 
of industrial patentability202 - the 2000 revision of the EPC, put into force on De-
cember 13, 2007, cancelled the rule. What used to be the rule under Art. 52(4) EPC 
is now added as c) under Art. 53 EPC:  
“European patents shall not be granted in respect of: c) methods for treatment of the human or 
animal body by surgery or therapy and diagnostic methods practiced on the human or animal 
body; this provision shall not apply to products, in particular substances or compositions, for 
use in any of these methods.” 
2. Utility and Industrial Applicability 
a) U.S. (Utility) 
Two statutory provisions establish the framework for analyzing the utility require-
ment. As recited in 35 U.S.C. § 101:  
“Whoever invents or discovers any new and useful process, machine, manufacture, or compo-
sition of matter, any new and useful improvement thereof, may obtain a patent therefor, sub-
ject to the conditions and requirements of this title.” 
The second provision with regard to the utility requirement is 35 U.S.C. § 112. It is 
related to the disclosure the patent applicant is obliged to make. Section 112, first 
paragraph explicitly requires a patent specification to disclose “the manner and 
process of making and using [the invention].” The concrete meaning of these two 
phrases has largely been developed by the courts. As for chemical research, chemi-
cal scientists often develop a chemical substance without a particular purpose in 
mind. Often, chemical compounds are synthesized which are believed to be useful 
some day for something, but for which no particular use is currently known. As for 
biotechnology, scientists may isolate interesting genes or gene fragments whose use 
is not known or completely analyzed. Sometimes researchers are able to understand 
that genes are triggered in many diseased cells, even though the protein that the gene 
is encoding is yet unknown.203 
In 1999, the office issued the Revised Utility Guidelines, as clarification of the fi-
nal Utility Examination Guidelines as published in 1995.204 These guidelines can be 
considered a direct reaction to public comments expressing doubts regarding the pa-
 
Bostyn, Sven J.R., Enabling Biotechnological Inventions in Europe and the United States: A 
Study of the Patentability of Proteins and DNA Sequences with Special Emphasis on the 
Disclosure Requirement, Munich 2001, 115. 
202   EPO, Special Edition No. 4, OJ 2007, 48.  
203   Merges, Robert Patrick/Duffy, John Fitzgerald, Patent Law and Policy: Cases and Materials, 
Newark, San Francisco, Charlottesville 2002, 229.  
204   1999 Revised Utility Guidelines, 64 Fed. Reg., 71440 (Dec. 21, 1999), which were published 
in response to comments regarding the earlier Guidelines, published at 60 Fed. Reg. 36263 
(1995).  
https://doi.org/10.5771/9783845221441, am 02.12.2021, 20:19:12
Open Access -  - http://www.nomos-elibrary.de/agb
 68
tentability of ESTs.  In particular, the PTO determined that it had received com-
ments that the 1995 Utility Guidelines would permit the patenting of ESTs “when 
the sole disclosed use of an EST is to identify other nucleic acids whose utility was 
not known, and the function of the corresponding gene is not known.”205 The 1999 
Revised Utility Guidelines also account for allegations that “PTO examination pro-
cedures would result in granting patents based on non-specific and non-substantial 
utilities, contrary to established case law.”206 Consequently, the 1999 Guidelines de-
termine that a “claimed invention must have a specific and substantial utility.”207 
The guidelines did not amend the rules of the 1995 Utility guidelines with regard to 
other aspects, such as “credibility” and “well-established” utility.  
In 2001, the USPTO again issued a new version of its guidelines on utility.208 The 
2001 Utility Guidelines provide a substantial amendment of the 1995 version.  Par-
ticularly, the guidelines require that utility is only created, if the utility of a patent 
application is “specific”, “substantial”, and “credible”.209  Furthermore, the 2001 
Utility Guidelines determine that - if it becomes apparent that an invention bears a 
“well-established utility” - the claim should not be rejected due to a lack of utility. A 
“well-established” utility is assumed if (a) a person skilled in the art would easily be 
able to determine why an invention is useful due to the properties of an invention, 
and (b) the utility is specific, substantial, and credible.210 As for a specific and sub-
stantial utility, the USPTO indicates that “throw-away”, “insubstantial”, and “non-
specific” utilities, such as the use of a complex invention as landfill are excluded.  
With regard to credibility, the guidelines held that “[c]redibility is assessed from the 
perspective of one of ordinary skilled in the art in view of the disclosure and any 
other evidence of record (e.g. test data, affidavits or declarations from experts in the 
art, patents or printed publications) that is probative of the applicant’s assertions.”211 
Thus, one must distinguish between applications defining an invention’s specific 
use and those indicating an ambiguous or unsubstantiated potential use. A general 
statement that a compound has “useful biological” properties and might aid in the 
treatment of some unnamed disorders is too vague to qualify as a specific utility. A 
“substantial utility” should establish a “real world” use. If a “real world” context for 
using the invention is not reasonably apparent from the record, then the asserted util-
ity is not substantial.212 It is inappropriate to label certain types of inventions as in-
capable of having a specific and substantial utility based solely on the setting in 
which the invention is used, for example, inventions used in a research or laboratory 
setting. Many research tools used in laboratory analysis and the assessment of com-
 
205   1999 Revised Utility Guidelines, 64 Fed. Reg. 71440, 71441. 
206   1999 Revised Utility Guidelines, 64 Fed. Reg. 71440, 71441.  
207   1999 Revised Utility Guidelines, 64 Fed. Reg. 71440, 71441. 
208   2001 Utility Guidelines, 66 Fed. Reg. 1092. (Jan. 5, 2001). 
209   2001 Utility Guidelines, 66 Fed. Reg. 1092, 1098.  
210   2001 Utility Guidelines, 66 Fed. Reg.1092, 1098.  
211   2001 Utility Guidelines, 66 Fed. Reg. 1092, 1098. 
212   Merges, Robert Patrick/Duffy, John Fitzgerald, Patent Law and Policy: Cases and Materials, 
Newark, San Francisco, Charlottesville 2002, 249. 
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pounds, such as gas chromatographs, screening assays, and nucleotide sequencing 
techniques, have a clear, specific, and substantial utility in a research or intermediate 
context. However, this evaluation alone does not focus on the invention’s overall 
utility in a patent sense. Instead, it is necessary to distinguish between inventions 
identifying a current and specific substantial utility and those requiring additional or 
future research to establish or verify usefulness. In this process, applicants’ use of 
labels such as “research tool”, “intermediate,” or “for research purposes” are not de-
terminative of whether the claimed invention has a specific, substantial and credible 
utility.213  
A number of cases illustrate how patent examiners and courts struggle with set-
ting the exact threshold for the utility requirement. In Brenner v. Manson214, the in-
ventor applied for a patent on an allegedly novel process for making certain known 
steroids. A patent examiner denied the application, and the denial was affirmed by 
the Board. The ground for rejection was the failure “to disclose any utility for the 
chemical compound produced by the process”.215 The failure was not cured, accord-
ing to the Patent Office, by the inventors reference to an scientific article revealing 
that steroids of a class, which included the compound in question, were undergoing 
screening for tumor-inhibiting effects in mice, and that a homologue adjacent to this 
steroid had proven effective in that role. The U.S. Supreme Court reconfirmed that 
one may patent only that which is “useful”. The reference to the article, however, 
could not create utility, since the “presumption that adjacent homologues have the 
same utility has been challenged in the steroid field because of a greater known un-
predictability of compounds in that field”.216 The court clearly stated that where the 
sole “utility” consists in its potential role as an object of use-testing, a practical or 
specific utility does not exist. A patent should be “no award for the search, but a 
compensation for its successful conclusion”.217   
In In re Brana, the applicants filed a patent application directed to compounds for 
use in combination with anti-tumor substances that were based on a specific chemi-
cal formula.218 The specification stated that the given substitutions produce com-
pounds with “better action and a better action spectrum than anti-tumor substances” 
established in a particular reference.219 The reference described a computer-assisted 
evaluation of specific chemicals which had been screened for anti-tumor activity by 
testing their efficacy in vivo. Further, in comparing the effectiveness of the claimed 
compounds with structurally similar compounds, the applicants’ patent specification 
disclosed the cytoxicity of the claimed compounds against human tumor cells, in 
 
213   Kunin, Stephen G/Nagumo, Mark/Stanton, Brina/Therkorn, Linda S./Walsh, Stephen, 
Reach-through Claims in the Age of Biotechnology, 51 American University Law Review 
April 2002, 609, 623. 
214   Brenner v. Manson, 383 U.S. 519 (1966). 
215   Brenner v. Manson, 383 U.S. 519, 521 
216   Brenner v. Manson, 383 U.S. 519, 532.  
217   Brenner v. Manson, 383 U.S. 519, 536.  
218   In re Brana, 51 F.3d 1560 (Fed. Cir. 1995). 
219   In re Brana, 51 F.3d 1560, 1562.  
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vitro, and held the opinion that these tests “had a good action”.220 The Court of Ap-
peals for the Federal Circuit concluded that the applicant’s disclosure complied with 
the requirements of 35 U.S.C. Section 112 (1). According to the court, the disclosed 
tumor models represent a specific disease against which the claimed compounds are 
alleged to be effective. In light of the given references, the applicant’s specification 
alleges a sufficiently specific use. Even if one skilled in the art would be convinced 
of the applicant’s asserted utility “… applicants proffered sufficient evidence to 
convince one of skill in the art of the asserted utility.”221 The provided test results 
showed that several compounds within the scope of the claims exhibited significant 
anti-tumor activity and thus would have been sufficient to satisfy applicants’ bur-
den.222 
The early Supreme Court reasoning of Brenner gained particular importance in 
the light of the patenting of cDNA sequences. Craig Venter, a scientist working at 
the National Institutes of Health (NIH), initiated a project involving the documenta-
tion of all cDNA sequences matching the mRNA for each gene in the active, pro-
tein-encoding DNA sequences in a human brain. The c in cDNA refers to “comple-
mentary”. A complementary DNA sequence is defined as the sequence matching the 
“genetic messenger” carrying the encoded information for a particular gene, the 
messenger RNA or mRNA.223 Since only the exons of a DNA strand are translated 
into protein, the RNA only consists of the complementary information of the exons 
themselves. The cDNA thus must be considered as the complement of the translated 
exons and consequently is distinguishable from the original DNA. Before Venter 
initiated his work, libraries of cDNA fragments had been documented, but no one 
had obtained detailed base pair sequences for each fragment. Venter had only to se-
quence a portion of the cDNA segments, and with that portion the gene sequence 
itself, the actual gene, could be identified or reconstructed. He named the partial se-
quences “expressed sequence tags” or “ESTs”. In a patent application, he claimed 
each of the ESTs he had produced. The U.S. National Institutes of Health (NIH) re-
quested a legal opinion on the validity of the patent application. The opinion denied 
validity, reasoning in light of Brenner:  
“Use of the ESTs as probes to obtain full cDNA sequences has no practical benefit unless and 
until the full sequences themselves may be used for some purpose beyond research. Subse-
quent research may well prove some of the genes useful for diagnosis or therapeutic purposes, 
but the information disclosed in the specification fails to identify which of the genes will be 
useful, or for which purposes. Practical utility of the sequences awaits determination of the 
function of the genes they are associated with …”224  
 
220   In re Brana, 51 F.3d 1560, 1563.  
221   In re Brana, 51 F.3d 1560, 1567. 
222   In re Brana, 51 F.3d 1560, 1567. 
223   Merges, Robert Patrick/Duffy, John Fitzgerald, Patent Law and Policy: Cases and Materials, 
Newark, San Francisco, Charlottesville 2002, 250.  
224   Eisenberg S. Rebecca; Merges,/Merges, Robert P., Opinion Letter as to the Patentability of 
Certain Inventions Associated with the Identification of Partial cDNA Sequences, 23 Ameri-
can Intellectual Property Law Association Q. J. 1995, 16-19. 
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Based on the opinion, Venter’s patent application was ultimately dropped by NIH 
after having created a storm of controversy.225 The demonstrated case law was final-
ly summarized in the U.S. utility guidelines, which had been issued in 1995 in re-
sponse to criticism of pervasive utility rejections involving biotechnology and thera-
peutic method claims.226  
In In re Fisher, the patent applicant attempted to claim five ESTs that coded for 
parts of certain proteins in maize plants.227 At the time Fisher filed the patent appli-
cation, he “did not know the precise structure or function of either the genes or the 
proteins encoded for by those genes”.  The application encompassed seven uses of 
the claimed ESTs in an attempt to satisfy the utility requirement.  The Federal Cir-
cuit concluded that “none of Fisher’s seven asserted uses meets the utility require-
ment of § 101.”228 The court clearly determined that an “application must show that 
an invention is useful to the public as disclosed in its current form, not that it may 
prove useful at some future date after further research,” and “must disclose a use 
which is not so vague as to be meaningless.”229 EST’s coding parts of proteins with 
unknown function were seen as merely “objects upon which scientific research 
could be performed with no assurance that anything useful will be discovered in the 
end.”230 The court found that Fisher had not actually used gene fragments for any of 
the listed uses in the real world.231 Consequently, Fisher’s invention lacks “substan-
tial” utility.232 Fisher’s patent application also does not have a “specific” utility, be-
cause “[a]ny EST transcribed from any gene in the maize genome has the potential 
to perform any one of the alleged uses.” Therefore, “nothing about Fisher’s seven 
alleged uses” makes the five claimed ESTs different from “any EST derived from 
any organism.”233  
b) Europe (Industrial Applicability)  
According to Art. 57 EPC, a patent must be susceptible to industrial application, 
which means that it can be made or used in any type of industry, including agricul-
ture. In compliance with the guidelines of the EPO, “industry” is construed in its 
 
225   Merges, Robert Patrick/Duffy, John Fitzgerald, Patent Law and Policy: Cases and Materials, 
Newark, San Francisco, Charlottesville 2002, 253, Straus, Joseph, Patenting Human Genes 
in Europe - Past Developments and Prospects for the Future, 26 IIC 920, 934 (1995). 
226   USPTO, Utility Examination Guidelines, 60 Fed. Reg. 36, 263 (1995). 
227   In re Fisher, 421 F.3d. 1365, 1372 (Fed. Cir. 2005). 
228   In re Fisher, 421 F.3d. 1365, 1370.  
229   In re Fisher, 421 F.3d. 1365, I371.  
230   In re Fisher, 421 F.3d. 1365, 1373.  
231   In re Fisher, 421 F.3d 1365, 1374.  
232   In re Fisher, 421 F.3d 1365, 1374.  
233   The court emphasized that “[t]he claimed ESTs themselves are not an end of Fisher’s re-
search effort, but only tools to be used along the way in the search for a practical utility.” In 
re Fisher, 421 F.3d 1365, 1374.   
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broad sense as including any physical activity of “technical character”, and a useful 
or practical art rather than an aesthetic art.234 The guidelines provide a list of indu-
strially applicable inventions. Generally, they state that an invention not correspond-
ing to the listed inventions will not be considered industrially applicable.235 The Im-
plementing Regulations to the EPC have incorporated the EU-Directive and require 
that the industrial application must be disclosed in patent applications for partial se-
quences of genes, Rule 29 (former Rule 23e(3)). 
The European patent system reacted also to the development that large numbers 
of ESTs and Single Nucleotide Polymorphisms (SNPS) in the U.S. were filed for 
patentability.236 The ‘Biotechnology Directive’ set forth in Recital 23 that a mere 
DNA sequence without the indication of a given function does not provide any tech-
nical information and therefore lacks industrial applicability. “Function” in this con-
text must be understood as any function causing a technically applicable result, such 
as use as a diagnostic marker or screening tool. In the cases in which a sequence or 
partial sequence is used to produce a protein or part of a protein, the industrial appli-
cability is only established if the patent application indicates which protein or part of 
a protein is produced or what function it serves (Recital 24). The EPO adopted this 
requirement in the Implementing Regulations to the EPC, Rules 26-29  EPC (former 
Rules 23b-23e EPC) and the case law of the Opposition Division approved the new 
established principles. In Novel V28 seven transmembrane receptor,237 the division 
had to examine whether the requirement of industrial application was satisfied. The 
patentee argued that pursuant to Art. 57 EPC the requirement of industrial applica-
tion of an invention is satisfied “if it can be made or used in any kind of industry”. 
Thus, he alleged that the disclosure of how to make and to use a protein would be 
sufficient. The Opposition Division disagreed, maintaining that such disclosure does 
not provide a credible function of a DNA sequence encoding a protein and thus re-
jected the patent based on a lack of industrial application. With regard to the applica-
tion of the Biotechnology Directive, the division stated: 
“The requirements of industrial application of biotechnology inventions are set by Rules 23b-
23e EPC which concern European patent application and patents. Thus, the provisions of said 
rule apply to the present procedure and the recitals of European Directive 98/44/EC are appli-
cable as supplementary means of interpretation. In view of the requirement of industrial appli-
cation as set in Art. 57 in conjunction with Rule 23b-e EPC, the invention cannot be acknowl-
 
234   Industrially requires that the invention as such can be manufactured industrially or used in 
any sort of industrial field, see Busse/Keukenschrijver, PatG, § 5, No. 8.  
235   Guidelines for Examination in the EPO, Part C-IV, 4, available at 
   http://www.epo.org/patents/law/legal-texts/guidelines.html, last checked on  
  January 21, 2008.  
236   The European, Japanese and United States Patent Offices conducted a Trilateral study on the 
patenting of EST (Trilateral Project B3b on “The Patentability of DNA Fragments). For an 
analysis of their approaches see, Howlett, Melanie J./Christie, Andrew F., An analysis of the 
approach of the European, Japanese and United States Patent office to Patenting Partial DNA 
Sequences (ESTs), 34 IIC 581 (2003). 
237   Decision of the Opposition Division of June 21, 2001, V28 receptor/Icos, OJ 2002, 293-308.  
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edged as industrially applicable because industrial applications are not disclosed in the patent 
application (Rule 23e(3)EPC).”238  
3. Novelty 
In the case of proteomic inventions, a major question which emerges is whether the 
three dimensional structure is sufficient to fulfill the novelty requirement. For such a 
classification, patent law principles related to the field of chemistry are of particular 
interest, because chemistry provides a comparable field of research. Stereochemistry 
is referred to as the study of the three-dimensional shape of molecules.239 With re-
gard to patent law, the novelty of diastereomers and enantiomers240is a frequently 
discussed issue.241 The precise details will be demonstrated in the course of the pro-
teomic-related case study below. At this point, the general statutory background as 
to novelty will be illustrated. To illustrate the entire legal terrain which proteomic 
inventions must face, the principles applicable to biochemistry and particularly clas-
sical protein research are also presented.  
a) U.S. 
Under 35 U.S.C. § 101, an invention must be “new.”242 In compliance with Section 
102(a), it lacks novelty if it is “known or used by others” in the United States, or 
“patented or described in a printed publication” in the US or a foreign country.243 
 
238   Decision of the Opposition Division of June 21, 2001, V28 receptor/Icos, OJ 2002, 293-308, 
303. 
239   For an introduction into the field of stereochemistry, see Alworth, William L., John Wiley & 
Sons, Inc., Stereochemistry and Its Application to Biochemistry, New York 1972.  
240   Isomers are compounds bearing the same atomic compositions, but different physical and/or 
chemical properties. Stereoisomers are isomers consisting of atoms that differ only by their 
orientation in space. Diasteromers are stereoisomers that are non-superimposable, but are not 
mirror images. Enantiomers are stereoisomers that are non-superimposable mirror images. 
See IUPAC Compendium of Chemical Terminology, available 
   at http://www.iupac.org/publications/compendium/index.html, last checked on January 21, 
2008.  
241   See particularly T12/81 Diastereomere, OJ 1982, 296; T990/96, N. Publ.(EPO 1998); 
T296/87 Enantionmers/Hoechst, OJ 1990, 195; T1048/92, N. Publ.(EPO 1994); T600/95, N. 
Publ.(EPO 1996); T1048/92, N. Publ.(EPO 1994). As for the U.S. patent law practice, see In 
re Doyle, 293 F.3d 1355 (Fed. Cir. 2002), also Domeij, Bengt, Pharmaceutical Patents in Eu-
rope, Stockholm 2000, 146.  
242   For a brief summary on the novelty requirement, see also Rader/Adelman, Cases and Mate-
rials on Patent Law, 248-249.  
243   As explained by Chisum, the meaning of the novelty requirement is further determined in 
Section 102(e) which „bars a patent on an invention described in a patent application pub-
lished under Section 122(b) or a patent by another filed in the United States before the inven-
tion thereof by the applicant for patent. In addition, “Section 102(g) bars a patent on an in-
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The distinction between the different paragraphs of 35 U.S.C. § 102 requires care-
ful examination. Subsection (f) can be interpreted as the requirement that the patent 
applicant has actually invented the subject matter. It is prohibited to derive or steal it 
from others. Furthermore, the provision covers two major aspects: the novelty re-
quirement as such and statutory bar subsections. Both requirements refer to timing 
issues. The novelty subsections are directed only to events that take part prior to the 
time of invention: 
§ 102 (a): “before the invention thereof by the applicant”, (e) (same expression), and (g): “be-
fore such person’s inventions thereof”.  
In contrast, the statutory bar subsections may be matched by events occurring after 
the invention. For instance, § 102(b) prohibits the granting of a patent if the invented 
subject matter was disclosed in a printed publication more than one year prior to fil-
ing for a patent. Likewise, subsections (c) and (d) are also triggered by events (ab-
andonment, foreign filing by the applicant) that takes place after the applicant’s in-
vention.244  
In sum, novelty requires the inventor to comply with subsections (a), (e) and (g). 
The inventor’s right to obtain a patent, however, will be lost if any event matches up 
with one of the statutory bars found in subsections (b) – (d). Therefore, the statutory 
bars are called “loss of right to patent”. It is thus important to note that the U.S. de-
fines novelty according to the date of invention. In contrast, Europe measures novel-
ty as of the filing date.245 The requirement that all elements of the claimed invention 
must be identically described in a single prior art reference (“All Elements Rule”), 
however, is valid in Europe as well as in the U.S. Accordingly, anticipation requires 
that every feature of the claimed invention must be taught - explicitly, implicitly or 
by incorporation by reference - in a single piece of prior art.246 There are no specific 
guidelines regarding the novelty examination practice of the USPTO.  
As for biological products, the “All Elements” rule often results in the question of 
how a given prior reference is distinguishable from a slightly modified recombinant 
form. In Scripps Clinic & Research Foundation v. Genentech, Inc.,247 the defendant 
held that the alleged invention related to a recombinant product was anticipated by a 
published dissertation and three declarations by its author. The cited dissertation, 
however, differed from the “fingerprint” identification of the invention (a VIII:C 
 
vention that before [a person’s] invention therof ... was made in this country by another in-
ventor who had not abandoned, suppressed, or concealed it.“[citation omitted], see Chisum, 
Donald, Chisum on Patents, Volume 1, § 3.01.  
244   Merges, Robert Patrick/Duffy, John Fitzgerald, Patent Law and Policy: Cases and Materials, 
Newark, San Francisco, Charlottesville 2002, 363.  
245   Merges, Robert Patrick/Duffy, John Fitzgerald, Patent Law and Policy: Cases and Materials, 
Newark, San Francisco, Charlottesville 2002, 363. 
246   Scripps Clinic & Research Found. v. Genentech, Inc. 927 F.2 d 1565, 1576 (Fed. Cir. 1991); 
Amgen, Inc. v. Hoechst Marion Roussel, Inc., 126 F.Supp. 2d 69, 91 (D.Ma.2001) Put sim-
ply, anticipation requires that every element of the claimed invention be previously de-
scribed in a single reference. 
247   Scripps Clinic & Research Found. v. Genentech, Inc. 927 F.2d 1565. 
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Factor) obtained by the patentee. The Court of Appeals for the Federal Circuit con-
cluded that the given prior art reference did not establish anticipation, in that it did 
not identically demonstrate each element of the claimed invention. Accordingly, the 
Court remanded the case for trial to determine whether there were differences be-
tween the “fingerprint” factor (human factor VIII:C) derived from plasma and that 
produced by recombinant technology, such as purity, specific activities, stability, 
and formulations.248 
Anticipation will be avoided if a claimed composition is of increased purity, in 
contrast to its unpurified appearance occurring in nature. In In re Bergstrom the in-
vention was related to two chemical compounds (PGE(2) and PGE(3)).249 The 
claims at issue were rejected due to the lack of novelty. The USPTO stated that the 
specification gave references indicating that the claimed compounds naturally oc-
curred in natural glandular material, or in a variety of fractions and liquors derived 
from the glandular material. The Court concluded that novelty existed, finding that 
the claimed compounds exhibited a higher purity than those occurring in nature and 
stated that “[p]ure materials necessarily differ from less pure or impure materials 
and, if the latter are the only ones existing and available as a standard of reference, 
as seems to be the situation here, perforce the ‘pure’ materials are ‘new’ with respect 
to them.”250 The court, however, emphasized that  
“[w]hether the claimed pure materials have the same usefulness or assortment of properties as 
the impure materials of the prior art … is a question having no bearing on the factual and legal 
matter whether pure materials are new vis-à-vis impure materials within the meaning of § 101, 
although it is but one of the factors to be considered in determining their obviousness under 35 
U.S.C. § 103.”251  
Accordingly, the court did not examine whether the purer compound is sufficiently 
different to constitute a “new and useful … manufacture, or composition of the mat-
ter, as required in 35 U.S.C. § 101”252 Section 101 is rather equated with the stan-
dard of novelty under § 101 and a more pure compound is considered to meet the 
 
248   Scripps Clinic & Research Found. v. Genentech, Inc. 927 F.2d 1565, 1576-1578, (Fed. Cir. 
1991). A number of further Federal Circuit decisions affirm that a prior art publication must 
be enabling in order to anticipate an invention, see Chisum, Donald, Chisum on Patents, 
Volume 1, § 3.04 [1][b][iii], FN 19, citing, for instance, Transclean Corp. v. Bridgewood 
Services, Inc. 290 F.3d 1364, 1362 (Fed. Cir. 2002); Bristol-Myers Squbb Co. v. Ben Venue 
Laboratories, Inc. 246 F.3d 1368, 1374 (Fed. Cir. 2002). 
249   In re Bergstrom , 427 F. 2d 1394 (C.C.P.A. 1970).  
250   In re Bergstrom , 427 F. 2d 1394, 1402. 
251   In re Bergstrom , 427 F. 2d 1394, 1402. 
252   The approach to the purity problem taken by the Court of Customs and Patent Appeals was 
fundamentally different than the approach taken in earlier cases. In, for instance, Parke-
Davis & Co. v. H.K. Mulford & Co. (1911), 189 F.95 (S.D.N.Y. 1911), aff’d 196 F.496, (2d. 
Cir. 1912), a compound was considered as new only if it differs “in kind“ from the old com-
pound.  Such a difference “in kind“ will normally be found only if the new pure compound 
has an entirely new utility from the old one. See also Merck & Co. v. Olin Mathieson Chem. 
Corp., 253 F.2d 156, 164 (4th Cir. 1958), Chisum, Donald, Chisum on Patents, Volume 1, § 
1.02[9].  
https://doi.org/10.5771/9783845221441, am 02.12.2021, 20:19:12
Open Access -  - http://www.nomos-elibrary.de/agb
 76
standard of novelty under § 102(a).  Patentability of the compound, however, is de-
cided under the question of non-obviousness.253 
The question of purity is treated differently with regard to the patenting of a me-
tabolite of a new drug.  In Schering Corp. v. Geneva Pharmaceuticals, Inc.254, the 
patent claimed a metabolite of a known drug (loratadine). The prior art disclosed this 
drug teaching that it could be administered to a human subject. It did not, however, 
disclose the later-patented metabolite. The Federal Circuit found that the claim to 
the metabolite was invalid, because of anticipation by inherency. The court, howev-
er, stated that a “proper” claim to the metabolite in synthetic or purified form would 
have had established novelty. The court explained that “[a] skilled patent drafter … 
might fashion a claim to cover the metabolite in a way that avoids anticipation. For 
example, the metabolite may be claimed in its pure and isolated form.”255  
Pursuant to Section 102(g), a patent is anticipated if “before the applicant’s inven-
tion thereof the invention was made in this country by another who had not aban-
doned, suppressed, or concealed it.” This provision is of a particular interest when 
parallel research is carried out by competing teams of invention entities.256  In Am-
gen, Inc. v. Chugai Pharmaceutical Co.,257 the claim to a purified and isolated DNA 
sequence expressing human erythropoietin was questioned to be anticipated by the 
previous work of others who had initially developed a probing strategy. Without the 
probing method, the isolation of the gene would not have been possible. However, 
the knowledge of the specific amino acid sequence of erythropoietin was necessary 
for isolating the gene. At the time the alleged prior invention was made, the specific 
amino acid sequence was still unknown. The Federal Circuit concluded that the prior 
disclosed probing method itself did not defeat novelty, because it did not disclose 
how to obtain the “purified and isolated DNA sequence”. The court determined that 
for an “adequate conception” of the invention, the inventor must be able to “describe 
his invention with particularity.”  This requires both “(1) the idea of the invention's 
structure and (2) possession of an operative method of making it”258 In contrast to 
the earlier invention, the claim at issue to the specific DNA probes provided all ne-
 
253   See, for instance, Ex Parte Gray, 10 USPQ2d 1922, 1927 (Bd. Pat. App. & Int’f 1989). 
  The approach taken to the issue of “more pure compounds“ in earlier cases continues the 
standard applied by the courts in more recent cases, see, for instance, Glaxo Group Ltd. v. 
Apotex, Inc., 376 F.3d.1339 at 1349 (Fed. Cir. 2004) (Patents claiming antibiotic drug and 
method of preparing such drug were not anticipated by prior art patent, despite testimony of 
expert that he was able to use prior art patent to create claimed formulation, in view of ex-
pert's admitted deviation from relevant example of prior art patent and his reading of one 
patent at issue prior to conducting his experiments.). 
254   Schering Corp. v. Geneva Pharmaceuticals, Inc., 339 F.3d 1373 (Fed. Cir. 2003).  
255   Schering Corp. v. Geneva Pharmaceuticals, Inc., 339 F.3d 1373, 1381.  
256   Chisum, Donald, Chisum on Patents, Volume 1, § 3.05[4].  
257   Amgen, Inc. v. Chugai Pharmaceutical Co.  927 F. 2d 1200 (Fed. Cir. 1991), cert. denied, 
112 S. Ct. 169 (1991). 
258   Amgen, Inc. v. Chugai Pharmaceutical Co.  927 F. 2d 1200, 1206.  
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cessary information.  Therefore, the court concluded that novelty was not destroyed 
under § 102(g) by the prior invention of the other researchers.259   
Similarly, the questioned claim of Fiers v. Sugano260 was directed to “a DNA 
which consists essentially of a DNA which codes for a human fibroblast interferon-
beta polypeptide.”261 The court reasoned that the DNA could be obtained by the 
knowledge of its specific nucleotide sequence. The mere knowledge of how to pre-
pare the DNA would not serve as a conception of the compound. The court stressed 
that anticipation “does not occur unless one has a mental picture of the structure of 
the chemical, or is able to define it by its method of preparation, its physical or 
chemical properties, or whatever characteristics sufficiently distinguish it”.262 Ac-
cordingly, a mere determination of the DNA by its principal biological property was 
not sufficient. In contrast, “a precise definition, such as by structure, formula, chem-
ical name, or physical properties” would be necessary in order to provide sufficient 
identification.263 
b) Europe  
Pursuant to Art. 54(a) EPC “an invention shall be considered to be new if it does not 
form part of the state of the art”. The state of the art, for the purpose of considering 
novelty, comprises “everything made available to the public by means of written or 
oral description, by use, or in any other way, before the date of the filing of the Eu-
ropean patent application” (Art. 54(2) EPC).264 In addition, “the content of European 
 
259   Amgen, Inc. v. Chugai Pharmaceutical Co.  927 F. 2d 1200, 1205-1207. The rule that anoth-
er inventor must have had an “adequate conception” of a new technology for anticipation 
was confirmed by Invitrogen Corp. v. Clonetech Laboratories, 429 F.3d 1052 (Fed. Cir. 
2005) (“competitor did not show by clear and convincing evidence that researcher conceived 
of genetically engineered reverse transcriptase enzyme with no RNase H activity, but having 
DNA polymerase activity, before critical date”). The prior inventor must be diligent in re-
ducing the invention to practice, see Monsanto Comp. v. Myogen Plant Science, 261 F.3d 
1356, 1370 (Fed. Cir. 2001) (“The evidence is sufficient … to support presumed jury find-
ings that Agracetus was diligent throughout the entire critical period in creating and testing 
the modified Bt genes”)  
260   Fiers v. Sugano, 984 F.2d 1164 (Fed. Cir. 1993).  
261   Fiers v. Sugano, 984 F.2d 1164, 1166.  
262   Fiers v. Sugano, 984 F.2d 1164, 1168. 
263   Fiers v. Sugano , 984 F.2d 1164, 1171. A patent interference is an administrative proceeding 
pursuant to 35 U.S.C. §§ 102(g) and 135(a). During such a proceeding the Board is author-
ized to determine not only priority of invention but also to redetermine patentability.  35 
U.S.C. § 6(b), see Capon v. Eshhar, 418 F.3d 1349, 1351, 1358 (Fed. Cir. 2005) (the Federal 
Circuit during interference examined the written description requirement, stating that an in-
vention must not be “fully presented,” if the claimed subject matter is known). 
264   A detailed description of what belongs to the state of the art is provided by the EPO decision 
EBA1/92, Availability to the public, OJ 1993, 277-280. (The Enlarged Board of Appeals 
held that “the chemical composition of a product is state of the art when the product as such 
is available to the public and can be analysed and reproduced by the skilled person, irrespec-
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patent applications as filed, of which the dates of filing are prior to the date referred 
to in paragraph 2 and which were published under Art. 93 on or after that date shall 
be comprised in the state of the art” (Art. 54(3) EPC. Thus, the EPC distinguishes 
between a real and a fictitious state of the art.265 The real state of the art comprises 
all knowledge made available to the public by means of written or oral description, 
other means such as video recording, sound recording, or the Internet.266 In order to 
preclude double patenting, the fictitious state of the art includes prior not disclosed 
patent applications, given that they have been published on or after the date of the 
more recent application (Art. 93 EPC) and that they are still effective, e.g. have not 
been withdrawn or otherwise become invalid.267 Hence, inventions that are already 
subject of another European patent are not patentable.268  
The Examination guidelines of the EPO instruct examiners to classify an inven-
tion as novel provided that it differs from what is known in the prior art.269 Examin-
ers consider prior art documents as of the effective date of the document. It is not 
permissible to combine separate items of prior art together, each document must be 
compared in isolation.270 This differs from what is considered in the context of the 
inventive step requirement. Pursuant to Article 56 EPC “an invention shall be consi-
dered as involving an inventive step if, having regard to the state of the art, it is not 
obvious to a person skilled in the art.” Thus, not the single document but the whole 
prior art is considered.271 Art. 54(2) EPC states that the relevant date for the deter-
mination of the state of the art is the filing date of the European Patent application. 
Pursuant to Art. 89 EPC, the date of filing can be replaced by the date of priority.272 
Unlike American patent law, European law requires absolute novelty (Art. 54(1) 
EPC).  
With regard to 3-D protein structures, a crucial question is whether the descrip-
tion of the tertiary structure is sufficient to establish novelty in cases in which the 
primary structure has already been disclosed. To answer this question, the case law 
 
tive of whether or not particular reasons can be identified for analyzing the composition”). 
Id. at 280. See also Cornish, William/Llewelyn, David, Intellectual Property: Patents, Copy-
right, Trade Marks and Allied Rights, 6th ed., London 2007, 181-82.    
265   Benkard/Melullis, EPÜ, Art. 54 Nos. 202-203. 
266   Benkard/Melullis, EPÜ, Art. 54, Nos. 33-51. 
267   Benkard/Melullis, EPÜ, Art. 54 No. 203; Straus, Joseph, Neuheit, ältere Anmeldungen und 
unschädliche Offenbarungen im europäischen und deutschen Patentrecht, GRUR Int. 1994, 
89, 94. 
268   Benkard/Melullis, EPÜ, Art. 54 No. 5. Prior PCT applications for which the EPO acts as the 
designated Office have the same effect if they have been translated into one of the official 
languages and the national fee has been paid, Art. 150(3) in conjunction with Art. 150(1), 
Art. 158(2) EPC, Singer/Stauder/Spangenberg, EPC – Vol. 1, No. 87. 
269   Guidelines for Examination in the EPO, Part C-IV, 7.1. 
270   Guidelines for Examination in the EPO, Part C-IV, 7.1. 
271   For mosaic consideration of prior art and the question of enablement, not merely the single 
document but all documents in combination are relevant, see Guidelines for Examination in 
the EPO, Part C-IV, 9.8. 
272   Singer/Stauder/Spangenberg, EPC, Vol. 1, Art. 54, No. 12; Rogge, Rüdiger, The concept of 
Novelty with Particular Regard to Conflicting Patent Applications, 28 IIC, 794 (1997). 
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related to classical protein research will be considered. In classical protein research 
(mostly related to the analysis of primary structure), a patent to a protein invention 
was considered to be novel pursuant to the following rules.273 The disclosure of the 
complete amino acid sequence destroyed the novelty of a protein. The majority of 
protein inventions, however, cannot be classified that easily. In some, the biological 
activity of a protein is known without any knowledge of the enzymatic complex 
causing that activity. In others, some characteristics of the enzyme-substrate com-
plex are disclosed, e.g. through determination of certain physical and chemical pa-
rameters of a partial purified protein. The question then is to determine whether the 
disclosure of an amino acid sequence, which was previously not known, is still suf-
ficient to establish novelty. For a classification of the above-mentioned cases, cer-
tain rules are applicable. The first principle is one of a series of principles developed 
by the German Federal Supreme Court regarding the characterization of macromole-
cular substances through process parameters. In Trioxane,274 the court stated that a 
description of a substance is only sufficient if it clearly identifies and distinguishes 
the substance from others. Accordingly, the information provided by prior art is only 
novelty destroying if it is sufficient for clear identification. The same standard is ap-
plied by the EPO. In T51/95 Mature leukocyte interferons/Hoffmann-La-Roche275 
novelty was acknowledged, since the claimed interferon molecule had not been un-
ambiguously characterized in the prior art. Thus, the patent – covering a human bac-
terial-produced leukocyte interferon – was granted.276  
aa) The principle of unambiguous parameters  
The application of a new parameter for the identification of a substance already 
clearly identified by a previously established parameter does not create novelty. 
Consequently, the disclosure of new characteristics of the same substance, e.g. the 
disclosure of the formula, biological activity or certain physical effect will not create 
novelty in such a case.277 If, however, a previously established parameter does not 
provide sufficient information for the clear identification of a substance, the disclo-
 
273   A detailed overview of the EPO’s decisions on novelty for protein inventions is provided by 
Jaenichen, Hans-Rainer/Mcdonell, Leslie A./Haley, James F., Jr., From Clones to Claims, 
Cologne, Berlin, Bonn, Munich 2002, 257-267. 
274   BGH, 3 IIC 226 (1972) - Trioxane. 
275   T51/95 Mature leukocyte interferons/Hoffmann-La-Roche, N. Publ. 
276   T51/95 Mature leukocyte interferons/Hoffmann-La-Roche, N. Publ., No. of the Reasons 19-
24; see also T 71/95 Immunoassay/Amersham International plc, N. Publ., No. of the Reasons 
8 (for finding lack of novelty a direct and unambiguous disclosure in the prior art is neces-
sary). 
277   Benkard/Melullis, EPÜ, Art. 54, No. 176. A new parameter, however, is sufficient for the 
description of a substance that differs from the already disclosed substance, if it clearly indi-
cates on what the difference is based, see Schulte/Moufang, PatG mit EPÜ, § 1, No. 348.  
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sure of further properties may still establish novelty.278 For instance, if only the bio-
logical activity of the protein is known in the prior art, the first isolation of the carri-
er responsible for such activity is enough for establishing novelty.  Even though the 
biological activity of a protein may be considered substantial information about such 
protein, it cannot be considered a sufficient parameter for its identification.279 In the 
case that all disclosed parameters can be combined and therefore establish sufficient 
and unambiguous substance identification, the disclosure of any further parameter 
does not create novelty.280 Due to the high number of similarities between different 
protein groups, many parameters, however, cannot be used for such accurate deter-
mination. Thus, it is more likely that a parameter will prove that the knowledge in-
cluded in the prior art is not providing the necessary information for identification. 
This has the following consequences. If the number of known parameters, e.g., mo-
lecular weight, statistical density, or melting point data of a compound281is high, the 
likelihood of novelty is low. If a variety of parameters and structural characteristics 
of a protein are already known in the prior art, it is not likely that this protein is pa-
tentable in terms of novelty at this stage. Even the characterization of the amino acid 
sequence is not sufficient for compliance with the novelty requirement if the protein 
is already determined accurately enough so that an unambiguous identification had 
been possible. Therefore, the description of a patent must not be considered incom-
plete for the sole reason that specific parameters are not included. The same prin-
ciple applies with regard to the amino acid sequence. The disclosure of a complete 
or incomplete amino acid sequence is not a necessary requirement of an unambi-
guous identification of a protein. 282  
In addition, the level of purification has been an important characteristic of identi-
fication in a number of chemical related cases decided by the European Patent Of-
fice.283 In Interleukin-1/Immunes Corporation, the opponents alleged that the 
claimed protein is no more purified than the protein disclosed by the state of the 
art.284 The Board acknowledged novelty, however, since there was no evidence that 
the protein preparation disclosed in the cited documents exhibited features of earlier 
disclosed inventions, reasoning that it would have been the opponent’s burden of 
proof to provide any corroborating evidence. The proffered unsubstantiated allega-
tions, the Board found, were not based on a comparative analysis and had to be dis-
 
278   Benkard/Melullis, EPÜ, Art. 54, No. 162-163;  Busse/Keukenschrijver, § 3 PateG No. 128. 
279   Rauh, Peter A./Jaenichen, Hans-Rainer, Neuheit und erfinderische Tätigkeit bei Erfindun-
gen, deren Gegenstand Protein oder DNA-Sequenzen sind -- Volker Vossius zum 60. Ge-
burtstag, GRUR 1987, 753, 755f. 
280   Benkard/Melullis, EPÜ, Art. 54, No. 162-163; Busse/Keukenschrijver, § 3 PateG No. 128. 
281   BGH, 3 IIC 226, 235 (1972) – Trioxane.  
282   Rauh, Peter A./Jaenichen, Hans-Rainer, Neuheit und erfinderische Tätigkeit bei Erfindun-
gen, deren Gegenstand Protein oder DNA-Sequenzen sind -- Volker Vossius zum 60. Ge-
burtstag, GRUR 1987, 753, 755f. 
283   Singer/Stauder, EPC, Vol 1, Art. 54 No. 63.  
284   T767/95 Interleukin-1/Immunes Corporation, N. Publ., No. of the Reasons 6.   
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regarded.285 In Vinylester-Crotonsäure/Hoechst, the Technical Board stated that “a 
known product does not necessarily acquire novelty merely by virtue of the fact that 
it is prepared in a purer form”, because the prove of novelty “cannot involve proper-
ties which are not attributable to the substance parameters of the product itself, i.e. 
which are not inherent in it.286 In Pure terfinadine/Albany ,287 the patent applicant 
attempted to argue that the claimed compound differed from the substances dis-
closed by the prior art, because it could not be achieved by conventional methods. 
The Board of Appeals, however, concluded that the applicant did not provide suffi-
cient evidence to support his assertions. In particular, the Board found that the prior 
art already included small amounts of the substance which were achieved by well-
established conventional methods.288  
If the invention consists of the modification of a known protein, the amended 
amino acid is considered to satisfy the novelty requirement.289 The question then 
arises whether the scope of the patent involving the original protein covers the mod-
ified protein. The issue of scope of protection is thoroughly discussed in Part IV of 
this study.290 Moreover, the publication of a protein in a protein database is only no-
velty destroying in the event that the provided information enables a skilled person 
to isolate such a protein.291 The same is true for in silico screening methods or writ-
ten formula descriptions.292 
As reconfirmed by the English House of Lords in Kirin-Amgen v. TKT, the new 
manufacture of a known product is not enough to satisfy the novelty requirement.293 
Here, one of the issues to be resolved was whether the recombinant ‘Epo’ produced 
by Amgen was novel or identical to the ‘Epo’ already part of the state of art, in par-
ticular the ‘uEpo’ which others had purified from urine.294 Amgen alleged that their 
recombinant product had a glycosylation pattern differing from the known ‘uEpo’. 
The court, however, denied such assertion, concluding that there was no clear dis-
 
285   T767/95 Interleukin-1/Immunes Corporation, N. Publ., No. of the Reasons 6-7.  
286   T205/83 Vinylester-Crotonsäure Copolymerisate/Hoechst, OJ 1985, 363, 369. 
287   T728/98 Pure terfinadine/Albany, OJ 2001, 319. The patent applicant particularly based his 
arguments on the earlier decision of T990/96 Erythro-compounds/Novartis, OJ 1998, 489. 
288   T728/98 Pure terfenandine/ALBANY, OJ 2001, 335; see also Benkard/Melullis, EPÜ, Art. 
54, No. 177.  
289   T 1208/97 Analogs/AMGEN, N. Publ., No. of the Reasons IX, where the patentee defended 
novelty based on the argument that the claim feature “has been modified,” which“necessarily 
implied a difference vis-à-vis the natural products.”  
290   Chapter 4 C IV 1.  
291   Benkard/Melullis, EPÜ, Art. 54, No. 164.  
292   T1165/06 Il-17 related polypeptide/Schering, N. Publ., No. of the Reasons  21.  
293   Kirin-Amgen Inc. and Others v. Hoechst Marion Roussel Limited and Others, [2005] R.P.C. 
9; as for the application of this principle in Germany, see Rauh, Peter A./Jaenichen, Hans-
Rainer, Neuheit und erfinderische Tätigkeit bei Erfindungen, deren Gegenstand Protein oder 
DNA-Sequenzen sind -- Volker Vossius zum 60. Geburtstag, GRUR 1987, 753, 756. 
294   Kirin-Amgen Inc. and Others v. Hoechst Marion Roussel Limited and Others, [2005] R.P.C. 
9, No. 87. The U.S. court decided on this subject in Amgen v. Hoechst Marion Roussel, Inc., 
126 F. Supp.2d 69 (D. Mass. 2001), see Welch, Andreas, Der Patentstreit um Erythropoietin, 
GRURInt. 2003, 579, 593. 
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tinction between ‘uEpo’ and the recombinant ‘Epo’.295 Following the approach taken 
by the EPO that “a new process is not enough to make the product new,” the House 
of Lords concluded that a difference in the method of manufacturing an identical 
product does not make it novel. Consequently, the House of Lords declared Am-
gen’s claim 26, which defined Epo as the product of recombinant gene expression 
invalid on the grounds of anticipation.296  
The decision can be considered a landmark for two reasons. First, it revoked Am-
gen’s claim 26 to recombinant Epo, a product, which had been very successful and 
powerful on the market for many years. In addition, the House of Lords changed a 
long existing English practice, which treated a product made by a new process as 
sufficient to distinguish it from an identical product which was already disclosed in 
the prior art.297 Thus, the case demonstrates how national legal principles are given 
up in favour of standards set forth by the EPO. As stated in the Technical Board de-
cision of Anspruchskategorien/IFF, claims to a product defined in terms of a process 
are only permissible if the product cannot be satisfactorily defined by reference to its 
composition, structure or other parameter. Otherwise, product-by-process claims are 
not allowed.298 Art. 64(2) EPC, however, enables a patentee to rely directly on his 
process claim to allege infringement of a product made by this process, which is - as 
concluded by the House of Lords in Amgen - “any practical argument for allowing 
[any other] product-by process claims is removed.”299 Thus, only if Amgen had been 
capable of proving that their ‘Epo’ was for the first time produced in a glycols form, 
the case would have been solved differently. Even though a person skilled in the art 
would have been able to generally develop a glycols form out of a non-glycols form 
with the knowledge being included in the state of the art, the glycols form of ‘Epo’ 
had not been anticipated. In sum, Kirin-Amgen v. Hoechst Marion can be considered 
an important step towards a harmonization of European patent law. 
 
295   Kirin-Amgen v. Hoechst Marion Roussel, [2005] R.P.C. 9, No. 95. 
296   Kirin-Amgen v. Hoechst Marion Roussel, [2005] R.P.C. 9, No. 101.  
297   As stated by Lord Hoffman in Kirin-Amgen v. Hoechst Marion Roussel, [2005] R.P.C. 9, 
No. 88. 
298   Anspruchskategorien/IFF, OJ EPO 1984, 309; Benkard/Melullis, EPÜ, Art. 52 No. 119; T 
150/82, N. Publ.The House of Lords referred to the European law in Kirin-Amgen v. 
Hoechst Marion Roussel, [2005] R.P.C. 9, No. 89.  
299   Kirin-Amgen v. Hoechst Marion Roussel, [2005] R.P.C. 9, 90; Art. 64(2) EPC states that 
“[if] the subject-matter of the European patent is a process, the protection conferred by the 
patent shall extend to the products directly obtained by such process.” See also Ben-
kard/Mellulis, EPÜ, Art. 54 No. 174, Benkard/Jestaedt, EPÜ, Art. 64, No. 20.  
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bb) The principles of second and further medical indications 
The development of first and second medical indications for pharmaceuticals by the 
Enlarged European Board of Appeal of the European Patent office300 are of major 
interest for proteomic inventions, since many of these patents may be directed to the 
treatment of diseases. The following discussion attempts to briefly present the un-
derlying theoretical structure of how novelty is derived from medical indications, 
keeping in mind the question of whether the principles are transferable to the field of 
proteomics.301  
The 2000 EPC revision, put into force on December 13, 2007, led to the amend-
ment of the law related to medical indications.302 As already mentioned, what used 
to be the rule under Art. 52 (4) EPC is now added as c) under Art. 53 EPC.303 Fur-
thermore, the conference established a new version of Art. 54 EPC, including the 
content of Art. 54 (5) EPC regarding the purpose-related substance protection for the 
first medical indication in Art. 54 (4). Finally, the provision was extended by a new 
paragraph (Art. 54(5) EPC), allowing claims for second and further medical indica-
tions, and reading as follows:  
“Paragraphs 2 and 3 shall also not exclude the patentability of any substance or composition 
referred to in paragraph 4 for any specific use in any method referred to in Art. 53(c), provided 
that such use is not comprised in the state of the art.”304 
Several patents are available for pharmaceuticals under the EPC. Generally, a prod-
uct patent may be obtained for a substance that provides absolute novelty and 
matches all further patentability requirements. Absolute novelty requires that the 
substance be not disclosed in any field of the art. Novelty is established, moreover, 
if the substance is clearly distinguishable from any known substance by at least a 
single technical characteristic.305 In addition, already-known substances are patenta-
ble as pharmaceutical means if they were not previously known as agents for treat-
ment or diagnosis. Unlike the U.S., under the EPC, novelty of such a claim, howev-
er, cannot be established by method for treatment claims, because Art. 53(c) (former 
Art. 52(4) EPC) declares methods of treatment and diagnosis practiced on the hu-
 
300   EBA 1/83, Second medical indication/Bayer, OJ 1985, 60; EBA 5/83, Second medical indi-
cation/Eisai, OJ 1985, 64; EBA 6/83, Second medical indication/Pharmuka, OJ 1985, 64; A 
detailed description is provided by Utermann, Jasper, Der zweckgebundene Verfahrensan-
spruch für Arzneimittel - Zwei Lösungen für die zweite Indikation, GRUR 1985, 813.  
301   As for the scope of protection provided for medical indications, see De Lacroix, Stefan 
Féaux, Auslegung von Zweckansprüchen in Verfahrenansprüchen - Zweite nichtmedizi-
nische Indikation, GRUR 2003, 282.  
302   Nack, Ralph/Phélip, Bruno, Diplomatic Conference fort the Revision of the European Patent 
Convention. Munich 20 – 29 November 2000, 32 IIC 200 (2001).  
303   Chapter 3 A II 1 a) bb).  
304   EPO, Special Edition No. 4, OJ 2007, 54; Nack, Ralph/Phélip, Bruno, Diplomatic Confer-
ence for the Revision of the European Patent Convention. Munich 20 – 29 November 2000, 
32 IIC 200, 204 (2001), Schulte/Moufang, PatG mit EPÜ, §3 Nos. 7-8.  
305   Schulte/Moufang, PatG mit EPÜ, § 1, Nos. 250-251.   
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man or animal body as being excluded from patentability.306 If previously known 
substances are useful for methods of treatment and diagnosis, their novelty is rather 
derived under the principles of first and further medical indications. In this respect, 
two Enlarged Board of Appeal decisions – still related to the rules valid before the 
2000 EPC Revision - must be considered landmarks307: 
In Second medical indication/Eisai308, the Enlarged Board of Appeals had to de-
cide whether a patent with claims directed to the use of a substance of composition 
for the treatment of human or animal bodies could be granted. The Board made a 
distinction between a claim directed to the “use of a substance or composition for 
the treatment for the human or animal body by therapy” and “a claim directed to the 
manufacture of substances or compositions for use in any methods for treatment of 
the human or animal body”. The first claim, the Board concluded, does not essential-
ly differ from a claim directed to “a method of treatment of the human or animal 
body by therapy with the substance or composition” and therefore is clearly in con-
flict with Art. 52(4) EPC. On the other hand, the latter claim involves without doubt 
inventions that satisfy the requirement of industrial applicability under Art. 52(1) 
EPC. The Board emphasized that this is essentially made clear in Art. 52(4) EPC, 
last sentence, but also can be derived from the definition of “susceptible of industrial 
application” in Art. 57 EPC, particularly because inventions “can be made or used in 
any kind of industry, including agriculture”. Furthermore, the Board argued with 
Art. 54(5), according to which the provisions relating to novelty shall not prohibit 
the patentability of any substance or compositions, comprised in the state of the art, 
for use in a method referred to in Art. 52(4), provided that its use for any such me-
thod is not comprised in the state of the art. Patent protection for such “first medical 
indication” would be available as a purpose-limited – covering, however, all medical 
uses, product protection.309 In a second step, the Board carefully considered the pos-
sibility of protecting second and further medical indications by means of a claim di-
rected to the use of a substance or composition for the manufacture of a medicament 
for a specified (new) therapeutic application.310 Accepting the practice of the Swiss 
 
306   As for the rational behind former Art. 52(4) EPC that is still applicable to the new Art. 53(c) 
EPC, see Jaenichen, Hans-Rainer/Mcdonell, Leslie A./Haley, James F., Jr., From Clones to 
Claims, Cologne, Berlin, Bonn, Munich 2002, 22. The policy behind the exclusion of Art. 
52(4) EPC is to ensure that those who carry out surgical, therapeutic, or diagnostic methods 
as part of the medical treatment of humans or animals should not  be hampered by exclusive 
rights of others; Ricker, Mathias, The exclusion of diagnostic methods from patentability by 
the EPC: a case for review? 22 Nature Biotechnology 2004, 1167, 1167.  
307   As landmark decision of the Technical Board of Appeals of the European Patent office T 
385/86, N. Publ., can be considered. Furthermore, the diverging decision T964/99, N. Publ., 
applies a significantly broader view, Ricker, Mathias, The exclusion of diagnostic methods 
from patentability by the EPC: a case for review?, Nature Biotechnology, 22 Nature Bio-
technology 2004, 1167, 1167.  
308   EBA 5/83, Second medical indication/Eisai, OJ 1985, 64.  
309   EBA 5/83, Second medical indication/Eisai, OJ 1985, 64, 64-66. 
310   EBA 5/83, Second medical indication/Eisai, OJ 1985, 64, 66. 
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Federal Intellectual Property Office, the Enlarged Board acknowledged patent pro-
tection for such claims.  
The decision Second medical indication/Bayer311 corresponds to the case law re-
ported above. The Enlarged Board had to decide whether to grant a use patent for a 
substance of which a therapeutic use had already been included in the prior art. The 
board rejected the claim directed to the use of a known compound X for the treat-
ment of disease Y, reasoning that such a claim falls under the exclusion from paten-
tability of “methods for treatment of the human or animal body” according to Art. 
52(4) EPC. However, it accepted the patent claim directed to the “use of a substance 
X for the manufacture of a medicament for therapeutic application Y”, concluding 
that novelty of a so-called “Swiss-claim” is determined through the new pharma-
ceutical use of that known substance.312 Thus, according to the Enlarged Board, the 
interpretation of the EPC does not result in general exclusion of second and further 
medical indications from patentability.  
Thus, claims directed to the use of a substance or composition for the design of a 
new drug with new and inventive therapeutic application are legally accepted. No-
velty exists due to the new therapeutic use. The inventive step (Art. 56 EPC) is es-
tablished if a person skilled in the art was not able to suggest such new therapeutic 
use.313 In sum, the following patents are available for medical compositions under 
the EPC:   
 A product patent: Pursuant to 54(1)(2) EPC in combination with Art. 53(c) EPC 
(former Art. 52 (4) EPC), substances or compositions are patentable, even if 
they are used in diagnostic methods or methods for treatment, provided that 
they are new and inventive.314 
 Purpose-related product patent: The provision that indicates the form of claim 
permissible for a first medical indication is Art. 54 (4) EPC (former Art. 54(5) 
EPC). Accordingly, in the case of a first medical use, i.e., when the invention 
results in the finding that a certain substance can be used pharmaceutically, a 
broad claim to a pharmaceutical composition containing the substance is al-
lowed without restriction to the actual identified medical use (first medical indi-
cation).315 
 
311   EBA 1/83, Second medical indication/Bayer, OJ 1985, 60.  
312   Utermann, Jasper, Der zweckgebundene Verfahrensanspruch für Arzneimittel - Zwei Lösun-
gen für die zweite Indikation, GRUR 1985, 813, 813. 
313   In T 0254/93 Ortho Pharmaceutical, N. Publ. (EPA 1997) the invention was rejected on 
grounds of the inventive step requirement, because it merely suggested that the combined 
administration of two known substancees causes the avoidance of “skinnatropie”.  
314   Singer/Stauder, EPC, Vol. 1, Art. 52, Nos. 82-87; see also Schulte/Moufang, PatG mit EPÜ, 
§ 1 Nos. 248, 250-252.  
315   Singer/Stauder, EPC – Vol. 1, Art. 54, Nos. 96-99; Schulte/Moufang, PatG mit EPÜ, § 1 
Nos. 248, 254, noting that the principle of first medical indications should provide incentives 
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 Use patent: When a further medical use of a substance already known to be 
pharmaceutically useful is identified, the EPC allows so-called second medical 
use claims in the Swiss-type format. These claims relate to the new use of an al-
ready known substance (second and further medical indication, incorporated in 
Art. 54(5) EPC).316 
4.  Nonobviousness and Inventive Step 
a) U.S. (Nonobviousness)  
According to 35 U.S.C. § 103, a patent claim is rejected “if the differences between 
the subject matter sought to be patented and the prior art are such that the subject 
matter as a whole would have been obvious at the time the invention was made to a 
person having ordinary skill in the art to which said subject matter pertains”.317 A 
patent application fails when, at the time the invention was made, the prior art re-
vealed sufficient information for one skilled in the art to produce the invention with 
“a reasonable expectation of success.”318Even though obviousness is treated as a 
 
for potential inventors of pharmaceuticals, whose inventive activity does not depend on 
whether the pharmaceutically used substance was absolutely new or merely new in the field 
of medicine.   
316   The principle of second and further medical indications determine how a known drug for the 
treatment of a particular disease can achieve patent protection for the treatment of other dis-
eases, see Singer/Stauder/Spangenberg,  EPC – Vol 1, Art. 54 No. 101.  
317   For a detailed overview of the requirement of obviousness and applying case law, see Chi-
sum, Donald, Chisum on Patents, Volume 2, Chapter 5, for an introduction, see particularly 
§ 5.01 As for the perspective of the skilled person of art on nonobviousness, see Eisenberg, 
Rebecca, “Obvious to whom? Evaluating Inventions from the Perspective of PHOSITA“, 19 
Berkeley Technology L. J. 885 (2004), with regard to the the Historical Development of the 
nonobviousness requirement, see Duffy, John F., Rethinking the Prospect Theory of Patents“ 
U.Chi.L.Rev. 439 (2004), see also Velander v. Garner, 348 F.3d 1359, 1363 (Fed. Cir. 2003) 
(The obviousness requirement is based on “(1) the scope and content of the prior art; (2) the 
level of ordinary skill in the prior art; and (3) the differences between the claimed invention 
and the prior art.”) 
318   Medichem, S.A. v. Rolabo, S.L., 437 F.3d 1157, 1165 (Fed. Cir. 2006) (To be sure, “to have 
a reasonable expectation of success, one must be motivated to do more than merely to vary 
all parameters or try each of numerous possible choices until one possibly arrived at a suc-
cessful result, where the prior art gave either no indication of which parameters were critical 
or no direction as to which of many possible choices is likely to be successful” (citation 
omitted). 
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question of law,319 the question of whether the claimed subject matter would have 
been obvious includes factual findings as “relevant secondary considerations”.320 
Relevant secondary considerations are (1) the scope and content of prior art; (2) 
the level of ordinary skill in the art; (3) the differences between the claimed subject 
matter and the prior art; and (4) significant, objective evidence of nonobviousness, 
such as long-felt need in the art, mercantile success, failure of others, copying, and 
unexpected results.321 Secondary considerations must be examined whenever they 
are present and must be given the same weight as to the primary considerations. The 
initial burden is on the examiner to mount a prima facie case of obviousness based 
on three criteria: 1) the suggestion or motivation in the reference or common general 
knowledge to modify the reference; 2) the reasonable expectation of success; and 3) 
the prior art reference suggesting all the claim limitations. Once the examiner estab-
lishes a prima facie case, the onus shifts to the applicant to demonstrate that the 
claimed invention is not obvious.322 The question of obviousness requires the evalu-
ation of the entire prior art. This is in contrast to the novelty factor, where each ele-
ment is considered separately. Regarding a claim to a DNA or cDNA molecule, the 
prior art must disclose a teaching of a specific, structurally definable compound that 
provides the obvious motivation or suggestion to alter the known compound. Accor-
dingly, prima facie obviousness exists, if the prior art at least gives a reasonable ex-
pectation of success. This includes guidance, which is sufficiently specific to draw 
 
319   Richardson-Vicks Inc. v. Upjohn Co., 122 F.3d 1476, 1479 (Fed. Cir. 1997) (The ultimate 
conclusion of whether a claimed invention would have been obvious is a question of law re-
viewed de novo based on underlying findings of fact reviewed for clear error.) 
320   Pfizer v. Apotex, 480 F.3d 1348, 1372 (Fed. Cir. 2007), (“Although secondary considera-
tions must be taken into account, they do not necessarily control the obviousness conclu-
sion.” (citation omitted) );  Eli Lilly and Co. v. Zenith Goldline Pharmaceuticals, Inc., 471 
F.3d 1369, 1380 (Fed. Cir. 2006) (“Among other things, Lilly proved extensive secondary 
considerations to rebut obviousness”). 
321   Syntex (U.S.A.) LLC v. Apotex, Inc., 407 F.3d 1371, 1378 (Fed. Cir. 2005), (the secondary 
consideration of commercial success exists largely to provide a means for patentees to show 
in close cases that subject matter that appears obvious is in law unobvious because a high 
degree of commercial success permits the inference that others have tried and failed to reach 
a solution (citation omitted); Graham  v. John Deere Company of Kansas City, 383 U.S. 1, 
17-18 (U.S. Supreme Court 1966), (“Such secondary considerations as commercial success, 
long felt but unsolved needs, failure of others, etc., might be utilized to give light to the cir-
cumstances surrounding the origin of the subject matter sought to be patented. As indicia of 
obviousness or nonobviousness, these inquiries may have relevancy.”). See also Chisum, 
Donald, Chisum on Patents, Volume 2, § 5.05[1] (Long-Felt Need - Failure to Others), [2] 
(Commercial Success), [5](Copying). 
322   In re Kumar, 418 F.3d 1361, 1366 (Fed. Cir. 2005) („In patent examination context, the pri-
ma facie case is a procedural tool requiring that examiner initially produce evidence suffi-
cient to support a ruling of obviousness, after which burden shifts to applicant to come for-
ward with evidence or argument in rebuttal.“); In re Harris, 409 F.3d 1339, 1343 (Fed. Cir. 
2005) („When the PTO shows prima facie obviousness, the burden then shifts to the appli-
cant to rebut.“) (citation omitted); See also Howlett, Melanie J./Christie, Andrew F., An 
analysis of the approach of the European, Japanese and United States Patent office to Patent-
ing Partial DNA Sequences (ESTs), 34 IIC 581, 590f (2003).  
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the attention of someone ordinary skilled in the art to the selection of parameters and 
choices necessary to obtain the invention, without undue experimentation. Conse-
quently, the prior art that provides the necessary motivation to produce the invention 
must enable an ordinary skilled person to do so.323  
Under 35 U.S.C. Section 102(e), a patent is precluded when the “invention was 
described in a patent granted on an application for patent by another filed in the 
United States before the invention thereof by the applicant.” In Hazeltine Research, 
Inc., the Supreme Court determined that Section 102(e) is considered a source of 
prior art under Section 103.324  Accordingly, the content adequately described in an 
issued United States patent is fully effective as a reference as of the date when the 
application for the patent was filed. Thus, Hazeltine views material as prior art for 
the purposes of determining obviousness at the time when the material is not availa-
ble to the public and is still secret.325 The decision further developed an earlier estab-
lished doctrine that “delays of the patent office ought not to cut down the effect of 
what has been done”326 The Supreme Court in Hazeltine concluded that this ratio-
nale extended to the determination of prior art pursuant to § 103 as well as for antic-
ipation.327 The court explained that the prior applicant has “done what he could to 
add his disclosure to the prior art.”328 In re Bartfeld329 further made clear that 
“[t]hough not anticipatory, a reference that would otherwise qualify as prior art un-
der 35 U.S.C. § 102(e) may form the basis of an obviousness rejection under § 103; 
hence, §102(e)/§ 103 rejections.”330 
Furthermore, two major decisions concerning the obviousness standard are Hybri-
tech, Inc. v. Monoclonal Antibodies331 and In re O’Farrell332. The first suggested a 
 
323   In re Inland Steel Co., 265 F.3d 1354, 1364 (Fed. Cir. 2001) (the prior art references identify 
a common problem … and give explicit guidance tying that parameter to the key parameter 
of another reference).  
324   Hazeltine Research, Inc. v. Brenner, 382 U.S. 252 (1965). See also Eli Lilly and Co. v. Ara-
digm Corp., 376 F.3d 1352, 1367 (Fed. Circ. 2004) (The examiner rejected all of the claims 
in Lilly's patent application stating that they were anticipated by, under section 102(e), or in 
the alternative obvious under section 103(a) with respect to a co-pending patent application 
claiming the same subject matter.)  
325   Hazeltine Research, Inc. v. Brenner, 382 U.S. 252, 254. Compare Riverwood International 
Corp. v. R.A. Jones & Co., 324 F.3d 1346, 1355-56, 66 (Fed. Cir. 2003). 
326   As established in Alexander Milburn Co. v. Davis Bournville, 270 U.S. 390 (1926).  
327   Hazeltine Research, Inc. v. Brenner, 382 U.S. 252, 256.  
328   Hazeltine Research, Inc. v. Brenner, 382 U.S. 252, 256; see also Chisum, Donald, Chisum 
on Patents, Volume 2, § 5.03[3][b]. 
329   In re Bartfeld, 925 F.2d 1450 (Fed. Cir. 1991).  
330   In re Bartfeld, 925 F.2d 1450, 1451 n.4 (Fed. Cir. 1991), see also Purdue Pharma L.P. v. 
Boehringer Ingelheim GmbH, 98 F. Supp.2d 362, 392 (S.D. N.Y. 2000), aff’d, 237 f.3d 1359 
(Fed. Cir. 2001) (citing Bartfeld; “a terminal disclaimer is incapable of overcoming a rejec-
tion on grounds of obviousness pursuant to 35 U.S.C. §§ 102(e) and 103.”); Chisum, Donald, 
Chisum on Patents, Volume 5, § 5.03[3][b]. 
331   Hybritech, Inc. v. Monoclonal Antibodies, 802 F.2d 1367 (Fed. Cir. 1986), cert. denied, 480 
U.S. 947 (1987) 
332   In re O’Farrell, 853 F.2d 894 (Fed. Cir. 1988). 
https://doi.org/10.5771/9783845221441, am 02.12.2021, 20:19:12
Open Access -  - http://www.nomos-elibrary.de/agb
 89
milder approach toward the validity of the claims than the latter.333 In Hybritech, a 
process patent on a “sandwich assay” for detecting the presence of antigenic sub-
stances in fluid samples using monoclonal antibodies was challenged.334 The district 
court rejected the claim due to obviousness, relying on prior art disclosing methods 
to prepare monoclonal antibodies and describing similar assays using conventional 
polyclonal antibodies.335 The Federal Court reversed the judgment of invalidity, em-
phasizing that prior art did not disclose more than “invitations to try monoclonal an-
tibodies in immunoassays” that “do not suggest how that end might be accom-
plished.”336 
In contrast, the Court in In re O’Farrell affirmed the rejection of claims due to 
obviousness.337 The claimed invention consisted of a method for producing proteins 
in bacterial host cells. It involved the insertion of the target gene in a plasmid in the 
DNA of a bacterial protein, followed by transfer of the protein into the bacterial 
host. In order to produce the gene for the bacterial protein, the host was prepared to 
“read through” and to express the target gene. In a further step, the expressed gene 
encoded a protein consisting of the amino acids derived from the genetic informa-
tion.338 The USPTO rejected the patent application under 35 U.S.C. § 103, reasoning 
that the prior art disclosed so much information regarding the claimed method that 
the latter would have been obvious to a person skilled in art.339 The inventor argued 
that the given prior art would not have rendered the claimed method obvious, given 
the significant unpredictability in this field of molecular biology. He alleged that the 
standard given was only a standard of “obvious to try”, which would not be suffi-
cient for a rejection.340 The Court of Appeal for the Federal Circuit agreed that “ob-
vious to try” was not the standard being examined under Section 103. Nevertheless, 
the court stated, the claim at issue should be considered as obvious, since obvious-
ness does not require absolute predictability of success. The existing possibility of 
unexpected success would not be sufficient to create nonobviousness.341  
 
333   Eisenberg, Rebecca, Patenting the Human Genome, 39 Emory Law Journal 1990, 721-745, 
731. 
334   Hybritech, Inc. v. Monoclonal Antibodies, 802 F.2d 1367, 1368-69. 
335   Hybritech, Inc. v. Monoclonal Antibodies, 802 F.2d 1367, 1371.  
336   Hybritech, Inc. v. Monoclonal Antibodies, 802 F.2d 1367, 1380. Disagreement recognized 
by Singh v. Brake, 222 F.3d 1362, 1369 (Fed. Cir. 2000) (“While the witnessing of the labo-
ratory notebooks fell far short of ideal, we do not agree that the belated witnessing under-
mines all corroborative value that these entries may possess. Under a "rule of reason" analy-
sis, the fact that a notebook entry has not been promptly witnessed does not necessarily dis-
qualify it in serving as corroboration of conception.”) 
337   In re O’Farrell, 853 F.2d 894.  
338   In re O’Farrell, 853 F.2d 894, 895, for a summary, see Eisenberg, Rebecca, Patenting the 
Human Genome, 39 Emory Law Journal 1990, 721-745, 732.  
339   In re O’Farrell, 853 F.2d 894, 901. 
340   In re O’Farrell, 853 F.2d 894, 902. 
341   In re O’Farrell, 853 F.2d 894, 903-904; Pfizer v. Apotex, 480 F.3d 1348, 1366 (Fed. Cir. 
2007) (“Although we recognize some degree of unpredictability of salt formation, the mere 
possibility that some salts may not form does not demand a conclusion that those that do are 
necessarily non-obvious.” (citation omitted)); Abbott Laboratories v. Andrx Pharmaceuti-
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This reasoning was confirmed in In re Deuel342, which involved a patent applica-
tion referring to DNA and cDNA molecules encoding a protein that stimulates cell 
division.343 The Federal Circuit held that the prior art, which included the encoded 
amino acid and an enabling method for isolating and purifying the DNA, was insuf-
ficient to render a claim directed to DNA or cDNA prima facie obvious. The court 
concluded that prior art disclosure of the amino acid sequence of a protein would not 
automatically make particular DNA molecules encoding the protein obvious because 
“the redundancy of the genetic code permits one to hypothesize an enormous num-
ber of DNA sequences coding for the protein.”344 
The readjustment of the nonobviousness requirement relating to the patenting of 
DNA process patents is of particular interest for inventions related to the proteomic 
sector, since it demonstrates how traditional legal standards can be readjusted in or-
der to cope with new technologies such as genomics. Based on the Biotechnological 
Process Patents Act of 1995, Section 103 was amended, with the result that the pri-
ma facie obviousness evidence was significantly simplified. The amendment was the 
final solution of a dilemma that started with the application of principles developed 
in the field of chemical inventions. In In re Durden,345 a process patent claim con-
cerning a chemical process had been rejected by the USPTO. The patent applicant 
argued on appeal that while individual process steps were obvious, the use of a nov-
el and nonobvious starting material and the production of a new and nonobvious 
product implied that the process should be patentable. The Court held that the use of 
a new starting material and the development of a patented product did not automati-
cally establish the nonobviousness of a process or the grant of a process patent. The 
Court argued that if every process using a new or novel material was granted a pa-
tent, then simple processes such as dissolving or heating would be patentable when 
using a new compound. This principle however, created a major problem for inven-
tors of a patentable composition of matter who wanted to apply for a biotechnologi-
cal processes patent making use of the (patented) composition of matter. Inventors 
of patentable compositions of matter used in a biotechnological process were unable 
to receive process patents for the use of the patentable composition. This resulted in 
 
cals, Inc., 452 F.3d 1331, 1352 (“The court concluded that they were not so similar as to be 
interchangeable in the context of polymers like HPMC, correctly rejecting the argument that 
“obvious to try” can establish obviousness.”) 
342   In re Deuel, 51 F.3d 1552 (Fed. Cir. 1995).  
343   In re Deuel, 51 F.3d 1552, 1554 (Fed. Cir. 1995). 
344   In re Deuel, 51 F.3d 1552, 1560. Not followed as dicta in Regents of University of Cal. v. 
Monsanto Co., 2005 WL 3454107 (N.D.Cal. 2005) (“It is true that one might argue that the 
cases leave open the question whether disclosure of the complete amino acid sequence of a 
protein--where specified by unique codons or otherwise described in such a way that knowl-
edge of outside genetic methods could be shown to identify all DNA sequences encoding the 
protein--can render claims to generic DNA sequences for that protein obvious. Nonetheless, 
such statements are dictum in both cases, and do not control the decision here.”); see also 
Hoscheid, Dale H./Hemmendinger, Lisa M., Biotechnology and the Federal Circuit, Wash-
ington D.C. 2000, 33. 
345   In re Durden, 763 F.2d 1406 (Fed. Cir. 1985).  
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the problem that “unless a patent on the process is obtained (or a patent on the final 
product), the final product could be prepared overseas and imported back into the 
U.S. for sale without infringing the patent on the materials used in the process”. 
For this reason, the U.S. Congress significantly amended Section 103. The re-
vised subsection provides that where a composition of matter meets the novel and 
nonobvious requirement under main section (103 a), a “biotechnological process” 
using or resulting in the patentable composition of matter must also be treated as 
nonobvious if the following five conditions are met.346  
 The biotechnological process and composition of matter be contained in the same application, 
separate applications, or separate applications having the same effective filing date;  
 both the biotechnological process and composition of matter are owned or subject to an as-
signment to the same person at the time the process was invented;  
 a patent issued on the process also contains the claims to the composition of matter used in or 
made by the process, or, if the process and composition of matter are in different patents, the 
patents expire on the same date;  
 the biotechnological process falls within the definition set forth in 103(b); and 
 a timely election proceeds under the provision of 103(b).347  
The amendment had a deep impact on the whole field of biotechnological patents. 
Its effects extend far beyond the process of examination. It establishes absolute pro-
tection from the defense in infringement litigation that qualifying biotechnological 
process claims are construed to be invalid for obviousness.  
Another characteristic of the nonobviousness requirement is significant for inven-
tors of protein structures. The application of a strict obviousness standard signifi-
cantly decreases the risk of permanent and harmful monopoly positions of gene pat-
ent holders. Although the USPTO issued several DNA patents based on the general 
requirements set forth above, it does not imply that the successful identification of a 
DNA sequence in a gene of interest will remain a nonobvious procedure. Specifical-
ly, scientific advances in biotechnology and related fields (such as improved cloning 
and identification techniques) will likely make future DNA sequences obvious as of 
the time they are identified. Moreover, advances in protein chemistry have facili-
tated to an increasing degree the separation, purification, and amino acid sequencing 
of proteins. Consequently, the cloning and sequencing of genes corresponding to 
these proteins may become a trivial scientific achievement well established as within 
the ordinary skill of biotechnological researchers. Claims to newly purified chemi-
cals have often been challenged in the past as obvious relative to naturally existing 
 
346   USPTO Notice, Guidance on Treatment of Product and Process Claims in Light of In re 
Ochiai, In re Brwouwer and 35 U.S.C. § 103(b), available at  
  http://www.uspto.gov/go/og/con/files/cons104.htm, last checked on January 21, 2008.  
347   USPTO Notice, Guidance on Treatment of Product and Process Claims in Light of In re 
Ochiai, In re Brwouwer and 35 U.S.C. § 103(b), available at  
  http://www.uspto.gov/go/og/con/files/cons104.htm, last checked on January 21, 2008.  
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impure products. In response, courts upheld the validity of those claims, concluding 
that nonobviousness was established by the fact that the inventor had shown the dif-
ficulty and unpredictability of synthesizing the desired gene. It is, however, likely 
that patent examiners in the near future will reject any claims to the protein-
encoding DNA sequence, provided sufficient information is available regarding the 
protein corresponding to the gene to enable its synthesis in pure form.348  
In Teleflex v. KSR349, Teleflex sued KSR arguing that one of KSR's products 
infringed Teleflex's patent involving an adjustable vehicle control pedal connected 
to an electronic throttle control. KSR assessed that the connection of the two 
elements was obvious, and the claim was therefore invalid. The district court ruled 
in favor of KSR, but the Court of Appeals for the Federal Circuit reversed the 
judgment.350 
The Supreme Court reversed the Federal Circuit holding, stating that claim 4 of 
the patent was obvious under the threshold of 35 U.S.C. §103. The Court found that 
in "rejecting the District Court’s rulings, the Court of Appeals analyzed the issue in 
a narrow, rigid manner inconsistent with §103 and our precedents," referring to the 
Federal Circuit's application of a "teaching, suggestion, or motivation" (TSM) test, 
under which “a patent claim is only proved obvious if the prior art, the problem's 
nature, or the knowledge of a person having ordinary skill in the art reveals some 
motivation or suggestion to combine the prior art teachings.”351 
The Supreme Court made clear that “[a] person of ordinary skill is also a person 
of ordinary creativity, not an automaton.”352 The judge acknowledged that his 
definition of a person having ordinary skill in the art does not necessarily conflict 
with other Federal Circuit cases that described a skilled person as having "common 
sense" and whose incentive was based on "implicitly in the prior art."353 The judge 
emphasized that his opinion had the purpose of correcting the "errors of law made 
by the Court of Appeals in this case" and does not necessarily overturn all other 
Federal Circuit rulings.354 
 
348   Eisenberg, Rebecca, Patenting the Human Genome, 39 Emory Law Journal 1990, 721-745, 
730-731. 
349   Teleflex, Inc. v. KSR International, 127 S. Ct. 1727 (Fed. Cir. 2007). 
350   Teleflex, Inc. v. KSR International, 127 S. Ct. 1727, 1727. 
351   Teleflex, Inc. v. KSR International, 127 S. Ct. 1727, 1729.  
352   Teleflex, Inc. v. KSR International, 127 S. Ct. 1727, 1742. 
353   Teleflex, Inc. v. KSR International, 127 S. Ct. 1727, 1743. 
354   Teleflex, Inc. v. KSR International, 127 S. Ct. 1727, 1743. 
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With regard to a general standard of obviousness, the Court ruled: 
“One of the ways in which a patent's subject matter can be proved obvious is by noting that 
there existed at the time of invention a known problem for which there was an obvious 
solution encompassed by the patent's claims.”355 
When the requirements for obviousness were applied to the question at issue, 
however the Court stated: 
“ordinary skill, facing the wide range of needs created by developments in the field of 
endeavor, would have seen a benefit to upgrading [the technology disclosed by the prior art] 
with a sensor.356 “ 
Hence, the court defined the recognition of a benefit as the crucial factor for any 
obviousness evaluation. This is, however, a different approach than asking whether 
someone had been motivated to make a chance, a threshold applied in earlier 
decisions.  
The decision started an intense debate over the impact on the TSM test and the 
earlier used “obvious to try” standard. This was particularly because, even though 
the Supreme Court did not reject the TSM test in general, it had referred to it with 
some critical language. More specifically, the judge found that obviousness  
"must not be confined within a test or formulation too constrained to serve its purpose."357  
Generally, KSR ruled against the approach restricting the use of a “common sense”, 
denying “rigid preventatives rules that deny factfinders recourse to common 
sense”.358 
The judge, however, made clear that the TSM test remains applicable to the 
question of obviousness, emphazising, however, that the manner in which the test is 
to be applied is newly instrued.”359 
In Leapfrog Enterprises, Inc. v. Fisher-Price, Inc., (Fed. Cir. May 9, 2007), the 
Federal Circuit interpreted the KSR case, holding the patent under review 
was invalid for being obvious.360 Accordingly, even though Teflex did not suddenly 
make all inventions obvious, Leapfrog shows that the Teflex approach is the now 
applied standard for defining obviousness.  
b) Europe (Inventive Step) 
Pursuant to Art. 56 EPC, an invention shall be considered as involving an inventive 
step if, having regard to the state of the art, it is not obvious to a person skilled in the 
 
355   Teleflex, Inc. v. KSR International, 127 S. Ct. 1727, 1742. 
356   Teleflex, Inc. v. KSR International, 127 S. Ct. 1727,  1744. 
357   Teleflex, Inc. v. KSR International, 127 S. Ct. 1727, 1746.  
358   Teleflex, Inc. v. KSR International, 127 S. Ct. 1727, 1742-1743. 
359   Teleflex, Inc. v. KSR International, 127 S. Ct. 1727, 1741.  
360   Leapfrog Enterprises, Inc. v. Fisher-Price, Inc., 485 F.3d. 1157 (Fed. Cir. 2007). 
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art. In this respect, the prior art is considered as a whole, i.e., the teachings of sepa-
rate prior art documents are combined together.361 
Several tests are used to determine inventive activity, such as the problem-
solution approach362 and the “could/would” test363. Indications for inventive activity 
include commercial success, surmounting of difficulties, disbelief and scepticism of 
experts, satisfaction of long existing needs and the finding of new and unexpected 
results.364 The relevant moment for determination is the filing/priority date and no ex 
post facto judgement is allowed.365  
The finding of unexpected results often occurs in the field of chemicals or phar-
maceuticals, where surprising effects or characteristics of substances are the out-
come of experimentation.366 Such surprising characteristics can include, for exam-
ple, reduced side effects, improved resorption and stability of the new protein.  Even 
if the isolation as such is not inventive, the surprising effect is sufficient to establish 
inventiveness.367  
In the field of chemical inventions, Triazole/Agrevo368 can be considered a major 
decision, in which the problem-solution-approach of the EPO was defended and ap-
proved against the appellant’s allegation that Art. 56 EPC did not expressly require 
that the subject matter of a patent application had to solve a technical problem. The 
Board of Appeals defined the “problem-solution-approach” as a “generally accepted 
legal principle” and held that the technical effect of the claimed invention is inhe-
rently connected to the determination of inventive step. The Board stated that what 
the skilled person would have done depends on the technical result they set out to 
achieve rather than “idle curiosity”. Lacking the solution to a technical problem, an 
 
361   Benkard/Jestaedt, EPÜ, Art. 56, No. 1. This differs from the examination of novelty, where 
it is not permissible to combine separate prior art documents together, see Chapter 3 A II 3 
b); T 153/85, OJ 1988, 1 “Alternative Claims”. 
362   The test asks whether a person skilled in the art not only theoretically “could” have prepared 
the claimed compounds, but whether he “would” have done so in view of the state of the art; 
Szabo, George S. A , The Problem and Solution Approach in the European Patent Office, 26 
IIC 457 (1995). 
363   T 513/90, Geschäumte Körper/Japan Styrene, OJ 1994, 154, 160f.; T 455/91 Expression in 
Yeast/Genentech, OJ 1995, 684, 730f; Guidelines for Examination in the EPO, Part C-IV, 
9.10.2.  
364   Kraßer, Rudolf, Patentrecht: ein Lehr- und Handbuch zum deutschen Patent- und Ge-
brauchsmusterrecht, europäischen und internationalen Patentrecht, 5. Aufl., München 2004, 
325-332. 
365   The desisive question is whether the person skilled in the art had been able to carry out the 
invention on the priority date without any inventive activity, see Busse/Keukenschrijver, 
PatG, § 4, No. 24. 
366   Busse/Keukenschrijver, PatG, § 4, No. 16, emphasize that an element is interpreted as a very 
strong sign for inventive activity. 
367   T 181/82 Spiroverbindungen/Ciba-Geigy, OJ 1984, 401, 409; T 57/84 Tolylfluanid/Bayer, 
OJ 1987, 53; T 939/92; OJ 1996, 309, 317. The fact that a chemical substance’s property was 
distinct from other chemical substances had been surprising for a person skilled in the art 
may be sufficient to establish inventive activity, see Busse/Keukenschrijver, PatG, § 4, 89. 
368   T 939/92, Triazone/Agrevo, OJ 1996, 309, 317.  
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invention would probably not involve any inventive step. The case dealt with claims 
for chemical compounds. The Board held that an arbitrary selection of chemical 
compounds that were structurally similar to the closest prior art could not involve 
any inventive step.  For the assessment of the inventive step, the examiner must 
study the claim, the closest prior art, and the difference in terms of features of the 
claim and the closest prior art. Then the examiner must determine whether the con-
clusion of all of the closest prior art documents would prompt the skilled person, 
faced with the technical problem, to adapt the closest prior art to arrive at something 
within the terms of the claim. The inventive step criteria must be examined in rela-
tion to all aspects of the claimed invention, including the underlying problem, the 
insight upon which the solution relies, the means constituting the solution, and the 
effect or results obtained. The ruling clearly describes the method of the “problem-
solution-approach”, describing the three main stages: e.g., determining the “closest 
prior art”; establishing the “objective technical problem” to be solved; and consider-
ing whether or not the claimed invention, starting from the closest prior art and the 
objective technical problem, would have been obvious to the skilled person.369  
With regard to the recombinant production of proteins, Human beta-
interferon/BIOGEN370 is an example of how the requirement of inventive step is 
analyzed. The Board of Appeal rejected a claim to a recombinant produced polypep-
tide displaying the immunological or biological activity of human beta-interferon (β-
IFN) for lack of an inventive step. The examiners concluded that the construction of 
the β-IFN expression vector per se does not require more than routine effort from 
the average skilled person. A skilled person could have reasonably expected the be-
ta-IFN cDNA to be expressed in the recombinant host as an active protein. Thus, the 
known properties of the human β-IFN contained a clear and obvious suggestion as to 
how to produce it.371  
In Milk production/MONSANTO372, the EPO adopted the U.S. standards of ana-
lyzing the obviousness requirement that had been established in In re O’Farrell. As 
in In re O’Farrell, the appellant alleged that a standard of “obvious to try” would 
not be sufficient for a rejection. The court followed the U.S. patent law by stating 
that obviousness does not require absolute predictability of success. The court clari-
fied that the need of experimentally confirming a reasonably expected result does 
not render an invention unobvious, determining that, in the case at issue, an average 
skilled person was provided “with a clear hint from the prior art pointing him in the 
direction of the claimed method.”373 
In sum, the European inventive step requirement is very similar to the U.S. law on 
obviousness: a patent claim lacks inventive activity if every element of the claim is 
included or suggested by the state of the art. The state of the art as such must pro-
 
369   T 939/92, Triazone/Agrevo, OJ 1996, 2.4 – 2. 7.  
370   T 207/94 Human beta-interferon/BIOGEN, N. Publ. 
371   T 207/94 Human beta-interferon/BIOGEN, N. Publ., No. of the Reasons, 22-44.  
372   T 249/88, Milk production/MONSANTO, N. Publ. 
373   T 249/88, Milk production/MONSANTO, N. Publ., No. of the Reasons, 8.  
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vide the motivation to combine several references to meet the claims. In the U.S., 
the decision of In re Deuel, however, made clear that prior art does not render a 
claim obvious, if the skilled person is permitted “to hypothesize an enormous num-
ber” of possibilities to carry out the invention.374  
5. Written description/patent description and sufficient disclosure 
Compared to other patentability requirements, the need to provide a written 
description fulfilling certain minimum standards (in the case of the U.S.) and to 
suffciently disclose the invention (in the case of Europe) has long been considered 
an issue of a somewhat lower importance. This has changed in recent years, not least 
as a consequence of the increasing complexity of explaining and demonstrating the 
nature and scope of biotechnological patents. 
a). U.S. 
In particular in the U.S., a controversial debate about whether and in what form 
patent law princples imply a “seperate” written description requirement has 
emerged. A review of this debate offers important lessons, not only for inventors of 
proteomic structures. Before going through the arguments that have dominated the 
discussion, the following section will first outline the basic statutory background, 
focusing on cases with a biotechnological subject matter.  
aa) Basic statuatory background 
Pursuant to Section 35 U.S.C. § 112(1), a patent application shall  
“contain a written description of the invention, and of the manner and process of making and 
using it in such full, clear, concise, and exact terms as to enable any person skilled in the art to 
which it pertains, or with which it is most nearly connected, to make and use the same, and 
shall set forth the best mode contemplated by the inventor of carrying out his invention.” 
The provision can be seen as containing four individual requirements, usually de-
nominated as: (1) written description, (2) enablement, (3) best mode and (4) defi-
niteness375. However, as discussed in detail below, the Federal Circuit has not deci-
sively clarified whether the written description requirement must be considered sep-
arately from enablement and best mode.   
 
374   In re Deuel, 51 F.3d 1552, 1560. See Chapter 3 A II 4 a).  
375   See Guidelines for Examination of Patent Applications under the 35 U.S.C. § 112, 1, “Writ-
ten description” Requirement, 66 Fed. Reg. 1099, 1014 (Jan. 5, 2001) [hereinafter Written 
Description Guidelines]. 
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The requirement of enablement demands that the applicant’s specification pro-
vides sufficient disclosure about the invention. Generally, the specification must 
provide enough instruction so that a person skilled in the art would not have to exer-
cise any “undue experimentation”376 to make and use the full scope of the claimed 
invention. 
In re Wands set forth the details of enabling.377 In this decision, a patent applica-
tion, referring to the disclosure of immunoassay methods for detecting the hepatitis 
B virus using high-affinity immunoglobulins, was rejected. The court stated that the 
application did not enable one to make and use the claimed invention. On appeal to 
the CAFC, the patentee argued that the application in fact was enabling because a 
DNA encoding the high-affinity immunoglobulin had been deposited with the 
American Type Culture Collection (ATCC) and was accessible to the public. Con-
sequently, a person skilled in the art would not have had to perform undue experi-
mentation to make the antibodies necessary for the claimed invention. The CAFC 
agreed that the patent application was complying with the enablement factor. In the 
decision, the court stressed the factors that should be considered when determining 
whether undue experimentation would be required to practice a claimed invention. 
The so-called Wands factors include:  
 The quantity of experimentation necessary to practice the claimed invention; 
 the amount of direction or guidance presented in the specification;  
 the presence or absence of working examples in the specification;  
 the nature of the invention;  
 the state of the prior art 
 the relative skill of those of ordinary skill in the art  
 the predictability or unpredictability of the art; and 
 the breadth of the claims.378 
Amgen, Inc. v. Chugai Pharm. Co. shows how the Federal Circuit applies the patent 
jurisprudence relating to chemical compounds to biotechnology, and provides a 
framework for the treatment of enablement in cases involving nucleic acid se-
quences.379 Amgen was the owner of a patent to a purified and isolated DNA se-
quence encoding the human erythropoietin (‘Epo’) gene. The district court invali-
dated a claim covering a “potentially enormous” number of ‘Epo’ analogs for lack 
 
376   In re Wands, 858 F.2d 731, 731 (Fed. Cir. 1988). See also Kunin, Stephen G/ Nagumo, 
Mark/ Stanton, Brinaet al., Reach-through claims in the age of biotechnology, 51 American 
University Law Review April 2002, 609-638, 630. 
377   In re Wands, 858 F.2d 731 (Fed. Cir. 1988). 
378   In re Wands, 858 F.2d 731, 731. 
379   Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200, 1206, 1212. (Fed. Cir. 1996) (“A gene is 
a chemical compound, albeit a complex one, and it is well established in our law that con-
ception of a chemical compound requires that the inventor be able to define it so as to distin-
guish it from other materials, and to describe how to obtain it.”) 
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of enablement.380 The Federal Circuit confirmed that the claims were not enabled, 
but instead based its conclusion on the lack of enablement of the underlying DNA 
sequences.  The court explained: 
“It is not necessary that a patent applicant test all the embodiements of this invention; what is 
necessary is that he provides a disclosure sufficient to enable one skilled in the art to carry out 
the invention commensurate with the scope of the claims.  For DNA sequences, that meant 
disclosing how to make and use enough sequences to justify grant of the claims sought. Am-
gen had not done that here.”381 
In In re Fisher,382 the Federal Circuit confirmed the rejection of enablement, “be-
cause the claimed ESTs were not disclosed as having a specific and substantial utili-
ty.”383 According to the court “it is well established that the enablement requirement 
of § 112 incorporates the utility requirement of § 101.”384  
In Falko-Gunter Falkner v. Inglis,385 the patent application claimed a 
novel type of vaccine production applicable to various types of “vector 
viruses”, such as adenoviruses, herpesviruses, poxviruses and retroviruses. In vac-
cinations using vector viruses, immunity against the target virus is achieved by ex-
posing the immune system to harmless fragments of the target virus. To prevent in-
fections through the viral vector itself, genes that cause a vector’s harmful effects 
have to be inactivated, traditionally by deleting an inessential gene from the respec-
tive genome. By devising a method in the course of which an essential gene is inac-
tivated, the inventors claimed to have discovered a substantially safer way of vac-
cine production. Moreover, the new method offered a solution to a fundamental 
problem of vaccine production. By growing vaccines in cells that were complemen-
tarily modified to produce the absent essential viral gene product “on behalf of” the 
vector virus, the difficulty of growing an inhibited or “attenuated” version of a virus 
was effectively circumvented.  
While being applicable to the various viruses mentioned above, the patented in-
vention dealt specifically with vaccines in which the vector virus is a poxvirus.386 
The specification, however, provided a detailed example of an embodiment that 
comprised herpes virus, not poxvirus, including identity of deleted essential se-
 
380   Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200, 1204.  
381   Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200, 1212.  
382   In re Fisher, 421 F.3d 1365 (Fed. Cir. 2005). For a summary of the factual background and 
the court’s ruling regarding the utility requirement, see Chapter 3 A II 2a.  
383   In re Fisher, 421 F.3d 1365, 1378.  
384   In re Fisher, 421 F.3d 1365, 1378, (citations omitted); see also In re Kirk, 376 F.2d, 936, 942 
(C.C.P.A. 1967) (“Necessarily, compliance with § 112 requires a description of how to use 
presently useful inventions, otherwise an applicant would anomalously be required to teach 
how to use a useless invention.”); In re Brana, 51 F.3d 1560, 1564 (Fed. Cir. 1995) (“Obvi-
ously, if a claimed invention does not have utility, the specification cannot enable one to use 
it.”). 
385   Falko-Gunter Falkner v. Inglis, 448 F.3d 1357 (Fed. Cir. 2006). 
386   Falko-Gunter Falkner v. Inglis, 448 F.3d 1357, 1360.  
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quences therein. The Federal Circuit nevertheless concluded that the patent was ade-
quately enabled, and explained:  
“[T]here is extensive disclosure of the selection of an essential gene, its deletion or inactiva-
tion and the production of a mutated virus with said deleted or inactivated gene, albeit for her-
pesvirus.” Moreover, because the differences between the herpesviruses and poxviruses were 
well known, this would have aided the person of ordinary skill in the art in her application of 
the lessons of the herpesvirus example in the construction of poxvirus vaccines. … the mere 
fact that the experimentation may have been difficult and time consuming does not mandate a 
conclusion that such experimentation would have been considered to be ‘undue’ in this art. In-
deed, great expenditures of time and effort were ordinary in the field of vaccine prepara-
tion.”387  
The court declared that a skilled person was clearly considered to be able “to identi-
fy the ‘essential’ poxvirus genes [by] relying on publications in professional journals 
that had disclosed the DNA sequence of the poxvirus genome along with the loca-
tions of the ‘essential regions,’… since a patent need not teach, and preferably 
omits, what is well known in the art.”388  
bb) Deposit requirements 
In order to overcome the difficulty of providing a detailed written description suffi-
cient to permit the production of complex living organisms, the courts accepted as a 
substitute the deposit of living material with a public depository. Public access to the 
deposited material was determined to be sufficient to satisfy Section 112, first para-
graph.389 This solution was established in In re Argoudelis.390 The United States 
Court of Customs and Patent Appeals (CCPA) assumed that “there can be no de-
scription in words alone of how to obtain the microorganism from nature”. 
A deposit was sufficient to satisfy the enablement requirement of Section 112, 
first paragraph, if (1) a public depository was used, (2) the deposit was made prior to 
the filing date of the application, (3) the depository and accession number were refe-
renced in the application as filed, (4) the depository was under a contractual obliga-
tion to maintain the deposited culture in the permanent collection, (5) the depository 
was under obligation to supply samples to persons having access to the pending ap-
plication, (6) the deposited organism would be made available to the public without 
restriction on the issue date of the patent, and (7) the cultures were not expected to 
undergo any physical changes rendering them unusable.391 
 
387   Falko-Gunter Falkner v. Inglis, 448 F.3d 1357, 1365.  
388   Falko-Gunter Falkner v. Inglis, 448 F.3d 1357, 1365, citing Spectra-Physics, Inc. v. Coher-
ent, Inc., 827 F.2d 1524, 1534 (Fed. Cir. 1987). 
389   Monsanto Co. v. Scruggs, 459 F.3d 1328, 1337 (Fed. Cir. 2006) (The written description 
requirement was satisfied because the '605 patent incorporates by reference deposits with the 
American Type Culture Center, which are publicly available.) 
390   In re Argoudelis, 434 F.2d 1390 (C.C.P.A. 1970). 
391   In re Argoudelis, 434 F.2d 1390, 1394.  
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In Feldman v. Aunstrup392, the court stated that the requirements established in 
Argoudelis were not mandatory. More specifically, a deposit in private foreign enti-
ties was deemed sufficient under Section 112. The essential criteria, the court rea-
soned, were that the culture was permanently available, and that access was assured. 
In In re Lundak, the court concluded that even the “deposit” of a microorganism in 
the inventor’s private laboratory may meet the standard of Section 112 at the time of 
filing, and that public depository is sufficient if it is made at any time prior to the 
issuance of the patent.393 The court further held that neither the postfiling depository 
nor the addition of the accession number to the pending application enlarges the dis-
closure of the specification by the addition of new matter.394  
cc) The debate on a separate written description requirement 
i. Background to the debate 
Soon after broad biotechnological claims had become standard practice, concerns 
were raised about their medium- and long-term effects on product innovation.395 In 
the ensuing debate about how to prevent overly broad claims, proposals ranged from 
legislative changes to a stricter approach to patent specification requirements.396 
With respect to the latter, a number of landmark decisions of the Federal Circuit 
Court further attracted substantial interest. A majority of Federal Circuit judges in-
terpreted Section 112, first paragraph of the U.S. Patent Act as imposing a “separate 
written description requirement”. More specifically, “written description” was seen 
as a requirement distinct from “enablement”, a view that has inspired an intense dis-
pute over the appropriateness of alternative patent drafting strategies and the legal 
certainty that can be reasonably expected when possessing a patent. Due to its wide-
ranging implications and its importance for the debates on the appropriate scope of 
protection, it is essential to review the court’s decision extensively.397 
In several cases, the majority of judges concluded that a patent serves not only to 
disclose to the public how to ‘make and use’ an invention, but also to indicate 
whether the inventor actually “possessed the invention” at the time the application 
was filed. Accordingly, an analysis pursuant to Section 112 would ask for two sepa-
 
392   Feldman v. Aunstrup, 517 F.2d 1351, 1352 (C.C.P.A. 1975). 
393   In re Lundak, 773 F.2d 1216, 1222 (Fed. Cir. 1985). 
394   In re Lundak, 773 F.2d 1216, 1223. 
395   See, for example, Schiermeier, Quirin, German agencies sound alarm on risks of broad gene 
patents, Nature 406, 2000, 111. 
396   Barton, John H., United States Law of Genomic and Post-Genomic Patens, 33 IIC 779, 782 
(2002), noting that after the Ely Lilly decision it is unlikely that a gene can be patented with-
out identification of its sequence.  
397   Mull, William C., Using the Written Description Requirement to Limit Broad Patent Scope, 
Allow Competition, and Encourage Innovation in Biotechnology, 14 Health Matrix: Journal 
of Law-Medicine 2004, 393, 393ff. 
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rate and independent requirements. First, the applicant must describe the invention 
so that a person skilled in the art can recognize the claim as what has actually been 
invented (i.e., actually or constructively “possessed”). Second, the description has to 
be drafted in a way that enables the public to make and use the full scope of the in-
vention.”398 
A minority of Federal Circuit Judges, headed by Judge Rader, strongly opposed 
the majority view, rejecting the appropriateness and legal consistency of a “separate 
written description requirement”. Without regard to enablement, the content of the 
written description and its adequacy to support the claims should only be considered 
in cases related to priority, but not in the context of patentability. In the view of the 
minority, such a reading would be consistent with earlier rulings by the Federal Cir-
cuit, which only examined enablement and best mode under §112.399  It would also 
be sufficient to accommodate Section 132, which prohibits the addition or amend-
ment of claims subsequent to the effective filing date that would add new matter to 
the application.400 
 
398   Amgen Inc. v. Transkaryotic Therapies, Inc., 314 F.3d 1313, 1330 (Fed. Cir. 2003).  In Re-
gents the University of California  v. Eli Lilly & Co., 119 F.3d 1559 at 1566 (Fed. Cir. 
1997), the Federal Circuit clearly determined that the § 112 analysis “requires a precise defi-
nition, such as by structure, formula, chemical name, or physical properties, not a mere wish 
or plan for obtaining the claimed … invention.” In Amgen, 314 F.3d at 1332 (Fed. Cir. 
2003), the threshold was narrowed down by the Federal Circuit’s statement that “Eli Lilly 
did not hold that all functional descriptions of genetic material necessarily fail as a matter of 
law to meet the written description requirement, rather, the requirement may be satisfied if 
the knowledge of the art of the disclosed function is sufficiently correlated to a particular, 
known structure.” Capon v. Eshhar, 418 F.3d 1349, 1360 (Federal Circuit 2005) weakened 
the Eli Lily doctrine much further with the statement that “[t]he predictability or unpredict-
ability of the science is relevant to deciding how much experimental support is required to 
adequately describe the scope of an invention.” Capon, however, fails to establish clear rules 
of how broad a patent specification must be drafted. Even though it states that prior art must 
be taken into account, more detailed information of how far this prior art consideration must 
be made, is missing. 
399   In re Gay, 50 C.C.P.A. 725, 309 F.2d 769, 772 (C.C.P.A. 1962). Originally, courts consid-
ered claims part of the disclosure, which is why they could not lack adequate description, see 
In re Smith, 481 F.2d 910, 914 (C.C.P.A. 1973) (“Where the claim is an original claim, the 
underlying concept of insuring disclosure as of the filing date is satisfied, and the description 
requirement has likewise been held to be satisfied.“) 
400   In Enzo Biochem., Inc. v. Gen-Probe International, 323 F.3d 956 at 977 Judge Rader starts 
his analysis with a detailed review of the origin and history of the written description re-
quirement (“[E]very patent system must have some provisions to prevent applicants from us-
ing the amendment process to update their disclosure (claims or specification) during their 
pendency before the patent office). In contrast, the judge refuses to analyse the written de-
scription in cases in which priority is not in question, Id. at 979 (“[W]ritten description does 
not examine the specification for ‘literal support’ of the claim language unless priority is in 
question.”). Chiron v. Genentech, 963 F.3d 1247 at 1255 (Fed. Cir. 2004) also exemplifies 
how the written description requirement is examined in the context of priority. (“[T]he writ-
ten description requirement prevents applicants from using the amendment process to update 
their disclosures.”). 
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The implications of these alternative solutions are wide-ranging. In particular, a 
‘separate written description requirement’ forces applicants to provide a much more 
detailed delineation of the nature, scope, and application of claims.401 Moreover, it is 
likely that certain subject matter cannot be patented until a later stage of understand-
ing of the invention and its potential embodiments. Similar to the utility require-
ment, an additional written description requirement may thus force inventors to de-
lay the filing of a claim, while at the same time limiting the broadness of a claim. 
This is particularly relevant for biotechnological inventions, as many generic inven-
tions may be enabled without a clear understanding of what the claim actually ap-
plies to. 
ii. Development of a ‘separate written description’ doctrine 
In Regents of the University of California v. Eli Lilly & Co402, the Federal Circuit 
held cDNA encoding rat insulin to be an insufficient written description to support 
claims to cDNAs encoding vertebrate, mammalian, or human insulin, even though 
the application included a method to isolate those cDNAs. The court clarified that 
“describing a method or preparing a cDNA or even describing the protein that the 
cDNA encodes does not necessarily describe the cDNA itself.”403 A description of a 
genus of cDNAs may be achieved by means of a recitation of a representative num-
ber of cDNAs, defined by nucleotide sequence, falling within the scope of the genus 
or of a recitation of structural features common to the members of the genus, whose 
features constitute a substantial portion of the genus.404 Thus, the court concluded, 
the § 112 analysis “requires a precise definition, such as by structure, formula, 
chemical name, or physical properties, not a mere wish or plan for obtaining the 
claimed chemical invention”, but “none of those descriptions appeared in that pa-
tent.”405  
The reasoning of Ely Lilly was adapted in further cases. In Carnegie Mellon v. 
Hoffman-La Roche406, a district court held that claims referring to plasmids for the 
controlled expression of DNA polymerase I derived from any bacterial source were 
invalid because the specification only described DNA polymerase I from E.coli. The 
court argued that the Lilly decision was applicable, stating that “there is nothing in 
the Eli Lilly decision to suggest that the Federal Circuit’s observations about the na-
 
401   Under Section 112, the applicant is required to disclose what he “regards as the invention.”  
Thus, although the disclosure may be used to help interpret the claims, the disclosure may 
evidence a variance from the nature of the invention that the applicant actually believed was 
invented (and thus was possessed at the time of filing).  Although inquiry may still be made 
into such differences between claim meaning and the invention during prosecution, they are 
no longer able to be raised in litigation to challenge the validity of the claims.  See Solomon 
v. Kimberley Clark Corp., 216 F.3d 1372, 1377 (Federal Circuit 2000).  
402   Regents of the University of California v. Eli Lilly & Co., 119 F. 3d 1559 (Fed. Cir. 1997). 
403   Regents of the University of California v. Eli Lilly & Co., 119 F. 3d 1559, 1567.  
404   Regents of the University of California v. Eli Lilly & Co., 119 F3d. 1559, 1569. 
405    Regents of the University of California v. Eli Lilly & Co, 119 F.3d 1559, 1566. 
406   Carnegie Mellon v. Hoffman-La Roche, Inc.; 148 F. Supp. 2d 1004 (N.D. Cal. 2001). 
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ture of DNA was applicable only to novel DNA and not to any DNA sequence. A 
similar finding is established in Bristol-Myers Squibb v. Rhone-Poulenc 
er.407Here, the district court held that a generic claim must be rejected because the 
patentee failed to provide a copy of a scientific article by the inventors indicating 
that they themselves did not believe the invention could be practiced as broadly as 
claimed. Therefore, inventors should warrant that the extent of the claims is com-
mensurate with the underlying science.  
Enzo Biochem v. Gen-Probe408 is another landmark decision in which the strict 
written description requirement was confirmed. In the case, the CAFC considered a 
patent directed to three nucleic acid probes that hybridize preferentially with the 
DNA of the bacterium causing gonorrhea. The broader claims of the patent recited 
the probes as binding preferentially to the gonorrhea organism rather than a closely 
related one. The court argued that because the patentee had described the probes on-
ly in terms of sequence function (preferential hybridization), the written description 
for the claimed invention was inadequate as a matter of law. The court considered 
that although a “description of the ability of the claimed probe to bind to N. gonorr-
hoeae may describe that probe’s function, it does not describe the probe itself. We 
reject Enzo’s characterization of the hybridization as a distinctive ‘chemical proper-
ty’ of the claimed sequence.” Therefore, it is inadequate to describe genetic material 
by what it does, such as hybridizing with N. gonorrhoeae, notwithstanding the labe-
ling of the described property as “chemical” or “functional”.  
In University of Rochester v. Searle et al.,409 the patentee claimed a method for se-
lectively inhibiting the activity of a particular protein by “administering a non-
steroidal compound that selectively inhibits activity of that protein in a human in 
need of such treatment”. The University of Rochester sought to enforce its patent 
relating to the “new generation” of pain relievers, which act selectively through the 
 
407   Bristol-Myers Squibb v. Rhone-Poulenc Rorer, 2001 WL 1512597.  
408   Enzo Biochem v. Gen-Probe, 323 F.3d 956 (Fed. Cir. 2002). The Federal Court ruled on the 
issue in a number of further decisions. For the direct history of the case, see Enzo Biochem, 
Inc. v. Gen-Probe Inc., 285 F.3d 1013, 62 (Fed. Cir. 2002). Opinion Vacated on Rehearing 
by Enzo Biochem, Inc. v. Gen-Probe Inc., 323 F.3d 956 (Fed. Cir. 2002). For Additional 
Opinion, see Enzo Biochem, Inc. v. Gen-Probe, Inc., 2002 WL 32063710, 63 U.S.P.Q.2d 
1618 (Fed. Cir. 2002) AND Appeal After Remand Enzo Biochem, Inc. v. Gen-Probe Inc., 
414 F.3d 1376 (Fed. Cir. 2005). Order Recalled and Vacated by Enzo Biochem, Inc. v. Gen-
Probe Inc., 143 Fed. Appx. 350 (Fed. Cir. 2005) (Not selected for publication in the Federal 
Reporter).  
409   University Of Rochester v. G.D. Searle & Co., Inc., 358 F.3d 916 (Fed.Cir. 2004). The Fed-
eral Circuit decided on the issue in a number of further decisions, see University of Roche-
ster v. G.D. Searle & Co., Inc., 249 F.Supp.2d 216 (W.D.N.Y. 2003). Decision Affirmed by 
University Of Rochester v. G.D. Searle & Co., Inc., 358 F.3d 916 (Fed. Cir. 2004). Rehear-
ing and Rehearing en banc denied by University of Rochester v. G.D. Searle & Co., Inc., 375 
F.3d 1303 (Fed. Cir. 2004) AND Certiorari denied by University of Rochester v. G.D. Searle 
& Co., Inc., 543 U.S. 1015 (2004).  
409   Warburg, Richard J./Wellman, Arthur/Buck, Todd/Ligler Schoenhard, Amy E., Patentability 
and Maximum Protection of Intellectual Property in Proteomics and Genomics, 22 Biotech-
nology Law Report 2003, 264, 269. 
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inhibition of COX-2. By doing so, these pain relievers achieve the desired effect 
(inhibition of pain) while avoiding some of the undesirable side effects (particularly 
stomach irritation) invoked by earlier pain relievers which inhibit both COX-2 and 
COX-1. The patent disclosed and claimed methods for screening compounds to 
identify those that selectively inhibited the COX-2 gene product while having mi-
nimal effect on COX-1 activity, and the specification identified a single compound 
(NS-398) which is a specific inhibitor of COX-2 activity.410  
The district court found the claims to be invalid for lack of an adequate written 
description, concluding that the patent did not disclose a specific compound, and 
provided no guidance on how to make or obtain any compound that fell within the 
scope of the patent’s claim.” 411 On appeal, the University contested the district 
court’s ruling that a claim drawn to a method of obtaining a biological effect in a 
human by administering a compound cannot, as a matter of law, satisfy the written 
description requirement without disclosing the identity of any such compound.412 
The Federal Circuit rejected this argument, stating that an adequate written descrip-
tion requirement would “describe the claimed invention so that one skilled in the art 
can recognize what is claimed.”413 Generalized language may be inadequate if it 
does not convey the detailed identity of an invention. The court explained that 
“[r]egardless whether a compound is claimed per se or a method is claimed that en-
tails the use of the compound, the inventor cannot lay claim to that subject matter 
unless he can provide a description of the compound sufficient to distinguish in-
fringing compounds from non-infringing compounds, or infringing methods from 
non-infringing methods.”414 
iii. The ‘dissenting line’  
The other line, followed by a minority of judges of the Federal Circuit, strictly de-
nies a separate written description requirement. The opinions and arguments under-
lying this “dissenting line” were most clearly articulated in the cases of Eli Lilly415, 
Enzo I and II, and Rochester416. For the opponents of a separate written description 
requirement, to make a distinction between the disclosure of how to ‘make and use’ 
an invention and a disclosure that shows that an invention has in fact been “pos-
sessed” is “contrary to logic and the statue itself.” Underpinning the dissenting line 
 
410   Warburg, Richard J./Wellman, Arthur/Buck, Todd/Ligler Schoenhard, Amy E., Patentability 
and Maximum Protection of Intellectual Property in Proteomics and Genomics, 22 Biotech-
nology Law Report 2003, 264, 269. 
411   University Of Rochester v. G.D. Searle & Co., Inc., 358 F.3d 916, 919.  
412   University Of Rochester v. G.D. Searle & Co., Inc., 358 F.3d 916, 920.  
413   University Of Rochester v. G.D. Searle & Co., Inc., 358 F.3d 916, 922-923.  
414   University Of Rochester v. G.D. Searle & Co., Inc., 358 F.3d 916, 926.  
415   Regents of the Univ. of Cal. v.. Eli Lilly & Co., 119 F.3d 1559 (Fed.Cir.1997). The decision 
was criticized in University of Rochester v. Searle, 375 F.3d 1303, 1307 (Fed. Cir. 2004). 
416   University of Rochester v. Searle, 375 F.3d 1303, 1307.  
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is the view that, Section 112, first paragraph requires that the patent document 
“enables” the invention in terms of providing information sufficient to allow one 
with ordinary skill in the art to make and use the invention without undue experi-
mentation. To advocate that the written description serves a purpose over and above 
the enablement factor leads to the anomaly that a patent specification could appar-
ently enable a skilled artisan to make and practice the entire invention, but still not 
prove that the inventor possessed the invented subject matter.417 
Besides arguing that “a straightforward reading of the text of Section 112 sug-
gests that the test for an adequate written description is whether it provides enough 
written information for others to make and use the invention,418 Judge Rader cited 
Federal Circuit precedent. He reasons that the cases419 established by the Federal 
Circuit’s predecessor concluded that the patent claims as such satisfy the written de-
scription requirement. Hence, the specification did not necessarily have to comply 
with a written description requirement.420 Moreover, Judge Rader argued that, prior 
to the Eli Lilly decision; the case law had not applied the written description re-
quirement to questions of validity. In contrast, the application of the principle was 
merely restricted to questions of priority in order to determine the first inventor of 
the claimed subject matter. The separate written description doctrine, according to 
Judge Rader’s view, created “enormous confusion.”421  
Affirming summary judgment in Enzo I, the Federal Circuit  extended the reach 
of Lilly. The claims at issue were directed to nucleic acid probes which where speci-
fied for bacteria that cause gonorrhea.  The patent described the binding affinity of 
claimed sequences, and deposited three probes that met the claim limitations.422 The 
court held that reference in the specification to deposits in public depositories of 
nucleic acid probes whose sequences were not disclosed in the specification, but 
which possessed a known functionality, may not satisfy the written description re-
quirement.423 The court argued that the inventor’s disclosure was “purely functional” 
because the hybridization conditions did not identify the sequences but merely de-
scribed what they do.424 Even though not binding for the court,425 the Judges also 
 
417   Judge Rader, dissenting from denial of en banc review, University of Rochester v. Searle, 
375 F.3d 1303, 1307. (Fed. Cir. 2004). 
418   Judge Rader, dissenting in Enzo (denial of en banc review), Enzo Biochem Inc. v. GenProbe 
Inc., 323 F.3d 956, 976 (Fed. Cir. 2002). 
419   In re Gay, 50 C.C.P.A. 725, 309 F.2d 769, 772 (C.C.P.A. 1962); In re Smith, 481 F.2d 910, 
914 (C.C.P.A. 1973) (“Where the claim is an original claim, the underlying concept of insur-
ing disclosure as of the filing date is satisfied, and the description requirement has likewise 
been held to be satisfied.”). 
420   Judge Rader, dissenting from denial of en banc review, University of Rochester v. Searle, 
375 F.3d 1303, 1307. 
421    Judge Rader, dissenting from denial of en banc review, University of Rochester v. Searle, 
375 F.3d 1303, 1308.  
422   Id.  
423   Enzo Biochem, Inc. v. Gen-Probe, Inc., 285 F.3d 1013 at 1020. (Fed. Cir. 2002) (Enzo I).  
424   Id. at 1018. 
425   Enzo I, 285 F.3d at 1019.  
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noted that the functional description failed to meet the written description guidelines 
established by the USPTO.426 While conceding that the inventors, unlike those in 
Lilly, had achieved more than “a mere wish or a plant of obtaining the claimed in-
vention”427, the majority finally held that the absence of sequence information could 
not be cured by public deposit.”428 
Judge Dyk’s dissenting opinion mainly focused on Lilly. In an attempt to high-
light the wide-ranging implications of this in his view, misguided decision, he stated 
that Lilly “is open to serious question”. Emphasizing the potentially unequal treat-
ment of different fields of innovation and the need for a consistent extrapolation of 
long-held legal practices, he warns that Lilly imposes a “unique written description 
requirement in the field of biotechnology” and departs form the general rule of “pos-
session” of the invention.429 In addition, he harshly criticized the majority’s view 
that sequence information could not be made public by public deposit, arguing that 
reference to a deposit “is an ideal way of satisfying the written description require-
ment.”430  
The Enzo I decision was intensively discussed within the legal profession, and 
raised serious concerns, especially within the biotech community itself.431 Against 
this background, the same panel of judges had to reconsider the case.432 Taking into 
account the USPTO’s Written Description Guidelines, the panel partly vacated its 
earlier position. The major aspect of the reversed conclusion was that, in some cases 
and under certain conditions, a description of the function of genetic materials will 
be sufficient to meet the written description requirement:  
“[T]he PTO has determined that the written description requirement can be met by showing 
that an invention is complete by disclosure of sufficiently detailed, relevant identifying charac-
teristics … i.e., complete or partial structure, other physical and/or chemical properties, func-
tional characteristics when coupled with a known or disclosed correlation between function 
and structure, or some combination of such characteristics.”433 
 
426   Guidelines for Examination of Patent Applications Under 35 U.S.C. 112, Para 1 “Written 
Description” Requirement, 66 Fed. Reg. 1099 at 1106 (Jan. 5, 2001) (“WD Guidelines”).  
427   Enzo I at 1018 (quoting Lilly, 119 F.3d at 1566).  
428   Enzo I at 1021.   
429   Id. at 1025 (dissenting opinion).  
430   Id. at 1027 (“The primary purpose of the statutory written description requirement is to pro-
vide notice to comptentitors and the public of the scope of the patent claims.”) 
431   See, e.g., Brief of Amicus Curiae United States at 1 Enzo Biochem, Inc. v. Gen Probe, Inc., 
323 F.3d 956 (Fed. Cir. 2002), cited in Judge Rader dissenting from denial of en banc review 
in University of Rochester v. G.D. Searle & Co., Inc., 375 F.3d 1303 (“That Enzo opinion 
caused an immediate firestorm”).  
432   Enzo Biochem, Inc. v. Gen-Prob, Inc., 323 F.3d 956 (Fed. Cir. 2002) (Enzo II).  
433   Id. at 964 (citing Guidelines for Examination of Patent Applications Under 35 U.S.C. 112, 
Para 1 “Written Description” Requirement, 66 Fed. Reg. 1099 at 1106 (Jan. 5, 2001)). Gen-
erally, the WD Guidelines are consistent with the Federal Circuit case law, as they require an 
applicant “permit a person skill in the art to clearly recognize [the] applicant had possession 
of the claimed invention.” 66 Fed. Reg. at 1105. As for nucleotide sequences, however, the 
Guidelines did not fully embrace the doctrine of a separate written description requirement 
as it was developed in Lilly.  
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Based on this more flexible set of principles, the court remanded the case to the 
district court, which was asked to determine whether the specification provided suf-
ficient information to “demonstrate possession of the generic scope of the claims” 
by the inventors.434 Emphasizing the significance of the deposits and the scope of 
the claims, the remand order entrusted the district court to determine whether the 
claimed subject matter had been sufficiently disclosed, as judged by a person skilled 
in the art.435  
While providing a more flexible interpretation, the court followed its earlier view 
that the mere possession is not sufficient for a disclosure. Enzo had claimed that it 
had shown “possession” of the claimed invention sufficient to meet the requirement 
of § 112 because it had effectively reduced three sequences within the scope of the 
claims to practice, Rejecting this argument, the court held that possession is merely 
“ancillary to the statutory mandate”. Without additional information, a claim lacks 
sufficient disclosure.436  
In stark contrast to Enzo I, the Enzo II panel rejected the view that a biological 
deposit referred to in the specification could not be considered part of the disclosure.  
It explained that: 
“references in the specification to a deposit in a public depository, which makes its contents 
accessible to the public when it is not otherwise available in written form, constitutes an ade-
quate description of the deposited material sufficient with the written description requirement 
of § 112 Para 1.”437 
In sum, the Federal Circuit allowed the rehearing of Enzo I, but rejected a petition to 
rehear the appeal en banc.438 In his dissent from this denial, Judge Rader argued that 
outside the context of resolving priority, no statute or precedent supports an inde-
pendent written description requirement.439 Judge Lourie’s concurring opinion re-
jected this criticism, noting that “[n]ew interpretations of old statutes in light of new 
fact situations occur all the time.”440 In light of the opinion, a strong written descrip-
tion standard will ensure that in exchange for the exclusive right to practice an in-
 
434   Id. at 966.  
435   Id. at 967. 
436   Id. at 969.  
437   Enzo II, 323 F.3d 965.  
438   Id. at  970.  
439   Id. at 978 (dissenting opinion) (“The function of the description requirement is to ensure that 
the inventor had possession, as of the filing date of the application relied on, of the specific 
subject matter later claimed by him. In sum, WD was a new matter doctrine, a priority po-
liceman.”) (citing In re Wertheim, 541 F.2d 257, 262 (C.C.P.A.A 1976). Based on this his-
torical genesis of the written description requirement, Judge Rader condluced that the re-
quirement’s sole purpose served  the “very clear function [of] preventing new matter from 
creeping into the claim amendments.” Id. Jdge Linn’s dissenting opinion raised similar ar-
guments. Id. at 987.  
440   Id. at 971.  
https://doi.org/10.5771/9783845221441, am 02.12.2021, 20:19:12
Open Access -  - http://www.nomos-elibrary.de/agb
 108
vention, a patentee must disclose both what the invention is and how to make and 
use it.441 
Judge Rader’s view is illustrated in his dissenting from denial of en banc review 
in University of Rochester v. Searle. For the Judge the fact that the court first “faith-
fully followed Eli Lilly” but later reversed the decision as being invalid means that 
the Eli Lilly description doctrine was misguiding.442 With regard to the “practical 
problems” that an application of the Eli Lilly position created, Judge Rader con-
cluded:  
“This new 1997 rule changes the established rules of claiming and disclosing inventions. 
Many biotechnological inventions predate Eli Lilly. Before the 1997 change, no inventor could 
have foreseen that the Federal Circuit would make a new disclosure rule. Without any way to 
redraft issued patents to accommodate the new rule, many patents in the field of biotechnology 
face serious and unavoidable validity challenges simply because the patent drafter may not 
have included the lengthy nucleotide sequences.”443  
Judge Rader further raises fundamental patent policy concerns:  
“Must a University or small biotech company expend scarce resources to produce every poten-
tial nucleotide sequence that exhibits their inventive functions? Perhaps more important for 
overall patent policy, must inventors spend their valuable time and resources fleshing out all 
the obvious variants of their last invention instead of pursing their next significant advance in 
the useful arts? Again, Eli Lilly and Rochester appear to have given little thought to these unin-
tended consequences.”444  
Hence, the Judge is particularly concerned that the described uncertainty may affect 
pharmaceutical and biotechnological industries, as patent protection has been de-
scribed as the industries’ “lifeblood.” Biotechnological drug design necessarily de-
pends on the expenditure of both time and money. Judge Rader further argues that a 
separate written description requirement extends uncertainty and imposes costs to 
the judicial system:  
“[A] trial court, as in this case, must first ask its jury whether the specification provides suffi-
cient information to enable one of ordinary skill in the art to make and use the invention. Then 
the trial court must ask the jury again to look at the same specification for information that an 
inventor of extraordinary skill “possessed” the invention. … Moreover, the trial court must 
give separate instructions and entertain separate witnesses on these inseparable patent rules to 
ensure adequate disclosure. Viewed in the practical terms of trial procedure and jury under-
standing, this 1997 doctrine unnecessarily complicates and prolongs patent enforcement.”445 
 
441   Id. at 971-972, 974-975. Judge Newman considered the patent description the “foundation of 
the patent specification.” 
442   Judge Rader dissenting from denial of en banc review, University of Rochester v. Searle, 
375 F.3d 1303, 1308 (Fed.Cir. 2004). 
443   Judge Rader dissenting from denial of en banc review, University of Rochester v. Searle,375 
F.3d 1303, 1313 (Fed.Cir. 2004).  
444   Judge Rader dissenting from denial of en banc review, University of Rochester v. Searle, 
375 F.3d 1303, 1313 (Fed.Cir. 2004). 
445   Judge Rader dissenting from denial of en banc review, University of Rochester v. Searle, 
375 F.3d 1303, 1314. The judge confirmed his opinion in his dissent from the order denying 
rehearing en banc in Lizardtech, Inc. v. Earth Resource Mapping, 433 F.3d 1373, 1376 (Fed. 
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Judge Linn also dissented from the court's decision not to hear the case en banc. He 
agreed with Judge Rader with regard to the “confusion our precedent in Eli Lilly and 
Enzo has engendered in establishing ‘written description’ as a separate requirement 
on which a patent may be held invalid.” Eli Lilly, Judge Linn stated, constituted the 
first time that the Federal Circuit had done so. According to Linn, the essential ques-
tion of Section 112, first paragraph is whether the written description describes the 
invention recited in the claims – themselves part of the specification – in a sense that 
it is sufficient to enable a person of ordinary skill in the art to make and use the 
claimed invention and practice the best mode contemplated by the inventor. Hence, 
Judge Linn argues, Eli Lilly “should be overturned”. According to his view, a sepa-
rate written description requirement creates “an inevitable clash between the claims 
and the written description” as the emphasis of the application. In his eyes, only the 
claims “establish the bounds of the right to exclude” and “construing Section 112 to 
contain a separate written description requirement beyond enablement and best 
mode creates confusion as to where the public and the court should look to deter-
mine the scope of the patentee’s right to exclude.”446  
Judge Dyk takes a midpoint between the other positions, reasoning that Section 
112 contains a separate written description requirement, which applies in the context 
of priority and validity disputes. However, he cautions his view by stating that his 
vote should not be taken as an endorsement of our existing written description juri-
sprudence. According to his view, it is necessary that satisfactory standards be ap-
plied to all fields of technology articulated.447  
The current dispute in the U.S. shows a high level of uncertainty surrounding a 
major patentability condition. But is the strict emphasis of a separate written de-
scription requirement necessary for adequate patent protection? Pursuant to claim 
constructing rules, the claims are the decisive element for the determination of 
scope. Thus, a person skilled in the art should be able to define the scope with the 
help of the claim language and the amendments made in the course of the patent ap-
plication process. A separate weight of the written description requirement, by con-
trast, obliges the patent applicant to provide a precise definition of the subject matter 
claimed in structural terms. If he is not capable of doing so, the claim fails. Such a 
focus on structural features makes it almost impossible to use functional terminolo-
gy in the patent claims. The inventor has rather to describe all compositions claimed 
by their chemical structure. Therefore, the enablement factor should be considered a 
sufficient means to evaluate whether the inventor does not try to claim beyond the 
 
Cir. 2006) (“This court’s written description jurisprudence has become opaque to the point 
of obscuring other areas of this court’s law.”).445   
446   Judge Linn dissenting from denial of en banc review, University of Rochester v. Searle, 375 
F.3d 1303, 1325. 
447   Judge Dyk concurring from denial of en banc review, University of Rochester v. Searle, 375 
F.3d 1303, 1327. 
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scope of what he has disclosed. Hence, a separate written description obligation ap-
pears unnecessary.448  
b) Europe (Sufficient disclosure) 
The European “sufficient disclosure” requirement is laid down in Articles 83 and 84 
EPC, the respective Implementing Regulation as well as in the EPO Guidelines for 
Examination. Under Art. 83 EPC, a European patent application must disclose the 
invention in “a manner sufficiently clear and complete for it to be carried out by a 
person skilled in the art.” Art. 84 EPC requires that patent claims are “supported by 
the description.”  The Implementing Regulation to the EPC, Rule 42(1)(e) (former 
Rule 27) states that the inventor is required to “describe in detail at least one way of 
carrying out the invention claimed.” Finally, The EPO Guidelines for Examina-
tion449 determine that the description must disclose sufficient detail to render it ap-
parent to the skilled person how to put the invention into practice without having to 
perform any undue burden or inventive activity.450 
Consistent with the diverse nature of biotechnological inventions, there are overly 
restrictive rules as to how much information has to be provided in a patent applica-
tion. In principle, even broad claims can be supported by disclosing merely one way 
of performing the claimed subject matter, provided that the invented effect can be 
easily achieved by the skilled person. In addition to the example provided, however, 
the application must contain sufficient information to enable the person skilled in the 
art to perform the invention over the whole area claimed.451 In all cases, the amount 
of technical details to be disclosed is highly context-specific. The more difficult it is 
to obtain the claimed effect, the more technical features and the more examples have 
to be provided.  
 
448   A different view is presented in Mull, William C., Using the Written Description Require-
ment to Limit Broad Patent Scope, Allow Competition, and Encourage Innovation in Bio-
technology, 14 Health Matrix: Journal of Law-Medicine 2004, 393-435, 435, concluding that 
“[t]he Federal Circuitis correctly applying the written description requirements part of the 
disclosure to limit broad claim scope in biotechnology patents. The written description re-
quirement is separate from the enablement requirement and applies to all claims.” 
449   Guidelines for Examination in the EPO, Part C-II, 4.9., available at  
  http://www.epo.org/patents/law/legal-texts/guidelines.html, last checked on January 21, 
2008. 
450   T727/95, Weyerhaeuser Company/Ajinomoto, OJ 2001, 1; Benkard/Schäfers, EPÜ, Art. 83, 
No. 48.  
451   See Guidelines for Examination in the EPO, Part C-II, 4.9., available 
   http://www.epo.org/patents/law/legal-texts/guidelines.html, last checked on January 21, 
2008; Benkard/Schäfers, EPÜ, Art. 83, No. 50; T435/91 Reinigungsmittel/UNILEVER, N. 
Publ., No. of the Reasons 4.1.2, 4.14. 
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As for biotechnological inventions more narrowly, a number of examination 
guidelines and implementing regulations are highly relevant.452 First, if the invention 
is defined in terms of a parameter, the application must provide a clear description 
of the methods used to determine the parameter values, unless the skilled person 
would be knowledgeable with regard to what method to use.453 Second, the deposit 
of biological material is regulated by Implementing Regulations to the EPC, Rules 
33 and 34 (former Rules 28 and 28a.)454 The deposit has to be made as of the filing 
date. This is contrary to U.S. patent law, where the deposit must be made at any time 
the patent is granted.455 Third, the EPO, in line with other patent offices worldwide, 
requires a written and computer-readable sequence protocol for the sufficient disclo-
sure of protein and gene inventions (Implementing Regulations to the EPC, Rule 
30(1) (former Rule 27 a)).456   
Large numbers of cases deal with the interpretation of Art 83 and 84 EPC. In Po-
lypeptide Expression/Genentech,457 the court ruled that an invention the claim on 
which prohibits from multiple uses can be enabled by disclosing a single use only. 
The case dealt with a patent application that had been rejected because the terms 
“plasmid” and “bacteria” were considered too broad, since some of them depended 
on yet unavailable entities. The Technical Board of Appeals, classifying the critical 
expressions as functional terms, approved that they were allowable if “such features 
cannot otherwise be defined more precisely without restricting the scope of the in-
vention and their reduction to practice was not an undue burden”.458  It argued that 
the inclusion of yet unavailable entities resembled the protocol of using broad ‘com-
prising-language’ and had to be seen as “normal practice in many technical 
 
452   Most of the relevant rules were released in a specific protocol, which determines how amino 
acid-related information should be released. See decision of the President of the EPO dated 
02.10.1998 concerning the representation of nucleotide and amino acid sequences in patent 
applications and the filing of sequence listings, see Suppl. No. 2 to OJ EPO 11/1998, 1-68; 
Singer/Stauder, EPC, Vol. 1, Nos. 70-75; Meyer-Dulheuer, K.-H., Der Schutzbereich von 
auf Nucleotid- oder Aminosäurensequenzen gerichteten biotechnologischen Patenten, GRUR 
2000, 179, 179. 
453   Guidelines for Examination in the EPO, Part C-II, 4.9. 
454   Singer/Stauder, EPC – Vol. 1, Nos. 76-101; Schulte/Moufang, PatG mit EPÜ, Nos. 449-516; 
also Straus, Joseph/Moufang, Rainer, Deposit and release of biological material for the pur-
poses of patent procedure: industrial and tangible property issues, Baden-Baden 1990, 69. 
The formal deposit requirements correspond to the provisions of the Budapest Treaty on the 
International Recognition of the Deposit of Microorganisms for the Purposes of Patent Pro-
cedure that was signed by almost all member states of the European Patent System. BGBl II 
984 II 679 = BIPMZ 84, 318 = TabuDPMA Nr. 635; Schulte/Moufang, PatG mit EPÜ, No. 
453; Busse/Keukenschrijver, PatG, § 34, No. 311. 
455   See In re Lundak, 227 USPQ 90 (CAFC 1985).  
456   See Meyer-Dulheuer, K.-H., Der Schutzbereich von auf Nucleotid- oder Ami-
nosäurensequenzen gerichteten biotechnologischen Patenten, GRUR 2000, 179, 179. The 
particular amino acid sequence must be determined; it is not sufficient to merely disclose the 
protein’s variant, see Busse/Keukenschrijver, PatG, § 34, No. 271. 
457   T 292/85, Polypeptide Expression/Genentech, OJ 1989, 275. 
458   T 292/85, Polypeptide Expression/Genentech, OJ 1989, 275, 283. 
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fields.”459 It is thus sufficient that at least one use is clearly indicated, which enables 
the skilled person to carry out the invention.460  
The Technical Board of Appeals has always denied the application of an official 
“one way rule.” Nevertheless, the analysis of their case law reveals that such a rule 
has been a frequently used practice.461 For example, the Board in Harvard remanded 
the decision of the opposition division that had limited the patent scope, and decided 
that the patent granted was confined to rodents and no longer to non-human mam-
mals. The Board held that, on the base of the Genentech ruling:  
“The description of the invention firstly ensures that the inventions can be reproduced on mice. 
And secondly, it may be assumed that the skilled person is aware – in the same way as in case 
T 0292/85 – of other suitable mammals on which the invention can likewise be successfully 
performed. There is thus no reason why the application should be refused.”462 
In Fuel oils/Exxon,463the Technical Board of Appeal narrowed down the potential 
for an overly broad interpretation of the patent description, by emphasizing that: 
“…the disclosure of one way of performing the invention is only sufficient within the meaning 
of Article 83 EPC if it allows the person skilled in the art to perform the invention in the whole 
range that is claimed.”464 
The exact way to interpret “whole range”, however, remained undetermined, as the 
Board made clear that such determination must be made on a case-by-case-basis.465  
In ALSTOM Holdings/ABB Patent GmbH466, the European Board of Appeals de-
termined that the person skilled in the art must be able to carry out the fundamental 
aspect of the technical teaching of an invention:467 
“[T]he disclosure in a patent application or patent must enable a person skilled in the art to car-
ry out successfully the claimed invention in practice in the whole range claimed… [I]t is … of 
no significance whether the invention could have been carried out in the form of a variant cov-
ered by the wording of the claim … if this variant does not correspond to the fundamental as-
pect of the technical teaching of the invention to which the only concrete embodiment dis-
 
459   T 292/85, Polypeptide Expression/Genentech, OJ 1989, 275, 284. 
460   T 292/85, Polypeptide Expression/Genentech, OJ 1989, 275, 284. In Biogen, the Technical 
Board approved the ruling of Genentech, stating that “…this provision has previously been 
interpreted by the Board of Appeal in decision T 292/85 … as being satisfied ‘if at least one 
way is clearly indicated enabling the skilled person to carry out the invention’. In other 
words, in the Board’s view, it is not necessary for the purpose of Article 83 and 100(b) EPC 
that the disclosure of a patent is adequate to enable the skilled man to carry out all conceiva-
ble ways of operating the invention which are embraced by the claims …” See T 0301/87, 
Biogen, OJ 1990, 325, 343. 
461   See Bostyn, Sven J.R., A European Perspective on the Ideal Scope of Protection and the 
Disclosure Requirement for Biotechnological Inventions in a Harmonized Patent System, 5 
The Journal of World Intellectual Property 2002, 1014, 1023-1024.  
462   T 19/90, Onco-mouse/Harvard (1990), OJ 1990, 476. 
463   T 409/91, Fuel oils/Exxon, OJ 1994, 653. 
464   T 409/91, Fuel oils/Exxon, OJ 1994, 653, 660. 
465   T 409/91, Fuel oils/Exxon, OJ 1994, 653, 660. 
466   T 1173/00, ALSTOM Holdings/ABB Patent GmbH, OJ EPO 2004, 16.  
467   T 1173/00, ALSTOM Holdings/ABB Patent GmbH, OJ EPO 2004, 16, 27. 
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closed refers… A variant which is clearly not based on the same technical effect is not suitable 
as a basis for generalizations of this type.”468  
Requiring that the “fundamental aspects of the technical teaching” have to be dis-
closed, does not imply an additional and separate written description requirement.  
In Kirin-Amgen, a case in which the claim at issue was directed to the recombinant 
production of Erythropoietin, the Board made clear that broad claims are generally 
allowed:469 
“…it is a fundamental principle of patent law that a claim can validly cover broad subject mat-
ter, even though the description of the relevant patent does not enable every method of arriving 
at the subject matter to be carried out. Otherwise no dominant patent could exist, and each de-
veloper of a new method of arriving at the subject matter would be free of earlier patents. In 
many cases in the field of biotechnology, patent protection would then become illusory.”470 
The Board thus made clear that patentability requirements may not be interpreted in 
a way that impedes the granting of broad patents. 
The decision of Production of Erythropoietin/Kirin-Amgen, Inc471 also exempli-
fies how limits are set regarding the deposit of biological material.  With the mere 
guidance of the disclosure and without deposit of recombinant host cells, the appel-
lants argued, the enablement of the claimed embodiments was only possible after 
exerting 4½ years of effort, “which was an unacceptable burden.”472 The appellees 
argued that “once the Epo gene was cloned and the sequence made available, it was 
straightforward for someone to clone and express the Epo gene.”473 In response to 
these arguments, the Board of Appeal stated that Art. 83 EPC only requires a deposit 
if others were not able to “repeat the invention at all.”474 It also made clear that un-
due burden could not be a rationale for requiring a deposit: 
“This concept relates more to cases where the route that the reader is to follow is so poorly 
marked that success is not certain. If the route is certain but long and laborious, the patentee is 
under no obligation to assist the disclosure by making actual physical samples, e.g. the “facto-
ry” available. To come to the opposite conclusion would be effectively to introduce a require-
ment to make the best mode immediately accessible to the public, and such a requirement is 
not part of the European patent system.”475 
In The General Hospital Corporation,476 the court made clear that “undue burden” is 
determined from the perspective of a person skilled in the art. The case is also rele-
vant because it directly refers to the need to disclose information that relates to the 
 
468   T 1173/00, ALSTOM Holdings/ABB Patent GmbH, OJ EPO 2004, 16, 26.  
469   Kiren-Amgen/Erythropoietin [2000] E.P.O.R. 135 (EPO 1998). See, more generally Bostyn, 
Sven J.R., A European Perspective on the Ideal Scope of Protection and the Disclosure Re-
quirement for Biotechnological Inventions in a Harmonized Patent System, 5 The Journal of 
World Intellectual Property 2002, 1014ff, 1026. 
470   Kiren-Amgen/Erythropoietin [2000] E.P.O.R. 135, 145.  
471   T 412/93, Production of Erythropoietin/Kirin-Amgen, Inc., [1995] E.P.O.R. 629. 
472   T 412/93, Production of Erythropoietin/Kirin-Amgen, Inc., [1995] E.P.O.R. 629, 633.  
473   T 412/93, Production of Erythropoietin/Kirin-Amgen, Inc., [1995] E.P.O.R. 629, 638.  
474   T 412/93, Production of Erythropoietin/Kirin-Amgen, Inc., [1995] E.P.O.R. 629, 657.  
475   T 412/93, Production of Erythropoietin/Kirin-Amgen, Inc., [1995] E.P.O.R. 629, 657.  
476   T 497/02, The General Hospital Corporation, N. Publ. (EPO 2004). 
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secondary and tertiary structure of proteins. The claim was directed to the use of a 
peptide in the preparation of an agent for the treatment of diabetes mellitus. The 
Board of Appeal rejected the claim for a lack of sufficient disclosure under Art. 83 
EPC, arguing that the patent application did not provide any evidence that the cited 
peptides were in fact performing the required biological activity. The skilled person 
therefore has to perform tests and experimentations that amount to an undue burden 
with no certainty of success. The board explained:  
“… that the biological activity of proteins is highly dependent on their secondary and tertiary 
structures, resulting from their primary structure… There is no basis in the application to con-
clude that any of the 31 peptides involved, or, if any, how many thereof will show secondary 
and tertiary structures, giving them properties that make them candidates for use in the treat-
ment of diabetes mellitus.”477 
To sum up, the European sufficient disclosure requirement is met by adequately 
enabling practice of the full scope of the claim and disclosing in the specification at 
least one method.  An inventor is required to provide sufficient information to ‘make 
and use’ the invention, but not to separately describe every single element of the pa-
tented subject matter. Applicants are required to provide the information necessary 
for a skilled person to carry out the invention in the whole area claimed without any 
undue experimentation.478  
Finally, and in contrast to the U.S. situation, it is worth noting that the cases 
represented above suggest that neither Art. 84 EPC nor Art. 83 EPC are used as a 
basis for a separate written description doctrine. This understanding is consistent 
with the principle that the claims, rather than the patent description are the decisive 
element of patent scope, a principle confirmed by further EPC provisions.479 
III. Conclusion 
The comparison of both patent systems shows that a major distinction remains be-
cause the U.S. law does not contain an explicit exclusion of patentability due to ethi-
cal concerns. In sum, however, the requirements of both systems are in many ways 
comparable to each other.480 The currently discussed reform of the U.S. legal system 
can be understood as a further step towards harmonization.481 The analysis in this 
 
477   T 0497/02, The General Hospital Corporation, No. of the Reasons 18.  
478   Schulte/Schulte, PatG mit EPÜ, § 34, Nos. 362, 367. It is not sufficient that the invention can 
be carried out generally, it is rather necessary that the skilled person is able to release the 
claimed invention into practice, see Busse/Keukenschrijver, PatG, § 34, No. 236. 
479   Schulte/Kühnen, PatG mit EPÜ, § 14, No. 12. Terms used within the patent claims must be 
interpreted in accordance to the skilled person’s understanding, Busse/Keukenschrijver, 
PatG, § 14, No. 66. 
480   Kleine, Tatjana/Klingelhöfer, Thomas, Biotechnologie und Patentrecht - Ein aktueller Über-
blick, GRUR 2003, 1, 10. 
481   The National Academies’ Board on Science, Technology and Economics and the Federal 
Trade Commission on modernizing U.S. patent law drafted recommendations that suggest 
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chapter has shown that the era of “genomics” did not require major changes of the 
patent law systems. The few cases of significant amendments, e.g., the renewal of 
Section 103 U.S.C.482 - out of the dilemma where the inventor of a patentable com-
position of matter used in a process was unable to receive a process patent for the 
use of this patentable composition - must be considered as mere simplifications ra-
ther than a change of principle. It is, however, not guaranteed that the reasoning 
specified above is sufficient to handle protein folding structure-related claims. In 
particular, an increasing number of claims directed to protein structures are related 
to software. It will be interesting to see whether this sector, which is related to 
bioinformatics, will draw on principles developed for the patentability of computer-
implemented inventions. The below case study will further examine this question. 
 
several amendments related to litigation and validity of patents. The provisions that have 
been reviewed by the American Intellectual Property Law Association (AIPLA) are likely to 
make the U.S. patent-related litigation simpler and less expensive for small businesses. The 
recommendations include preserving a “flexible, unitary, open-ended patent system” to 
“reinvigorate the non-obviousness standard”, to “institute a postgrant open review 
procedure”, to “strengthen the USPTO capabilities”, to “shield some research uses of 
patented inventions from infringement liability”, to “limit the subjective elements of patent 
litigation,” and to “harmonize the U.S., European, and Japanese patent examination 
systems”. In addition, the proposals include having a period that allows the challenge of 
patents within a nine to twelve months period, and a first-to-file system; see DeSanti, Susan 
S./Cohen, William E./Levine, Gail F./Greene, Hillary J./Bye, Matthew, Wroblewski, 
Michael et al., To Promote Innovation: The Proper Balance of Competition and Patent Law 
and Policy, 2003; Merrill, Stephan A./Levin, Richard C., Myers, Mark B., A Patent System 
for the 21st Century, Washington D.C. 2004; American Intellectual Property Law Center, 
AIPLA Response to the National Academies Report entitled “A Patent System for the 21st 
Century”, Washington D.C. 2005; as for the legislative process, see Kintisch, Eli, U.S. 
Patent Reform Begins Long journey Through Congress, 308 Science 2005, 1725. The pro-
posals have been summarized in the Patent Reform Act of 2007 that was introduced on April 
18, 2007 in both the House of Representatives and the Senate. As of the writing, it is still 
pending; see 2008 Patent Reform Update, Fish & Richardson PC, available at  
  http://www.fr.com/news/articledetail.cfm?articleid=490, last checked on on January 21, 
2008; see also statement of Jon W. Dudas, Under Secretary of Commerce for Intellectual 
Property and Director of the United States Patent and Trademark Office before the Commit-
tee on the Judiciary United States Senate, see "Patent Reform: The Future of American Inno-
vation" June 6, 2007, available at http://www.uspto.gov/web/offices /com/speeches/2007 
jun06.htm, last checked on January 21, 2008.   
482    See Chapter 3 A II 4 a.  
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B. Case study related to protein 3-D-structure related inventions 
I. Introductory Remarks 
1. Aim of the study 
Determining compliance of the statutory requirements for patentability cannot be 
carried out by applying rules per se. A better approach is accomplished on a case-
by-case basis. Thus, a case study is used to elucidate the legal principles. The fol-
lowing study is based on examples made available by the Trilateral Project WM4483, 
which provides a report on comparative study of protein 3-D structure-related 
claims. The study initially provides background information and proceeds to illu-
strate how the European Patent Office (EPO), the Japanese Patent Office (JPO) and 
the United States Patent and Trademark Office (USPTO) are presently treating pro-
tein inventions in terms of patent law.484 The rules set forth have not been officially 
adopted, but provide substantial guidelines for legal practitioners that seek patent 
protection.485 The author will briefly present the approaches made by the USPTO 
and the EPO.486 A further step will then examine the given suggestions in the light 
of existing patent law regulations. Under those circumstances in which the proposals 
from the EPO and USPTO lack clarity, the author will further develop the existing 
ideas and apply classical patent and case law principles that have been used in the 
field of chemistry and genomics. In summary, the following chapters attempt to 
document the types of patent claims that could be issued and to whom, and to illu-
strate differences in the criteria being applied by the USPTO and EPO.  
Irrespective of the new techniques that have been developed due to advanced 
knowledge about protein structures, proteomic inventions have to comply with the 
same principles that have been applied for classical protein inventions in the past. 
Where these principles are not sufficient to cope with the challenge of 3-D inven-
tions, further development is needed.   
 
483   This case study is based on examples provided by the Trilateral Project WM4, Comparative 
studies in new technologies (biotechnology, business methods, etc.), Report on comparative 
study on protein 3-dimensional (3-D) structure related claims (Nov. 2002) (hereinafter Tri-
lateral 3-D protein structure related claims Comparative Study), available at 
  http://www.trilateral.net/, last checked on January 21, 2008.                                                                        
484   The study has significant implication for the biotechnology industry, Shimbo, Itsuki/ Naka-
jima, Rie/Yokoyama, Shigeyuki/Sumikura, Koichi, Patent protection for protein structure 
analysis, 22 Nature Biotechnology 2004, 109, 109.  
485   Vinarov, Sara D., Patent protection for structural genomics-related inventions, Journal of 
structural and functional genomics 2003, 191, 198. 
486   Since it is not the subject matter of this analysis, the Japanese view will not be regarded.  
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2. Major fields of 3-D protein structure inventions 
The number of inventions in the field of proteomics has significantly increased after 
the disclosure of the human genome. First of all, certainly the improved knowledge 
in genetics pushed forward the further disclosure of protein structures. Scientists, 
however, also started to focus intensely on protein research and increased invest-
ment. 3-D protein structure inventions play an important role in a number of fields. 
The following attempts to provide an examination of claims related to protein struc-
tural properties per se, including an analysis of claims to 3-D structure defined  by 
structural coordinates and claims to protein crystals. The next chapter will then fo-
cus on proteomics and bioinformatics, including the assessment of claims to in-silico 
screening methods related to tertiary protein structure and identified compounds. Fi-
nally, claims directed to data related to structural features will be examined.487   
II. Proteomics and protein structural properties per se 
1. Structure defined by structural coordinates and protein crystals 
a) Claims 
As a first step, claims directed to the polypeptide per se are examined. The first 
group of cases consists of a claim related to a protein having the structure defined by 
structural coordinates and of another  claim that refers to the crystalline form of a 
protein. The structure definition is based on NMR spectroscopy. With regard to the 
claim directed to the crystalline protein structure, one must consider that protein 
crystallization is only possible with a very low percentage of all existing polypep-
tides. Particularly, hydrophic, (for example membrane proteins) are not available in 
crystalline form, and it is generally possible to achieve crystalline forms of only 5 % 
of proteins.488 Thus, the advantages of this particular claim do not reduce general 
difficulties of protein patenting. 
The actual claims read as follows: 
 
Claim 1:  
An isolated and purified protein having the structure defined by structural coordinates as 
shown in a specific figure. 
 
487   A number of articles focuses on the Trilateral Study conducted by the patent offices, see for 
example Masuoka, Kunihisa, Study on the Ways of Protection of Post-Genome Research 
Products, IIP Bulletin 2002, 84-95; Vinarov, Sara D., Patent protection for structural genom-
ics-related inventions, Journal of structural and functional genomics 2003, 191-209. 
488   Peters, Linde, Postgenomik, http://home.t-online.de/home/linde.peters/intro.htm#postgen0, 
Part IV, 3. 
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Claim 2:    
A crystalline form of protein P having unit cell dimensions of a=4.0nm, b=7.8nm, and 
c=11.0nm. 
b) Background 
The claim description of Claim 1 reports the 3-D structure of protein P, including 
the coordinates of the amino acid side chains, the source organism for protein P and 
the molecular weight of protein P. Additionally, it provides experimental data and 
illustrates that the protein, when active, lowers blood pressure. The structural coor-
dinates were derived from a solution phase protein by NMR at O.2nm resolution. 
The prior art does not include any references that reveal the 3-D structure of the pro-
tein. However, it demonstrates a protein from the same source organism having the 
same specific function and approximately the same molecular weight.489 With regard 
to the claim related to the crystalline protein form, a nucleotide sequence encoding 
the amino acid sequence of protein P is known in the art. The description explains 
that the administration of protein P was previously shown to lower blood pressure. 
The inventor alleged the novel production of a stable crystalline form of protein P. 
The crystalline form of protein P was inactive. The description provides experimen-
tal data of how to synthesize the crystals and demonstrates that the protein, when 
active, lowers blood pressure. Related prior art methods used in protein P crystalli-
zation have all been unsuccessful, so that there existed clear technical difficulty in 
reproducing the claimed crystalline form of protein P.490 
c) Solutions proposed by the EPO and the USPTO 
Regarding the claim directed to the isolated and purified protein (Claim 1), the EPO 
maintained that the claim would not be directed to a subject matter excluded under 
Art. 52(2) EPC.491 The claimed subject matter complies with the requirements of 
 
489   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 1-79, 7ff. 
490   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 9. 
491   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
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industrial application, clarity, enablement and support. The claim, however, fails the 
novelty requirement, since the prior art already contains a protein from the same 
source organism with approximately the same characteristics. The EPO stresses, 
however, that novelty and inventive step can be accepted if the applicant provides 
the evidence of novelty over the prior art protein. The structural data fully defines 
the protein, including the deducible primary sequence.492   
As to claim 2, which refers to a crystalline form of a protein, the EPO states that 
the claim is directed to a patentable subject matter according to Art. 52(1) EPC. Ad-
ditionally, the claimed subject matter complies with the requirements of clarity, 
enablement and support. The requirements of novelty, inventive step and industrial 
application are given, since the prior art does not include crystals of protein P and 
also did not illustrate the synthesis of protein P crystals. The EPO suggested, how-
ever, to produce the protein in a stable form. The crystals should be used for deter-
mination of the 3 D structure and those atomic coordinates, which are useful in in 
silicio screening methods and rational drug design.493  
The USPTO maintains that an isolated and purified protein (Claim 1) may be 
considered either a composition of matter or a manufactured product and therefore 
can be considered as statutory subject matter according to 35 U.S.C. § 101.494 As-
suming that there is no evidence that the asserted utility of lowering blood pressure 
when administered lacks credibility, the claimed protein has a specific, substantial, 
and credible utility and thus satisfies the utility requirement of 35 U.S.C. § 101. 
Based on the information that is provided by the specification, a person of ordinary 
skill in the art is able to synthesize the claimed protein. With respect to the “how-to-
use prong”495 of the enablement requirement, the claimed isolated and purified pro-
tein P must, so ruled the USPTO, be effective in modulating blood pressure without 
undue experimentation. Under this circumstances, the claimed method complies 
with the enablement requirement of 35 U.S.C. § 101.  
The USPTO further states that the patentee provides sufficient structural informa-
tion such that one skilled in the art recognizes that the inventor is in possession of 
the invention as claimed. Thus, the written description requirement is fulfilled. 
 
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 35. 
492   Vinarov, Sara D., Patent protection for structural genomics-related inventions, Journal of 
structural and functional genomics 2003, 191, 203. 
493   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 35f. 
494   Vinarov, Sara D., Patent protection for structural genomics-related inventions, Journal of 
structural and functional genomics 2003, 191, 203. 
495   “The how-to-use-prong of section 112 incorporates, as a matter of law, the requirement of 35 
U.S.C. § 101 that the specification discloses a practical utility for the invention… if the ap-
plication fails as a matter of fact to satisfy 35 U.S.C. § 101, then the application also fails as 
a matter of law to enable one of ordinary skill in the art to use the invention under 35 U.S.C. 
§ 112,” see In re Ziegler, 992 F.2d 1197, 1200-01, 26 USPQ2d 1600, 1603 (Fed. Cir. 1993). 
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Moreover, the USPTO applies its general practice to the case. Pursuant to this, the 
examiner rejects the claims as anticipated by, or alternatively as obvious when com-
pared with the reference under the following circumstances: An inventor claims a 
synthesis in terms of a property or characteristic. The synthesis existing in the prior 
art appears to be the same as that of the claimed composition, but the particular 
property or characteristic was not explicitly disclosed by the reference. The rejection 
is thus supported by evidence or reasoning supporting the indifference over the ref-
erence.  
An initial search therefore is limited to a conventional prior art search. The patent 
examiner does a text search with initial search terms referring to the genus and/or 
species of organism from which the claimed protein was prepared along with an ap-
proximate molecular weight. Evidence of impact on blood pressure associated with 
any proteins found in this search is also considered. A search for an appropriate pro-
tein and nucleic acid is also to be made provided the 3-D structure is sufficient to 
derive amino acid sequence information.496 
In the case at issue, the prior art demonstrates a protein originating from the same 
source organism, having the same specific function and approximately the same mo-
lecular weight. Although the prior art does not include the atomic coordinates as 
claimed, the atomic coordinates are an inherent property or characteristic of the 
claimed protein in a particular state. Lacking evidence that the state defined by the 
coordinates represents a form distinguishable from that for the protein present in the 
prior art, the claim must be rejected according to 35 U.S.C. § 102 as being antic-
ipated by, or alternatively, as obvious when compared with the prior art protein (35 
U.S.C. § 103). This situation corresponds to the situation in which a claimed protein 
is characterized by amino acid sequence, but is otherwise identical to a prior art pro-
tein that has yet to be sequenced. The Patentee may overcome the rejection by sub-
mitting evidence proving that the prior art protein is not the same as, or an obvious 
variant of, the protein described in the prior art. 497  
As for the protein crystal (Claim 2), the USPTO held that it refers to a composi-
tion of matter and is therefore patent-eligible subject matter. Assuming that (1.) it is 
well established in the art that a crystalline form of a protein can generally be re-
constituted in an active form, and (2.) there is no evidence that the utility of lower-
ing blood pressure by administering a reconstituted active form of protein P lacks 
credibility, the claim form has a specific substantial and credible utility as an inter-
mediate in preparing the active form of Protein P. This result persists, even though 
the claimed crystalline form of protein P is inactive. As to the enablement require-
 
496   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 65. 
497   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 64-66. 
https://doi.org/10.5771/9783845221441, am 02.12.2021, 20:19:12
Open Access -  - http://www.nomos-elibrary.de/agb
 121 
ment, the specification demonstrates the synthesis of the claimed crystals. With re-
gard to the “how-to-use prong” of the enablement requirement it must be assumed 
that the claims comply with the utility requirement of 35 U.S.C § 101. Additionally, 
it is necessary to determine whether one skilled in the art could use the claimed in-
vention without undue experimentation. If one skilled in the art could use the 
claimed protein crystal to make the active form of protein P and thereafter use pro-
tein P to modulate blood pressure without undue experimentation, the claimed me-
thod would satisfy the enablement requirement of 35 U.S.C. § 112. Since the struc-
ture of protein P is provided, the claim complies with the written description re-
quirement. The novelty requirement is met, since the prior art teaches that a crystal 
of protein P differs from known forms of protein P. As to obviousness under 35 
U.S.C. § 103, there is no prior art reference demonstrating or suggesting a crystal of 
protein P or related proteins. Although a general desire to obtain the crystal structure 
of any given protein exists, the methodology of doing so is highly unpredictable and 
specific to each individual protein. Without this expertise in the art of protein crys-
tallization, the synthesis of a specific known protein in crystalline form is nonob-
vious.498  
d) Discussion 
As for novelty of the isolated and purified protein (Claim 1), the EPO applies prin-
ciples that have been developed by a German court for the patentability of chemical 
substances. As established in the Trioxane decision of the German Federal Supreme 
Court499, a chemical substance can be described sufficiently and unambiguously by 
different parameters. A parameter existing in prior art is novelty-destroying, if it is 
specific enough to unambiguously identify a substance. Thus, one must closely ex-
amine the value of a given parameter by determining its capacity to individualize a 
particular substance.500 If a protein is already unambiguously identified by its prima-
ry structure, the creation of novelty due to 3-D structural data is anticipated. The 
USPTO reaches, on distinct but similar grounds, the same solution. 
Prima facie, the patent offices’ rejection of Claim 1 might give rise to the notion 
that the establishment of novelty for proteins defined by structural coordinates will, 
more generally, face substantive hurdles. To put this impression into perspective 
(and to shed further light on the novelty requirement in cases in which the prior art 
includes the primary structure), it is useful to compare Claim 1 with claims in which 
 
498   Vinarov, Sara D., Patent protection for structural genomics-related inventions, Journal of 
structural and functional genomics 2003, 191-209.  
499   BGH, 3 IIC 226 (1972) –Trioxane. 
500   Bostyn, Sven J.R., Enabling Biotechnological Inventions in Europe and the United States: A 
Study of the Patentability of Proteins and DNA Sequences with Special Emphasis on the 
Disclosure Requirement, Munich 2001, 81.  
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the three-dimensional structure does play a more prominent role, such as in the case 
of prion proteins. 
As explained earlier501 the long-held hypothesis that the amino acids in all cases 
code for a single unique tertiary structure cannot be held anymore. The prion protein 
(PrP) occurs in two different folding types. The normal, cellular PrP (PrP C) is con-
verted into PrP Sc through a posttranslational process.502 As detailed in Chapter II, 
this pathogenic prion form causes neurodegenerative disorders, such as bovine 
spongiform encephalopathy (BSE), its human equivalent Creutzfeld-Jakob disease 
(CJD), Kuru and Scrapie. In the case of prions, the 3-D protein structure consequent-
ly is a more reliable parameter than the amino acid sequence and must be sufficient 
to match the novelty requirement. Other neurodegenerative disorders such as Alz-
heimer's disease or Parkinson's disease are not considered to be prion-based, rather 
are caused by misfolded 3-D protein structure. Even though the precise molecular 
structure has not yet been identified, it is already clear that these diseases are ac-
companied by amyloidal brain plaques.503 Thus, the 3-D structure can be expected to 
be the key parameter in these cases as well.504   
The European Patent Office had not yet dealt with novelty in prions. Cases re-
lated to stereochemistry, the study of the 3-D shape of molecules, however, involve 
similar issues. The major focus of stereochemistry is stereoisomers that are com-
pounds consisting of the same atoms and bonds, but possessing different 3-D struc-
tures. The major kinds of stereoisomers are enantiomers, i.e. mirror image stereoi-
somers, and diastereomers which is simply any stereoisomer that is not an enanti-
omere.505  
In T 12/81 the Technical Board of the European Patent office did yet not clearly 
determine that the spatial form of a stereoisomer suffices to establish novelty, find-
ing that a prior art document anticipated a claim directed to diastereomers, even 
though it did not specify the exact spatial form of the diastereomers. 506 The Board 
explained that the prior art document that disclosed a chemical substance described 
by its structural formula failed to explicitly mention the particular stereospecific 
 
501   See Chapter 1 and Chapter 2 B II 2.  
502   Prusiner, Stanley B., Nobel Lecture, 95 PNAS 1998, 13363, 13363. 
503   A protein called β-amyloid, discovered in 1984, was found to be the primary component of 
the brain’s plaques. According to the amyloid hypothesis, the build-up of β amyloid causes 
Alzheimer’s disease by destroying brain cells.Travis, John, Saving the Mind Faces High 
Hurdles, 309 Science 2005, 731, 732 
504   Diagnostic methods that rely on 3-D information include ‘positron emission tomography’ 
(PET) ‘fluorescent staining assay’, ‘immunoassay’ and ‘electron microscopic assay’, see 
Masuoka, Kunihisa, Study on the Ways of Protection of Post-Genome Research Products, 
IIP Bulletin 2002, 84, 89. 
505    See Organic Chemistry Online (Published by Paul R. Young), Stereochemistry: Isomerism 
in Carbon Compounds, available http://www.chem.uic.edu/web1/OCOL-II/WIN/HOME. 
HTM, last checked January 21, 2008.  
506   T 12/81, N. Publ., No. of the Reasons 17.  The reaction of the literature on this decision of 
the Board of Appeals was moderately critical, see Hüni, Albrecht, Zur Neuheit bei chemis-
chen Erzeugnissen in der Spruchpraxis des Europäischen Patentamts, GRUR 1986, 461, 462.  
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configuration. The Board concluded that nevertheless the document anticipates the 
particular stereospecific configuration, because the stereospecific configuration must 
be considered the inevitable result of one of a number of processes adequately de-
scribed in the prior art document.507  
The rule that the precise asymmetric form of a stereoisomer must be considered 
novel in comparison with disclosed racemates is set forth in T296/87.508 In this case, 
the Technical Board of the European Patent Office had to decide upon the issue of 
whether novelty of Enantiomers was anticipated by the description of a racemic 
mixture, a mixture of equal amounts of left- and right-handed enantionmers.509 The 
patent description determined racemates in the state of the art by means of expert 
interpretation of the structural formula and scientific terms.510 The problematic issue 
with regard to novelty was that this did not sufficiently specify the precise configu-
ration of the enantiomers at issue.511 Due to the asymmetric carbon atom contained 
in the formula, enantiomers can occur in a plurality of conceivable spatial configura-
tions. With the patent description only determining the racemic mixture, a more spe-
cific determination of the spatial enantiomers configuration was lacking. The EPO’s 
Board of Appeal applied the principles developed in the German Trioxan decision 
stating that a chemical substance is held to be new if it is distinguishable from a 
known substance in an unambiguous parameter.512 The Board concluded that this 
configuration is such a parameter. The Board explained that the specific racemates 
included in the prior art do not alone provide any information related to the configu-
ration in individualized form. Consequently, the description of the racemate mixture 
bears insufficient information to unambiguously determine enantiomers lacking a 
reliable parameter.513  
The principle of that an enantiomer is considered new with regard to a racemic 
mixture is affirmed and further developed in T 1048/92.514 Here, the crucial prior art 
document referred to the enantiomer within an example. Further, it contained a 
‘Markush formula’ that included the exemplified subject. With regard to this Mar-
kush formula, it was indicated that the formula includes “various optically active 
 
507   T 12/81, N. Publ.No. of the Reasons 5-17.  The Board concluded that “the concept of novel-
ty must not be given such a narrow interpretation that only what has already been described 
in the same terms is prejudicial to it”, see T 12/81, N. Publ., No. of the Reasons 5; also Do-
meij, Bengt, Pharmaceutical Patents in Europe, Stockholm 2000, 146.  
508   T 296/87 Enantionmers/HOECHST, OJ 1990, 195, 206, 207. 
509   T 296/87 Enantionmers/HOECHST, OJ 1990, 195, 206. Separating different forms of enan-
tiomers bears significant difficulties, because they have nearly identical properties, see Do-
meij, Bengt, Pharmaceutical Patents in Europe, Stockholm 2000, 148. 
510   “The situation is different if the state of the art includes enantiomers, howsoever designated 
(D, d, L, l or + or -), which are specifically named and can be produced”, see T296/87 Enan-
tionmers/HOECHST, OJ 1990, 195, 207.  
511   D- and L-enantiomers 
512   T 296/87 Enantionmers/HOECHST, OJ 1990, 195, 206-207. 
513   T 296/87 Enantionmers/HOECHST, OJ 1990, 195, 207.   
514   T 1048/92, N. Publ. (EPO 1994).  
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isomers” and that “the invention embraces such optically active isomers”.515 The 
Board of Appeal held that novelty was established. It reasoned that the applicant had 
chosen one of the two conceivable configurations of the subjects being exemplified 
in the prior art document. With regard to the indications concerning the occurrence 
of optical isomers made in the prior art document, the Board concluded that they did 
not refer to the individual substance distinguished by its steric form as disclosed by 
the patent applicant.516  
With the 3-D protein structure determining the protein’s function, it is the most 
unambiguous parameter. Hence, the tertiary folding type is comparable to the 
asymmetric configuration of enantiomers. In light of principles developed in the 
above-described decisions from the field of stereochemistry and in the landmark of 
Trioxane, the tertiary folding structure can suffice to match the novelty require-
ment.517 The primary structure of a protein does not always contain sufficient infor-
mation to unambiguously determine a substance. This is illustrated by the case of 
prions. The amino acid sequence does not provide sufficient information regarding 
folding of the prion protein at the tertiary level. The determination of the amino acid 
sequence lacks important information as to whether a normal, cellular prion (PrP C) 
or the diseased form (PrP Sc) is given. As a consequence, data related to the folding 
type of a protein can still establish novelty, even though the amino acid is complete-
ly known and publicized. This principle, however, is only applicable to proteins that 
occur in a plurality of 3-D structures. In cases in which the state of the art teaches 
that there typically exist only single folding stages, the amino acid sequence must be 
considered the most reliable parameter. 518   
The USPTO precisely determines with regard to Claim 1 that a patent applicant 
must prove that the state defined by the coordinates represents a form distinguisha-
ble from that for the protein present in the prior art. The office thus applies its gen-
eral practice regarding what is considered novel. As stated in Fiers v. Sugano, “a 
precise definition, such as structure, formula, chemical name or physical properties 
is necessary for providing sufficient identification”.519 This information is provided 
if the patent applicant offers evidence that the claimed compound is less ambiguous 
 
515   T 1048/92, N. Publ., No. of the Reasons II. A ‘Markush formula’ is the most concise means 
of defining a class of chemical compounds in a claim, see T 1020/98, N. Publ., No. of the 
Reasons 3.1. (EPO 2003).  
516   T 1048/92, N. Publ., No. of the Reasons 2.5. See also: Domeij, Bengt, Pharmaceutical Pa-
tents in Europe, Stockholm 2000, 149.  
517   For the Trioxane decision, see Hirsch, Fritjoff, Neuheit von chemischen Erfindungen, GRUR 
1984, 243, 244.  
518   As to the applicable principles, see: Rauh, Peter A./Jaenichen, Hans-Rainer, Neuheit und 
erfinderische Tätigkeit bei Erfindungen, deren Gegenstand Protein oder DNA-Sequenzen 
sind -- Volker Vossius zum 60. Geburtstag, GRUR 1987, 753, 755; also: Bostyn, Sven, A 
test too far? A critical analysis of the (non)-patentability of diagnostic methods and conse-
quences for BRCA gene type patents in Europe, Bioscience Law Report 2001/2002, 111-
121. 
519   Fiers v. Sugano, 984 F. 2d 1164, 1172 (Fed. Cir. 1993). 
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than what is considered state of the art. Again, numerous U.S. patents granted in the 
field of stereochemistry are based on this assessment of novelty.520  
As to Claim 2 related to a crystalline form of a protein, the EPO applies estab-
lished principles for the patenting of chemical inventions. Generally, chemical sub-
stances of the same chemical composition must be considered identical. However, it 
is not impossible that two substances with the same molecule structure can be 
viewed as being distinct. They must therefore be distinguishable through reliable 
parameters. The discrimination of chemical substances of a same chemical composi-
tion does not only depend on their form (polymorph) but also on their physical cha-
racteristics.521 As stated in Trioxan and stated earlier, the crucial characteristic of a 
particular chemical compound for determining novelty does not necessarily need to 
be its chemical constitution. The chemical formula of a chemical substance is rather 
only one of a variety of existing criteria that can be used for classification.522 The 
fact that a chemical formula is generally the most reliable definition of a substance 
does not mean that other definitions do not exist. It is comparable to the definition of 
substance based on its physical parameter. There is not just a single method of de-
termining the novelty of a chemical compound, but rather a wide variety of me-
thods.523  
The EPO’s statements regarding other patent requirement can be clearly followed. 
The solution of the technical problem to establish a crystalline form of protein P 
clearly involves an inventive step, because it cannot a priori be expected that the 
crystalline protein form consists of any advantages compared to the form that is re-
ported in the prior art. Moreover, it would not have been obvious to a skilled person 
how to translate protein P into its crystalline form.524 The claimed crystalline form 
of protein P is advantageous. The inactive form can be reconstituted into an active 
form, and administration of the reconstituted active form of protein P is known to 
result in the reduction of blood pressure. Such characteristics and the knowledge, 
 
520   See for example U.S. Patent 7,211,580: McDonald, Andrew/Bergnes, Gustave/Feng, Bai-
nian/Morgans, Jr., David J./Knight, Steven David/Newlander, Kenneth A./Dhanak, Da-
shyant/Brook, Christopher A., Compounds, compositions and methods, South San Francisco, 
CA; Philadelphia, PA 2007. 
521   The coherency of polymorphs and particular features is widely known in the field of anor-
ganic chemistry. For example, the polymorphic form of carbon can occur as carbon black, 
graphite or diamond, the polymorphic form of calcium carbonate as crayon or marble, and 
the polymorphic form of aluminium oxide in a- and g- modifications. Polymorphic characte-
ristics also exist in organic chemistry. Hirsch, Fritjoff, Die Bedeutung der Beschaffenheit 
chemischer Stoffe in der Patentrechtssprechung, GRUR 1978, 263, 264; see also Wachen-
feld, Joachim, The Patenting of Protein Structures, http://www.vossiusandpartner.com/ 
eng/publication/mip-yearbook.html 2002, Comment.  
522   BGH, 3 IIC 226 (1972) – Trioxane.  
523   Hirsch, Fritjoff, Die Bedeutung der Beschaffenheit chemischer Stoffe in der Patent-
rechtssprechung, GRUR 1978, 263, 264; BGH, 3 IIC 226 (1972) – Trioxane. 
524   Hirsch, Fritjoff, Die Bedeutung der Beschaffenheit chemischer Stoffe in der Patent-
rechtssprechung, GRUR 1978, 263, 265. 
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which this crystalline form provides about the three dimensional structure of protein 
P allow for the protein’s use in drug design.  
The USPTO applies In re Bergstrom525 to Claim 2, finding that novelty exists due 
to the fact that the crystalline form of protein P differs from any known form of pro-
tein P. Claims directed to products having distinguishable physical forms comply 
with the novelty requirement, even where their utility is identical to that of the 
known product.526 Consequently, novelty is accepted. With the methodology of ob-
taining protein crystals being highly unpredictable, it is also consequent that the Of-
fice accepts non-obviousness under 35 U.S.C. §103.  
2. Protein Domains 
As for the second group, the EPO had to examine an invention involving structural 
protein features as binding pockets and protein domains.527 A binding pocket or so-
called active center of a protein is responsible for the catalytic mode of function. It 
consists of polypeptides that are specifically folded. Due to the specific concave 
structure within the enzyme, the active center/binding pocket can bind to a suited 
substrate. In general, there exist six different types of enzymes, oxidoreductases, 
transferases, hydrolases, lyases, isomerases and ligases.528 Of major importance are 
hydrolases that split a substrate under “hydrolytic” conditions.529 Hydrolosys refers 
to the splitting of a chemical compound with adsorption of a water molecule.530   
A protein domain is a discrete portion of a protein assumed to fold independent of 
the rest of the protein and possessing its own function. Thus, it is a region of a pro-
tein’s amino acid sequence that has evolutionary, structural, and functional signific-
ance. Pharmaceutical researchers are most interested in protein domains because 
they determine the “active” or “binding” sites of molecules. The combination of 
domains in a single protein determines its overall function. Generating a set of struc-
tures representative of most of the possible folds for specific protein domains is the 
basis of interpreting the structures for new proteins based on known fold-structure 
 
525   In re Bergstrom, 427 F. 2d 1394, 1401-1402 (C.C.P.A. 1970). 
526   Schering Corp. v. Geneva Pharmaceuticals, 339 F.3d 1373, 1380 (Fed. Cir. 2003)(“[T]his 
court's conclusion on inherent anticipation in this case does not preclude patent protection 
for metabolites of known drugs.”); also In re Cofer, 354 F.2d 664, 666 (C.C.P.A. 1966). 
527   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 9. 
528   Whitford, David, Proteins, Structure and Function, Chichester, West Sussex, U.K. 2005, 
191.  
529   Whitford, David, Proteins, Structure and Function, Chichester, West Sussex, U.K. 2005, 
191.  
530   Whitford, David, Proteins, Structure and Function, Chichester, West Sussex, U.K. 2005, 
202.  
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relationships.531 The particular protein domain shows a significantly higher signaling 
activity. The transduction of signals at the cellular level refers to the movement of 
signals from outside the cell to the inside and thus to the question of how membrane 
receptors transfer information from the environment into the cell’s interior. Approx-
imately half of the 25 largest protein families that are encoded by the human genome 
deal primarily with information processing. Signal movement can be simple. For 
example, some receptors constitute channels, which, upon ligand interaction, allow 
signals to be passed in the form of small ion movement either into or out of the cell. 
These ion movements lead to changes in the electrical potential of the cells that, in 
turn, propagates the signal along the cell. More complex signal transduction in-
volves the coupling of ligand-receptor interactions to many intracellular events.532 
a) Claims 
The comparative study used the following claims to specify the rules suggested for 
the patenting of binding pockets and protein domains.   
 
1. An isolated and purified molecule comprising a binding pocket of protein P     defined by the 
structural coordinates of amino acid residues 223, 223, 227, 295, 343, 366, 370, 378 and 384 
according to Fig. 1. 
2.  An isolated and purified polypeptide consisting of a portion of protein P starting at one of 
amino acids 214 to 218 and ending at one of amino acids 394 to 401 of protein P as set forth 
in SEQ ID NO: 1.533  
 
531   Available at http://www.genomicglossaries.com/content/proteomics.asp., last checked on 
January 21, 2008. Another arrangement of structural features and functional groups impor-
tant for biological activity is a pharmacophore. A pharmacophore is an arrangement of struc-
tural features and functional groups important for biological activity. Thus, it refers to the 
atoms that are involved in the binding of a ligand binding pocket as a whole. If, for example, 
the binding pocket of a protein consists of 30 binding pockets out of which five are involved 
in the binding of a particular pharmacophore, those five create the pharmacophore of the 
mentioned ligand. The binding pockets of the protein and of the ligand must fit together. As 
for pharmaceutical drugs, a pharmacophore is the functionally relevant portion and it assists 
in determining a protein’s entire 3-D structure, see Masuoka, Kunihisa, Study on the Ways 
of Protection of Post-Genome Research Products, IIP Bulletin 2002, 84-95, 91. 
532   Berg, Jeremy M./Tymoczko, John L./Stryer Lubert, , Biochemistry, New York, NY, 2002, 
395-424. 
533   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 9. 
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b) Background 
Protein P is a known protein whose amino acid sequence has been demonstrated. 
The patent description provided experimental data and explained that the protein 
lowers blood pressure. The patentees claimed that they had made a novel discovery, 
specifically that the active residues in the binding pocket of protein P consist of the 
above mentioned amino acids. The description specified that the possible peptides 
that begin with any amino acid from position 214 to 218 and end with any amino 
acid from position 394 to 401 of SEQ ID NO: 1 are protein domains that are able to 
fold into an active binding pocket of protein P. In addition, the description provided 
evidence regarding the above mentioned domain. It was explained that the domain 
showed a significantly higher signaling activity compared to the entire protein P 
when activated by a natural ligand of protein P. Neither is information available de-
monstrating the position of the binding pocket of protein P, nor reports suggesting a 
protein structure domain containing the described binding pocket.534  
c) Solutions proposed by the EPO and the USPTO 
The EPO, firstly, addressed the language of claim 1. The office suggested replacing 
the word “molecule” by “polypeptide” or compound. If a “molecule” were claimed, 
the claim would not be sufficiently disclosed, as a molecule as such was not enabled. 
A claim directed to “polypeptide” would not be directed to any subject matter ex-
cluded under Art. 52(2) EPC and comply with the requirements of industrial appli-
cability, clarity, enablement and support.  
The EPO rejects Claim 1 on the ground of novelty. Since prior art already in-
cludes protein P, the state of the art also comprises the binding pocket. Thus, the 
natural polypeptide would be prejudicial to the novelty of the claimed subject mat-
ter.535  
With regard to Claim 2, the EPO finds that it is directed to a patentable subject 
matter according to Art. 52(1) EPC. The requirements of clarity, enablement and 
support are satisfied. The furnished description would provide sufficient detail re-
garding the variable ends of the polypeptide. The polypeptide should not be relevant 
to the blood pressure lowering activity of the claimed portion. The EPO also ac-
cepted the novelty, inventive step and industrial application requirements. It states 
 
534   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 9. 
535   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 36. 
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that the specified portion of protein P was not disclosed in the prior art. Further, 
there was no demonstration or suggestion that this portion may exhibit a higher sig-
naling activity compared to the complete protein P.536 
The USPTO stressed that Claims 1 and 2 are patentable, eligible subject matter 
because they are each directed to a composition of matter (an isolated and purified 
molecule). Moreover, Claims 1 and 2 meet the utility requirement of 35 U.S.C. § 
101 since polypeptides exhibiting the binding pocket as defined in the claim are 
shown to have a higher signaling activity than protein P when activated by a natural 
protein P ligand. Further, protein P is known to lower blood pressure when active. 
Lacking a written description and encompassing a broader scope than is enabled by 
the specification, Claim 1 is rejected under 35 U.S.C. § 112, first paragraph. The 
claim does not comply with the written description requirement, because it recites a 
“molecule” defined only by the “structure” of 9 amino acid residues from a source 
polypeptide of at least 161 residues. From the view of the USPTO, the recited struc-
ture is open-ended and only determines a portion of the claimed molecule. The mo-
lecule is defined as a polypeptide, but it might also include residues that are not 
amino acids or amino acid derivatives. Protein P and the 40 fragments shown to be 
active all have the naturally occurring amino acid sequence of protein P. They do 
not constitute a representative number of species of the claimed genus, which in-
clude polypeptide and non-polypeptide molecules, to allow one of skill in the art to 
envision all members of the genus. Therefore, they do not provide an adequate writ-
ten description of the genus.  
As to the enablement requirement, the specification enables the full-length protein 
P and the specifically disclosed fragment. However, the specification does not ena-
ble all molecules encompassed by Claim 1. For the binding pocket to function, the 9 
residues must be in the same spatial relationship to each other as they are in the nat-
ural polypeptide or the polypeptide fragments disclosed in the specification. The to-
tal number of molecules encompassed by the claim is extremely large. This is due to 
the fact that there are a large number of residues within the pocket that can be 
changed to comprise any one of 20 amino acids. Additional unspecified moieties 
may be included on either end of the binding pocket thereby generating a vast num-
ber of molecules encompassed by the claim. Further, a lack of guidance exists re-
garding structural changes, which may be made in the amino acid sequence between 
and around the active residues in order that the resulting polypeptide retains its 3-D 
structure and activity at the binding pocket. Therefore, it requires undue experimen-
tation to make and use the invention over the entire scope claimed in Claim 1.537 
 
536   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 36. 
537   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 68f. 
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Claim 2, however, complies with the enablement and written description require-
ments. It is limited to fragments of protein P that contain the binding pocket de-
scribed in the specification to retain binding activity and the signaling activity of 
protein P. The USPTO further stressed that Claim 1 recites open “comprising” lan-
guage. Thus, the Claim encompasses natural protein P. Claim 1 is anticipated by 
protein P and therefore lacks novelty according to 35 U.S.C. § 102. Claim 4 is di-
rected explicitly to fragments of protein P consisting of the amino acid residues 
comprising the binding pocket and retaining binding and signaling activity. These 
fragments are not included in the prior art and are not rendered obvious based on the 
known amino acid sequence of the entire protein P.538  
d) Discussion 
Considering the statements provided by the patent offices, it must be noted that the 
EPO provides only very brief conclusions, whereas the USPTO gives a more de-
tailed description of its reasoning. The two offices adopted similar approaches in 
their assessment of Claims 1 and 2. They found that the patentable subject matter is 
easily satisfied. The criteria of description and enablement warranted more analysis. 
Both the EPO and the USPTO held that Claim 1 referring to a molecule does not sa-
tisfy the written description requirement. It is remarkable that the offices do not refer 
to the enablement factor in the context of comprising language, which they only ex-
amine with regard to novelty. The matter of “comprising language” has been the 
subject of a number of discussions.539  
The USPTO referred to the character of “open comprising language” with regard 
to the patenting of DNA fragments (ESTs) in consideration of the “written descrip-
tion guidelines” of January 5, 2001. 540 In Footnote 13 of the official document, the 
office states:  
“A determination of what the claim as a whole covers may result in a conclusion that specific 
structures such as a promoter, a coding region, or other elements are included. Although all 
genes encompassed by this claim share the characteristic of comprising SEQ ID NO: 1, there 
may be insufficient description of those specific structures (e.g. promoters, enhancers, coding 
regions, and other regulatory elements) which are also included.” 
Moreover, the office specified its view in the “Synopsis of Application of Written 
Description Guidelines”541:  
 
538   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 69. 
539   Krefft, Alexander Richard, Patente auf human-genomische Erfindungen: Rechtslage in 
Deutschland, Europa und den USA, München 2003, 281.  
540   Guidelines for Examination of Patent Applications under the 35 U.S.C. 112, P1, “Written 
Description” Requirement, 66 FR 1099 (January 5, 2001). 
541   Synopsis of Application of Written Description Guidelines, available at 
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“In the case of a partial cDNA sequence that is claimed with open language (comprising), 
the genus of, e.g., “A cDNA comprising [a partial sequence],” encompasses a variety of sub-
genera with widely varying attributes. For example, a cDNA’s principle attribute would in-
clude its coding region. A partial cDNA that did not include a disclosure of any open reading 
frame (ORF) of which it would be a part, would not be representative of the genus of cDNAs 
because no information regarding the coding capacity of any cDNA molecule would 
be disclosed. Further, defining “the” cDNA in functional terms would not suffice in the ab-
sence of a disclosure of structural features or elements of a cDNA that would encode a protein 
having a stated function. (…)"542 
In the course of the Synopsis, the USPTO referred to a specific claim which was re-
jected due to its comprising language. The USPTO in this case argued the following:  
 “Here, the specification discloses only a single common structural feature shared by members 
of the claimed genus, i.e., SEQ ID NO: 16. Since the claimed genus encompasses genes yet to 
be discovered, DNA constructs that encode fusion proteins, etc., the disclosed structural fea-
ture does not "constitute a substantial portion" of the claimed genus. Therefore, the disclosure 
of SEQ ID NO: 16 does not provide an adequate description of the claimed genus. Weighing 
all factors, 1) partial structure of the DNAs that comprise SEQ ID NO: 16, 2) the breadth of 
the claim as reading on genes yet to be discovered in addition to numerous fusion constructs 
and cDNAs, 3) the lack of correlation between the structure and the function of the genes 
and/or fusion constructs; in view of the level of knowledge and skill in the art, one skilled in 
the art would not recognize from the disclosure that the applicant was in possession of the ge-
nus of DNAs which comprise SEQ ID NO: 16. Conclusion: The written description require-
ment is not satisfied.”543 
Accordingly, the USPTO in the case of the synopsis rejected the DNA claim on the 
basis that the comprising language is too broad for sufficient enablement. The argu-
ments outlined in the above cited example, however, do not equally apply to the pro-
teomic case at issue. As to the synopsis, the USPTO alleges that the breadth of claim 
regarding genes yet to be discovered in addition to numerous fusion constructs and 
cDNAs leads to a lack of enablement. The case at issue, by contrast, involves a pro-
tein (P) that is already included in the prior art and thus disclosed. The breath of 
claim consequently only refers to features that are already state of the art. Thus, the 
use of comprising language does not lead to a lack of enablement. The term “com-
prise” is not rejected as failing the enablement factor in general, but only in the case 
where sufficient enablement is not provided by the given written description and/or 
by the prior art. This differentiated view of the phrase “comprise” complies with 
former statements provided by both patent offices. In the Trilateral report consider-
ing the patenting of ESTs, the USPTO stated that “comprising claim” indeed would 
 
   http://www.uspto.gov/web/menu/written.pdf, p. 31-32, last checked on January 21, 2008.  
542   In this context the USPTO referred to the claim formulation of Regents of the University of 
California v. Eli Lilly & Co., 119 F3-D 1559, 1569, 43 USPQ2d 1398, 1406 (Fed. 
Cir. 1997). Here, a description of a genus of cDNAs had been achieved by means of 
a recitation of a representative number of cDNAs, defined by nucleotide sequence, falling 
within the scope of the genus or of a recitation of structural features common to the members 
of the genus, which features constitute a substantial portion of the genus. 
543   “Synopsis of Application of Written Description Guidelines available at: http://www.uspto. 
gov. /web/menu/written.pdf, 31, last checked on January 21, 2008. 
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be broader than the “consisting claim”.544 The crucial question, however, would be 
whether the invention could be carried out in light of the In re Wands factors, which 
serve to assess sufficient enablement. 545  
In Ak Steel Corp. v. Sollac, the Federal Circuit extensively commented on the in-
terpretation of “comprising” and “consisting”, holding that a “comprising claim” 
must be considered as “open-ended”.546 Accordingly, the court does generally accept 
“comprising language” under the written description requirement. The question of 
sufficient enablement rather has to be assessed by the analyses of the In re Wands 
factors and does not primarily depend on the question of what is included from a 
comprising claim. Moreover, the question must be decided on the grounds of each 
given case.547 
The EPO also considered the interpretation of the terms “comprising”/ ”consist-
ing” on various occasions, that collectively mirror a differentiated approach. In the 
course of the Trilateral Project related to the patenting of DNA fragments the offices 
held that 
“We are not able to see any difference when judging invention activity with respect to the 
claim language “consisting of” or “comprising”. 548 
As to the particular “comprising claim” directed to ESTs the office states that it does 
not include DNA with unlimited length, but rather lengths that are still suitable for 
the purpose of DNA micro array technologies. In T 759/91, the Board of Appeal of 
the EPO had already extensively analyzed the issue stating that 
“While in everyday language the word "comprise" may have both the meaning "include", 
"contain" or "comprehend" and "consist of", in drafting patent claims legal certainty normally 
requires it to be interpreted by the broader meaning "include", "contain" or "comprehend".549 
Applying the principles set forth above to the claim at issues, it appears consequent 
that both offices reject claim one. The office applies its well established practice that 
a claim should only encompass as much as is contained in the description. Here, the 
description provides information exclusively regarding the polypeptide chain of the 
 
544   Trilateral Project B3b Comparative study on biotechnology patent practices, Theme: Pat-
entability of DNA fragments, available at: http://www.european-patent-office.org/tws/sr-3-
b3b.htm. 
545   In re Wands, 858 F.2d 731, 731 (Fed. Cir. 1988). (The enablement requirement must be de-
termined in light of “a. The quantity of experimentation necessary to practice the claimed in-
vention; b. The amount of direction or guidance presented in the specification; c. The pres-
ence or absence of working examples in the specification; “ d. The nature of the invention; e. 
The state of the prior art; f. The relative skill of those of ordinary skill in the art; g. The pre-
dictability or unpredictability of the art; and; h. The breadth of the claims ). 
546   Ak Steel Corp. v. Sollac, 344 F.3d 1234, 1239, 1244-1245 (Fed. Cir. 2003). The court fur-
ther explains that the phrase “consisting essentially of” in a patent claim represents a middle 
ground between the open-ended term “comprising” and the closed ended phrase “consisting 
of”. 
547   Ak Steel Corp. v. Sollac, 344 F.3d 1234, 1244-1245. 
548   Ak Steel Corp. v. Sollac, 344 F.3d 1234, 1244-1245. 
549   T 759/91, N. Publ., No. of the Reasons 2.2. (EPO 1993). See also T 711/90, N. Publ., No. of 
the Reasons 2.2. (EPO 1993).  
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protein. Yet, the entire molecule contains additional information not supported by 
the disclosed description. Therefore, the USPTO consequently applies its written 
description guidelines, stating that: 
“The claimed invention as a whole may not be adequately described if the claims require an 
essential or critical feature which is not adequately described in the specification and which is 
not conventional in the art or known to one of ordinary skill in the art“550 
It is also consequent that the two offices discuss the comprising language with re-
gard to novelty. They both found that claim 1 does not satisfy the novelty require-
ment, whereas they concur that the novelty of Claim 2 is established. Notwithstand-
ing the details provided by the USPTO, it is unclear as to how novelty of Claim 2 is 
derived.  The EPO rejects the novelty of Claim 1 on the grounds of that the prior art 
already reported protein P, meaning that the state of the art also encompasses the 
binding pocket. Hence, the natural polypeptide is prejudicial to the novelty of the 
claimed subject matter.551 The EPO found the novelty of Claim 2 to be given, stating 
that the prior art did not disclose the specified portion of protein P. The state of the 
art does not suggests this portion to exhibit an unexpected elevated signaling activity 
compared to the whole protein P.552The USPTO further stresses that Claim 1 is an-
ticipated by protein P and therefore lacks novelty. Due to its open “comprising” lan-
guage, the claim encompasses natural protein P. The office accepts the novelty of 
Claim 2 by reasoning that it is directed only to fragments of protein P that were not 
included in the prior art or were obvious. Hence, the “comprising language” does 
not only result in a lack of written description, but also in a lack of novelty. With 
“comprising” being understood in a broader sense than “consisting”, Claim 1 en-
compasses the entire protein P, meaning that it overlaps with what is included in the 
prior art. According to the Board of Appeal of the EPO, such “overlapping claims” 
do not focus sufficiently on the specific part of the selection invention.553 If a skilled 
person, however, is able to carry out the invention according to the description of the 
prior art that is used for the support of the new invention, the patent application does 
not match the standards of a selection invention. Therefore, Claim 1 fails to meet the 
novelty requirement. In accordance with statements of the patent offices set forth 
above, only the novelty of Claim 2 can be acknowledged.  
 
550   Guidelines for Examination of Patent Applications Under the 35 U.S.C. 112, P1, “Written 
Description” Requirement, 66 FR 1099 (January 5, 2001). 
551   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 36. 
552   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 36. 
553   T 279/89, N. Publ., 4.2 (EPO 1991), see also T 279/89, N. Publ., 4.2 (EPO 1991); T 666/89, 
OJ 1993, 495; T 255/91, OJ EPO 1993, 318; Blumer, Fritz, Formulierung und Änderung der 
Patentansprüche im europäischen Patentrecht, München 1998, 358. 
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Could novelty be established, assuming that the claim used “consisting language” 
instead of “comprising language”? Novelty might be derived under the principles of 
the first and second medical indication pursuant to Art. 54(5) EPC. As mentioned in 
Chapter III, a case of a first medical use exists if the invention resides in the initial 
discovery that a certain substance can be used for medical treatment. In this event, a 
broad claim to a pharmaceutical composition containing the substance is allowed 
without restriction of the actually identified medical use. When a further medical use 
of a substance already known to be pharmaceutical useful is identified, the EPO al-
lows so-called ‘second medical use’ claims in the Swiss-type format.554 These 
claims relate to a new use of an already known substance. Although the principles of 
first and second medical indication are applicable to field of proteomics, the claim at 
issue does not meet the requirements of Art. 54(5) EPC. Lacking Swiss-type format, 
it is not directed to a further use of protein P. The claims merely refer to a new cha-
racteristic of protein P and thus cannot be considered novel under the principles of 
first and second medical indications.  
Novelty might further exist under the principles developed for ‘selection inven-
tions.’555 A selection invention refers to an invention in which the constituting ele-
ments are derived from the species conception of a generic invention.556 Specifical-
ly, the compound as such has been reported by the prior art, but the more selective 
structure/pure form etc., remains undisclosed as it falls within the classification of 
the already known protein.557 Accordingly, a selection invention refers to technical 
contents that are not explicitly disclosed by the generic invention.558 In Thiochchlo-
roformates/HOECHST that refers to a process of preparation of a chemical com-
pound, the Board determined that a selection invention exists:  
 
554   Busse/Keukenschrijver, PatG, § 5 No. 33; § 3 No. 201.   
555   Guidelines for Examination in the EPO, Part C-IV, 911a explain that “the subject-matter of 
selection inventions differs from the closest prior art in that it represents selected sub-sets or 
sub-ranges. If this selection is connected to a particular technical effect, and if no hints lead-
ing the skilled person to the selection exist, then an inventive step is accepted (this technical 
effect occurring within the selected range may also be the same effect as attained with the 
broader known range, but to an unexpected degree). The criterion of ‘seriously contemplat-
ing’ mentioned in connection with the test for novelty of overlapping ranges should not be 
confused with the assessment of inventive step. For inventive step, it has to be considered 
whether the skilled person would have made the selection or would have chosen the overlap-
ping range in the hope of solving the underlying technical problem or in expectation of some 
improvement or advantage. If the answer is negative, then the claimed matter involves an in-
ventive step.“ See also Cornish, William/Llewelyn, David, Intellectual Property: Patents, 
Copyright, Trade Marks and Allied Rights, 6th ed., London 2007, 194.   
556   See T 0012/90, N. Publ., No. of the Reasons 3.3.1 (EPO 1990); the patentee claimed novelty 
on the ground of selective group of chemical compounds. The board rejected, considering 
the selection as being too broad.  
557   Blumer, Fritz, Formulierung und Änderung der Patentansprüche im europäischen Patent-
recht, München 1998, 345.  
558   Turrini, Enrico, The Concept of Novelty – A Review of the Case Law of the Board of Ap-
peal of the European Patent Office, 22 IIC 932, 938 (1991).  
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“if the sub-range selected is narrow ... and sufficiently far removed from the known range illu-
strated by means of examples. The sub-range is novel not by virtue of an effect which occurs 
only within it; but this effect permits the inference that what is involved is not an arbitrarily 
chosen specimen from the prior art but another invention (purposive selection).”559 
In other words, a) the selected sub-field is required to be narrow, b) the selected 
field is sufficiently far removed from the known range illustrated by working exam-
ples, c) the sub-field must not merely be randomly selected, but should be the result 
of a more tightly focused technical teaching and d) the selected area should not pro-
vide a mere embodiment of the prior art description, but another invention.560  
These principles developed by the Board of Appeal of the European Patent Office 
for the field of chemistry561 are also applicable to protein-related inventions. Like a 
chemical compound, a protein consists of distinct structural features, which can be 
compared to a variety of structural items. The composition of those structural items 
can be considered as being similar to the composition of chemical features. With re-
gard to the claim at issue, the binding pocket/protein domain of Claims 1 and 2 are a 
narrow field of the disclosed protein P. Being excluded from any working examples 
known in the prior art, a) and b) are thus satisfied. The focus on the binding pocket 
structure is intensive and results in a specific selection, and thus complies with c). 
Consequently, the claim at issue meets the novelty requirement under the principles 
for selection inventions. Moreover, the involvement of an inventive step is 
required.562 With respect to the selection invention a person skilled in the art should 
not be allowed to complete the technical problem.The selection invention563 that is 
deemed to be nonobvious involves an outstanding effect, property, or use when 
compared with the compounds in the known generic invention.564 It has been deter-
mined that the binding pocket exhibits higher signaling activity which can be de-
fined as an outstanding effect. As to what has been included in the prior art, the ele-
vated signaling activity must be considered an unexpected result and thus can be de-
 
559   T198/84 Thiochchloroformates/HOECHST, OJ 1985, 209. 
560   Blumer, Fritz, Formulierung und Änderung der Patentansprüche im europäischen Paten-
trecht, München 1998, 345; T 279/89, N. Publ.; see also Domeij, Bengt, Pharmaceutical Pa-
tents in Europe, Stockholm 2000, 157-168, 164. 
561   Further decisions of the Board of Appeals related to selection inventions are T247/91, N. 
Publ.(EPO 1982); T45/91, N.Publ. (EPO 1992); T198/84, OJ 1985, 209; T133/92, N. 
Publ.(EPO 1994). As for the German case law, see Hirsch, Fritjoff, Neuheit von chemischen 
Erfindungen, GRUR 1984, 243, 245 and the cited decisions therein.  
562   Blumer, Fritz, Formulierung und Änderung der Patentansprüche im europäischen Patent-
recht, München 1998, 348. 
563   The principles of the selection invention thus do not fit under the typical “three-step-
examination” of state of the art, novelty and inventive step. Since novelty already depends 
on the inventiveness, the third step, the “inventive step”m is inherent in the novelty analyses, 
see Blumer, Fritz, Formulierung und Änderung der Patentansprüche im europäischen Paten-
trecht, München 1998, 348. 
564   Blumer, Fritz, Formulierung und Änderung der Patentansprüche im europäischen Patent-
recht, München 1998, 358. 
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fined as being nonobvious. Consequently, both claims meet the inventive step re-
quirement.  
The U.S. patent law system is also familiar with the principles related to selection 
inventions.565 The taken approach resembles the European one. A “selection inven-
tion” refers to a species or subgeneric invention directed to a prior art reference (i) 
possessing novelty over the closest disclosed embodiment of that prior art reference; 
and (ii) being within the scope of that prior art reference. As under European patent 
law, the crucial element is the distance of the closest embodiment to the claimed in-
ventions. The major question is whether that closest embodiment raises a prima fa-
cie case of obviousness.566 The chemical case law is split in this respect.567 In re Su-
si, the court found a chemical invention to be prima facie obvious where the broad 
prior art disclosure includes at least some of the compounds claimed by the appli-
cant, and the prior art chemicals were of a class to be used for the same purpose as 
the compounds of the applicant.568 Thus, any disclosure that includes the chemical 
materials claimed by the applicant would render the claimed materials obvious and 
require an applicant to rebut the prima facie case with evidence of non-
obviousness.569 The rational established in Susi was followed by several other deci-
sions. In Merck & Co. v. Biocraft Laboratories Inc., the applicant claimed solely one 
of 1200 embodiments disclosed by the prior art.570 The court found that when the 
prior art teaches the skilled person that any of the 1200 embodiments could be used; 
a case of prima facie exists. The court held that this was especially true, because the 
claimed composition was used for the same purpose taught by the prior art.571 A dif-
ferent line of determining obviousness was set forth with the decision of In re 
 
565   A number of further decisions related to selection inventions are cited by Wegner, Harold, 
Patent Law in Biotechnology chemicals & Pharmaceuticals, New York 1994, 161 and 167. 
See also In re Petering, 301 F.2d 676, 133 USPQ 275 (C.C.P.A.), indicating that a prior ge-
nus could be an anticipation of alter species or Kalman v. Komberly Clark Corp., 713 F.2d 
760, 771, 218 USPQ 781, 789. More recently, the CAFC decided in CFMT, Inc. v. Yieldup 
International Corp. 349 F.3d 1333 (Fed. Cir. 2003) that additional inventive work does not 
alone show enablement. Developments related to selection inventions do not cast doubt on 
enablement of the original invention, see also Eli Lilly v. Zenith Goldline, 364 F.Supp.2d 
820 (S.D.Ind. 2005) (“Inventions based on the identification or selection of a specific mate-
rial or compound with particularly desirable properties within a previously disclosed genus 
of such materials or compounds do not violate any of the substantive requirements for pat-
entability”). 
566   Wegner, Harold, Patent Law in Biotechnology Chemicals & Pharmaceuticals, New York 
1994, 160-161. 
567   The principle that it is allowed to claim a narrow range within a broad range disclosed by the 
prior art is also referred to as “the doctrine of selection inventions”, see Varma, Ani-
ta/Abraham, David, DNA is different: legal obviousness and the balance between biotech in-
ventors and the market, Harvard Journal of Law & Technology 1996, 53, 69.  
568   In re Susi, 440 F.2d 442 (C.C.P.A. 1971). 
569   In re Susi, 440 F.2d 442, 446.  
570   Merck & Co. v. Biocraft Laboratories Inc., 874 F.2d 804 (Fed. Cir. 1989), cert. denied, 493 
U.S. 975 (1989). 
571   Merck & Co. v. Biocraft Laboratories Inc., 874 F.2d 804, 807.  
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Jones.572 The Federal Circuit held that a prima facie obviousness based on structural 
similarity was not raised where the claimed chemical compound was a subspecies of 
a broad genus. The court concluded that “we decline to extract from Merck the rule 
that … regardless of how broad, a disclosure of a chemical genus renders obvious 
any species that happens to fall within it.” The court distinguished Merck by stating 
that the claimed species was not specifically disclosed, but merely encompassed by 
the broad and general prior art teaching. This rational was approved and further de-
veloped by In re Baird.573 The applicant’s claim involving a bisphenol A574 had been 
rejected as being prima facie obvious over prior art disclosure of a broad genus of 
diphenols.575 The court accepted the claim, stating that there was nothing in the prior 
art suggesting that a skilled person should select bisphenol A from among more than 
100 million diphenols included in the broad genus disclosed in the prior art. The 
court explained that “[a] disclosure of millions of compounds does not render ob-
vious a claim to three compounds, particularly when that disclosure indicates a pre-
ference leading away from the claimed compounds.”576 Finally, in In re Bell, the 
Federal Circuit addressed of what is understood as an inordinately large number of 
possibilities that faces one skilled in the art attempting to arrive at the claimed DNA 
sequence.577 The Court followed the rational set forth in re Jones, stating that a pri-
ma facie case of obviousness requiring a person skilled in the art to select among a 
large number of choices is not properly decided.578  
Although the cited case law is not unambiguous, the breadth of claims must be 
considered the crucial factor with regard to the obviousness requirement. As for the 
claim at issue, it follows that the claim meets the requirements of novelty and non-
obviousness, provided that the patent applicant uses “consisting language” instead of 
open “comprising language”.  
 
572   In re Jones, 958 F.2d 347 (Fed. Cir. 1992). 
573   In re Baird, 16 F.3d 380 (Fed. Cir. 1994). 
574   Bisphenol A is a chemical substance (phenol) that is used to make polycarbonate plastic. 
575   Phenols represents a group of chemical compounds consisting of a hydroxyl group (-OH) 
linked to an aromatic hydrocarbon group; such as phenol (C6H5OH). 
576   In re Baird, 16 F.3d 380, 382.  
577   In re Bell, 991 F.2d 781 (Fed. Cir. 1993).  
578   In re Bell, 991 F.2d 781, 784; see also Varma, Anita/Abraham, David, DNA is different: 
legal obviousness and the balance between biotech inventors and the market, Harvard Jour-
nal of Law & Technology 1996, 53, 73, and cited case law. The authors also provide a de-
tailed discussion of the In re Bell decision.  
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III. Proteomics and Bioinformatics 
The following claims concern proteomic technologies involving in-silico screening 
methods and the identified compounds thereof, as well as inventions involving the 
3-D structural data of proteins per se. All these inventions are part of the rapidly 
evolving area of bioinformatics. In-silico screening consists of computerized simula-
tions of the three-dimensional structure of a given polypeptide and was already in-
troduced in Chapter II. The current availability of new information technologies 
enables scientists to compare a gross amounts of structural data. Therefore, ap-
proaches such as in-silico screening are increasingly replacing earlier in-vivo579 and 
in-vitro methods. 
The major goal of in-silico methods is to identify compounds which can bind to a 
computerized protein. In addition to applications for new methods, patent offices are 
confronted with an increasing number of patent applications related to the results 
from in-silicio screening. Specifically, we have seen in recent years the filing of ap-
plications involving the identification of candidate compounds which would theoret-
ically form the most stable complex with the computerized 3-D models of proteins. 
The latter, again, are the subject of an increasing number of applications filed in re-
cent years. Through methods such as NMR structure determination, X-ray 
crystallography and protein homologous-comparison, the speed of 3-D structure 
identification has increased steadily. Claims are often directly directed to in-silicio 
screening methods, since applications argue that the findings they put forth are a ne-
cessary precondition for compound identification. 
Combined with a number of other influences, these new forms of research have 
resulted in the development of bioinformatics. Bioinformatics, in turn, refers to ‘the 
application of quantitative analytical techniques to the modeling of biological sys-
tems’.580 More specifically, the term describes the development and employment of 
computer-implemented algorithms and data processing methods directed to data 
analysis and interpretation.581 The latter are then used in the design of new pharma-
 
579   Within a living organism or body. For example testing conducted on whole animals, such as 
mice.  
580   Vorndran, Charles/Florence, Robert L., Bioinformatics: Patenting the Bridge between In-
formation Technology and the Life Science, 93 IDEA - The Journal of Law and Technology 
2003, 93-131, 94. Bioinformatics draws researchers from the fields of biology, computer 
science, statistical mathematics, and linguistics.  
581   Rimmer, Matthew, Beyond Blue Gene: Intellectual Property and Bioinformatics, 34 IIC 31, 
31 (2003) defines “bioinformatics” as “the art and science of using computer systems to 
store, manage and analyse biological information that brings together the diverse disciplines 
of mathematics, statistics, engineering, and computer science to map and model genes and 
proteins”. The purpose of bioinformatics changes in relation to the improved organization of 
vast amounts and numerous types of biological information, and the clarification of the bio-
logical or medical significance of such information through its analyses. See also Masuoka, 
Kunihisa, Study on the Ways of Protection of Post-Genome Research Products, IIP Bulletin 
2002, 84, 85. 
https://doi.org/10.5771/9783845221441, am 02.12.2021, 20:19:12
Open Access -  - http://www.nomos-elibrary.de/agb
 139 
ceuticals.582 The area of bioinformatics has not only attracted a large amount of ven-
ture capital in recent years.583 It also poses a number of fascinating questions in the 
area of intellectual property rights protection. Among other things, it is closely re-
lated to the hotly debated issue of software implemented inventions, which has even 
been subject of an initiative of the European Commission.584 
1. In-silico screening methods 
One field which the patent offices had to consider were claims related to in-silico 
screening methods. As explained earlier, in-silico methods are computerized ways of 
searching for compounds, using the protein three-dimensional structural data regard-
ing protein active sites.585 The selection of compounds is achieved by evaluating 
their desirability in a computational model based on mathematical methods.586 The 
method of in-silico screening therefore illustrates the major importance compute-
rized techniques have for proteomic inventions. An increasing number of scientific 
studies are being carried out through the use of computers, a development that has 
come to be known as “in-silico biology”.587  
 
582   Krefft, Alexander Richard, Patente auf human-genomische Erfindungen: Rechtslage in 
Deutschland, Europa und den USA, München 2003, 35, who notes that bioinformatics is one 
of the most promising sectors of genomics. In particular, the ability to simulate entire cells 
in-silico (‘e-cell simulation’) is likely to have a large impact on life science in general. 
Against this background, the Human Genome Project can be understood as yet the greatest 
achievement of bioinformatics. Fernandez, Dennis/Chow, Mary, Intellectual Property Strate-
gy in Bioinformatics and Biochips, Journal of Patent and Trademark Office Society, June 
2003, 465, 465, provide another definition, stating that bioinformatics is understood as “the 
convergence of analytical and computational tools with the discipline of biological re-
search”.  
583   The rapid growth of bioinformatics has created an environment of rigorous competitive ef-
forts to create proprietary positions in areas of commercial interest. In the U.S., this devel-
opment motivated increasing filings of patent applications for bioinformatics-based inven-
tions. In 1999 alone, 289,448 such applications have been filed in the USPTO; see Hultquist, 
Steven J./Robert Harrison, and Yongzhi Yang, Patenting Bioinformatic Inventions: Emerg-
ing Trends in the United States, 20 Nature Biotechnology 2002, 743, 743. 
584   Proposal for a Directive of the European Parlament and of the Council on the patentability of 
  computer-implemented inventions, COM(2002) 92 final of 20.2.2002. See also Chapter 3 B 
III 1 a cc i.  
585   Chapter 2 E III 4.  
586   Camebridge Healthtech Institute, in-silico & molecular modeling glossary available at: 
http://www.genomicglossaries.com/content/ molecular _modeling_gloss.asp, last checked on 
January 21, 2008. 
587   Vorndran, Charles/Florence, Robert L., Bioinformatics: Patenting the Bridge between In-
formation Technology and the Life Science, 93 IDEA - The Journal of Law and Technology 
2003, 93, 127 stresses that scientists already possessing the requisite computational ability 
are at a significant advantage, since they are able to accomplish the demands of various in-
dustries.  
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a) Claim 1 
Claim 1 of the set of claims considered in this context reads: 
A method of identifying compounds that can bind to a protein P, comprising the steps of: 
a) The application of a 3-dimensional molecular modeling algorithm to the atomic coordinates 
of protein P to determine the spatial coordinates of the binding pocket of protein P.  
b) The electronic screening of the stored spatial coordinates of a set of candidate compounds 
against the spatial coordinates of the protein P binding pocket with the goal of identifying 
compounds that can bind to protein P.588  
aa) Background 
Protein P was a known protein whose amino acid sequence was also established. 
The description indicated that the activity of protein P was known to result in lower-
ing blood pressure. It provided the atomic coordinates of protein P, but did not in-
clude the position of its binding pocket. Instead, the specification provided general 
information on programs predicting the binding pocket of proteins and general in-
formation commonly used for in-silico screening programs. Prior art had demon-
strated methods of peptide modeling and binding using rational drug design, but 
there was a clear technical difficulty in obtaining the claimed atomic coordinates of 
protein P. It was assumed in the specification that by using the binding pocket pre-
diction program and in-silico screening program, the person skilled in the art could 
identify compounds binding to the given protein. The description provided no work-
ing examples of identifying compounds using the atomic coordinates of protein P. 
The specification contemplated that by using the binding pocket prediction program 
and in-silico screening program, the person skilled in the art could identify com-
pounds binding to the given protein. The prior art did not include 3-D coordinates of 
protein P. It did not teach computer programs for prediction of the binding pocket of 
proteins. Several in-silico screening programs referring to predicted binding pockets 
of proteins are already established.589    
 
588   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 10. 
589   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 10. 
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bb) Patent Offices Analysis 
The EPO concludes the in-silico claim to be a patentable invention under Art. 52(2) 
and 52(3) EPC, since it is directed to a method linked to a technical contribution 
through the use of technical data. Absent any working examples, however, the 
claimed method does not disclose sufficient information to comply with the disclo-
sure and enablement requirements. The patentee only offers the filing of further 
technical information in the future. Presently, he does not provide sufficient evi-
dence to ensure a correct prediction of binding-pockets positions.590 
The USPTO considers the claims to constitute a patentable subject matter, refer-
ring to the ‘State Street rationale’.591 In State Street, the court reasoned that to quali-
fy as patent-eligible subject matter, an invention must accomplish a practical appli-
cation.592 With regard to the claim at issue, the method steps apply to a set of struc-
tural parameters and the result set provides a number of lead compounds with an in-
creased probability of binding to the used protein. Hence, the method provides “a 
useful, concrete and tangible result” that can be used to guide further screening. Ir-
respective of the recitation of specific structural coordinates, the claims are directed 
to in-silico screening methods that have a practical application. Consequently, the 
methods must be considered statutory subject matter under the State Street rationale. 
593  
The utility requirement of 35 U.S.C. § 101 depends on the utility of the candidate 
compounds identified by the screening methods. Utility is present if the specification 
discloses that the binding compounds may be used either to stimulate activity of pro-
tein P to reduce blood pressure or, in cases of hypertension, to inhibit the activity of 
protein P  and thus cause an increase in blood pressure. An assertion of either or 
both of these uses for a protein P binding compound that is credible to one skilled in 
the art would be sufficient as a specific, substantial, and credible utility. Although 
 
590   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 37. 
591   See State Street Bank & Trust Co. v. Signature Financial Group Inc., 149 F.3d 1368, 1373 
(Fed. Cir. 1998). The ‘useful result’ aspect of the practical application test presupposes sig-
nificant functionality. See Arrhythima Research Tech. v. Carazonix Gorp., 958 F.2d 1053, 
1057 (Fed. Cir. 1992).  
592   Managing Intellectual Property 2003, Issue 132, p. 38, In State Street the court overturned 
the long-accepted rule that business methods were not statutory subject matter. In favour of 
banks, software companies and the nascent internet industry, the court said that methods of 
doing business should be treated the same way as any other patentable invention. It thus ex-
tended the holding of the earlier decision, In re Alappat, 33 F.3d 1526 (Fed. Cir. 1994), 
which had affirmed the patentability of computer programs.  
593   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 71. 
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the specification describes that protein P, when active, lowers blood pressure, there 
is no indication of a correlation between binding activity and activation. Absent of a 
known or disclosed correlation between binding and activation, the identification of 
compounds which bind to protein P lack a specific, substantial, and credible utili-
ty.594  
The USPTO determines the principles of enablement by considering several fac-
tors. Enablement depends on the selection, with mere general guidance, from the 
specification, of one or more programs to identify the binding pocket of protein P. 
Further, identification of the binding pocket must be demonstrated to be valid. Final-
ly, in order for the conditions of enablement to be fulfilled there must be an expecta-
tion of success in identifying compounds that bind to protein P, and the amount and 
nature of experimentation required to select candidate compounds must be clear.  
The office alleges that enablement is likely to fail unless the binding pocket iden-
tification is known to be highly predictive. The amount of experimentation required 
to identify and confirm the binding pockets is likely to be undue, since the program 
would yield multiple possible binding pockets. Thus, a person skilled in the art 
would have to choose the most likely predicted binding pockets in order to verify the 
actual pocket. Since the binding pocket is not confirmed prior to screening, the sets 
of possible binding compounds could be completely devoid of compounds that bind 
to protein P. Moreover, even if the claimed methods identify compounds that bind to 
protein P, the specification does not demonstrate the use of these compounds with-
out undue experimentation.595  
The USPTO further states that the claimed methods satisfy the written description 
requirements of 35 U.S.C. § 112, first paragraph. The specification includes the 
elements that are necessary to carry out the claimed method, such that one skilled in 
the art would have recognized that the patentee indeed possessed the claimed inven-
tion. It also teaches prior art programs that can be used to identify the binding pocket 
and to screen for candidate binding compounds. In addition, the specification deter-
mines the structural coordinates of protein P required by the pocket prediction and 
screening programs.596  
The USPTO further claims a lack of clarity under 35 U.S.C. § 112, second para-
graph, because the claim is directed to a process, but does not set forth any particular 
 
594   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 71. 
595   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 72. 
596   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 72. 
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steps involved in the process. Since the prior art did not disclose any 3-D coordi-
nates, the U.S. office acknowledges novelty. However, prior art renders the inven-
tion obvious. The computer algorithm used to identify compounds that can potential-
ly bind protein P is known and is unmodified. Consequently, the difference between 
the prior art and the claimed invention as a whole is limited to descriptive material 
stored on a machine. Data fed into a known algorithm whose purpose is to compare 
or modify those data using a series of processing steps is considered non-functional 
descriptive material, because there is no alteration of the process. Consequently, the 
claimed invention is directed to a method of using a known comparison in order to 
compare data sets. An invention does not become nonobvious merely because new 
data becomes available for analysis. Non-functional descriptive material cannot 
overcome nonobviousness of an invention that would have otherwise been ob-
vious.597 
cc) Discussion 
i. The discussion on the patentability of computer-implemented inventions in Europe 
For a better understanding of the EPO’s decision to accept the patentability of the in-
silico method (claim 1), it is beneficial to fully take into account the intense discus-
sion surrounding the patentability of computer-implemented inventions taking place 
in Europe.598 While the EPO has already granted large numbers of patents involving 
computer programs, two issues have exposed patentees and other groups to a 
significant risk. First, differences in national interpretations of the EPC have created 
a large amount of ambiguity related to the scope of protection for various classes of 
patents in different member states. Second, the fact that the EPC itself explicitly 
excludes “computer programs as such” from patentable subject matter has added to 
existing uncertainties. As to the latter, the EPO established its current practice to 
grant computer-implemented inventions by a number of decisions. In “Computer 
program product/IBM”599 the Board of Appeals of the EPO acknowledged the pa-
tentability of computer-implemented inventions if any “further technical effect” is 
provided. The Board reasoned:  
 
597   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 73. 
598   Nack, Ralph, Neue Gedanken zur Patentierbarkeit von computerimplementierten Erfindun-
gen - Bedenken gegen Softwarepatente - ein déjà vu?, GRUR Int. 2004, 771, 771; Nack, 
Ralph, Sind jetzt computerimplementierte Geschäftsmethoden patentfähig? GRUR Int. 2000, 
853, 853 emphasizing that the discussion increasingly focuses on the question of whether the 
patent system as such should be criticized.  
599   T 1173/97, Computer program product/IBM, OJ 1999, 609.  
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“A computer program product is not excluded from patentability under Art. 52(2) and (3) EPC 
if, when it is run on a computer, it produces a further technical effect which goes beyond the 
“normal” physical interaction between program (software) and computer (hardware).”600 
The decision of Computer program product/IBM thus specifies the meaning of Art. 
52 EPC. According to Art. 52(2) EPC, computer programs shall not be regarded as 
inventions within the context of Art. 52(1) EPC and are therefore excluded from pa-
tentability. Art. 52(3) EPC, however, establishes an important limitation to the scope 
of this exclusion: the exclusion applies only to the extent to which a European patent 
application or a European patent relates to programs to computers “as such”.601 
Since the technical character is generally accepted as an essential requirement for its 
patentability within the context of the application of the EPC (see Rules 27 and 29 
EPC), the exclusion of computer programs as such from patentability would mean 
that such programs are considered mere abstract creations, lacking in technical cha-
racter.602 Computer programs cannot be considered as having technical character for 
the very reason that they are software programs. This technical character, however, 
can be exhibited by further effects derived from the execution of the instructions 
given by the computer program.603 In “Computer program product/IBM, the court 
required a particular further technical effect such as a piece of software managing an 
“industrial process”, “the working of a piece of machinery” or an “internal function-
ing” of a computer itself.604  
In Two Identities/COMVIK605, the Board further determined that the requirement 
of a technical character permits the invention „to have a mix of technical and "non-
technical" features, even if the non-technical features should form a dominating 
part.“606 An invention is patentable „even if the technical was not the dominat-
ing part of the invention. “607  
In the following cases, the Board of Appeals of the EPO appears to weaken the 
standards for computer related inventions by accepting claims for computer methods 
“using technical means”. 608 In Microsoft, the invention involved “a method in a 
computer system having a clipboard for performing data transfer of data in a clip-
board format.”609 The Board determined that the invention has “technical character” 
 
600   T 1173/97, Computer program product/IBM, OJ 1999, 609, 628-623, see also T 208/84, OJ 
1987, 14; T 26/86, N. Publ.(EPO 1989); T 209/91, N. Publ. (EPO 1991); T 6/83, OJ 1990, 5; 
T 158/88, OJ 1991, 566; T 769/92, OJ 1995, 525; T 59/93, N. Publ (EPO 1994). 
601   Schulte/Moufang, PatG mit EPÜ, § 1 No. 156. 
602   Vicom/X-ray Apparatus, OJ 1987, 14; Singer/Stauder, EPC, 3rd ed., Art. 52, Nos. 36-39.  
603   Benkard/Melullis, EPC, Art. 52, 207, stating that the decision finally gave up the limits 
originally set forth by the EPC.  
604   T 1173/97, Computer program product/IBM, OJ 1999, 609, 628. 
605   T 641/00, Two Identities/COMVIK, OJ 2003, 352, 356-357.  
606   T 641/00, Two Identities/COMVIK, OJ 2003, 352, 356.   
607   T 641/00, Two Identities/COMVIK, OJ 2003, 352, 356, see also T 935/97 Computer pro-
gram product, RPC 1999, 861; T 931/95, Controlling pension benefits system, OJ 2001, 441. 
608   T258/03, Auction method/Hitachi, OJ 2004, 575, 585; T 0411/03 GRUR Int. 2006, 851 – 
Microsoft (Board of Appeals 2006). 
609   T 0411/03, GRUR Int. 2006, 851, 851  – Microsoft. 
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because it is “used independently of any cognitive content to enhance the internal 
operation of a computer” for “facilitating the exchange of data among various appli-
cation programs.”610 By assisting “the user in transferring no-file data into files”, the 
invention “solves a problem” by “technical means” and goes beyond the “elementa-
ry interaction of any hardware and software of data processing.”611  
The literature is generally consistent with the EPO’s approach to accepting com-
puter related inventions under certain circumstances.612 Benkard/Melullis, however, 
emphasizes that the patentability standard should not be satisfied if a result or effect 
is merely “carried out” by a computer. Under this view, it is necessary that “a tech-
nical teaching” establishes the “technical effect” independently from the computer 
application.613 Busse/Keukenschrijver agrees with Benkard/Melullis, but stresses that 
a technical effect cannot be caused by the mere application of software.  Under this 
perspective it is, however, also not justified to use the fact that software is applied as 
an argument against a technical contribution.614  
Once granted, however, a European patent becomes subject to the national patent 
laws of each country “in respect of which it is granted.” (Art.64 I). According to Art. 
64 III EPO, “any infringement of a European Patent shall be dealt with by national 
patent law. 615 The fact that a European patent to a computer-implemented invention 
might be challenged under the law of designated member states causes a high level 
of uncertainty for patent applicants and potential investors.616 Although the basic 
national laws on patentability are in principle uniform as between themselves and 
the provisions of the European Patent Convention, the detailed interpretation is the 
task of the courts. In other words, they are not bound to follow the decisions of the 
EPO’s appellate bodies and may, in the event of conflict, respect their own legal tra-
ditions.617 With respect to the interpretation of computer-implemented inventions, 
this has lead to legal divergences. In contrast to the EPO case law, the U.K. juri-
sprudence considers computer program-related inventions which consist of a method 
for performing business to be not patentable, even if a technical contribution ex-
ists.618 According to German case law, it had been assumed that the patentability of 
 
610   T 0411/03, GRUR Int. 2006, 851, 853  – Microsoft. 
611   T 0411/03, GRUR Int. 2006, 851, 853  – Microsoft. 
612   Schulte/Moufang, PatG mit EPÜ, § 1 No. 156.  
613   Benkard/Melullis, EPC, Art. 52 No. 219.   
614   Busse/Keukenschrijver, PatG, § 1 No. 75.  
615   Benkard/Jestaedt, EPÜ, § 64 No. 29-43.; as for the German practice, see Schulte/Kühnen, 
PatG mit EPÜ, § 139 No. 6. 
616   Krieger, Albrecht, Wann endlich kommt das europäische Gemeinschaftspatent? – Zwei Brü-
der als Kämpfer für den Schutz des geistigen Eigentums in Deutschland, in Europa und in 
der Welt, GRUR 1998, 256, 259. 
617   Benkard/Jestaedt, EPÜ, § 64 No. 29. 
618   Merrill Lynch [1989] RPC 561 (Court of Appeal). There also exists divergence with regard 
to the form of possible claims allowable. The U.K patent office and German court allow 
program product claims in the form approved in the EPO Board of Appeal decisions Com-
puter program product I and II, see T1173/97, OJ 1999, 609 (EPO 1998) and T0935/97, N. 
Publ.(EPO 1999), where an additional “technical contribution” is required.  The Netherlands 
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business methods having a technical aspect was allowable, even if the only technical 
contribution that exists is non-technical.619 This is illustrated by the cases of “Auto-
matic Sales Control”620 and “Speech Analysis Apparatus”621. Although the German 
Federal Supreme Court later clarified its interpretation by determining that the ade-
quate approach is the one followed by the EPO Board of Appeals, specifically that 
an inventive technical contribution is decisive for the requirement of the inventive 
step, the earlier decisions still serve as an example of how legal interpretation may 
result in major changes to the scope of patentability at the national level.622 Address-
ing this situation, the European Commission presented a proposal in 2002 for a Di-
rective on the Patentability of computer-implemented inventions.623 The major goal 
of this proposal was to harmonize national patent laws with respect to the patentabil-
ity of computer-implemented inventions by making the conditions of patentability 
more transparent. Any sudden change in the legal position, in particular any exten-
sion of patentability to computer programs “as such” should be avoided.624 The draft 
provoked much criticism from opponents of extensive patent protection.625 When the 
directive was voted on by the European Parliament on September 24, 2003 numer-
ous amendments were introduced which reflected concerns from diverse back-
grounds. Opponents of the directive claimed that the proposal would introduce U.S.-
style regimes on behalf of large companies that were able to acquire unlimited soft-
ware patents. Further, the directive would open the door to trivial patents after the 
 
patent office, by contrast, allowed a claim to computer software without any additional con-
tribution outside the computer, stating that already the download of software on the comput-
er creates a technically distinct machine, see Netherland Patent Office CR 1986, 541; CR 
1988, 29. This conclusion, however, is contrary to Art. 52 II EPC that prohibits the patenta-
bility of computer programs “as such”, see Benkard/Melullis, PatG, § 52, No. 189. 
619   Nack, Ralph, Sind jetzt computerimplementierte Geschäftsmethoden patentfähig?, GRUR 
Int. 2000, 853. 
620   Federal Patent Court, 32 IIC 328 (2001) – Automatic Sales Control (Automatische Ab-
satzsteuerung). 
621   BGH, 33 IIC 343 (2002) – Speech Analysis Apparatus (Sprachanalyseeinrichtung).  
622   BGH 33 IIC 232 (2002) – Logic Verification (Logikverifikation); Benkard/Melullis, EPÜ, 
Art. 52 No. 209.  
623   Proposal for a Directive of the European Parliament and of the Council on the patentability 
of computer-implemented inventions, COM(2002) 92 final of 20.2.2002; an overview is 
provided by Kraßer, Rudolf, Patentrecht: ein Lehr- und Handbuch zum deutschen Patent- 
und Gebrauchsmusterrecht, europäischen und internationalen Patentrecht, 5. Aufl., München 
2004, 166-171. See also Nack, Ralph, Die patentierbare Erfindung unter den sich wandeln-
den Bedingungen von Wissenschaft und Technologie, München 2002, 268. 
624   Proposal for a Directive of the European Parliament and of the Council on the patentability 
of computer-implemented inventions, COM(2002) 92 final of 20.2.2002, 11.; Nack, Ralph, 
Die patentierbare Erfindung unter den sich wandelnden Bedingungen von Wissenschaft und 
Technologie, München 2002, 271 argues that the principles set forth by the Technical Board 
of Appeals of the European Patent Offices should be applied, but the prohibition to patent 
computer programs as such abolished. 
625   The Foundation for a Free Information Infrastructure (FFII) is leading a campaign against 
the directive, claiming it would establish a ‘situation comparable to the U.S.’.  
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U.S. example, such as Amazon’s ‘one-click’ method.626 On July 5, 2005, the Euro-
pean Parliament, however, finally rejected the initiative. As a response to the rejec-
tion, the European Commission declared that it would not attempt to submit any 
more proposals related to the issue.627  
ii. Classification of In-Silico Screening Methods in Europe 
As stated earlier, the EPO accepts the patentability of Claim 1628 to the in-silico me-
thod, arguing that an algorithm for the simulation of a 3-D protein represents a tech-
nical contribution through the use of technical data. The reasoning, however, fails to 
explain why an algorithm is meant to be a technical contribution. Particularly in 
light of the fact that neither the statutory background, nor the existing case law pro-
vides an unambiguous definition of what is understood as technical contribution, it 
is beneficial to consider the EPO analysis more closely. This requires a more com-
prehensive analysis of the invention as such that goes beyond the aspects of comput-
er-implementation. In addition, a more precise determination of patentability re-
quirements is necessary. The questions that arise are the following:  Why does the 
claim at issue in an in-silico method establish a technical contribution sufficient for 
patentability? Why is it considered more than “mere technical data” or “abstract 
ideas”, both of which would be excluded from patentability under Art.52 II (a) EPC?  
To find an answer to these questions, the fact that an in-silico claim belongs to the 
field of bioinformatics is of major importance. As explained earlier, bioinformatics 
refers to the use of computing methods to study biological processes. An in-silico 
claim visualizes a biological process, namely the creation of a protein-ligand com-
plex and thus is covered by this category. 629   
The EPO’s analysis does not address the biological aspects that are included in 
the claim.  It merely stresses that the claim includes the use of data for computerized 
compound libraries. Hence, the patent office only emphasizes the computer-related 
aspects of the claim, but does not take into account that the data relates to a molecu-
lar biological process. The latter, however, is a central characteristic of the inven-
tion. The question of whether the invention establishes a technical contribution can-
 
626   Schulte/Moufang, PatG mit EPÜ, § 1, No. 161. 
627   FAZ of July, 6, 2005, S. 13 (Nr. 154); TAZ of July 7, 2005, S. 8 (No. 7709). 
628   A method of identifying compounds that can bind to a protein P, comprising the steps: 
  a) The application of a 3-dimensional molecular modelling algorithm to the atomic coordi-
nates of protein P to determine the spatial coordinates of the binding pocket of protein P.  
  b) The electronic screening of the stored spatial coordinates of a set of candidate compounds 
against the spatial coordinates of the protein P binding pocket with the goal of identifying 
compounds that can bind to protein P; see European Patent Office, Japan Patent Office, 
United States Patent and Trademark Office, Trilateral Project WM4, Comparative Studies in 
New Technologies (Biotechnology, Business Methods, etc.), Report on Comparative Study 
on Protein 3-Dimensional (3-D) Structure Related Claims, Vienna 2002, 10. 
629   Chapter 3 B III.  
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not be assessed without referring to the biotechnological nature of the claim. An in-
silico screening method demonstrates the protein’s ability to bind with certain com-
pounds and thereby particularly refers to the protein’s function. As explained in 
Chapter II, proteins perform a wide variety of functions, such as to provide catalytic 
activity or (in the case of receptor proteins) to detect chemical signals.630 Since these 
functions define the characteristics of the biological binding process, they are critical 
elements of the in-silico method. Biological functions related to proteins typically 
control a wide range of processes in the living organism. The computer-based visua-
lization of a biological function translates and transfers a biological mechanism (that 
is, a technical effect) into a virtual space, where the (in vivo) technical effect is re-
produced in silicio. The biological function is performed independently from the 
computer software. The computerized protein of the claimed method in-vivo per-
forms a particular biotechnological effect by binding compounds or regulating inhi-
bitor activity. Hence, a significant effect is present outside the software-hardware 
relationship of the computer. Biological functions related to proteins thus must be 
considered “further technical effects which go beyond the normal physical interac-
tion between software and hardware” as required under the standards developed by 
the EPO. 631   
Therefore, patent examiners and courts should examine bioinformatic claims, 
such as the one at issue directed to an in-silico method, in light of the simulated bio-
logical process. The patent law system should consider in-silico methods patentable 
subject matter, provided that the computerized molecule in-vivo performs a signifi-
cant biological function. In summary, the author agrees with the EPO’s decision to 
accept the patentability of in-silico methods (Claim 1). Rather than to exclusively 
focus on the question of whether the computerized data is used for the screening of 
other computerized databanks, the analysis of an in-silico claim should take into ac-
count the underlying biological process. If measurable biological effects exist, these 
should be considered adequate to establish patentability.632 
 
630   Chapter 2 B.  
631   T 1173/97, Computer program product/IBM, OJ 1999, 609, 618; also T 641/00, Two Identi-
ties/COMVIK, OJ 2003, 352, 356, see also T 935/97 Computer program product, RPC 1999, 
861; T 931/95, Steuerung eines Pensionssystems, OJ 2001, 441; T 258/03, Auction 
method/Hitachi, OJ 2004, 575, 585; T 411/03 GRUR Int. 2006, 851 – Microsoft. 
632   Masuoka, Kunishisa, Ways of Protecting New Technology Related Inventions in the Life 
Science Field, IIP Bulletin 2003, 28-34, 32. It is also suggested that the novelty of an in-
silico screening process is assessed on grounds of the underlying information. Bearing tech-
nical significance, information on new tertiary protein structures should thus be considered 
positive element for the creation of novelty.  
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iii. Classification of In-Silico Screening Methods in the U.S. 
As for the USPTO’s statement, the Office confirmed the patentable subject matter 
due to the State Street633 rationale. Under this doctrine, an invention must comply 
with the technological arts. To the extent that the invention is nonobvious, technolo-
gical contribution is not required. The mere fact that the invention uses a computer 
or software is sufficient to bring it within the technical art if it also provides a “use-
ful, concrete and tangible result”.634 Thus, a particular technical contribution pro-
vided by the invention is not required. The case of State Street Bank & Trust Co. v. 
Signature Financial Group Inc. referred to a business method which was performed 
with the aid of a computer. 635 Concerning this matter, the court held that three cate-
gories of subject matter are not patentable: laws of nature, natural phenomena, and 
abstract ideas. Consequently, mathematical algorithms as mere abstract ideas are not 
patentable inventions. However, once an algorithm is applied, it becomes a patenta-
ble invention if it generates tangible results.636 In Diamond v. Diehr637, the Court had 
determined that “certain types of mathematical subject matter, standing alone, 
represent nothing more than abstract ideas until reduced to some type of practical 
application.”638 Hence, a mathematical algorithm must be applied in a “useful way”. 
Applying Diamond, the court in State Street held that such a useful practical applica-
tion of an abstract idea is achieved provided it produces “a useful, concrete and tang-
ible result”.639 As to the claim at issue, it must be determined whether “the mathe-
matical algorithm is directly or indirectly recited”. If a mathematical algorithm is 
found, it must then be decided whether it is “applied in any manner to physical ele-
ments or process steps”.  
The claim at issue considers a method that involves a simulated protein. The po-
lypeptide is based on algorithm data that determine the 3-D folding structure. Being 
an applied algorithm and producing a useful, concrete and tangible result, the in-
silico method falls within the State Street doctrine and therefore constitutes a patent-
able subject matter.  
The USPTO rejected the claim for lack of utility, because the description does not 
indicate whether there is a correlation between binding activity and activation of 
 
633   State Street Bank & Trust Co. v. Signature Financial Group Inc, 149 F. 3d 1368 (Fed. Cir. 
1998).  
634   State Street Bank & Trust Co. v. Signature Financial Group Inc, 149 F. 3d 1368, 1372.  
635   State Street Bank & Trust Co. v. Signature Financial Group Inc, 149 F. 3d 1368, 1373;  In re 
Lowry, 32 F.3d 1579 (Fed. Cir. 1994) (claim to data structure stored on a computerreadable 
medium which increases the efficiency of the computer is held to be statutory subject mat-
ter), In re Warmerdam, 33 F.3d 1354 (Fed. Cir. 1994) (claim directed to data structure per se 
held nonstatutory subject matter if data structure did not cause functional change in com-
puter) 
636   State Street Bank & Trust Co. v. Signature Financial Group Inc, 149 F. 3d 1368, 1375. 
637   Diamond v. Diehr, 450 U.S. 175, 182 (1981). 
638   In re Alappat, 33 F.3d 1526, 1557 (Fed. Cir. 1994). 
639   Diamond v. Diehr, 450 U.S. 175, 182. 
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protein P. Thus, the Office requires the indication of a pharmaceutical effect. The 
need for a particular pharmaceutical effect to comply with the utility requirement 
had already been established in the context of the patentability of in vitro screening 
methods. Certainly, the final drug design must be considered “useful”. In the context 
of mass screening of expansive compound libraries – as the first step in discovering 
the lead compound for a new drug – the only demonstrated activity of the lead com-
pound is a mere binding affinity to the in vitro or computerized receptor.640 This 
binding activity is essential for the determination of a “practical use”, i.e., the phar-
maceutical effect of a screened compound.641 In Cross v. Lizuka642 the Court of Ap-
peals for the Federal Circuit held that the mere inhibition of an enzyme by a com-
pound was enough to establish a “practical use”.643 In Cross, however, the applicant 
provided exact experimental data regarding the inhibition process that included in-
formation subject to the correlation of binding activity and activation, which is es-
sential for the binding process. The specification explained the following:    
“The imidazole derivatives … of this invention are novel compounds which are not described 
in literature, and which possess a strong inhibitory action for thromboxane synthetase from 
human or bovine platelet microsomes, and which exhibit a strong inhibitory action for biosyn-
thesis or thromboxane A sub2 in mammalia including human. In general, a satisfactory inhibi-
tory effect is found at a level of molar concentrations of 2.5 x 10-8, for example, 2-[p-(1-
imidaoylmethyl) phenoxy]-acetic acid hydrochloride produce the about 50% inhibitory effect 
at the molar concentration of 2.5 x 10-8. Accordingly, the imidazole derivatives of this inven-
tion are extremely useful as therapeutical medicines for diseases caused by thromboxane A 
sub2, such as inflammation, hypertension, thrombus, cerebral apoplexy, asthma, etc.”644  
Based on this information, the court found that the screened compounds provided 
sufficient data to comply with the utility requirement.645 The claim at issue, by con-
trast, lacks any experimental data and thus cannot provide any “practical use”. The 
in-silico method itself, which is described by the claim language, only provides hy-
pothetical information. The applicant had to provide additional in vitro testing in or-
der to verify that the underlying technical problem of finding useful agents indeed 
had been solved.646 The given specification does not disclose any working examples. 
It should provide more information pertaining to the actual screened compound and 
not only to the method itself.  
As to enablement, the USPTO stated that the given claim does not satisfy the 
“how to make” prong of 35 U.S.C. § 112. The factors the USPTO considers with 
regard to enablement follow the principles the Federal Circuit developed in In re 
 
640   Ducor, Phillippe, New drug discovery technologies and patents, 22 Rutgers Computer and 
Technology law journal (RUCTLJ) 1996, 369, 425. 
641   Ducor, Phillippe, New drug discovery technologies and patents, 22 Rutgers Computer and 
Technology law journal (RUCTLJ) 1996, 369, 425. 
642   Cross v. Lizuka 753 F.2d 1040 (Fed. Cir. 1985). 
643   Cross v. Lizuka 753 F.2d 1040, 1046. 
644   Cross v. Lizuka 753 F.2d 1040, 1044. 
645   Cross v. Lizuka 753 F.2d 1040, 1049. 
646   Lonati, Milena, Patentability of receptors and screening methods: does in silico screening 
pose new legal problems?, Bioscience Law Report 2000/2001, 144, 145. 
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Wands.647 The enablement standard developed in In re Wands includes the quantity 
of experimentation necessary to practice the claimed invention, the amount of guid-
ance presented in the specification, the presence or absence of working examples, 
and the predictability or unpredictability of the art.648   
In addition, the Federal Circuit in University of Rochester v. G.D. Searle & Co es-
tablished the principle that even if a three-dimensional structure of a protein is 
known it is not possible for an ordinary skilled person to predict a candidate com-
pound for the binding pocket without undue experimentation.649  The court stated 
that this could be different in a case based on the complementariness of a nucleic 
acid and a protein. In non-genetic situations, that correspondence could be less clear. 
In this context, the Federal Circuit reasoned:  
“Given the sequence of a single strand of DNA or RNA, it may therefore have become a rou-
tine matter to envision the precise sequence of a “complementary” strand that will bind to it. 
(…). Even with the three-dimensional structures of enzymes such as COX-1 and COX-2 in 
hand, it may even now not be within the ordinary skill in the art to predict what compounds 
might bind to and inhibit them.”650 
Since the specification does not teach the use of potential candidate compounds 
which respond to the computerized screening method, the “how to use” prong of 
Section 112 is not satisfied, either. A strong correlation exists between the “how to 
use” prong of the enablement requirement and the requirement for a disclosure of 
practical utility found in 35 U.S.C. § 101. This principle has been confirmed in vari-
ous decisions.651 
The claim does not meet the threshold requirement of clarity and precision under 
35 U.S.C. Section 112, second paragraph. Since the potential candidate compounds 
are not being included in the claim language, the application does not describe the 
particular subject matter of the invention. The scope of the invention sought to be 
patented is the finding of lead compounds as one step of the screening process. The 
claim only refers to the application of the algorithms in order to simulate the three-
dimensional structure and to the potential screening of binding compounds. The ac-
 
647   In re Wands, 858 F.2d 731 (Fed. Cir. 1988). 
648   In re Wands, 858 F.2d 731, 731. 
649   University of Rochester v. G.D. Searle & Co.; Inc, 358 F.3d 916, 925 (Fed. Cir. 2004). 
650   University of Rochester v. G.D. Searle & Co.; Inc, 358 F.3d 916, 925. Actually the court set 
its argument in the context of the written description factor. However, since there is a “sig-
nificant overlap” between both requirements, the statement can also be applied with regard 
to enablement, University of Rochester v. G.D. Searle & Co.; Inc, 358 F.3d 916, 921 (cita-
tion omitted).  
651   Process Control Corp. v. Hyd Reclaim Corp., 190 F.3d 1350, 1358 (Fed. Cir. 1999) (“If a 
patent claim fails to meet the utility requirement because it is not useful or operative, then it 
also fails to meet the how-to-use aspect of the enablement requirement.”); In re Brana, 51 
F3d 1560, 1569 (Fed. Cir. 1995) (classifying practical utility as an implicit requirement of 
the enablement provision); Brooktree Corp. v. Advanced Micro Devices, Inc., 977 F.2d 
1555, 1571 (Fed. Cir. 1992) (clarifying that if the subject matter of a patent is inoperable, 
then the patent may fail to meet both the utility requirement and the enablement require-
ment). 
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tual binding process is not part of the claim language. In In re Wiggins the Federal 
Court concluded that  
“If the scope of the invention sought to be patented is unclear from the language of the claim, a 
rejection will lie under the second paragraph of 35 U.S.C. 112”652  
The USPTO further rejects the claim for rendering the invention obvious under Sec-
tion 103. The office applied the “Examination Guidelines for Computer-Related-
Inventions” of February 28, 1996653, which describe computerized data as falling 
between “functional descriptive material” and “non-functional descriptive material”. 
The Guidelines define “functional descriptive material” as “data structures and com-
puter programs, which impart functionality when encoded on a computer-readable 
medium.” “Non-functional descriptive material, in contrast, “includes but is not li-
mited to music, literary works and a compilation or mere arrangement of data”. As 
to obviousness, the Guidelines state:  
“[A] rejection of the claim as a whole under § 103 is inappropriate unless the functional de-
scriptive material would have been suggested by the prior art. Non-functional descriptive ma-
terial cannot render non-obvious an invention that would have otherwise been obvious.”654  
The guidelines further provide:  
“[A] process that differs from the prior art only with respect to non-functional descriptive ma-
terial that cannot alter how the process steps are to be performed is not sufficient to achieve the 
utility of the invention.”655 
The principles applied by the USPTO correspond with existing case law of the 
CAFC. In In re Gulack, the court stated that when descriptive material is not func-
tionally related to the substrate, the descriptive material will not distinguish the in-
vention from the prior art in terms of patentability.656 In Ex parte Carver, by con-
trast, the court characterized the given material as “functionally-descriptive, because 
the signals at issue were used to actuate and control sound recording responsive de-
vice structure to produce the appellant’s disclosed acoustic phenomena.657 
From a comparative point of view, the USPTO maintains a stricter approach than 
the EPO. Although both the U.S. and the European patent offices classify the claim 
as computer-implemented invention, the USPTO concludes that the claim must be 
rejected for rendering the invention obvious. The Office argues that the 3-D protein 
data is fed to an algorithm that is already state of the art. Absent any alteration or 
modification of the algorithm, the office concludes that the invention is obvious. 
 
652   In re Wiggins, 488 F.2d 538, 541 (C.C.P.A. 1973). 
653   Examination Guidelines for Computer-Related-Inventions, [Federal Register: February 28, 
1996 (Volume 61, Number 40) 7478-7492, available at: 
  http://www.kuesterlaw.com/swguide.htm, last checked on January 21, 2008.  
654   Examination Guidelines for Computer-Related-Inventions, VI, available at: 
  http://www.kuesterlaw.com/swguide.htm, last checked on January 21, 2008.  
655   Examination Guidelines for Computer-Related-Inventions, VI, available at: 
   http://www.kuesterlaw.com/swguide.htm, last checked on January 21, 2008.  
656   In re Gulack, 703 F.2d 1381, 1385 (Fed. Cir. 1983). 
657   Ex parte Carver, 227 USPQ 465, 470 (Bd. Pat. App. & Int. 1985). 
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Given that there is no functional relationship between the data and the algorithm, the 
office considers the 3-D protein structure non-functional descriptive data.  
Is such a classification, however, adequate for an obviousness standard in the 
field of bioinformatics? 658 Pursuant to 35 U.S.C. § 103, a patent claim is rejected “if 
the differences between the subject matter sought to be patented and the prior art are 
such that the subject matter as a whole would have been obvious at the time the in-
vention was made to a person having ordinary skill in the art to which said subject 
matter pertains”.659 The statute clearly states that the invention must be considered 
“as a whole.”  The inventions at issue, however, do not only refer to the data itself. 
Rather, they include the simulation of a complex biological process, namely the 
emulation of a protein and of its binding ligands. They not only establish the de-
scriptive data as such, but also the imitation of a biological operation performed by 
such data. One could argue that the USPTO fails to sufficiently take into account 
these biological features expressed by the data, and, consequently, does not consider 
the patented subject matter “as a whole.” 
For an evaluation of the entire invention, the key question must be whether a per-
son skilled in the art is able to (a) predict the protein-ligand complex and (b) simu-
late it through the claimed in-silico method without involving inventive activity. In 
the claim at issue, the prior art does not include any similar in-silico screening me-
thod. In addition, the data necessary to simulate the protein by applying the algo-
rithm must be obtained through extensive in-vitro testing. Consequently, neither part 
(a) nor part (b) of the above question can receive a positive answer, implying that 
the claim would not render the invention obvious. Against this background, it ap-
pears reasonable to argue that the claim should be accepted under the U.S. patent 
law system.  
b) Claim 2 
Claim 2 of the set of claims being directed to “in-silico screening methods” reads as 
follows:  
A method of identifying compounds which can bind to protein P by comparing the 3-D struc-
ture of candidate compounds with a specific 3-D molecular model which comprises the fol-
lowing steps:  
The given 3-D molecular model shows the positions of heteroatoms in the amino acids build-
ing out of the binding pockets of protein P (i.e., amino acids 223, 224, 227, 295, 343, 366, 370, 
378, 384) wherein said hydrogen bonds can form hydrogen bonds with hydrogen bonding 
functional groups in a candidate compound.  
 
658   Vorndran, Charles/Florence, Robert L., Bioinformatics: Patenting the Bridge between In-
formation Technology and the Life Sciences, 93 IDEA - The Journal of Law and Technolo-
gy 2003, 93, 121.  
659   Chapter 3 A II 4 a.  
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Steps (1) through (n) describe a data processing method in which  
(a) the coordinate data of the 3-D molecular model is input in a data structure such that the in-
teratomic distances between the atoms of protein P are easily retrieved.  
(b) the distances between hydrogen-bonding heteroatoms of different candidate compounds 
and the heteroatoms that form the binding pocket in the 3-D molecular model are compared 
thereby allowing the identification of those candidate compounds which would theoretically 
form the most stable complexes with the 3-D molecular model binding pockets of protein P, 
based on optimal hydrogen bonding between the two structures.660  
aa) Background 
Protein P is an established protein whose amino acid sequence is also clear. The de-
scription explains that the activity of protein P was previously known to result in 
lowering blood pressure. The description gives the atomic coordinates of protein P 
as a co-crystal with its natural ligand, and gives a logical explanation that the active 
residues in the binding pocket of protein P consists of specific and determined ami-
no acids. The description demonstrates how the 3-D molecular model incorporates 
the 3-D structure of the binding pocket. It provides working examples of the claimed 
methods in which a number of compounds are identified. It also provides experi-
mental data of the actual binding affinities of the compounds identified. Pursuant to 
that data, a skilled person would infer that the claimed method may be used to iden-
tify a number of compounds which bind sufficiently to protein P such that a biologi-
cal effect results. No prior art suggested the 3-D coordinates of protein P. However, 
the prior art included in-silico screening programs that compare the 3-D structure of 
candidate compounds with the 3-D molecular model of the binding pocket of a pro-
tein of interest. Prior art also demonstrates the method of storing coordinates data to 
optimize the interatomic distance information.661  
bb) Patent Offices’ Analysis 
The EPO states that the invention disclosed is patentable. The claim refers to a me-
thod having a link to a technical contribution that is characterized by technical fea-
tures. This activity is not regarded as a presentation of information or as a pure ma-
thematical method, excluded by Art. 52(2)(d) or (a) of the EPC, respectively, but 
rather as the use of the structural data. Because the description reports experimental 
 
660   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 10ff. 
661   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 11ff. 
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data that includes information about identified compounds, the requirements of 
clarity, enablement and support are satisfied. Novelty, inventive step, and industrial 
application are present, since the prior art did not disclose or suggest the 3-D coor-
dinates of protein P. The claimed method is considered to be novel, nonobvious and 
industrially applicable.662  
The USPTO also agrees that a patentable subject matter is given. In addition, the 
utility requirement of the claimed methods is satisfied, since the utility of the candi-
date compounds identified through screening is also provided. With regard to the 
enablement factor, the USPTO differs from the EPO. The Office held that the speci-
fication adequately described and enabled one skilled in the art to make the claimed 
method of screening, by virtue of working examples that identified compounds that 
bind to protein P. The working examples provide sufficient guidance regarding the 
screening program. In addition, they show the effectiveness of the screening pro-
gram in using the disclosed 3-D coordinates of protein P to identify ligands binding 
with sufficient affinity such that a biological effect would be expected by one skilled 
in the art. With respect to the “how-to-use-prong” of the enablement requirement, 
the specification demonstrates that protein P, when active, lowers blood pressure. 
However, there is no indication as to whether there is a correlation between binding 
activity and the modulation of blood pressure. The USPTO, nevertheless, states that 
if compounds binding protein P could be used to modulate blood pressure without 
undue experimentation, the claimed method would comply with the enablement re-
quirement of 35 U.S.C. § 112.663  
The Office further concluded that the claim can be considered novel. The claims 
are obvious with regard to the prior art if the claimed data-processing method used 
to identify compounds that can potentially bind protein P, i.e., steps (1) through (n), 
would have been obvious to one skilled in the art. Consequently, the claimed me-
thod would have been prima facie obvious over the prior art because steps (1) 
through (n) appear in the prior art methods.664 
 
662   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 37. 
663   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 73. 
664   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 74f.  
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cc) Discussion 
The in-silico methods of Claim 2 differ from the prior in-silico related invention 
(Claim 1) in two ways. First, the language of Claim 2 includes information related to 
identified compounds which are defined by size and shape. Second, the description 
provides particular working examples that report the specific binding process. Thus, 
the differences are all related to compounds that respond to the screening process. 
Both offices treat the claim slightly differently than Claim 1. The EPO accepts the 
claim due to the working examples that are reported in the description. Sufficient 
disclosure (Art. 83 EPC) and support (Art. 84) requirements are thus met. The USP-
TO concurs with the EPO regarding the written description and enablement re-
quirement, but maintains its divergent view regarding the definition of algorithms 
data as non-functional data. Therefore, the USPTO rejects the claim due to obvious-
ness.  
Yet, the results being developed by both offices must be reconsidered. The ques-
tion of whether the applicant is allowed to claim protection for the compounds that 
can be identified by a screening process has been the subject of various discussions, 
in particular in the context of “reach-through” claiming. Reach-through claiming re-
fers to claim language which is broad enough to dominate future compound discove-
ries that can be used for rational drug design.665 With regards to the claim at issue, it 
remains to be established whether it fulfills the currently required measurements of 
case law. A series of decisions in biotechnology cases developed a very demanding 
written description requirement and a high standard for enablement. The claim at 
issue cannot be considered a typical reach-through claim. The applicant does not 
simply claim all molecules performing the function of binding the receptor, without 
providing any information regarding the structure of the ligand. By contrast, the 
claim provides theoretical information about the size and shape of binding sites of 
the computerized method and of responding compounds, which are based on protein 
analysis techniques such as protein crystallization. Thus, the claim reports a descrip-
tion of the structure necessary to complete the entire screening. The strategy fol-
lowed by the patent claimer certainly succeeds in overcoming reach-through claim-
ing problems. Nevertheless, recent decisions of the Federal Circuit as well as of the 
Technical Board of Appeal have taken a very severe approach toward claim scope. 
In addition, it was previously demonstrated that one panel at the Federal Circuit 
Court ruled in favor of a demanding written description requirement. The currently 
required high standards for enablement establish high demands for developers of in-
silico methods, regardless of whether the illustrated dispute can be decided on behalf 
of such a separate obligation. Thus, the drafting method of the claim at issue is 
fraught with a number of scientific and legal hazards. Even though the applicant 
provides working examples which prove that his speculations regarding the structure 
of functional ligands are correct, the prior art may bear surprises rendering the patent 
 
665   OECD, Genetic Inventions, Intellectual Property Rights and Licensing Practices, Paris 2002, 
63.  
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invalid. A broad claim to a set of compounds lacks novelty even if a single member 
of the genus was reported in the prior art. This principle applies even if the proper-
ties of the prior art compound causing it to fall within the scope of the claim were 
merely inherent, and not reported. Provided only one prior art ligand bears the shape 
and size demonstrated by the claim, and therefore responds to the in-silico protein, 
the patent is invalid. Many molecules have been reported by prior art, but relatively 
few have been defined by size and shape. Straight-forward searches are rarely able 
to identify compounds falling within the scope of claims that are defined in terms of 
fit within a reported binding pocket.666  
Finally, it must be stressed that patentability on in-silico screening methods can 
only succeed in relation to the patentability of the target used in the method. The en-
tire screening method is not completed until the compound is identified. The discov-
ery of a new receptor, however, is the key ingredient of the screening method; the 
other steps are merely routine.667  
2. Structural Data of proteins per se  
a) Claims and Claim Background 
Another method of drafting claims in proteomics is to refer to the 3-D structural data 
of the protein per se. The claims of the trilateral study WM4 concerning 3-D struc-
tural data of the protein per se read as follows.  
Claim 1:  
A computer model of protein P generated with the atomic coordinates listed in a specific fig-
ure.  
Claim 2: 
A data array comprising the atomic coordinates of protein P as set forth in Fig. 1 which, when 
acted upon by a protein modeling algorithm, yields a representation of the 3-D structure of 
protein P.  
Claim 3: 
A computer-readable storage medium encoded with the atomic coordinates of protein P as 
shown in Fig. 1.  
The specification classifies protein P as novel. Experimental data is provided 
and it is explained that the protein, when active, lowers blood pressure. The pro-
 
666   Eisenberg, Rebecca S., Reaching through the Genome, In: Perspectives on Properties of the 
Human Genome Project; Kieff, F. Scott Ed. Amsterdam, 2003; 209, 225. 
667   Lonati, Milena, Patentability of receptors and screening methods: does in silico screening 
pose new legal problems?, Bioscience Law Report 2000/2001, 144, 144. 
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tein modeling algorithms are well known in the prior art. The description pro-
vides the atomic coordinates of protein P, and asserts that the coordinates can be 
used for in-silico screening methods. The prior art does not include any refer-
ence that teaches or suggests protein P.668 
b) Patent Offices’ Analysis 
As for claim 1, the EPO reasons that a computer model is not considered to be a pa-
tentable invention, since it merely presents the atomic coordinates of a single protein 
molecule as such. The model does not offer any technical problem solution and does 
not provide any further technical effect. Consequently, the claim at issue does not 
meet the requirements of a patent-eligible subject matter under Art. 52(2)(d) EPC, 
which excludes presentations of information from patentability. Further, the EPO 
states that the claimed invention does not provide sufficient information for an ade-
quate prior art search. Consequently, a search cannot be carried out under Art. 54 
EPC. Hence, it is not necessary to examine whether such a prior art search would 
identify any references that demonstrate or suggest protein P.669   
With regard to Claim 2, the EPO states that the claimed invention cannot be con-
sidered as a patentable subject matter, since a data array is a mere presentation of 
information and excluded under Art. 52(2)(d) EPC.670  
As for Claim 3, the EPO states that a storage medium does not qualify for a pa-
tent-eligible subject matter pursuant to Art. 52(2)(d), because it only determines the 
atomic coordinates of a single protein molecule in space, without providing a partic-
ular technical character. The data merely includes cognitive content in a generalized 
manner.671 The EPO notes that the claim is distinct from cases in which the Technic-
al Board of Appeals had acknowledged computer storage to be patentable. In con-
 
668   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 7. 
669   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 34. 
670   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 34. 
671   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 35. 
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trast to the claim at issue, the particular data referred to a computer program with a 
further technical effect.672  
The USPTO holds that Claim 1 is not tangibly embodied and thus must be consi-
dered as non-functional descriptive material per se. Since descriptive material is 
considered as an abstract idea, the claim at issue cannot be acknowledged as patent-
able subject matter pursuant 35 U.S.C. § 101.  
As to Claim 2, the USPTO states that it is directed to a mere compilation or ar-
rangement of data. With the 3-D coordinates consisting of non-functional descrip-
tive material without physical structure, they must be interpreted as abstract ideas 
which do not qualify as patentable subject matter. See In re Warmerdam673, where 
the court stated that descriptive material per se is not patent-eligible subject matter. 
As to the specification, the decisive element is that the atomic coordinates of protein 
P can be used for in-silico screening methods. Presupposing that the identified com-
pounds can provide a specific, substantial, and credible utility, the claim at issue 
meets the utility requirement. However, such a specific, substantial, and credible 
utility cannot be acknowledged when the correlation between binding activation and 
compounds binding protein P are not disclosed. The specification only determines 
that protein P, when active, lowers blood pressure. It fails to provide any detailed 
information regarding binding activity or inhibitor regulation. A sufficient disclosure 
must include information about how the compounds can be used. Their use could 
either be directed to a stimulation of proteins P’s activity to reduce blood pressure, 
or, in cases of hypotension, to an inhibition of the activity of protein P causing an 
increased blood pressure. Absent of any of these assertions, a specific, substantial, 
and credible utility is not acceptable.674 The enablement requirement is satisfied. 
Based on the disclosure that protein modeling algorithms are well known in the art, 
and the complete description of the atomic coordinates of protein P, claims 1 and 2 
are enabled for how to make the claimed method and are adequately described.  
The how-to-use prong is not satisfied by the disclosure, unless the patent specifi-
cation provides information regarding the binding activity or inhibitory regulation 
amounting to a specific, substantial, and credible utility. Regarding enablement, the 
patent description must teach one skilled in the art to use the claimed invention 
without undue experimentation.675  
 
672   T 1173/97, OJ 1999, 609, the EPO applied its guidelines, see Guidelines for Examination in 
the EPO,  Part C-IV.2 
673   In re Warmerdam; 33 F.3d 1354, 1361, 31 USPQ2d 1754, 1760 (Fed. Cir. 1994). 
674   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 63. 
675   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 63. 
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With regard to Claim 3, the USPTO maintains that the structural data of protein 
must be considered non-functional descriptive material because the claimed inven-
tion only refers to protein data stored on a computer-readable medium. It is merely 
stored so as to be read by a computer without creating any functional interrelation-
ship, either as part of the stored data or as part of the computing processes carried 
out by the computer. Thus, the 3-D coordinates do not impart functionality to either 
the data or the computer. With non-functional descriptive material being stored in a 
computer-readable medium as an abstract idea, it cannot be defined/classified as pa-
tent eligible subject matter pursuant to 35 U.S.C. § 101.676 As mentioned above, the 
specification does not include any functionality related to either the data or the com-
puter, and therefore must be understood as non-functional descriptive material. De-
scriptive material that is not functionally related to the substrate does not distinguish 
the invention from the prior art for patentability purposes.677  
c) Discussion  
In contrast to the treatment of in-silico methods, the EPO rejects the claims for lack 
of a further technical effect. The USPTO again classifies the claims as merely in-
cluding non-functional descriptive material and rejects the claims due to obvious-
ness. Applying the reasoning established in In re Warmerdam, the USPTO con-
cludes that no patentable subject matter is established. The question in In re War-
merdam is whether the claim directed to a specific data process goes beyond the 
simple manipulation of abstract ideas. Absent any such effect, no patentable subject 
matter could be acknowledged.678  
The approach taken by both patent offices is consequent in light of their general 
practices regarding the treatment of databases.679 Nevertheless, scientists could ar-
 
676   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 64. 
677   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 64. 
678    In re Warmerdam , 33 F.3d 1354, 1361.  
679   In Europe, investment in the compilation of the data might be protected under sui generis 
rights. The use of a considerable amount of data will only be allowed with the permission of 
the database owner. In practice, access to these databases will be subject to payment of a li-
censing fee. Due to a lack of originality, the data as such, i.e., the mere sequence as pieces of 
written information, are not protectable under copyright. Consequently, the information of 
the sequences may be used freely, see Bostyn, Sven J.R., Living in an (im)material world: 
bioinformatics and intellectual property protection, 01 Journal of International Biotechnol-
ogy Law 2004, 2-10; 54-61, 59. For a precise and detailed overview of German and interna-
tional approaches to database protection see further Nack, Ralph, Nationaler und internatio-
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gue that the patent offices do not sufficiently take into account biophysical concepts, 
such as the importance of non-covalent bonds,680 native vs. denatured states of pro-
teins, etc. Patent offices allow patents on standard chemical formulae which are, in 
fact, merely 2-D coordinates of molecules combined together with some standard 
rules of chemical connectivity. 3-D coordinates of proteins, by contrast, are not 
deemed to be patentable, although they too demonstrate standard rules of chemical 
connectivity between the atoms. From a legal perspective, the offices distinguish be-
tween computer storable data and the established chemical practice to determine 
compounds by a chemical formula. From a scientists’ perspective, however, it ap-
pears that the dimensionality (i.e., 1-D, 2-D, 3-D) in which the coordinates are 
represented determines the patentability of a molecule.681  
3. Compounds identified by in-silico screening methods 
Advances in proteomics resulted in the discovery of great numbers of new protein 
“targets”. Due to new computerized methods, compound libraries could be increased 
in size. Progress in the development of screening assays, particularly “high-
throughput screening” technologies (HTS)682, enables scientists to screen such libra-
ries for their potential protein targets and effects within a very short time.683 The de-
sign and development of screening methods, which must be considered as research 
tools, is generally time-consuming and expensive. 
Furthermore, economic value emerges only after years of investment and only in 
the case that the development of a new drug succeeds. The use of the screening tar-
get is usually made at a stage in which further steps of drug design are not yet fore-
seeable.684 If the sale of the pharmaceutical is successful, however, high revenues 
 
naler Rechtsschutz von Datenbanken (Q182), GRUR 2004, 227. The treatment of data 
through mechanism other than patent law is no major subject of this study. 
680   Covalent bonds arise as a result of the sharing of one or more pairs of bonding electrons. 
681   Vinarov, Sara D., Patent protection for structural genomics-related inventions, Journal of 
structural and functional genomics 2003, 191, 203.  
682   A “high throughput screening” is a computerized technique of rapidly searching for mole-
cules with desired biological effects from very large compound libraries (up to 60,000 per 
day), see Burke, Adrienne J., Blowing a Path for HTP Proteomics, Genome Technology 
2003, 24, 24; Bader, Joel S./Chaudhuri, Amitabha/Rothberg, Jonathan M./Chant, John, Gain-
ing confidence in high-throughput protein interaction networks, 22 Nature Biotechnology 
2004, 78.  
683   Wolfram, Markus, 'Reach-Through Claims' and 'Reach-Through licensing' - Wie weit kann 
Patentschutz auf biotechnologische Research Tools reichen? Mitteilungen der deutschen Pa-
tentanwälte 2003, 57, 58. 
684   See Figure 8 at Chapter 2 E III 3.  
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can be expected. It is thus understandable that the owners of research tools are inter-
ested in receiving a share of such profits.685 
Inventors attempt to protect the products they develop with the help of their re-
search tools, such as in-silico methods, by including the identified compounds in the 
claim language.  
a) Claims 
A claim involving the described method may be drafted as follows:   
Compounds686 identified by  
A method of identifying compounds that can bind to a protein P, comprising the steps of: 
a) The application of a 3-dimensional molecular modeling algorithm to the atomic coordinates 
     of protein P to determine the spatial coordinates of the binding pocket of protein P.  
b) The electronic screening of the stored spatial coordinates of a set of candidate compounds  
     against the spatial coordinates of the protein P binding pocket with the goal of identifying  
     compounds that can bind to protein P.687  
b) Patent Offices’ Analysis 
The EPO holds that the claim meets the requirement of a patentable subject matter 
since it refers to identified compounds. When the claimed invention does not pro-
vide enablement over the entire range of claimed embodiments, the requirement of 
sufficient disclosure is not met. A prior art search is limited to the example provided 
by the description.688 The invention cannot be considered novel, since the natural 
ligand is already state of the art and thus prejudicial to novelty.  
 
685   Wolfram, Markus, 'Reach-Through Claims' and 'Reach-Through licensing' - Wie weit kann 
Patentschutz auf biotechnologische Research Tools reichen?, Mitteilungen der deutschen Pa-
tentanwälte 2003, 57, 58.  
686   Claim 2 of the same case. 
687   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 10. Another U.S. patent No. 6,083,711 entitled “Proteases 
compositions capable of binding to said site, and methods of use thereof” covers compounds 
screened by 3-D in-silico structure defined by structural coordinates, see Eisenberg, Rebecca 
S., Reaching through the Genome, In: Perspectives on Properties of the Human Genome Pro-
ject; Kieff, F. Scott Ed. Amsterdam, 2003; 209, 225. 
688   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 37. 
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The USPTO concludes that Claim 2 refers to a statutory subject matter. The claim 
only satisfies the utility requirement of 35 U.S.C. § 101 if the specification teaches 
that the binding compounds may be used to either stimulate activity of protein P to 
reduce blood pressure, or in cases of hypotension, inhibit the activity of protein P to 
cause an increase in blood pressure. Nevertheless, the claim must be rejected, both 
due to a lack of enablement and of a sufficient description under the principles de-
veloped in Regents of the University of California v. Eli Lilly.689 Since one skilled in 
the art would come to the conclusion that the inventors were not in possession of the 
claimed invention, the claim fails to comply with the written description require-
ment. It is not sufficient that the claim at issue is directed to a “compound identified 
by an in-silico method”; rather the claim language has to include specific structural 
or functional characteristics.690  
The USPTO further determines that the claim does not comply with the enable-
ment requirement for the “how-to-make” prong of 35 U.S.C. § 112, first paragraph. 
The patent lacks a disclosure of any particular structure for the claimed compound. 
The specification does not provide any guidance or working example in this unpre-
dictable art. Thus, an artisan would not have been unable to make the claimed com-
pound without undue experimentation. An assay for finding a product is not equiva-
lent to a positive recitation of how to synthesize such a product. The USPTO main-
tains that the claimed invention does not comply with the “how to use” prong of 35 
U.S.C. § 112, first paragraph. The specification does not show how to administer the 
claimed compound so as to effect a viable blood pressure treatment regimen. Treat-
ment/administration protocols depend upon the nature of the compound being admi-
nistered as well as the clinical condition of the patient. In the absence of additional 
information, a skilled person would not have been able to use the undisclosed com-
pound(s) for treatment without undue experimentation.  
As for novelty, Claim 2 is rejected as anticipated by the prior art compound, par-
ticularly if a search yielded one of the compounds tested experimentally in the speci-
fication. It would be rejected as being anticipated, or rendered prima facie obvious 
by the prior art under two conditions. First, the prior art demonstrates agonists or 
antagonists of protein P, and second, the examiner can provide evidence to support 
the judgment that prior art compounds inherently fall within the scope of the 
claim.691 
With regard to the written description requirement, the USPTO holds that the 
claim at issue is directed to a genus of compounds identified by the method of Claim 
2. Moreover, the specification discloses at least some examples of the structure of 
compounds within the scope of the claim. Nevertheless, there is no evidence of a 
 
689   Regents of the University of California v. Eli Lilly, 119 F.3d 1559 (Fed. Cir. 1997). 
690   Regents of the University of California v. Eli Lilly, 119 F.3d 1559.  
691   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 76. 
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structure/function relationship per se between the disclosed compounds and any oth-
ers that might be found using the claimed method. Structurally identified characte-
ristics of the genus members are not disclosed. Thus, the claimed invention is not 
supported by a sufficient written description. The rejection might be overcome with 
a demonstration of objective evidence. This evidence must support the proposition 
that the selected disclosed compounds are representative of the structure of the 
group of molecules identified by the claimed method.692  
c) Discussion  
aa) Reach-through-Claims 
Both offices classify the claim as a reach-through claim.693 Consequently, they treat 
it similarly to inventions involving identified compounds of in-vitro screening me-
thods.694 The question is whether such claims are patentable. Reach-through claims 
use a claim language broad enough to include future product discoveries without 
providing any information, such as structure coordinates or other elements.695 The 
inventor does not only claim the structure of a protein, but also of compounds that 
bind to the protein, even though the latter is still unknown at the time the claims are 
drafted.  In terms of in-silico methods, the applicant not only claims the compute-
rized screening method, but also the compounds, which might be identified by such 
methods.696 The topic of reach-through claims has been the subject of various dis-
cussions.697 After an increasing number of applications contained claims drawn to 
 
692   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002; Vinarov, Sara D., Patent protection for structural genomics-
related inventions, Journal of structural and functional genomics 2003, 191, 205.  
693   As for reach-through claims, see Straus, Joseph, Reach-through claims and research tools as 
recent issues of patent law in: Estudios sobre propiedad industrial e intellectual y derecho de 
la competencia, Curell Suñol, M./et al. (Eds.): Grupo Español de la AIPPI, Barcelona, 2005, 
921. The need of inventors to protect screened proteins emerged in the ‘post-genomic’ era 
where proteins capable of becoming the targets of drug development are identified rapidly 
and in large quantities. This is also emphasized in Masuoka, Kunihisa, Study on the Ways of 
Protection of Post-Genome Research Products, IIP Bulletin 2002, 84, 89.  
694   As “in-vitro” is understood “outside the living body and in an artificial environment”; see at 
Medline Plus, Medical Dictionary, available at: http://www2.merriam-webster.com/cgi-
bin/mwmednlm?book=Medical&va=in%20vitro, last checked on January 21, 2008.  
695   OECD, Genetic Inventions, Intellectual Property Rights and Licensing Practices, Paris 2002, 
63. 
696   Lonati, Milena, Patentability of receptors and screening methods: does in silico screening 
pose new legal problems?, Bioscience Law Report 2000/2001, 144, 145.  
697   Eisenberg, Rebecca S., Reaching through the Genome, In: Perspectives on Properties of the 
Human Genome Project; Kieff, F. Scott Ed. Amsterdam, 2003; 209, 225 who argues that le-
gal provision of reach-through rights should follow indications in the market that such allo-
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include all potential pharmaceutical candidate compounds identified by assaying, the 
issue was examined in the course of a trilateral study in 2001.698 In this case, the pa-
tent offices agreed not to accept claims reaching beyond that embodied by the pa-
tent. Applying those principles, the USPTO refused to grant the claim at issue. The 
hypothetical claim to compounds which bind to the receptor is rejected, since the 
applicant only discloses the function of the ligand without revealing information re-
garding its structure. Hence, the office is relatively tolerant with regard to the ob-
viousness and utility criterion, but applies a particularly strict written description re-
quirement. Relying on the principles developed in the Regents’ of California699 and 
Enzo700 cases, the office supports a separate written description requirement.701 The 
importance of the discussion, however, is attenuated by the fact that the claim at is-
sue is also rejected due to a lack of enablement. When a skilled person is unable to 
make and use the invention without undue experimentation, the ‘how-to-make’ and 
‘how-to-use’ prongs are not met. In sum, reach-through claims are subject to the 
same standards as all patent claims. An invigorated written description requirement 
generates a high threshold level to the granting of reach-through claims. With the 
USPTO also refusing to grant reach-through claims because of a lack of enablement, 
the dispute as to where to set the limits of a written description obligation is, howev-
er, not dispositive.  
The EPO analysis is in accordance with German patent law developed in the field 
of chemicals. In the Trioxan702 decision, the German Federal Supreme Court held 
that an unambiguous identification of the patented subject matter is the factual basis 
for not only the grant of the patent requirement but also for the start of the examina-
tion procedure made by the patent offices. The court discusses the first issue by ana-
lyzing how to reward the inventor appropriately on the one hand, and provide suffi-
cient legal certainty on the other. Rewarding the inventor appropriately means, how-
ever, the court stated, that an inventor should only receive the advantages of a patent 
 
cations are appropriate; also Kunin, Stephen G/ Nagumo, Mark/ Stanton, Brinaet al., Reach-
through claims in the age of biotechnology, 51 American University Law Review April 
2002, 609, provides a good overview how reach-through claims are treated by the USPTO 
applying the B3b Trilateral Study on reach-through claims undertaken by the Patent offices 
of Japan, the U.S. and Europe. Clark, Vici, Reach-through infringement: what are the limits? 
6 Bio-Science Law Review 2000/2001, 249-252 who gives an overview about the legal situ-
ation in the U.K. For a comparative treatment, see OECD, Genetic Inventions, Intellectual 
Property Rights and Licensing Practices, Paris 2002, 63.  
698   Trilateral Project B3b Comparative study on “reach-through claims”, San Francisco, Cali-
fornia, USA 2001. 
699   Regents of the University of California v. Eli Lilly & Co., 119 F.3d 1559 (Fed. Cir. 1997). 
700   Enzo Biochem v. Gen-Probe, 323 F.3d 956 (Fed. Cir. 2002). 
701   Rochester illustrated how courts treat reach-through claims that have already been issued by 
the USPTO. The patent involving reach-through claims was based on the identification of 
molecules and processes in Cox-2 pathway. The claims to unidentified COX-2 inhibitors 
such as Celebrex were held to be invalid; See University of Rochester v. G.D. Searle & Co.; 
Inc, 358 F.3d 916 (Fed. Cir. 2004). 
702   BGH, 3 IIC 226 (1972) – Trioxane. 
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if he discloses a new technical teaching to the public. The teaching of a substance 
invention under German law consists of making a substance available and providing 
at least one way to prepare it. Applying these principles to the claim at issue, the 
claim to the identified compounds of an in-silico method lacks both requirements 
and thus no “reward” can be provided to the inventor. With regard to unambiguous 
identification, the court in Trioxane emphasized that a claim must be drafted so pre-
cisely that it clearly demonstrates which substances are included in the claim lan-
guage. Patent offices must be enabled to determine whether a substance already be-
longs to the prior art or not. Again, the principles established in Trioxane apply: if a 
substance is not described by its structural formula, any parameter that enables a 
clear distinction is sufficient for description. Claim language as “identified through 
…” does not provide such a distinction. Thus, it does not meet the standards for  pa-
tentability.703  
bb) Reach-through licensing 
Another approach to protecting pharmaceutical inventions, instead of by broad 
reach-through claims is by reach-through licensing. The basic idea of this contract 
strategy is that the patent holder restricts access to his patented screening technology 
to those who agree to share future drug sales with him in the form of royalties. The 
specific characteristics of such royalties may violate existing anti-trust laws. The 
question of whether they are allowed influences the drafting of licensing contracts 
but also the amount of damage awards that can be claimed in the course of the in-
fringement process. On the one hand, critics may claim that reach-through practices 
excessively reward those who rest on their laurels at the expense of those who carry 
research forward. On the other hand, it may be seen as a valuable way to allow early 
innovators to realize that their discoveries contribute to subsequent research. Wheth-
er the statutory background and existing case law is allowing the practice of reach-
through licensing, will be discussed below.  
i. Statutory background in Germany 
A patent establishes a monopoly position that is authorized by legislation. If the pa-
tentee extends such a position by drafting personal licensing agreements that go 
beyond what is allowed by patent law, existing antitrust law rules may be violated. 
In order to prevent the monopoly right provided for the patentee from being ex-
tended beyond its legislative limitations by licensing contracts, the German competi-
 
703   Wolfram, Markus, 'Reach-Through Claims' and 'Reach-Through Licensing' - Wie weit kann 
Patentschutz auf biotechnologische Research Tools reichen?, Mitteilungen der deutschen Pa-
tentanwälte 2003, 57, 60; BGH, 3 IIC 226 (1972) – Trioxane. 
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tion law restricts the freedom of contract. Sections 17 and 18 of the Act of restraints 
of competition (ARC)704 state that licensing agreements for the sale or use of certain 
intellectual property rights shall only contain such restrictions on the licensee that 
are covered by the scope of the intellectual property right as such. According to Sec-
tion 17 para 1 sentence 2 ARC, only restrictions pertaining to the nature, extent, 
field of use, quantity, territory or duration of the right of use are allowed. The share 
of future profits is not addressed by this provision, which is why reach-through 
royalties are not covered. Reach-through royalties may, however, qualify for an ex-
emption under Section 17 para 3 ARC if the licensee’s economic freedom of move-
ment or the market competition is “not unfairly restricted and if competition on the 
market is not substantially impaired because of the extent of the restrictions.” In the 
event that research tools are used for identifying substances, the licensee will typi-
cally apply for a patent in order to protect such substances. During the duration of 
the patent, the substances are excluded from market competition. If no competition 
exists, an agreement regarding reach-through royalties does not thereby establish 
any restraint on the market. Furthermore, if the freedom of movement of the licensee 
is not restricted, an exemption will be granted. This is typically the case when par-
ties agree upon moderate royalties. The exemption is considered to be granted if the 
cartel office does not reject the application within a period of three months.705  
Another approach for protecting pharmaceutical inventions is through “milestone 
payments”. In order to save the share of future profits, the parties agree upon pay-
ments triggered by contractual achievements. Typically, they are directed to major 
project events such as the beginning of pre-clinical or clinical trials or the achieve-
ment of drug approval. Milestone payments can be understood as escrows706 and 
thus are acceptable under antitrust laws.707 
 
ii. Legal situation under U.S. law 
In the U.S., the topic of reach-through licensing is subject to heated discussion. The 
National Institutes of Health (NIH) rejects the idea of reach-through royalties due to 
policy reasons. It is claimed that they restraint research and the distribution of re-
search tools. Only in exceptional cases are receivers of NIH subsidies allowed to 
conclude reach-through-licensing agreements.708 
 
704   “Gesetz gegen Wettbewerbsbeschränkungen” 
705   Kraßer, Rudolf, Patentrecht: Ein Lehr- und Handbuch zum deutschen Patent- und Ge-
brauchsmusterrecht, europäischen und internationalen Patentrecht, 5. Aufl., München 2004, 
981. 
706   “Aufschiebend bedingte Verpflichtung zur Zahlung einer Pauschallizenzgebühr für die Be-
nutzung des Research tools” 
707   Wolfram, Markus, 'Reach-Through Claims' and 'Reach-Through licensing' - Wie weit kann 
Patentschutz auf biotechnologische Research Tools reichen?, Mitteilungen der deutschen Pa-
tentanwälte 2003, 57, 63. 
708   Department of Health and Human Services/National Institutions of Health: “Principles and 
Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Dissemi-
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Licenses providing reach-through royalties may give rise to antitrust issues under 
the patent misuse doctrine.709 The doctrine requires that the alleged infringer demon-
strate that the patent owner has unlawfully broadened the scope of the patent with a 
resulting anti-competitive effect. In Zenith Radio Corp. v. Hazeltine Research, Inc., 
the Court of Appeals held that patent misuse is established if the grant of a patent 
license is conditioned upon payment of royalties on products, which do not involve 
the teaching of the patent.710 The patentee “extend(s) the monopoly of his patent to 
derive a benefit not attributable to use of the patent’s teachings” if “the leverage of a 
patent” is used to “garner as royalties a percentage share of the licensee’s receipts 
from sales of other products.711 Patent misuse thus must be assessed if the patentee’s 
actions affect competition in unpatented goods or otherwise extends the economic 
effect beyond the scope of the patent grant.712 There are several cases which deal 
with the question of whether reach-through royalties are considered to be patent mi-
suse.  
In Sibia Neuroscience, Inc. v. Cadus Pharm. Corp., the infringing activity con-
sisted of the use of a patented screening method to detect antagonists713 and agon-
ists714 of proteins. The district court for the Southern District of California assessed 
damages, based on the calculation of a “reasonable royalty” of $18 million. The 
amount was calculated with the assumption that the parties had agreed upon reach-
through royalties. With the subsequent invalidation of the patent by the CAFC due 
to obviousness in the light of the prior art715, this type of damage assessment was not 
further examined. In Ajinomoto Co. v. Archer Daniels Midland, the claim was di-
rected to methods of producing bacteria to make amino acids. The district court as-
sessed damage awards by determining a royalty of $1.23/kg of amino acid sold. 
With the parties not disputing this calculation, it was not subject to any further dis-
cussion.716 In addition, the decision of Bayer v. Housey assists in dealing with the 
details of patent misuse. In the district court decision, the court found that the plain-
tiffs sufficiently stated a claim of patent misuse reasoning that 
 
nating Biomedical Research Resources, Final Notice”, U.S. Federal Register Notice 64 FR 
72090, 23.12.1999, http://ott.od.nih.gov/pdfs/64FR28205.pdf, last checked on January 21, 
2008.  
709   For a comparative analyis of the patent misuse doctrine see Riziotis, Dimitrios, Patent Mi-
suse als Schnittstelle zwischen Patentrecht und Kartellrecht, GRURInt. 2004, 367. 
710   Zenith Radio Corp. V. Hazeltine Research, Inc., 395 U.S. 100, 135. (Fed. Cir. 1969). 
711   Zenith Radio Corp. V. Hazeltine Research, Inc., 395 U.S. 100, 136. 
712   See C.R. Bard, Inc. v. M3 Sys., Inc., 157 F.3d 1340, 1372 (Fed. Cir. 1998).   
713   An antagonist is a substance that attenuates the effects of an agonist by binding to the agon-
ist’s binding sites. See glossary, available at http://www.adrenoceptor.com/abc.htm, last 
checked on January 21, 2008. 
714   An agonist is a substance that binds to a receptor and activates it, producing a pharmacologi-
cal response (such as contraction, relaxation, secretion, enzyme activation, etc.), see glos-
sary, available at http://www.adrenoceptor.com/abc.htm, last checked on January 21, 2008. 
715   Sibia Neuroscience, Inc. v. Cadus Pharm. Corp.225 F.3d 1349 (Fed. Cir. 2000). 
716   The CAFC in Ajinomoto Co. v. ADM Co., 228 F.3d 1338 held that the claims at issue were 
valid and infringed by a commercial process using bacteria made by these methods.  
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“Certain practices that do not equal per se patent misuse may constitute misuse if a court de-
termines that such practices do not reasonably relate to the subject matter within the scope of 
the patent claims. If "the practice has the effect of extending the patentee's statutory rights and 
does so with an anti-competitive effect, ... the finder of fact must decide whether the ques-
tioned practice imposes an unreasonable restraint on competition”.717  
For the reasons set forth above, the legal treatment of reach-licensing agreements is 
yet not clear. Hence, it is advisable to handle such strategy with caution.  
IV. Conclusion 
Based on the study of the different approaches provided by the European and the 
U.S. patent offices, it can be concluded that both offices largely share the same 
views with respect to the patentability requirements of 3-D protein structures-related 
claims.718 Yet, different approaches exist with regard to the patentability of in-silico 
screening methods. The European Patent office accepts the claim, assuming a pa-
tentable subject matter due to a further technical effect of the computerized inven-
tion. The USPTO, by contrast, rejects the claim, concluding there is obviousness due 
to the understanding that the algorithm is considered as non-functional descriptive 
material.  
The study shows that an inventor seeking patent protection for 3-D protein struc-
tures should obey the following guidelines.719 Generally, a patent applicant should 
provide accurate and precise information regarding the 3-D structural coordinates. 
Furthermore, a precise description of how the structural analysis was carried out 
should be provided in the patent specification. Isolated and determined 3-D protein 
structures establish novelty, if the inventor proves that the tertiary structure coordi-
nates are a more unambiguous parameter than the amino acid sequence already dis-
closed in the prior art.  
The further rule that novelty can be derived from physical morphology applies 
principles developed in the field of chemical inventions. The possibility of creating 
novelty through the principles of selection inventions are also in line with classical 
chemical patent principles. The question of dependency from the patent covering the 
whole protein is another key factor and will be discussed below.  
 
717   Bayer v. Housey, 169 F.Supp.2d 328, 331 (District Court of Deleware 2001). 
718   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 32; also Vinarov, Sara D., Patent protection for structural ge-
nomics-related inventions, Journal of structural and functional genomics 2003, 191, 206. 
719   Vinarov, Sara D., Patent protection for structural genomics-related inventions, Journal of 
structural and functional genomics 2003, 191, 207, who emphasizes that understanding how 
patent offices will analyze structural genomics-based inventions is crucial for formulating 
strategies in patent prosecution and litigation.  
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As for proteomics claims in the field of bioinformatics, principles from both 
computer-implemented inventions and inventions involving biological material 
should apply. Therefore, the author suggests that a further technical effect, as well as 
the acknowledgement of functional descriptive material, may be derived from the 
biological function the protein performs in-vivo.  
As for compounds screened by in-silico methods, the strategy to draft reach-
through claims should be handled with caution. With strict conditions set out for the 
written description/sufficient disclosure requirement and enablement factor, it may 
be advisable to use other approaches such as milestone payments or reach-through 
licensing methods. As long as the claim defines the identified compound by size and 
shape, it is not considered a reach-through claim. In order to meet the patentability 
requirements of written description/sufficient disclosure and enablement, it is advis-
able for applicants to disclose theoretical information about the size and shape of 
binding sites within the computerized method and in responding compounds. Inven-
tors, however, must take into account that such claims involve a high risk that they 
will be rendered invalid. Even if only one prior art ligand has the shape and size 
demonstrated by the claim and would therefore respond to the in-silico protein, the 
claim lacks novelty. With many molecules being reported in prior art, but not all of 
them defined by size and shape, the concrete risk of a destruction of novelty is diffi-
cult to assess.720   
Finally, it must again be emphasized that the patentability of 3-D protein structure 
is a key factor in the treatment of a number of frequently occurring neurodegenera-
tive disorders. With the increased aging of society, Alzheimer’s, one of the diseases 
based on amyloid brain plaques, is increasingly reported worldwide. Prion-based 
diseases, such as BSE or CJD, accompany industrial developments such as intensive 
mass animal farming.721 In view of these diseases, there clearly is a need for cost-
effective drugs related to the treatment of prion diseases. Because the tertiary folding 
stage of the infectious proteins is the major cause of this diseases, effective treat-
ment must be based on knowledge of their 3-D structure. Research must specifically 
emphasize the visualization of the structural transition from the normal, cellular 
prion, Prp C to the diseased form, Prp Sc. As yet, the understanding of the structural 
biology of the pathogenic conversion, however, remains incomplete in many 
 
720   Eisenberg, Rebecca S., Reaching through the Genome, In: Perspectives on Properties of the 
Human Genome Project; Kieff, F. Scott, ed. Amsterdam 2003; 209, 225. 
721   A major risk for the development of CJD is the treatment with growth hormones. Two doc-
tors in France were charged with involuntary manslaughter of a child who had been treated 
with growth hormones derived from corpses. The child contracted Creutzfeldt-Jakob Dis-
ease. According to French studies, there have been 24 reported cases of CJD in children who 
had been subject of growth hormone treatments between 1983 and mid-1985. Fifteen of 
these persons have died. It now appears possible that hundreds of children in France have 
been treated with growth hormone derived from dead bodies at the risk of contracting CID; 
see U.S. Patent 6916419 “Device for Removal of Prions from Blood, Plasma and other Liq-
uids” by Prusiner, Stanley B./Safar, Jiri G., Oakland, CA 2005.  
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ways.722 There exist a large number of patents related to prions.723Inventions range 
from methods related to the modification724 and detection725 of prions or models of 
prion diseases726, to methods related to antibodies727 or devices for removal of prions 
from blood, plasma and other liquids.728 Only recently, have scientists developed an 
artificial protein that can trigger a neurological disorder similar to BSE. They pro-
duced a normal prion protein fragment in bacteria and folded it into larger, abnor-
mally shaped structures. These structures were then injected into the brains of mice. 
The animals began to show symptoms similar to  those occurring in BSE.729 Hence, 
the field of prion research plays a crucial role in the proteomic era and it can be ex-
pected that a plurality of patent applications will be filed in the near future. In view 
of the importance of these technologies, the patent law systems must provide ade-
quate protection. Since the tertiary stage is the crucial element, this protection is on-
ly achieved if the 3-D structure is sufficient to create novelty, irrespective of wheth-
er the primary sequence of the protein is already included in the prior art. 
 
722   For example, it is unknown exactly which structural regions of PrP C bear the crucial proper-
ties for the conformational change to occur. It is also not disclosed which regions of PrP Sc 
bear the infectious properties; see U.S. Patent 6916419, “Device for Removal of Prions from 
Blood, Plasma and other Liquids” by Prusiner, Stanley B./Safar, Jiri G., Oakland, CA 2005. 
723   The Nobel laureate Stanley B. Prusiner has been involved in the development of at least 40 
patents granted in between 1996 and 2005, available at http://patft.uspto.gov/, last checked 
on January 21, 2008.  
724   International Patent Application WO/2002/049460 “Method for modifying the protein struc-
ture of prions PrP in a targeted manner” by Kortschak, Fritz, Berlin 2003. 
725   U.S. Patent 7208281 „Ligands used for detecting prions” by Kiesewetter, Holger/Salamar, 
Abdulgabar, Berlin 2003. 
726   U.S. Patent 6767712  “Models of prion disease” by Prusiner, Stanley B./Carsten, Korth, 
Oakland, CA 2004. 
727   U.S. Patent 6858397, PrusinerAntibodies specific for native PrPsc by Stanley B/Williamson, 
R. Anthony/Burton, Dennis R., Oakland; La Jolla 2005. 
728   U.S. Patent 6916419 “Device for Removal of Prions from Blood, Plasma and other Liquids” 
by Prusiner, Stanley B./Safar, Jiri G Oakland, CA 2005. 
729   See BBC News from July 30, 2004, available at: http://news.bbc.co.uk/go/pr/fr/-
/1/hi/health/3936519.stm, last checked on August 1, 2005. 
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Chapter 4: Scope of Protection 
A. Introductory Remarks 
Patent law should strike a reasonable balance between the competitive concerns of 
open access and exclusivity. Open access can facilitate knowledge distribution and 
collaboration in advancing science. Exclusivity can ensure interest and financial in-
vestment in scientific research and development.730 When the first DNA sequence 
patents were granted, a lively debate about their adverse effect on research and de-
velopment emerged. The debate climaxed when the NIH filed a patent application, 
which included an enormous number of cDNA without any indication of function.731 
Although the USPTO finally rejected the NIH application, existing concerns per-
sisted.732 Specifically, several observers raised the question of whether future inno-
vations related to a certain protein structure could potentially infringe existing DNA 
claims. In this case, it was argued, R&D expenditures by companies that do not pos-
sess any cDNA patents could be severely limited, thus leading to an undersupply of 
innovative capacity.733 
The issue was regarded particularly pressing because at the time of the first DNA 
patents, it was not understood how the now abundant genetic information could be 
transformed into medical and pharmaceutical applications. In particular, many re-
searchers expected that genetic information would be used quite directly in medical 
treatments, for example in the form of gene therapies.734 Others, however, hypothe-
sized that other aspects of the encoded protein, for example its tertiary structure, 
would have to be identified first. Given this information, it would then be possible to 
develop sensible therapies. In this situation, however, a DNA patent with a very 
broad scope would likely be detrimental to a dynamic biotechnological progress. 
Consequently, the question of whether the scope of protection of DNA patents 
would provoke infringements by (yet unrealized) proteomic inventions was dis-
cussed intensively.735 On the one hand, the idea of allowing a company to patent a 
genetic sequence that has been around since the beginning of life was perceived as 
 
730   Sung, Lawrence M., Patenting nonassociated polymeric structures (NAPS): implications for 
structural genomic data release, 4 Journal of Structural Functional Genomics 2003, 211, 211. 
731   Straus, Joseph, Abhängigkeit bei Patenten auf genetische Information - ein Sonderfall, 
GRUR 1998, 314, 314. 
732   See Chapter 3 A II 2 a.  
733   Widge, Alik, Patent Pending: A Primer on Gene Patents, Pittsburgh 2003, 3-4; available at 
http://www.amsa.org/pdf/genepatents.pdf, last checked on January 21, 2008. 
734   Widge, Alik, Patent Pending: A Primer on Gene Patents, Pittsburgh 2003, 4, available at 
http://www.amsa.org/pdf/genepatents.pdf, last checked on January 21, 2008.  
735   Service, Robert F., Gene and Protein patents get ready to go head to head, 294 Science 2001, 
2082. 
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moderately alarming. On the other hand, the design of new gene-based pharmaceuti-
cals in the U.S. requires years of commitment and immense capital investments. 
Without the ability to receive protection, companies would have no means of reco-
vering the costs of their investments and innovation would be blocked.736 
With genetic patent holders typically owning exclusive rights to the recombinant 
produced protein, basic conflicts between 3-D related claims and DNA patents are 
expected to emerge. However, a detailed examination of potential conflicts may also 
reveal that their relevance is limited, and that the patent system does strike an ap-
propriate balance between open access and exclusivity. In the end, the issue is re-
duced to a thorough analysis of claim construction regarding both literal and equiva-
lent infringement. The following chapters attempt to provide such an analysis, fo-
cusing on the scope of 3-D protein structure related claims. First, general aspects of 
claim construction and its relation to the scope of protection of biotechnological in-
ventions will be discussed. Second, chapter IV. C. seeks to explore the scope of re-
combinant protein claims with regard to infringement through the use of 3-D protein 
structures.  
B. Claim construction in the U.S. and in Europe 
I. Claim construction and doctrine of equivalents in the U.S. 
1. Claim Construction 
In the U.S., the determination of infringement depends in the first place on claim 
construction.737 In case of a conflict, the court must interpret whether or not a used 
product/process falls within what is covered by the patent scope.738 The Federal Cir-
 
736   Fernandez, Dennis/Chow, Mary, Intellectual Property Strategy in Bioinformatics and Bio-
chips, Journal of Patent and Trademark Office Society June 2003, 465, 466.  
737   NTP, Inc. v. Research In Motion, Ltd., 418 F.3d 1282 (Fed. Cir. 2005) (“Claim construction 
is a matter of resolution of disputed meanings and technical scope, to clarify and when nec-
essary to explain what the patentee covered by the claims, for use in the determination of in-
fringement” [citation omitted]); Sarnoff, Joshua, The Doctrine of Equivalents and Claiming 
the Future after Festo, 14 The Federal Circuit Bar Journal 2004, 403, 404. 
738    35 U.S.C. Section 271 (a) states: “Except as otherwise provided in this title, whoever without 
authority makes, uses, offers to sell, or sells any patented invention during the term of the 
patent therefor, infringes the patent.” As for the infringement of process patents, Section 271 
(g) U.S.C. provides that: “Whoever without authority imports into the United States or offers 
to sell, sells, or uses within the United States a product, which is made by a process patented 
in the United States shall be liable as an infringer, if the importation, offer to sell, sale, or use 
of the product occurs during the term of such process patent. In an action of infringement of 
a process patent, no remedy may be granted for infringement on account of the noncommer-
cial use or retail sale of a product unless there is no adequate remedy under this title for in-
fringement on account of the importation or other use, offer to sell, or sale of that product. A 
product which is made by a patented process will, for purposes of this title, not be considered 
 
https://doi.org/10.5771/9783845221441, am 02.12.2021, 20:19:12
Open Access -  - http://www.nomos-elibrary.de/agb
 175 
cuit has characterized claim construction as “the central issue of every patent ap-
peal”.739 Indeed, since the decision in Markman v. Westview Instruments, Inc.740, it 
has taken on paramount significance, often of case-dispositive nature. In Markman I, 
the Federal Circuit (en banc) ruled that “the interpretation and construction of patent 
claims, which determine the scope of the actual patent right, is a matter of law ex-
clusively for the court.”741 In Markman II, the Supreme Court decided that claim 
construction was an issue for the judge rather than the jury.742 Furthermore, the Su-
preme Court affirmed Markman I, stating that claims must be compared with the ac-
cused product or process in order to determine whether each limitation of the claim 
is met, either literally or under the doctrine of equivalents. Claim construction must 
be handled carefully, since any mistake can distort the entire infringement analy-
sis.743 After Markman II, the Federal Circuit stated that claim construction is purely 
a matter of law with no underlying or subsidiary issues of fact.744 Hence, the Federal 
Circuit reviewed a district court’s reasoning regarding claim construction without 
deference. Claim construction therefore is a question of law, which is reviewed de 
novo on appeal, “including any allegedly fact-based questions that are presented”.745 
Patent claims must be construed “objectively and without reference to the accused 
device.746 A court first evaluates the intrinsic evidence, such as the patent itself, its 
claims, written description, and the prosecution history. As for the prosecution histo-
ry, all relevant arguments made which are included in the specification must be con-
sidered.747 The starting point for ascertaining the meaning of a patent claim is its 
language. In general, terms in a patent claim are given their ordinary meaning to one 
of ordinary skill in the relevant art. The meaning of a claim term is as it would be 
 
to be so made after (1) it is materially changed by subsequent processes; or (2) it becomes a 
trivial and nonessential component of another product.”  
739   Sulzer Textil v. Picanol, 358 F.3d 1356, 1366 (Fed. Cir. 2004); Minco v. Combustion Engi-
neering, 95 F.3d 1109, 1114 (Fed. Cir. 1996).  
740   Markman vs. Westview Instruments, Inc., 52 F.3d 967 (Fed. Cir. 1995) (en banc). (“Mark-
man I”), affirmed in 517 U.S. 370 (1996) (“Markman II”) (claim construction is an issue for 
the judge rather than the jury) 
741   Markman I, 52 F.3d 967, 977.  
742   Markman II, 517 U.S. 370, 391(1996). 
743   Markman II, 517 U.S. 370 at 370. See also Weiss, Robert C./Miller Todd R., Practical tips 
enforcing and defending patents, 85 Journal of the Patent and Trademark Office Society 
2003, 791, 793.  
744   Cybor, 138 F.3d, 1448 (Fed. Cir. 1998) 
745   Cybor, 138 F.3d, 1448, 1455 (“[The Supreme] Court held that the totality of claim construc-
tion is a legal question to be decided by the judge.”), also Weiss, Robert C./Miller Todd R, 
Practical tips enforcing and defending patents, 85 Journal of the Patent and Trademark Of-
fice Society 2003, 791, 794. 
746   Vivid Tech., 200 F.3d, 795, 803 (Fed. Cir. 1999) (“[T]hose terms need to be construed that 
are in controversy”). 
747   Depuy Spine, Inc. v. Medtronic Sofamor Danek, Inc., 469 F.3d 1005, 1014 (Fed. Cir. 2006) 
(“In determining the meaning of the disputed claim limitation, court looks principally to the 
intrinsic evidence of record, examining the patent claim language itself, the written descrip-
tion, and the prosecution history, if in evidence.”) 
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interpreted by one skilled in the art, until clear evidence is provided that proves that 
the inventor intended a different meaning. In order to determine what the ordinary 
meaning is, a court may rely on general and technical dictionary definitions.748 In 
addition to such “intrinsic” evidence, the court may also use “extrinsic evidence”, 
such as treatises, inventor testimony, dictionary definitions, and expert testimony to 
interpret patent claims to determine the meaning of the claims to a person having 
ordinary skill in the art.749 The extent to which one should rely on such evidence, 
rather than intrinsic evidence in the specification and prosecution history is largely 
in dispute. In Phillips v. AWH Corp.,750 the CAFC thoroughly discussed the limita-
tions of extrinsic evidence. The Court explained that “[extrinsic evidence] is unlike-
ly to result in a reliable interpretation of patent claim scope unless considered in the 
context of the intrinsic evidence.”751 Nevertheless, the court emphasized that “… 
extrinsic evidence can help educate the court regarding the field of the invention and 
can help the court determine what a person of ordinary skill in the art would under-
stand claim terms to mean”.752 In summary, courts rarely rely on inventor testimony 
regarding meaning, both because of the obvious interest of the inventor and because 
the inventor’s meaning is not directly relevant to the understanding of the person 
skilled in the art.753 Hence, claim construction presupposes the consideration of var-
ious elements, such as used terms, the definition provided in the specification, the 
prosecution history, arguments made by the applicant, the disclosure of the prior art, 
and knowledge of those skilled in the relevant art. Further extrinsic evidences in-
clude treatises or inventor and expert testimony.754 
 
748   Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005) (en banc) (“[R]ecourse to the speci-
fication is limited to determining whether the specification excludes one of the meanings de-
rived from the dictionary, whether the presumption in favor of the dictionary definition of 
the claim term has been overcome by an explicit definition of the term different from its or-
dinary meaning or whether the inventor has disavowed or disclaimed scope of coverage, by 
using words or expressions of manifest exclusion or restriction, representing a clear dis-
avowal of claim scope.” citation omitted); Weiss, Robert C./Miller Todd R , Practical tips 
enforcing and defending patents, 85 Journal of the Patent and Trademark Office Society 
2003, 791, 800f.  
749   Panduit Corp. v. HellermannTyton Corp., 451 F.3d 819, 827 (Fed. Cir. 2006) (“However, if 
the language of the contract is ambiguous, then the court may consider extrinsic evidence to 
determine the intent of the parties.”) 
750   Phillips v. AWH Corp., 415F.3d 1303, 1313 (Fed. Cir. 2005)(en banc) 
751   Phillips v. AWH Corp, 415F.3d 1303, 1313. 
752   Phillips v. AWH Corp, 415F.3d 1303, 1313. 
753   Weiss, Robert C./Miller Todd R., Practical tips enforcing and defending patents, 85 Journal 
of the Patent and Trademark Office Society 2003, 791, 809. 
754   Vitronics Corp. v. Conceptronic, Inc., 90 F.3d 1576, 1584 (Fed. Cir. 1996) (“Only if there 
were still some genuine ambiguity in the claims, after consideration of all available intrinsic 
evidence, should the trial court have resorted to extrinsic evidence, such as expert testi-
mony”); Weiss, Robert C./Miller Todd R., Practical tips enforcing and defending patents, 85 
Journal of the Patent and Trademark Office Society 2003, 791, 800. Since Vitronics, the Dis-
trict court became more lenient, see Pitney Bowes, 182 F.3d 1298, 1309 (Fed. Cir. 1999) 
(“[I]t is entirely appropriate, perhaps even preferable, for a court to consult trustworthy ex-
trinsic evidence to ensure that the claim construction it is tending to from the patent file is 
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After the claim has been construed, the second step of claim construction requires 
that every element in each asserted claim must be compared to the accused product 
or process. If each element is found in the product or process being used, literal in-
fringement is established. This is often called the “all-elements” rule.755 In sum, the 
patent claims, understood by a person skilled in the art, are the decisive element of 
claim construction. Furthermore, patent files can be used to interpret the claims and 
this interpretation is made from the time of infringement.756 
2. Doctrine of equivalents 
If literal infringement is not established, the patent may still be infringed under the 
doctrine of equivalents according to which “[t]he scope of the patent is not limited to 
its literal terms but instead embraces all equivalents to the claims described.”757 The 
idea of extending claims beyond their literal meaning had been addressed in early 
U.S. case law.758 In the decision Winans v. Denmead759, the Supreme Court ruled on 
three major points, stating that “specifications are to be construed liberally” and the 
terms “cylindrical and conical” are to cover “octagonal and pyramidal”.760 In Sanita-
ry Refrigerator Co. v. Winters,761 the Supreme Court further determined that the 
“Triple Identity Test” or “function-way-result-test” were an appropriate means for 
defining equivalents. Pursuant to this method, equivalents exists if a product “per-
forms substantially the same function in substantially the same way to obtain the 
same result”.762 The applicable principle is that “if two devices do the same work in 
substantially the same way, and accomplish substantially the same result, they are 
the same, even though they differ in name, form or shape”.763 In Graver Tank764, the 
 
not inconsistent with clearly expressed, plainly apposite, and widely held understandings in 
the pertinent technical field.”). 
755    Depuy Spine, Inc. v. Medtronic Sofamor Danek, Inc., 469 F.3d 1005 (Fed. Cir. 2006). 
756   Warner-Jenkinson v. Hilton Davis, 520, U.S. 17 (1997); W.E. Hall Co., Inc. v. Atlanta Cor-
rugating, 370 F.3d 1343, 1353 (Fed. Cir. 2004).  
757   Doctrine of Equivalents defined in Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 
535 U.S. 722 (2002) (Festo VIII). The doctrine was first adopted in Winans v. Denmead, 56 
U.S. 330 (1854) and further developed in Graver Tank v. Linde, 339 U.S. 605, (1950) and 
Warner-Jenkinson v. Hilton Davis, 520 U.S. 17 (1997). The “Festo Litigation” is of major 
importance for what is considered equivalent, see below at footnotes 767, 780ff.  
758   Goodyear Dental Vulcanite Co. V. Davies, 102 U.S. 222, 228 (1880); Bergen-Babinecz, 
Katja/Hinrichs, Nikolaus/Jung, Roland/Kolb, Georg, Zum Schutzbereich von US-Patenten: 
Festo und eine deutsche Sicht, GRURInt. 2003, 487, 490.  
759   Winans v. Denmead, 56 U.S. 330 (1854); Chisum, Donald, Chisum on Patents, Volume 5A, 
§ 18.02[1], stating “Winans v. Denmead (1853) was the first decision to use the doctrine of 
equivalents to do serious damage to the literal meaning of the language of a patent claim.” 
760   Winans v. Denmead, 56 U.S. 330, 341, 332. 
761   Sanitary Refrigerator Co. v. Winters, 280 U.S. 3 (1929). 
762   Sanitary Refrigerator Co. v. Winters, 280 U.S. 30, 42, 50.  
763   Union Paper-Bag Machine Co. v. Murphy, 97 U.S. 120 (1877). 
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Supreme Court made a further statement, ruling that an alternative method for de-
termining equivalents is the ‘insubstantiality of differences test’. The question that 
emerges in the context of this method is whether persons reasonably skilled in the 
art would have known of the interchangeability of an ingredient not contained in the 
patent with one that was.765 The ‘modern’ doctrine of equivalents has been substan-
tially characterized by the more recent ‘Festo-litigation’.766 Since Festo primarily 
focuses on limitations of the doctrine rather than its pre-conditions, these decisions 
are illustrated below.767 
The reach of non-literal infringement is restrained by a number of legal tenets, 
such as the “all elements” rule, the prior art, public dedication, and the doctrine of 
prosecution history estoppel. The “all elements-rule” requires that equivalency exists 
only for an accused product or process that contains all of the limitations of a claim, 
either literally or equivalently. Thus, a skilled artesan must examine the doctrine of 
equivalents element by element. In the event of a missing element, there is no in-
fringement unless an equivalent for this missing element exists.768 In Warner-
Jenkinson769, the Supreme Court stated in this context:  
“It is important to ensure that the application of the doctrine, even as to an individual element, 
is not allowed such broad play as to effectively eliminate that element in its entirety.”770  
Hence, the all-elements rule sets the level of generality of the invention at which 
equivalents and a literal presence are to be determined. Warner-Jenkison, however, 
fails to explain what constitutes an “element” or limitation that sets that level.  
The restraint of non-literal infringement by the prior art rule has been established 
in Wilson771, where the Federal Circuit ruled that 
 
764   Graver Tank v. Linde Air Products Co., 339 U.S. 605 (1950), see also Bergen-Babinecz, 
Katja/Hinrichs, Nikolaus/Jung, Roland/Kolb, Georg, Zum Schutzbereich von US-Patenten: 
Festo und eine deutsche Sicht, GRURInt. 2003, 487, 488. 
765   Graver Tank v. Linde Air Products Co., 339 U.S. 605 at 609; some parts of literature follow 
the view that the ‘function-way-result’ test must be conducted in the course of the ‘insubs-
tantiality of differences test’, see Bergen-Babinecz, Katja/Hinrichs, Nikolaus/Jung, Rol-
and/Kolb, Georg, Zum Schutzbereich von US-Patenten: Festo und eine deutsche Sicht, 
GRURInt. 2003, 487, 488. 
766   The Festo litigation started in 1994 when the District Court for the District of Massachusetts 
held that Shoketsu had infringed patents belonging, the Festo company under the doctrine of 
equivalents; see Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 1994 WL 1743984 
(D.Mass 1994) (Festo I).  With regard to this ‘modern’ doctrine of equivalents, see Sarnoff, 
Joshua, The Doctrine of Equivalents and Claiming the Future after Festo, 14 The Federal 
Circuit Bar Journal 2004, 403.  
767   See end of same subchapter, Chapter 4 B I 2.  
768   Depuy Spine, Inc. v. Medtronic Sofamor Danek, Inc., 469 F.3d 1005, 1016 (Fed. Cir. 2006). 
(„Each element contained in a patent claim is deemed material to defining the scope of the 
patented invention, and thus the doctrine of equivalents must be applied to individual ele-
ments of the claim, not to the invention as a whole.“).  
769   Warner-Jenkinson v. Hilton Davis, 520 U.S. 17 (1997). 
770   Warner-Jenkinson v. Hilton Davis, 520 U.S. 17, 29.  
771   Wilson Sporting Goods Co. v. David Geoffrey & Assoc., 904 F.2d 677 (Fed. Cir. 1990) 
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“a patentee should not be able to obtain, under the doctrine of equivalents, coverage which he 
could not lawfully have obtained from the PTO by literal claims … since prior art always lim-
its what an inventor could have claimed, it limits the range of permissible equivalents of a 
claim.”772 
As a possible test for the prior art limitation of equivalents, the court evaluated the 
construction of a hypothetical claim literally, including the asserted equivalent, and 
tested whether its scope was permissible in the light of prior art. For the court such 
testing was preferable, since it “permits a more precise analysis than determining 
whether an accused product would have been obvious from the level of prior art”.773  
Pursuant to the public dedication rule, patentees who fail to claim predictable al-
ternatives and draft claims more narrowly than what is disclosed by the provided 
written description cannot rely on the doctrine of equivalents.774 Rejecting the appli-
cation of the doctrine, Judge Rader in Sage concluded:  
“The claim at issue defines a relatively simple structural device. A skilled patent drafter would 
foresee the limiting potential of a [narrowly drawn structural limitation]. No subtlety of lan-
guage or complexity of the technology, nor any subsequent change in the state of the art, such 
as later-developed technology, obfuscated the significance of this limitation at the time of its 
incorporation into the claim. If Sage desired broad patent protection …, it could have sought 
claims with fewer structural encumbrances… However, as between the patentee who had a 
clear opportunity to negotiate broader claims but did not do so, and the public at large, it is the 
patentee who must bear the cost of its failure to seek protection for this foreseeable alteration 
of its claimed structure.”775 
Pursuant to the Federal Circuit’s decision in Maxwell a subject matter disclosed in 
the specification but not claimed is “dedicated to the public”.776 A patentee shall be 
prevented from filing narrow claims, avoiding examination of broader claims but 
seeking to extend the patent scope through the doctrine of equivalents.  
A further key limitation on the scope of equivalents is the prosecution history.777 
This doctrine states that a patentee cannot recapture through equivalents what he has 
surrendered during patent prosecution. This rule has been substantially characterized 
by the above-mentioned ‘Festo-litigation’.778In the decision Festo Corp. v. Shoketsu 
Kinyoku Kogyo Kabushiki Co. (2002)779, the Supreme Court reversed an en banc 
Federal Circuit decision780 which had held that, if a claim is narrowed for any reason 
 
772   Wilson Sporting Goods Co. v. David Geoffrey & Assoc., 904 F.2d 677, 684. 
773   Wilson Sporting Goods Co. v. David Geoffrey & Assoc., 904 F.2d 677, 684. See also Sar-
noff, Joshua, The Doctrine of Equivalents and Claiming the Future after Festo, 14 The Fed-
eral Circuit Bar Journal 2004, 403, 447.  
774   Sage Prods., Inc. v. Devon Indus., Inc., 126 F.3d 1420, at 1424-25 (Fed. Cir. 1997). 
775   Sage Prods., Inc. v. Devon Indus., Inc., 126 F.3d 1420, at 1420 (Fed. Cir. 1997), also Adel-
man, Martin J./Rader, Randall R./Thomas, John R./Wegner, Harold C., Cases and materials 
on patent law, St. Paul 2003, Chapter 15, Section 15.2. 
776   Maxwell v. J. Baker Inc., 86 F.3d at 1106-1107 (Fed. Cir. 1996). 
777   Geißler, Bernhard, Noch lebt die Äquivalenzlehre, GRURInt 2003, 1, 4-6. 
778   See footnote 758.  
779   Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722 (2002) (Festo VIII).  
780   Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 234 F.3d 558, 564 (Fed. Cir. 2000) 
(en banc) (Festo VI).  
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related to patentability during prosecution, resorting to the doctrine of equivalents 
for the claim element at issue is totally barred (“complete bar” rule).781The Supreme 
Court ultimately adopted to a “flexible bar” approach under which even narrowed 
claims could still be entitled to some range of equivalents.782 The Federal Circuit on 
remand determined, to some extent, the manner in which issues of prosecution histo-
ry estoppel would be assessed.783 All narrowing amendments made to comply with 
any provision of the patent laws give rise to a presumption that equivalents have 
been surrendered. This presumption, however, can be rebutted in various ways, each 
of which appears difficult to establish. The rebuttal examination is a legal issue for 
the judge to decide, even though it includes underlying factual issues. Legal practi-
tioners frequently complain that the Festo litigation and the resulting rules of prose-
cution history estoppel have added a high degree of unpredictability to the doctrine 
of equivalents. The examination of what is considered an unacceptable diver-
sion/narrowing amendment certainly depends on a case-by-case analysis and might 
often be difficult to predict. Applicants, however, know that if they surrender subject 
matter they might later have to suffer the most consequences. Hence, it is likely that 
most if not all applications will avoid surrender.784  
In Warner-Jenkinson, the court also concluded that the time for determining 
equivalency is the time of infringement.785 It must be emphasized that the question 
of whether equivalency exists is based on the post-issued/later-arising knowledge of 
technological interchangeability of elements. Thus, a product or process may be held 
equivalent if it encompasses a technological element either invented after the patent 
is issued or discovered to be a substitute after that time. This principle applies when-
ever the later-arising technological substitute was, or could have been, considered by 
the inventor as part of the invention, provided that the substituted element does not 
entirely negate the claimed limitation it does not represent. Consequently, the doc-
trine of equivalents expands the patent’s scope over time.786 Hence, the purpose of 
the U.S. doctrine of equivalents is principally to address the unforeseeable. A patent 
drafter must include every foreseeable application in his claim to anticipate how new 
technology would be applied in a fashion that every reasonable drafter of patent 
claims would also foresee.  
 
781   Teague, Brian J., Festo and the Future of the Doctrine of Equivalents, 3 Journal of Intellec-
tual Property 2004, 1-19, 3. 
782   Festo VIII., 535 U.S. 722, 738 (2002).  
783   Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., No. 95-1066, 2003 WL 22220526 
(Fed. Cir. 2003) (Festo IX). 
784   Sarnoff, Joshua, The Doctrine of Equivalents and Claiming the Future after Festo, 14 The 
Federal Circuit Bar Journal 2004, 403, 430.  
785   Warner-Jenkinson v. Hilton Davis, 520, U.S. 17, 19. 
786   Sarnoff, Joshua, The Doctrine of Equivalents and Claiming the Future after Festo, 14 The 
Federal Circuit Bar Journal 2004, 403, 410.  
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II. Claim construction and Doctrine of equivalents under German law 
1. Claim Construction 
The core provisions for the interpretation of claims are Art. 69(1) EPC, and § 14 
GPA, which state: 
The extent of the protection conferred by a European patent or a European patent application 
shall be determined by the terms of the claims. Nevertheless, the description and drawings 
shall be used to interpret the claims. 
The rule is read in light of the Protocol on the Interpretation of Art. 69 of the Con-
vention. Art. 1 of the Protocol states: 
“Art. 69 should not be interpreted in the sense that the extent of the protection conferred by a 
European patent is to be understood as that defined by the strict, literal meaning of the wording 
used in the claims, the description and drawings being employed only for the purpose of re-
solving an ambiguity found in the claims. Neither should it be interpreted in the sense that the 
claims serve only as a guideline and that the actual protection conferred may extend to what, 
from a consideration of the description and drawings by a person skilled in the art, the patentee 
has contemplated. On the contrary, it is to be interpreted as defining a position between these 
extremes which combines a fair protection for the patentee with a reasonable degree of certain-
ty for third parties.”  
Thus, the first sentence deals with the interpretation of claims, ruling that claims 
should not be read literally and descriptions and drawings only serve the purpose of 
resolving any ambiguity existing in the claims. The second sentence does not refer 
to the interpretation of claims. It clarifies, rather, that one cannot go beyond the 
claims to what, on the basis of the specification and drawings, it appears that “the 
patentee has contemplated”. Finally, the last sentence indicates that, in constructing 
the scope of protection according to the content of the claims but avoiding literalism, 
the courts of the contracting states should aim at “a fair protection for the patentee 
with a reasonable degree of certainty for third parties.”787  
An illustrative example of claim construction is provided by the earlier mentioned 
decision of Amgen/TKT788, where the English House of Lords had to decide wheth-
er TKT‘s ‘GA-Epo’ (Dynepo), produced by a process called “gene activation”, in-
fringes Amgen’s patent related to the recombinant ‘Epo’.789 The presentation of the 
decision is particularly useful in demonstrating the different steps of claim interpre-
tation.790 The process of TKT’s gene activation involved the introduction of a nu-
 
787   Kirin-Amgen Inc v. Hoechst Marion Roussel, [2005] R.P.C. 9, 2004 WL 2330204, Meier-
Beck, Peter, Aktuelle Fragen der Schutzbereichsbestimmung im deutschen und europäischen 
Patentrecht, GRUR 2003, 905, 905. 
788   Kirin-Amgen Inc v. Hoechst Marion Roussel, [2005] R.P.C. 9, 2004 WL 2330204, see also 
Chapter III Part A 2 C (b). As for earlier decisions on the subjects see Welch, Andreas, Der 
Patentstreit um Erythropoietin , GRURInt. 2003, 579, 592. 
789   Chapter 3 A II 3 a.  
790   As remarked by Rüdiger Rogge, then presiding judge of the 10th (intellectual property) Sen-
ate of the Bundesgerichtshof, “decisions of other countries on the extent of protection af-
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cleotide sequence into the genome of a human cell upstream of the erythropoietin 
gene. The nucleotide sequence “effectively overrode the regulator, which normally 
switched off the gene, and thus switched it on.” TKT’s cells contained endogenous 
erythropoietin DNA with respect to the coding regions, but also an exogenous pro-
moter construct that was introduced upstream of that endogenous DNA.791 Amgen’s 
patent claimed the expression of erythropoietin in mammalian cells using DNA in-
serted in a hybrid vector of bacterial plasmid and viral genomic origins. Amgen only 
asserted the infringement of claim 19 and 26, since TKT did not produce any GA-
erythropoietin in the United Kingdom and the alleged infringement was based on 
TKT’s importation of ‘GA-EPO’.792 The critical issue the House of Lords had to 
discuss was whether a skilled person would classify “host cell” as meaning a cell 
which is host to the DNA sequence coding for ‘Epo’.793 A different understanding 
put forward by Amgen was that it can involve a sequence which is endogenous to 
the cell such as the human ‘Epo’ gene expressing ‘GA-Epo’, as long as the cell is 
host to some exogenous DNA. In the TKT method, such a cell hosts the “gene acti-
vation sequence”.794 As a first step, the judge interviewed a number of skilled per-
sons as witnesses, all of whom said that they would have interpreted Claim 1 to be 
directed to a “DNA sequence coding for ‘Epo’ which had been isolated or synthe-
sized and was suitable for expression in a host cell.”795 Furthermore, the judge relied 
on the language used in the patent description. The court concluded that the terms 
“for use in securing expression … of a polypeptide” refer to the DNA encoding for 
‘Epo’ instead of the control sequence which “switches on” the expression of endo-
genous DNA. This interpretation, the judge reasoned, was supported by paragraph 
(b) of Claim 1, which broadened the claim to sequences that hybridized under strin-
gent conditions to “the protein coding regions”.796 The judges therefore concluded 
that a person skilled in the art would not classify the endogenous coding sequence 
that expressed TKT’s ‘Epo’ as falling within claim 1.797 The Amgen/TKT decision 
shows that the issue of whether a patent claim can cover later-arising technologies is 
decided on the level of claim construction.  
The patentable subject matter is understood objectively and does not depend on 
the subjective perception of the patentee. It is not the court's task to detect what the 
inventor intended to claim but what he claimed in fact. Each feature of the subject 
matter must be interpreted objectively.798 The claims are read giving the words, the 
 
forded by Art. 69 EPC can be seen as important contributions to the jurisprudence of Ger-
many,” cited by Lord Hoffman in Kirin-Amgen Inc v. Hoechst Marion Roussel, [2005] 
R.P.C. 9, No. 74.  
791   Kirin-Amgen Inc v. Hoechst Marion Roussel, [2005] R.P.C. 9, No. 8.  
792   Kirin-Amgen Inc v. Hoechst Marion Roussel, [2005] R.P.C. 9, No. 7.  
793   Kirin-Amgen Inc v. Hoechst Marion Roussel, [2005] R.P.C. 9, No. 53. 
794   Kirin-Amgen Inc v. Hoechst Marion Roussel, [2005] R.P.C. 9, No. 53. 
795   Kirin-Amgen Inc v. Hoechst Marion Roussel, [2005] R.P.C. 9, No. 54. 
796   Kirin-Amgen Inc v. Hoechst Marion Roussel, [2005] R.P.C. 9, No. 55. 
797   Kirin-Amgen Inc v. Hoechst Marion Roussel, [2005] R.P.C. 9, No 58. 
798   Benkard/Ullmann, Patentgesetz, § 14, No. 75.  
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meaning, and scope that they normally have in the relevant art.799 In contrast to 
American patent law, it is not customary under the European patent law system to 
rely on the prosecution history for claim interpretation.800 Facts of the prosecution 
history can only be used for the determination of scope if reported in the patent 
specification. The German Federal Supreme Court, for example, interpreted a decla-
ration of the patent applicant that patent protection is not sought for a certain em-
bodiment in light of the principle “venire contra factum proprium”.801 Accordingly, 
a patentee could not claim the patent to cover such an embodiment in a later trial 
against an alleged infringer, if the patent was based on such waiver and the infringer 
had been part of the earlier proceedings.802  Furthermore, not the time of infringe-
ment, but the time of priority, is decisive.803 
2. Doctrine of equivalents 
As in the US, a patent claim can be infringed literally, or under the doctrine of 
equivalents, directly or indirectly. As claim construction rules, the principles devel-
oped for the determination of equivalents rely on the Protocol on the interpretation 
of Art. 69 EPC. The protocol was amended after the revision of the European Patent 
Convention in 2000. The newly added Art. 2 states for equivalents that “[f]or the 
purpose of determining the extent of protection conferred by a European patent, due 
account shall be taken of any element which is equivalent to an element specified in 
the claims. “804 This rule fails to provide a definition of equivalents. Therefore, it 
permits national courts to interpret the doctrine of equivalents in a flexible and fair 
way.  The word “elements” aims to fit with claim language used for chemical inven-
tions.805 Patent claims have to be understood not only as the starting point but also as 
the decisive element.806 The major goal of a scope extension under the doctrine of 
equivalents is to combine fair protection for the patentee with a reasonable degree of 
certainty for third parties. On the one hand, an applicant cannot be required to fore-
see all potential cases where a competitor may depart from the literal meaning of the 
 
799   BGH, 30 IIC 932 (1999) – Tension Screw (Spannschraube); Meier-Beck, Peter, Aktuelle 
Fragen der Schutzbereichsbestimmung im deutschen und europäischen Patentrecht, GRUR 
2003, 905, 906. 
800   Benkard/Scharen, EPÜ, Art. 69, No. 27.  
801   BGH, 25 IIC 420, 420 (1994) - Moistening Device I (Weichvorrichtung I). 
802   Busse/Keukenschrijver, PatG, § 14, No. 74.  
803   Benkard/Scharen, EPŰ, Art. 69, No. 64.  
804   Meier-Beck, Peter, The Scope of Patent Protection - The test for Determining Equivalents, 
36 IIC 339, 340 (2005); who notes that Art. 69(1) EPC remains unchanged and merely lays 
down by what means the extent of protection should be determined. 
805   Nack, Ralph/Phélip, Bruno, Diplomatic Conference for the Revision of the European Patent 
Convention, Munich, 20 – 29 November 2000, 32 IIC 200, 207 (2001). 
806   See Chapter 4 B II 2.V. 
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claims.807 On the other hand, the principle of legal certainty requires that a person 
using the patent must be able to understand with ease what is protected.808 The suit-
able standard for determining equivalents is considered to be the person skilled in 
the art.809  
a) Moulded Curbstone 
Before 1978, patents were granted under the „Three-Parts-Doctrine“ (Drei-
teilungslehre). Under this approach, the patent scope was based on the patentable 
subject matter.810 The patentable subject matter was considered the technical teach-
ing included in the patent claims and understood by the skilled person without in-
ventive activity, but in light of the patent description, potential drawings, skilled 
knowledge and the state of the art.811  
The newer law is summarized in the case of Moulded Curbstone.812 In this deci-
sion, the invention was a moulded curbstone, which assured safe and reliable drai-
nage of rainwater accumulating at the side of a street. The alleged infringer had used 
conventional stones in the form of cubes or bricks and conventionally rounded curb-
stones. The German Federal Supreme Court confirmed the doctrine of equivalents, 
stating that: 
 “[t]he question is whether a person skilled in the art … is able to clear up the problem solved 
by the invention with equally effective means, i. e. to achieve the desired success with other 
means which also lead to the same result. Solutions, which the average person skilled in the art 
can determine due to his professional knowledge as being equally effective based on consider-
ations oriented to the invention paraphrased in the claims, will generally fall within the scope 
of protection of the patent.”813  
 
807   BGH, 24 IIC 507 (1993) – Helium Injection (Heliumeinspeisung); Meier-Beck, Peter, The 
Scope of Patent Protection - The test for Determining Equivalents, 36 IIC 339, 340 (2005). 
808   BGH, GRUR 1992, 594, 596 - Mechanische Betätigungsvorrichtung; Reimann, Tho-
mas/Köhler, Martin, Der Schutzbereich europäischer Patente zwischen Angemessenheit und 
Rechtssicherheit - Anmerkungen zu den Entscheidungen des BGH 'Kunststoffrohrteil', 
'Custodiol I', 'Custodiol II', 'Schneidmesser I', 'Schneidmesser II', GRUR 2002, 931, 931; 
Meier-Beck, Peter, The Latest Issues in German Patent Infringment Proceedings, 32 IIC 505, 
511 (2001). 
809   Meier-Beck, Peter, The Scope of Patent Protection - The test for Determining Equivalents, 
36 IIC 339, 341 (2005). With regard to literal claim construction, the person skilled in the art 
analyzes and considers the patent claim against the background of his technical knowledge, 
using description and drawings to assist in claim interpretation. 
810   RGZ 2, 325 - Mülltonne; RG GRUR 1940, 543, 545 - Hochglanzphotographien; RG GRUR 
1942, 51 - Wischdochte; RG GRUR 1944, 22f - Wellblechofenbekleidung.  
811   Lindenmaier, Fritz, Der Schutzumfang des Patentes nach der neueren Rechtssprechung, 
GRUR 1944, 49, 53; Busse/Keukenschrijver, § 14 No. 13.  
812   BGH 18 IIC 795 (1987) – Moulded Curbstone (Formstein). 
813   BGH 18 IIC 795, 799 (1987) – Moulded Curbstone (Formstein). 
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In addition, the court ruled that “the defense that the embodiment attacked and 
claimed to be an equivalent does not represent a patentable invention in view of the 
prior art is admissible.”814Accordingly, the defendant of an infringement process can 
defend himself, arguing that the claimed embodiment “is known from the prior art, 
but also by the fact that it is obvious in view of the prior art” (“Moulded Curbstone 
objection”).815 This general understanding of the law comports with the legal 
framework adopted by most member states of the EPC, although significant differ-
ences with respect to the method of determination of scope, or the exact protection 
granted, remain.816 
b) Further Decisions  
The ruling established in Moulded Curbstone was confirmed several times by the 
German Federal Supreme Court. In its decision Ione Analysis,817 the court stated that 
the mere approval of an equal effect is not sufficient for equivalents. Rather, the per-
son skilled in the art must be able to predict and determine the means necessary to 
achieve the equal effect. Accordingly, if the patent claims do not suggest to a person 
skilled in the art that the described protocol can be modified and still achieve equal 
effects, equivalents do not exist. This standard, the court emphasized, is required by 
the principle of legal certainty.818 The importance of legal certainty has been af-
firmed in the decision Handle Cord for Battery in which the German Federal Su-
preme Court criticized the decision of the lower court to interpret the claims predo-
minantly on the grounds of the patent description.819 The claims must entirely de-
scribe the essential elements of the invention. Recapitulating, the court ruled that the 
claims are no longer merely a point of departure but the decisive basis (“massgeb-
liche Grundlage”) for determining the extent of protection. As for equivalents, a 
skilled person should thus be able to determine the equivalent scope on grounds of 
the claim, his general skills in the art, and simple experimentation.820  
The German Federal Supreme Court has developed clear guidelines for dealing 
with equivalents in a number of cases related to the question of whether figures or 
measurements allow some degree of approximation (and if so, to what degree). Be-
low,821 a concrete claim analysis under German law will closely examine the deci-
 
814   BGH 18 IIC 795, 800 (1987) – Moulded Curbstone (Formstein). 
815   BGH 18 IIC 795, 800 (1987) – Moulded Curbstone (Formstein); Meier-Beck, Peter, The 
Scope of Patent Protection - The test for Determining Equivalents, 36 IIC 339, 344 (2005). 
The author formulates the question of whether the variant, having regard to the state of the 
art, lacks novelty, or is obvious to a person skilled in the art.  
816   Domeij, Bengt, Pharmaceutical Patents in Europe, Stockholm 2000, 314. 
817   BGH, 22 IIC 249 (1991)  –  Ione Analysis (Ionenanalyse). 
818   BGH, 22 IIC 249, 255 (1991)  –  Ione Analysis (Ionenanalyse). 
819   BGH, 22 IIC 104 (1991) - Handle Cord for Battery Case (Batteriekastenschnur). 
820   BGH, 22 IIC 104, 106 (1991) Handle Cord for Battery Case (Batteriekastenschnur). 
821   Chapter 4 c IV 3 b)  aa).  
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sions of Plastic Pipe, 822 Custodiol I823, Custodiol II824, Cutting Blade I825 and Cut-
ting Blade II826. The major principles derived from these cases will then be applied 
to 3-D protein structure related claims. Also, the principles regarding the cases in 
which infringement is based on inventive activity will be reviewed and – if neces-
sary – applied to the context of proteomic inventions. In principle, the time for de-
termining infringement is the priority date.827 
III. Research/Experimental Use Exemption 
Finally, this chapter will briefly discuss the limitations of patent protection through 
the means of experimental use exemption. This is not primarily a question of how 
the patent scope is determined. Nevertheless, the question of appropriate scope must 
take into account that a sufficient research exemption enables scientists to use pa-
tented knowledge without establishing infringement. This possibility assigns a dif-
ferent weight to the question of what the public can expect from an inventor in ex-
change for the public protection of his intellectual property rights.  
1. Germany 
The German Patent System provides an explicit statutory research exemption.828 Ac-
cording to Section 11 No. 2 GPA, research is explicitly excluded from the patent 
right.829 The provision provides that “the rights conferred by a patent shall not ex-
tend to acts done for experimental purposes that are related to the subject-matter of 
the patented invention.” The German Federal Supreme Court dealt intensively with 
 
822   BGH, 34 IIC 302 (2003) – Plastic Pipe (Kunstoffrohrteil). 
823   BGH, GRUR 2002, 523 – Custodiol I. 
824   BGH, 34 IIC 197 (2003) – Custodiol II. 
825   BGH, 33 IIC 873 (2002) - Cutting Blade  I (Schneidmesser I).  
826  BGH, GRUR 2002, 519 – Cutting Blade II (Schneidmesser II).  
827  BGH, 33 IIC 525, 535 (2002) – Snow Removal Plate (Räumschild); Kraßer, Rudolf, Patent-
recht: ein Lehr- und Handbuch zum deutschen Patent- und Gebrauchsmusterrecht, europäi-
schen und internationalen Patentrecht, 5. Aufl., München 2004, 753; Busse/Keukenschrijver, 
PatG, § 14, No. 90. 
828Kraßer, Rudolf, Patentrecht: ein Lehr- und Handbuch zum deutschen Patent- und Gebrauchs-
musterrecht, europäischen und internationalen Patentrecht, 5. Aufl., München 2004, 812-
816; see further Straus, Joseph, On the Admissibility of 'Biological Equivalents Tests' Dur-
ing the Patent Term for Obtaining a Regulatory Approval for Patented Drugs by Third Par-
ties, AIPPI Journal of the Japanes Group November 1998, 211; Herrlinger, Karolina A., Die 
Patentierung von Krankheitsgenen: dargestellt am Beispiel der Patentierung der Brustkrebs-
gene BRCA 1 und BRCA 2, München 2005, 234.  
829  Straus, Joseph, Abhängigkeit bei Patenten auf genetische Information - ein Sonderfall, GRUR 
1998, 314, 318. 
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the question of research exemption in its Clinical Trials cases.830 In Clinical Trial I, 
the defendants were conducting clinical studies with the active substance interferon 
gamma to ascertain further indications.831 The Federal Supreme Court determined 
that it was in the public interest that clinical trials for finding further medical uses be 
excluded from patent infringement, but only if the tests are performed in the course 
of knowledge acquisition.832 According to the Court’s view, it was irrelevant that the 
tests also could be used for obtaining regulatory marketing approval:  
“Since the patent act, without further restrictions, exempts from the effect of the patent any act 
for test purposes that focuses on the subject matter of the invention, it cannot be of any conse-
quence to the admissibility of such tests for what purposes they are being conducted, whether 
they are intended, possibly, to substantiate an application of pharmaceutical approval, or 
whether they represent a purely scientific research project.”833  
Based on the above, all testing activities are exempted provided they are performed 
in the course of knowledge acquisition and are directed to the subject matter of the 
invention. This includes methods used in order to determine the effects of sub-
stances, which were disclosed in previous applications.834 In Clinical Trials II, the 
defendant conducted clinical trials to confirm results obtained in animal tests and at 
the same time to gather data necessary for the pharmaceutical approval and market-
ing of his product.835 The conducted process resulted in a recombinant, human Eryt-
hropoietin (“EPO”) called rHu Epo-Merckle. The plaintiff alleged that the amino 
acid sequence of this “Epo” product corresponded exactly with the amino acid se-
quence of his patented “Epo”, why the patent was infringed.836 The District Court 
held that the patent was infringed and the Higher District Court rejected the defen-
dant’s appeal. The Higher District Court found that the conducted activities were not 
directed to further development and improvement of the patented compound, but 
rather were “undertaken only in order to obtain data for the legal pharmaceutical 
permission and therefore served commercial interests rather than scientific purpos-
 
830  See BGH, 28 IIC 103, 103 (1997) - Clinical Trials I (Klinische Versuche I); [1998] R.P.C. 
423 
Clinical  Trials II ; Federal Constitutional Court, 1 BvR 1864/95 of 05/10/2000, paragraphs 
No. 1 - 38, http://www.bverfg.de/entscheidungen/ rk20000510_1bvr186495en.html, last 
checked on January 21, 2008. See also Garde, Tanuja, The Effect of Disparate Treatment of 
the Experimental Use Exemption on the Balancing Act of 35 U.S.C. § 104, 35 IIC 241, 255 
(2004). 
831   BGH, 28 IIC 103, 103 (1997) - Clinical Trials I (Klinische Versuche I).  
832   BGH, 28 IIC 103, 103 (1997) - Clinical Trials I (Klinische Versuche I). 
833   BGH, 28 IIC 103, 111 (1997) - Clinical Trials I (Klinische Versuche I).  
834   Straus, Joseph, On the Admissibility of “Biological Equivalents Tests” During the Patent 
Term for Obtaining a Regulatory Approval for Patented Drugs by Third Parties, AIPPI Jour-
nal of the Japanese Group November 1998, 211, 225-226. 
835   [1998] R.P.C. 423, 423 - Clinical Trials II (Klinische Versuche II), with an early and detailed 
analysis of the underlying decision of the lower district court, see Straus, Joseph, Zur Zuläs-
sigkeit klinischer Untersuchungen am Gegenstand abhängiger Verbesserungserfindungen, 
GRUR 1993, 308, 311; further Garde, Tanuja, The Effect of Disparate Treatment of the Ex-
perimental Use Exemption on the Balancing Act of 35 U.S.C. § 104, 35 IIC 241, 256 (2004). 
836   [1998] R.P.C. 423, 427 - Clinical Trials II (Klinische Versuche II).   
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es.”837 The German Federal Supreme Court held that the defense of experimental use 
applies to all experimental acts that are directed to the subject matter of the inven-
tion. 838 The exemption would be granted “regardless of the purpose for which these 
results will ultimately be used.”839 Thus, section 11 No. 2 GPA “exempts clinical 
experiments with a protective agent even in a case where these experiments were 
exclusively … carried out in order to obtain data” for pharmaceutical approval.840 
Accordingly, the alleged research activities were found to be permissible under Sec-
tion 11 No. 2 GPA.841 
In 2000, five years after the Clinical I ruling of the Federal Supreme Court, the 
Federal Constitutional Court addressed the question of whether the exemption for 
clinical trials to find further indications of the active agent of interferon gamma 
(used in the drug polyferon) was constitutional.842 The exclusive licensee of the pa-
tent to polypeptides with human interferon gamma properties complained that the 
lower court’s reading of Section 11 No. 2 GPA, to “regard clinical trials which in-
volve a pharmaceutical drug under patent protection as acts of use to which the ef-
fects of the patent do not extend”, was not compatible with Art. 14(1), sentence 1 
GG, which set forth the protection of ownership.843 The Federal Constitutional Court 
confirmed the ruling of the lower court, affirming that “unlimited protection of the 
patent …. is not justified in cases in which this hinders technical development.”844 
The Federal Constitutional Court admitted, that the clinical trials at issue could lead 
to the grant of use patents which otherwise would not have been obtained, but found 
that this was something the patentee had to tolerate, as he could “only be rewarded 
for their own contribution to technical advancement.”845 Therefore, the court con-
cluded that the lower court’s reading of Section 11 No. 2 GPA did not infringe Art. 
14(1), sentence 1 GG.846  
 
837   [1998] R.P.C. 423, 423 - Clinical Trials II (Klinische Versuche II). See also Garde, Tanuja, 
The Effect of Disparate Treatment of the Experimental Use Exemption on the Balancing Act 
of 35 U.S.C. § 104, 35 IIC 241, 257-258 (2004). 
838   [1998] R.P.C. 423, 432-433 - Clinical Trials II (Klinische Versuche II). 
839   [1998] R.P.C. 423, 431 - Clinical Trials II (Klinische Versuche II). 
840   [1998] R.P.C. 423, 432 - Clinical Trials II (Klinische Versuche II). 
841   [1998] R.P.C. 423, 438 - Clinical Trials II (Klinische Versuche II). 
842   Federal Constitutional Court, 1 BvR 1864/95 of 05/10/2000, paragraphs No. (1 - 38), avail-
able at http://www .bverfg.de/entscheidungen/rk20000510_1bvr186495en.html, last checked 
on January 21, 2008.  
843   Federal Constitutional Court, 1 BvR 1864/95 of 05/10/2000, paragraphs No. 1, available at  
  http://www.bverfg. de /entscheidugen/rk20000510_1bvr186495en.html, last checked on 
January 21, 2008. 
844   Federal Constitutional Court, 1 BvR 1864/95 of 05/10/2000, paragraphs No. 30, available at  
  http://www.bverfg.de/entscheidungen/ k20000510_1bvr186495en.html, last checked on 
January 21, 2008. 
845   Federal Constitutional Court, 1 BvR 1864/95 of 05/10/2000, paragraphs No. 31, available at 
  http://www.bverfg.de/entscheidungen/rk20000510_1bvr186495en.html, last checked on 
January 21, 2008. 
846   Federal Constitutional Court, 1 BvR 1864/95 of 05/10/2000, paragraphs No. 36, available at  
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It remained questionable whether the research exemption provided by the German 
courts covers the special case of bioequivalence trials.847 Bioequivalence trials are 
carried out to prove for a third party, e.g., the marketing approval institution, that a 
generic product is bioequivalent, i.e. produces same effects like a patented sub-
stance.848 Based on the above, the general rule laid down in the Clinical Trial cases 
is that the research exemption under German law covers any act conducted for the 
acquisition of knowledge, notwithstanding the purpose for which this knowledge is 
eventually used. Hence, the law requires finality with respect to the testing activity 
and its specific purpose. The testing activity must refer to the patented subject matter 
and its technical teaching and be performed for gaining knowledge about its decisive 
properties, effects and uses. Furthermore, studies and research must be undertaken 
for the advancement of technological progress. Finally, even if all these require-
ments are met, clinical trials may still not be covered by the research exemption, if 
they were performed to such an extent that a justification on research grounds is no 
longer valid. 849 
Bioequivalence trials exclusively focus on showing that a generic drug product 
has identical properties as the patented product.850 They serve the main purpose of 
demonstrating that a generic drug has properties identical to a patented pharmaceuti-
cal. The properties, and effects, including side effects of the active patented ingre-
dient, however, have already been analyzed and are generally known at the time the 
bioequivalent trial is conducted. Typically, bioequivalence is tested early on in order 
to enter the market as soon as possible after a patent expires. Thus, instead of clari-
fying properties, effects, possible uses and production feasibility of the patented 
drug, bioequivalence trials reflect competitive goals, such as an optimized marketing 
price. Their performance neither intends to ascertain knowledge about the patented 
subject matter, nor relates to its technical teaching. Under the principles developed 
in Clinical Trials I and II and confirmed by the Federal Constitutional court, bioe-
 
  http://www.bverfg.de/entscheidungen/rk20000510_1bvr186495en.html, last checked on 
January 21, 2008. 
847    Straus, Joseph, On the Admissibility of “Biological Equivalents Tests“ during the Patent 
Term for Obtaining a Regulatory Approval for Patented Drugs  by Third Parties, AIPPI 
Journal, November 1998, 211, 229.  
848   Straus, Joseph, On the Admissibility of “Biological Equivalents Tests“ during the Patent 
Term for Obtaining a Regulatory Approvla for Patented Drugs by Third Parties, AIPPI Jour-
nal, November 1998, 211, 217. As defined in 21 CFR 320.1(e), bioequivalency means “the 
absence of a significant difference in the rate and extent to which the active ingredient or ac-
tive moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available 
at the site of drug action when administered at the same molar dose under similar conditions 
in an appropriately designed study.” 
849   Straus, Joseph, On the Admissibility of „Biological Equivalents Tests“ during the Patent 
Term for Obtaining a Regulatory Approvla for Patented Drugs  by Third Parties, AIPPI 
Journal, November 1998, 211, 229. 
850   Straus, Joseph, On the Admissibility of „Biological Equivalents Tests“ during the Patent 
Term for Obtaining a Regulatory Approval for Patented Drugs  by Third Parties, AIPPI 
Journal, November 1998, 211, 217. 
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quivalence trials must therefore be considered patent infringement. Any research 
that obviously does not result in any contribution to the technological progress can-
not justify an exemption from a patent.851 
The question of whether bioequivalent test activities fall under the research ex-
emption must be decided differently under the subsequently adopted Bolar-type ex-
emption.852 In September 2005, the Bolar-type exemption of the EU Directive 
2004/27/EC on the Community Code relating to medicinal products for human use 
was implemented into the German Patent Law.853 Section 11 No. 2(b) GPA now ex-
empts all trials and studies that are necessary to obtain marketing approval for the 
European Union or for one of the Member States. These activities, including trials 
conducted by generic product manufacturers, are typically not covered by the re-
search exemption, since the experiments have an obvious commercial motivation 
and are not of a purely scientific nature.854  
2. U.S. 
The U.S. patent system has long provided an experimental use exception.855 Its juri-
sprudential origin is Whittmore vs. Cutter, 1 Gall.856, where the court determined 
that an infringer must have the intention to use a patented invention for commercial 
profit. The court held that 
 
851   Straus, Joseph, On the Admissibility of „Biological Equivalents Tests“ during the Patent 
Term for Obtaining a Regulatory Approval for Patented Drugs  by Third Parties, AIPPI 
Journal, November 1998, 211, 230. 
852   The term “bolar” is derived from Roche Products, Inc. v. Bolar Pharmaceutical Co., Inc., in 
which the Federal Circuit reversed the lower court’s decision in Roche, and determinded that 
“use” under Section 271(a) U.S.C. to cover any “use” of patented subject matter, including 
using a patented compound to ascertain knowledge for obtaining the approval of a generic 
version of that compound. See Roche Products, Inc. v. Bolar Pharmaceutical Co., Inc., 733 
F.2d 858, 865-66 (Fed. Cir. 1984).  As a result, the U.S. Congress adopted Section 271(e)(1); 
Vihar R. Patel, Are patented research tools still valuable? Use, intent, and a rebuttable pre-
sumption: a proposed modification for analyzing the exemption from patent infringement 
under 35 U.S.C. § 271(e)(1), 47 IDEA 407, 413.  
853   Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 
amending Directive 2001/83/EC on the Community code relating to medicinal products for 
human use, available at http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX 
:32004L0027:EN:HTML, last checked on January 21, 2008. Art. 10(6) of the Directive reads 
as: „Conducting the necessary studies and trials with view to the application of paragraphs 1, 
2, 3, and 4 [of Art. 10 2004/27/EC] and the consequential practical requirements shall not be 
regarded as contrary to patent rights or to supplementary protection certificates for medicinal 
products“. 
854     Pfaff, Esther, “Bolar” Exemptions - A Threat to the Research Tool Industry in the U.S. and 
the EU?, 38 IIC 258, 259 (2007).  
855   Herrlinger, Karolina A., Die Patentierung von Krankheitsgenen: dargestellt am Beispiel der 
Patentierung der Brustkrebsgene BRCA 1 und BRCA 2, München 2005, 262. 
 856   Whittemore v. Cutter, 1 Gall. 429, 29 F. Cas, 1120, 1121 (C.C.D. Mass. 1813). 
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“it could never have been the intention of the legislature to punish a man who constructed such 
a machine merely for philosophical experiments, or for the purpose of ascertaining the suffi-
ciency of the machine to produce its described effects.”857  
In Madey v. Duke858, the CAFC substantially narrowed the experimental use excep-
tion. Madey, a former Professor at Duke University, owned two patents covering 
equipment in the laboratory of Duke. After a dispute, he left the university. Never-
theless, Duke continued to use some of the patented instruments. Subsequently, Ma-
dey sued Duke for, among other things, infringement of the two patents.859 The 
Court found that the conducted research is not exempted from patent infringe-
ment.860 Instead, the Court concluded that a “very narrow and strictly limited expe-
rimental use defense” is solely available if the use of the invention is “for amuse-
ment, to satisfy idle curiosity, or for strictly philosophical inquiry”.861 Furthermore, 
one can only rely on the defense if the use is “in furtherance of the alleged infring-
er’s legitimate business, regardless of commercial applications” or of its status as 
profit or non-profit.862  
With regard to inventions involving biotechnological material, Section 271(e)(1) 
U.S.C. provides an exception from infringement for activities involving the devel-
opment and submission of information for U.S. Food and Drug Administration 
(FDA) approval.863 The provision states that 
[i]t shall not be an act of infringement to make, use, offer to sell, or sell within the United 
States or import into the United States a patented invention (other than a new animal drug or 
veterinary biological product (as those terms are used in the Federal Food, Drug, and Cosmetic 
Act and the Act of March 4, 1913) which is primarily manufactured using recombinant DNA, 
recombinant RNA, hybridoma technology, or other processes involving site specific genetic 
manipulation techniques) solely for uses reasonably related to the development and submission 
of information under a Federal law which regulates the manufacture, use, or sale of drugs or 
veterinary biological products. 
 
857   Whittemore v. Cutter, 1 Gall 429, 29 Fed. Cas. 1120, 1121. By “philosophical” experiments 
Justice Story was referring to “natural philosophy,” the term later used for what we today 
understand as “science”, see Integra Lifesciences I, Ltd. v. Merck KgaA, 331 F.3d 860, 
(C.A.Fed. (Cal.) 2003), 875 (FN8). 
858   Madey v. Duke University, 307 F.3d 1351, (Fed. Cir. 2002), cert. denied by Duke University 
v. Madey, 539 U.S. 958 (2003). 
859   Madey v. Duke University, 307 F.3d 1351, 1352-1353; Garde, Tanuja, The Effect of Dispa-
rate Treatment of the Experimental Use Exemption on the Balancing Act of 35 U.S.C. § 104, 
35 IIC 241, 245-246 (2004). 
860   Madey v. Duke University, 307 F.3d 1351, 1362, see also Lentz, Edward T., Pharmaceutical 
and Biotechnology Research After Integra and Madey, 23 Biotechnology Law Report 2004, 
265, 271. 
861   Madey v. Duke University, 307 F.3d 1351, 1362. 
862   Madey v. Duke University, 307 F.3d 1351, 1362. 
863   The rule to permit experimentation with patented inventions by exempting from infringe-
ment those activities that are related to seeking regulatory approval from the federal govern-
ment is also referred to as “clinical research exemption”, see Steffe, Eric K./Shea, Tomothy 
J., JR., Drug Discovery and the Clinical Research Exemption from patent Infringement, 22 
Biotechnology Law Report August 2003, 369, 369. 
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In Merck and Integra864, the US Supreme Court dealt with the question of whether 
uses of patented inventions in preclinical research, the results of which are not ulti-
mately included in a submission to the Food and Drug Administration (FDA), are 
exempted from infringement by 35 U. S. C. §271(e)(1).865 The Federal Circuit Court 
had clearly confirmed previously the application of this rule, allowing a broader in-
terpretation of experimental use exception “solely for uses reasonably related to the 
development and submission of information”.866 The Federal Circuit held that 
Merck’s research was not clinical testing to supply information to the FDA, but only 
biomedial research to identify pharmaceutical compounds, which is why Integra’s 
patents were infringed.867 The U.S. Supreme Court reasoned that the legislator did 
not intend Section 271(e)(1) to be so narrowly interpreted and that any infringing 
activity related to pre-clinical research cannot be classified as infringement:: 
“The use of patented compounds in preclinical studies is protected under §271(e)(1) at least as 
long as there is a reasonable basis to believe that the compound tested could be the subject of 
an FDA submission and the experiments will produce the types of information relevant to an 
IND or NDA. The statutory text makes clear that §271(e)(1) provides a wide berth for the use 
of patented drugs in activities related to the federal regulatory process, including uses rea-
sonably related to the development and submission of any information under the FDCA. “868 
On remand from the Supreme Court, the CAFC applied the broad interpretation of 
the research exemption to the Integra case and reversed the district court’s judgment 
of infringement.869 Applying the principles set forth by the Supreme Court, the 
CAFC concluded that the allegedly infringing experiments were conducted “for the 
purposes of determining the optimum candidate angiogenesis inhibitor and proceed-
ing with commercial development of the selected candidate in compliance with reg-
ulatory procedures.”870 The Court determined that the FDA research exemption de-
pends on “whether the threshold biological property and physiological effect had 
already been recognized as to the candidate drug:”871 Therefore, the fact that 
Merck’s experiments “contributed to scientific knowledge does not deprive them of 
 
864   Merck KGaA v. Integra Lifesciences I, Ltd., 545 U.S. 193 (2005). The earlier Federal Cir-
cuit’s decision Merck KgaA v. Integra Lifesciences I, 331 F.3d 860 (Fed. Cir. 2003) was va-
cated and remanded. See also Lentz, Edward T., Pharmaceutical and Biotechnology Re-
search After Integra and Madey, 23 Biotechnology Law Report 2004, 265. 
865   The exemption is governed by the Hatch-Waxman Act (1985): It shall not be an act of in-
fringement to make, use, offer to sell, or sell… or import… a patented invention solely for 
uses reasonably related to the development and submission of information under a federal 
law which regulates the manufacture, use or sale of drugs… (§ 35 US.C. § 271(e)(1). 
866   Merck KGaA v. Integra Lifesciences I, 331 F.3d 860, 868.  
867   Merck KgaA v. Integra Lifesciences I, 331 F.3d 860, 866-868. 
868   Merck KGaA v. Integra Lifesciences I, Ltd., 545 U.S. 193, 193. The ruling of the Supreme 
Court direcltly applies the reasoning of Eli Lilly & Co. v. Medtronic, Inc., 496 U. S. 661, 
665–669. 
869   Merck KGaA v. Integra Lifesciences I, Ltd., 496 F.3d 1334 (Fed. Cir. 2007).  
870   Merck KGaA v. Integra Lifesciences I, Ltd., 496 F.3d 1334, 1340. 
871   Merck KGaA v. Integra Lifesciences I, Ltd., 496 F.3d 1334, 1347. 
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a safe-harbor benefit of Section 271(e)(1) when the requirement therefore was 
met.”872  
Although the Merck decision did not establish a clear research exception, it clari-
fied the scope of the legislative exception for research in the context of drug and 
medical device development for regulatory approval. Neither the Supreme Court nor 
the CAFC examined on remand whether there exists any historical experimental use 
exemption to infringement. The CAFC avoided the question of how a case based on 
research-tool patents should be decided, referring to a post-hearing letter in which 
the parties had stated that those were not at issue.873 In a dissenting opinion, Judge 
Rader disagreed with the conclusion that the court had not ruled on the questions of 
research tools patents, finding that two of these patented processes “have no applica-
tion outside the laboratory”.874 From his view, the leading opinion “expands the ex-
emption beyond the Supreme Court limits on the provision to eliminate protection 
for research tool inventions.”875 Under the Supreme Court ruling, the § 271(e)(1) 
exemption covers research related to information that will ultimately be submitted to 
the FDA,  not “patented processes and tools beyond the scope of the patented com-
pounds” covered by such a research exemption.876  
In sum, the European patent system provides a much broader opportunity to con-
duct free research than the U.S. system. The German case, where even activities re-
lated to the commercialization of the product are covered, is a good example. Fur-
ther harmonization of both systems877, e.g., an adaptation of the European standard 
in the U.S., may create conditions preventing US scientists from conducting their 
research abroad where broader research is allowed without causing any risk of pa-
tent infringement.878 
 
872   Merck KGaA v. Integra Lifesciences I, Ltd., 496 F.3d 1334, 1347. 
873   Merck KGaA v. Integra Lifesciences I, Ltd., 496 F.3d 1334, 1348. 
874   Merck KGaA v. Integra Lifesciences I, Ltd., 496 F.3d 1334, 1349. 
875   Merck KGaA v. Integra Lifesciences I, Ltd., 496 F.3d 1334, 1348. 
876   Merck KGaA v. Integra Lifesciences I, Ltd., 496 F.3d 1334, 1348.  
877   The different approaches of the European and U.S. patent law system are also caused by dif-
ferent university cultures. In Europe, universities usually are public institutions, whereas 
universities in the U.S. are often organized in a similar fashion to private companies. In spite 
of being a public institution, the University of California, for example, is the leading patent 
holder in the biotech sector, Malakoff, David, Intellectual property. NIH roils academe with 
advice on licensing DNA patents, 303 Science 2004, 1757, 1757.  
878   The decision of Bayer v. Housey stongly emphasiszed the incentive of scientists to conduct 
research abroad. Garde, Tanuja, The Effect of Disparate Treatment of the Experimental Use 
Exemption on the Balancing Act of 35 U.S.C. § 104, 35 IIC 241, 259 (2004). Nevertheless, 
the Human Genome Organization (‘HUGO’) recommends that the European model of expe-
rimental use exception is used as a universal template, see Straus, Joseph, HUGO Statement 
on the Scope of Gene Patents, Research Exemption, and Licensing of Patented Gene Se-
quences for Diagnostics, 2003, 2.  
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C. Use of 3-D protein structure (concrete claim analysis) 
As mentioned earlier, the first patents on gene sequences did raise concerns regard-
ing their potentially undue scope of protection.879 Did these critical voices prove to 
be correct? To answer this question, it is important to ask whether claims on later 
disclosed structural properties depend on previously granted gene patents or other 
intellectual property rights. Patent dependency refers to a situation in which a new 
invention cannot be used without the infringement of an earlier one. It applies, al-
though the scope of protection of the earlier patent does not include the technical 
teaching of the later one as such. The German case law did solve this situation of 
conflict by determining that the use of a dependent patent without the approval of 
the earlier patentee is not allowed.880 However, the holder of the earlier patent is not 
allowed to use the later invention without the approval of this patentee. Thus, the 
right of the earlier patentee to prohibit the use of the later patent does not result in a 
right to actually use the later-issued patent.881 Patent dependency, however, is only 
established if the later-developed invention can be carried out without any further 
inventive activity of the person skilled in the art. In Segmentation Device for Trees, 
the plaintiff owned the German patent No. 29 18 622 (the “contract patent”) for the 
process for segmenting logs into wood products. The defendant was the proprietor 
of German patent No. 35 14 892 (the ‘892 patent’) to a “process and device for 
chipping wood, in particular for segmenting logs with wanes by chipping.”882 The 
parties concluded a license agreement. Thereby, the plaintiff granted the defendant a 
license for the “contract patent” in exchange for a certain license fee. The German 
Federal Supreme Court had to decide whether the license agreement covered the use 
of defendant’s ‘892 patent. The lower court held that the patented invention of the 
defendant was a further development of the contract patent that fine-tuned and ad-
justed its technology. More specifically, it had to be seen as an equivalent of the 
contract patent, which a person skilled in the art would be able to predict and carry 
out. Therefore, the invention of the defendant was considered an equivalent means, 
which depended on the contract patent and was covered by its scope of protection.883 
The German Federal Supreme Court found that the additional cutting blade used 
within the patented process of the patentee could only be considered an equivalent 
device to the technology covered by the process patent if it did not involve any in-
 
879   Chapter 3 A II 2 a); see also Straus, Joseph, Abhängigkeit bei Patenten auf genetische In-
formation - ein Sonderfall, GRUR 1998, 314; further Pietzcker, Rolf, Die sogenannte Ab-
hängigkeit im Patentrecht, GRUR 1993, 272. 
880   Busse/Keukenschrijver, PatG, § 9, No. 39. 
881   Straus, Joseph, Abhängigkeit bei Patenten auf genetische Information - ein Sonderfall, 
GRUR 1998, 314, 316; siehe auch: Krieger, Ulrich, Abhängige Patente und ihre Verwertung 
(Frage 97), GRURInt. 1989, 216, 216.  
882   BGH, 26 IIC 261, 262 (1995) - Segmentation Device for Trees (Zerlegevorrichtung für 
Baumstämme). 
883   BGH, 26 IIC 261, 266 (1995) - Segmentation Device for Trees (Zerlegevorrichtung für 
Baumstämme). 
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ventive activity.884 Based on this reasoning, the court remanded the case to the lower 
court with the direction to reconsider whether the invention of the defendant re-
quired any inventive efforts by a person skilled in the art. In such a case, the court 
determined, patent dependency under the principle of the doctrine of equivalents 
would not be established.885   
The answer as to whether patent dependency in the case of 3-D protein structure 
claims exists will be provided by means of a concrete claim analysis. This will be 
accomplished from the perspective of an absolute compound protection, the most 
applied principle in Europe and the U.S. In Europe, the European Directive 
98/44/EC was interpreted on behalf of an absolute scope.886 In Germany, absolute 
compound protection is the leading principle except for the patenting of human ge-
nome sequences, for which § 1a GPA incorporates the principle of purpose-related 
compound protection.887 In the U.S., the patent scope is discussed in the context of 
claim construction.888  Broad claims are allowed if sufficiently supported by a writ-
ten description.889  
First, it will be attempted to determine whether the use of 3-D structures obtained 
from natural sources and from crystalline proteins violates patents related to a re-
combinant protein. A major focus will then be the question of infringement through 
the use of sequence-dissimilar proteins sharing common folds. This issue resembles 
the problem with protein variants and demonstrates why the legal principles existing 
in this area are of particular interest. The next step will focus on the relationships 
between selection inventions and inventions involving the entire molecule. Further, 
the use of identified compounds is examined with respect to an infringement of the 
underlying patented screening method. Finally, some remarks will be made with re-
gard to the infringement of 3-D protein analysis techniques. Claim constructing rules 
of both Europe and the U.S. will play a particular role in the application of the doc-
trine of equivalents.  
 
884   BGH, 26 IIC 261, 267 (1995) - Segmentation Device for Trees (Zerlegevorrichtung für 
Baumstämme). 
885   BGH, 26 IIC 261, 269 (1995) - Segmentation Device for Trees (Zerlegevorrichtung für 
Baumstämme). 
886   Benkard/Scharen, EPÜ, Art. 69, No. 45. The before applied principle of absolute compound 
protection was not changed with the implemenation of the directive. See also Feldges, Joa-
chim, Ende des absoluten Stoffschutzes? Zur Umsetzung der Biotechnologie-Richtlinie, 
GRUR (2005) 977, 981.  
887  § 1a (4) GPA states: “If the subject matter of the invention is a sequence or partial sequence 
of a gene the structure of which is identical to the structure of a natural sequence or partial 
sequence of a human gene, its use, the susceptibility of industrial application of which is 
concretely described … is to be included into the claim.” 
888   Phillips v. AWH Corp., 415F.3d 1303, 1313 (Fed. Cir. 2005) (en banc). 
889   As for the dispute surrounding the requirement of such “separate written description”, see  
Chapter 2 A III 1c) bb). 
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I. Use of 3-D structure from naturally obtained proteins 
A first question that has to be addressed is whether the use of a 3-D structure from 
naturally obtained proteins automatically infringes the patent covering the recombi-
nant produced protein. As an example, consider patents that are directed towards 
methods for preparing “erythropoietin products” from urine or other human 
sources.890 In recent years, a number of inventions from this group reached patent 
offices. A representative claim to such a product can be expressed as follows:891 
A method for the preparation of an erythropoietin product having no inhibitory effect against 
erythropoiesis which comprises the steps of  
(a) adsorbing a crude erythropoietin product obtained from the urine of healthy human onto a 
weakly basic anion exchanger from a neutral or weakly acidic aqueous solution in the presence 
of an inorganic neutral salt in a concentration in the range from 0.1 to 0.2 mole per liter, and  
(b) eluting the thus adsorbed erythropoietin product with an aqueous eluant solution containing 
an inorganic neutral salt in a concentration in the range from 0.5 to 0.7 mole per liter. 892 
In view of such a claim and its relation to a patented recombinant protein, it is at 
least possible that anyone who uses the patented proteins may be an infringer and 
consequently may be liable for damages. According to patent law standards, in-
fringement exists if a patented product or process is used. To establish infringement 
of the recombinant protein’s patent, it is therefore reasonable to require that the ge-
netic information must be used. Obtaining a protein from natural sources, however, 
does not require the use of any recombinant methods. The protein is isolated as such 
and is independently obtained from the genetic encoding process.893 Consequently, 
no infringement exists. Claims directed to natural purified proteins must be con-
 
890   U.S. patent, No. 3,033,753, discloses a method for isolating erythropoietin from sheep blood 
plasma. Low yields of a crude solid extract containing erythropoietin are provided. Further 
isolation techniques encompass immunological procedures. Antibodies directed to erythro-
poietin are produced by injecting an animal, such as a rat or a rabbit, with human erythro-
poietin. The immune system of the animal recognizes the injected substance as a foreign an-
tigenic compound and stimulates the production of antibodies against the antigen. When the 
blood is extracted, the antigenic activity remains in the serum. The unpurified serum may 
then be used in assays to detect and complex with human erythropoietin. The resulting pro-
teins, however, encompass various disadvantages. The serum antibody is ‘polyclonal’ in na-
ture and will combine with substances other than erythropoietin. (See description of U.S. pa-
tent No. 5, 547,933 (August 20, 1996)). Even if other polyclonal and monoclonal antibodies 
used by different methods may provide highly useful material for the detection of erythro-
poietin, it appears unlikely that they can provide sufficient quantities. 
891   Note that below we consider an invention that entails the use of erythropoietin’s structural 
properties in the context of compounds identified through 3-D screening methods. 
892   U.S. Patent No. 4,397,840 “Novel erythropoietin product and method for the preparation 
thereof” to Takezawa, et al, Tokyo 1983.  
893   U.S. Patent No. 4,397,840 “Novel erythropoietin product and method for the preparation 
thereof” to Takezawa, et al, Tokyo 1983. 
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strued as being limited to the amino acid as such. Patent dependency is not estab-
lished. 
This result holds both for Europe and the U.S., with a similar line of reasoning. 
Although natural proteins contain the information from the underlying genetic code, 
they do not belong to the patent directed to the gene sequence. The naturally occur-
ring protein is therefore not included in the patent coverage of gene patents. To un-
derstand this result, one can also refer to the distinction between discovery and in-
vention. Non-isolated, naturally occurring gene sequences are considered discove-
ries.894 Thus, proteins that are encoded by naturally occurring gene sequences are 
also discoveries. The isolation of a gene is the basic requirement for establishing the 
gene’s patentability.895 The non-isolated gene in its natural environment (e.g. the 
human body) cannot be viewed as novel. Consequently, a naturally occurring pro-
tein that was encoded by a naturally occurring gene sequence is not covered by pa-
tents directed to isolated genes. Further, it fails to create novelty, unless it is sepa-
rated and purified from its natural surroundings.896 
From this perspective, it would seem to be cost-effective to make extensive use of 
naturally obtained proteins, because licensing expenditures would not accrue. How-
ever, attempts to obtain proteins from natural sources have proven relatively unsuc-
cessful. For example, large amounts of erythropoietin are necessary for research 
purposes, clinical testing, and pharmaceutical applications. The last include medical 
treatments of kidney diseases or other disorders in which the human organism fails 
to sustain production of erythropoietin. The prospects for recombinant procedures 
are therefore much better, in terms of a full characterization of mammalian erythro-
poietin as well as of the provision of high amounts for diagnostic and clinical use.897 
Generally, the amounts produced in nature are too small and not sufficient to design 
a new drug. Complicated and sophisticated laboratory techniques must be used and 
generally result in high impurity or unstable pharmaceutical end products.898 Moreo-
 
894   Krefft, Alexander Richard, Patente auf human-genomische Erfindungen: Rechtslage in 
Deutschland, Europa und den USA, München 2003, 267. Thus, the U.S. patent law requires 
that a claim referring to a gene sequence must always contain the term “isolated”, e.g. “iso-
lated polynucleotide”. 
895   Krefft, Alexander Richard, Patente auf human-genomische Erfindungen: Rechtslage in 
Deutschland, Europa und den USA, München 2003, 89. 
896   Herdegen, Matthias, Patents on Parts of the Human Body: Salient Issues under EC and WTO 
Law, 5 The Journal of World Intellectual Property 2002, 145ff. The rights conferred by a pa-
tent do not extend to the human body and its elements in their natural environment. Patent 
protection does not include natural substances themselves. 
897  As for the prospects of recombinant procedures, see Straus, Joseph, Zur Zulässigkeit klini-
scher Untersuchungen am Gegenstand abhängiger Verbesserungserfindungen, GRUR 1993, 
308, 309. 
898   Problem discussed in Amgen Inc. v. Hoechst Marion Roussel, Inc., 314 F.3d 1313 (Fed. Cir. 
2003). 
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ver, various attempts to isolate erythropoietin from urine resulted in unstable and 
biologically inactive preparations of the hormones.899 
II. Use of 3-D structure from recombinant proteins 
Recombinant techniques are presently more successful for the production of thera-
peutically effective amounts of proteins.900 In this context, the first question that 
emerges is whether the use of the recombinantly produced protein 3-D structures 
infringes the patent involving the gene sequence. This query is easily solved if the 
sequence identical protein is used. The patent to the gene sequence that encodes for 
such a protein is literally infringed under Section § 271(a) U.S.C./Section 139 (1) 
GPA. It is irrelevant as to whether the protein is used specifically with regard to its 
3-D structure. Although the claim to the gene sequence and the encoded protein does 
not include the structural coordinates as claimed, the structural coordinates are an 
inherent property of the claimed protein in a particular state. As illustrated in Part II, 
proteins automatically fold into their final folding stage after they are encoded by 
the underlying nucleotides.901 The folding process is initiated as soon as the RNA 
translates the genetic information. Hence, the use of these proteins includes the ter-
tiary or quaternary structure of the protein and not merely the amino acid sequence 
in its primary folding stage. Recombinant processes encode the protein as a whole, 
e.g., in its entire tertiary structure. Thus, a patent to the recombinantly produced ter-
tiary structure automatically covers the recombinantly produced primary structure, 
the amino acid sequence. Accordingly, any patent to the recombinantly produced 3-
D protein structure automatically depends on the earlier issued patent to the recom-
binantly produced amino acid sequences. In other words, in using the subject matter 
of the 3-D structure patent, the patentee will need to infringe the exclusive rights be-
longing to the patentee of the amino acids sequences.902 This reasoning further com-
plies with Art. 9 of Directive 98/44/EC stating that the scope of biotechnological in-
ventions extends to “all material in which the product [consisting of genetic infor-
mation] is incorporated”. The term “incorporated” must be interpreted as referring to 
genetic information that “is inserted by means of a technical process”.903 A recombi-
 
899   As stated in U.S. Patent 5,441,868 “Production of recombinant erythropoietin” to Linn, F.K 
(Thousands Oaks 1995): “Prior attempts to obtain erythropoietin in good yield from plasma 
or urine have proven relatively unsuccessful. Complicated and sophisticated laboratory tech-
niques are necessary and generally result in the collection of very small amounts of impure 
and unstable extracts containing erythropoietin.” 
900   See, for example, U.S. Patent 5,441,868 “Production of recombinant erythropoietin” to Linn, 
F.K (Thousands Oaks 1995). 
901   Chapter B II.  
902   Unless the experimental use exception applies.  
903   Krefft, Alexander Richard, Patente auf human-genomische Erfindungen: Rechtslage in 
Deutschland, Europa und den USA, München 2003, 267. 
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nant protein contains genetic information that was inserted by a recombinant tech-
nology.  
Legal questions arise if known recombinant technologies are improved or mod-
ified in order to enable proteomic research.904 With recombinant technologies fre-
quently involving problems in 3-D protein structure determination, this issue typi-
cally occurs in the field of proteomic research tools. Most proteomic studies must 
recognize that the proteome changes constantly. Modifications and interactions, 
binding activity, and self-regulatory adjustments all ensure that the proteome sensi-
tively reacts to the environment. In this context, European patent No. 0636183 
“Compositions and Methods For Protein Structural Determinations” is of particular 
interest.905 It focuses on the improvement of a recombinant method in order to ena-
ble NMR spectroscopy, which otherwise had not been possible. More specifically, 
the patent involves a new composition and method for the determination of 3-D 
structures of proteins expressed in cultures of mammalians or insects cells by NMR 
spectroscopy.906 It takes into account that most mammalian proteins contain signifi-
cant post-translational modifications that cannot be effected in bacterial or yeast sys-
tems. Existing studies on mammalian and insect cell produced proteins have also 
been unsatisfactory. Therefore, the patented invention provides a novel method for 
creating a mammalian or insect cell culture which is capable of producing the pro-
tein of interest in a nutrient medium containing all amino acids that are essential for 
the growth of the cell - in a configuration that permits NMR spectroscopy. The pa-
tent is specifically directed to proteins that cannot be analyzed by x-ray crystallogra-
phy, such as mammalian cell proteins.907 Claim 1 of European Patent No. 0636183 
to “Compositions and Methods For Protein Structural Determinations” reads as fol-
lows:  
„A method for determining three-dimensional structural information of a protein, which com-
prises the steps of (a) growing, under protein-producing conditions, a mammalian or insect cell 
culture which is capable of producing the protein of interest in a nutrient medium which con-
tains all amino acids that are essential for growth of the cells and which contains assimilable 
sources of carbohydrate, essential minerals and growth factors, wherein the amino acids and 
any other substrate used by the cells for protein synthesis in such nutrient medium are substan-
tially isotopically labeled; (b) isolating the labeled form and (c) subjecting the protein to NMR 
spectroscopic analysis to determine information about its three-dimensional structure. 908” 
The question must be asked of whether the use of the above invention infringes pa-
tents involving similar recombinant technologies for the production of the same 
amino acid sequences. On the one hand, different recombinant technologies produc-
 
904   Straus, Joseph, Zur Zulässigkeit klinischer Untersuchungen am Gegenstand abhängiger Ver-
besserungserfindungen, GRUR 1993, 308, 310.  
905   European Patent No. 0636183 “Compositions and Methods for Protein Structural Determina-
tions” by Brown, Jonathan M., Columbia 1994. 
906   Id.  
907   Id.  
908   European Patent No. 636183 “Compositions and Methods for Protein Structural Determina-
tions, by Brown, Jonathan M., Columbia 1994.  
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ing the same amino acid sequences typically use the same gene sequences, which is 
why infringement should be constituted. On the other hand, Claim 1 is directed to a 
recombinant technology that for the first time provides a sufficient basis for any 
conduct of NMR spectroscopy. The question thus is whether it follows that in-
fringement is not established. The new NMR approach, however, still relies on al-
ready patented recombinant technology. In conclusion, the method claimed in Claim 
1 must be considered an improvement of earlier invented and patented mammalian 
expression systems. Consequently, Claim 1 depends on any earlier issued patents 
directed to recombinant technologies being used in the new NMR-related approach 
and infringement of those patents is constituted.909  
III. Use of 3-D structure from crystallized proteins 
An alternative to obtaining protein 3-D structures from natural or recombinant 
sources is to crystallize them.910 Protein crystals are not only used for the determina-
tion of structural properties, but have a number of other applications. Lately, studies 
have shown that they are useful as a means of achieving controlled drug administra-
tion. With most drugs being rapidly cleared by the organism following medication, 
stabilizing a desired drug level in the organism is considered a major challenge. Pro-
tein crystals provide significant benefits in the controlled delivery of protein drugs 
such as insulin or interferon. To ascertain the prescription of correct dosages, uni-
form sizes must be produced.911  
A patent on protein crystals can be directed either to the crystallization of the pro-
tein via a particular procedure, or to the obtained crystals themselves. To establish a 
comprehensive understanding of related claims, it is useful to consider a number of 
examples, both from the U.S. and Europe. A second step then focuses on the ques-
tion of infringement. The following illustrates a U.S. patent claim to the crystals 
themselves:  
A crystal of a protein-ligand complex comprising a protein-ligand complex of an N-terminal 
truncated IF4E and a ligand, wherein the crystal effectively diffracts X-rays for the determina-
tion of the atomic coordinates of the protein-ligand complex a resolution of greater 5.0 
Angstroms; wherein …”912 
 
909   The development of the new method might, however, be covered by the research exemption, 
as for the German case (§ 11 No. 2 GPA), see Straus, Joseph, Zur Zulässigkeit klinischer 
Untersuchungen am Gegenstand abhängiger Verbesserungserfindungen, GRUR 1993, 308, 
310.  
910   Chapter 2 E II 2 a).  
911   Basu, Sujit K./Govardhan, Chandrika P./Jung, Chu W./Margolin, Alexey L., Protein crystals 
for the delivery of biopharmaceuticals, 4 Expert Opinion on Biological Therapy 2004, 301, 
301. 
912   US Patent No. 5,872,011”Crystal of protein-ligand complex containing an N-terminal trun-
cated eIF4E, and methods of use thereof”, by Burley, Stephan K./Nahum, Sonnen-
berg/Marcotrigiano, Joseph/Gingras, Anne-Claude, New York 1999. 
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The claim has been filed by Rockefeller University, which obtained U.S. patent No. 
5,872,011 entitled “Crystal of a protein-ligand complex containing an N-terminal 
truncated eIF4E, and methods of use thereof.”913 The invention involves a form of 
the messenger RNA 5’ cap-binding protein that can be crystallized with a ligand to 
form a crystal with sufficient quality to allow detailed crystallographic data to be 
obtained. Furthermore, the invention comprises the crystals and the three-
dimensional structural information, and includes procedures for related structural 
based drug design using the obtained crystallographic data. As a preferred method, 
sitting-drop vapor diffusion is utilized to grow the crystal. 
By comparison, a claim directed to the crystallization of the protein via a particu-
lar procedure can be expressed as in the following claim of US Patent No. 
5,872,011:  
  A method for determining the three-dimensional structure of a co-complex of [the specified 
protein] ... which comprises (a) x-ray diffraction data for crystals of the co-complex, and (b) 
utilizing a set of atomic coordinates selected from the group consisting of [the protein]; a por-
tion thereof; and coordinates having a room mean square deviation therefrom with respect to 
conserved protein backbone atoms of not more than 0.65 ANG to define the three-dimensional 
structure of the co-complex. 914 
The claim is directed to the design of an immunosuppressive agent for the treatment 
of patients suffering from autoimmune disorders and for recipients of transplanted 
organs. Research efforts have led to the identification of a protein, tyrosine kinase, 
as a crucial element for immune responses. It was found that blocking the biological 
function of ZAP-70 leads to immunosuppression. The invention therefore proposes 
the design of a 3-D structure-based inhibitor of the ZAP-70 protein. It includes the 
cloning, expression and purification of the ZAP-70, its crystallization, the determi-
nation of its tertiary structure and the design of the suitable inhibitor. Using recom-
binant techniques, the patent depends on any existing patents with regard to such 
techniques.915 
 
913   US Patent No. 5,872,011 ”Crystal of protein-ligand complex containing an N-terminal trun-
cated eIF4E, and methods of use thereof”, by Burley, Stephan K./Nahum, Sonnen-
berg/Marcotrigiano, Joseph/Gingras, Anne-Claude, New York 1999. 
914   US Patent 5,872,011 “Three dimensional structure of a ZAP tyrosine protein kinase fragment 
and modeling methods” by Hatada, Marcos H./Lu, Xiaode/Laird, Ellen R./Karas, Jennifer 
L./Zoller, Mark J./Holt, Dennis A., Cambridge, MA 2001. The term ZAP-70 refers to ‘Zeta-
chain-associated protein kinase 70’. It is a member of the protein tyrosine kinase family and 
is normally expressed in T cells and natural killer cells. It plays a critical role in the initiation 
of T-cell signaling. ZAP-70 is expressed in T cells and tumors of T-cell lineage. A high level 
of ZAP-70 expression appears restricted to a subgroup of chronic lymphocytic leukemia 
(CLL). The ZAP-70 gene is in chromosome 2q12, see: http://www.medterms.com 
/script/main/art.asp?Art.key=23234, last checked on January 21, 2008. Protein kinases are 
targets for treatment of several diseases. For a description, see Noble, Martin E. M./Endicott, 
Jane A./Johnson, Louise N., Protein kinase inhibitors: insights into drug design from struc-
ture, 303 Science 2004, 1800-1805.  
915   Id.  
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Besides these two characteristic claims, it is useful to consider two further exam-
ples of patents granted by the EPO, to show the potential variations inherent in 
claims directed to crystallization. First, the European patent EP1518925 issued in 
2005 covers an invention involving a novel crystal of a glucokinase protein and a 
drug design method using the 3-D structure coordinates obtained using this crystal. 
The glucokinase protein is crystallized and its 3-D structure thereof analyzed. In a 
second step, a binding compound for glucokinase is designed on the basis of the 
coordinate for the resulting three-dimensional structure.916 Second, European Patent 
EP1212365, issued in 2002, covers the crystal structures of domains of the receptor 
protein tyrosine kinase (RPTK) and their ligands. Determination and use of the 
RPTK and their ligands are included. Further, the patent discloses the following in-
formation: one amino acid group of the receptor includes a 3-D structure of an 
extracellular domain of RPTKs. The 3-D structure of RPTKs can facilitate the de-
sign and identification of modulators of RPTK function. Other such structures can 
include RPTK ligands, such as stem cell factor or a fragment thereof. Modulators of 
RPTK function can be used to treat disease mediated by inappropriate RPTK activi-
ty.917  
Having reviewed several representative claims, one has to ask whether the use of 
3-D protein structure obtained from a protein crystal infringes the patent to the re-
combinantly produced amino acid sequence. At first glance, it seems that a protein-
crystal-invention does not involve any information which could establish dependen-
cy from an underlying gene patent. The process of crystallization as such does not 
make any use of gene-related information necessary. Protein crystals are obtained 
from saturated protein solutions.918 Their production is only possible if sufficient 
purified proteins are available. Accurate crystallization requires a method capable of 
producing large amounts of proteins with correct functional characteristics. So far, 
attempts to obtain proteins from natural sources have proven relatively unsuccessful, 
which is why most inventions related to drug design or pharmaceutical products pre-
fer the use of recombinant proteins. Recombinant technologies provide the neces-
sary amount and the purification state required for stable end products. Thus, most 
inventions, such as the one discussed above for the ZAP-70 protein, tend to the use 
of recombinant proteins.919  
 
916   European Patent No. 1518925 “Crystal of Glucokinase Proteins, and method for drug design 
using the crystal” by Kamata, Kenji/Nagata, Yasufumi/Toshiharu, Iwana, Tokyo 2003. 
917   European Patent No. 1212365 “Crystal Structures of Domains of Receptor Protein Tyrosine 
Kinase and Their Ligands” by Schlessinger, Joseph/Hubbard Stevan/Mohammadi, 
Moosa/Plotnikov, Alexander/Zhang, Zhongtao/Kong, Xiang-Peng, New York 2002.  
918   The term protein solution refers to proteins in aqueous form, see Whitford, David, Proteins: 
Structure and Function, Chichester, West Sussex, U.K., 358.  
919   US Patent No. 5,872,011 “Three dimensional structure of a ZAP tyrosine protein kinase 
fragment and modeling methods” by Hatada, Marcos H./Lu, Xiaode/Laird, Ellen R./Karas, 
Jennifer L./Zoller, Mark J./Holt, Dennis A., Cambridge, MA 2001. The patent specification 
determines a ‘naturally occurring’ gene encoding the protein being used in the invention. 
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As for infringement, both patent law systems, i.e. 35 U.S.C. Section 271(a) and § 
139(a) GPA require, among others, that a product “is used.” Hence, the patent to the 
3D crystal may be infringed under the following circumstances. First, anyone who 
uses the crystallographic data may be liable for damages. Second, anyone who re-
constructs and uses the coordinates of the structural features, even with some delibe-
rate errors, may be liable for damages, provided that the existing errors are not es-
sential.920 The patent to the recombinant production of a certain protein is infringed 
if the process of obtaining a protein crystal includes the use of patented recombinant 
processes for the production of such protein. If crystals are obtained without any in-
volvement of patented recombinant techniques, no infringement is constituted. 
These rules are applicable to both, 35 U.S.C. Section 271(a) and § 139(a) GPA.  
From a licensee perspective, the use of protein crystals also appears to be cost-
effective. Nevertheless, existing difficulties with crystallization techniques have re-
sulted in the issuance of a relatively small number of patents related to crystalline 
forms.921 With crystallizing techniques constantly improving, this might change in 
the near future. Large firms are addressing the challenge of optimizing protein crys-
tallization. With high quality crystals being largely dependent on a suitable envi-
ronment, a main focus is the optimization of crystallization conditions.922 Expe-
rience shows that crystallization in a microgravity environment produces crystals 
having improved properties over crystals prepared under the normal gravity on 
earth.923 Hence, scientists use the International Space Station, which provides access 
to such an environment, for conducting intensive experimental projects. Meanwhile, 
national agencies, such as the National Aeronautics and Space Administration 
(NASA)924 have become leading federal institutions in promoting and funding pro-
tein crystallization research. Improved crystallization conditions will help to optim-
ize the properties of obtained crystals, resulting in more accurate 3-D protein struc-
tures and advances in drug design.  
 IV. Use of new proteomics technologies: An example using sequence-dissimilar 
proteins sharing common 3-D fold  
The issue of whether patent claims should be interpreted broadly enough to 
encompass later-arising technologies that were unknown at the priority date has 
 
920   Barton, John H., United States Law of Genomic and Post-Genomic Patens, 33 IIC 779, 788 
(2002). 
921   See USPTO and EPO databases. As stated in Burley, Stephan K./Nahum, Sonnen-
berg/Marcotrigiano, Joseph/Gingras, Anne-Claude, Crystal of protein-ligand complex con-
taining an N-terminal truncated eIF4E, and methods of use thereof, New York, NY 1999, 
Only few protein crystals have been produced with sufficient quality. 
922   See Chapter 2 E II 2 a.  
923   http://liftoff.msfc.nasa.gov/shuttle/msl/science/pcg.html, last checked on January 21, 2008.  
924   http://www.nasa.gov/, last checked on January 21, 2008. .  
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been the frequent subject of discussions.925 The topic is of major importance in the 
field of proteomics. With the number of disclosed 3-D protein structures constantly 
increasing, novel proteins might be revealed having the same functions as earlier 
patented proteins. These later-identified proteins can be considered new 
technologies for accomplishing known effects. As mentioned above, there exist a 
number of proteins with essentially no sequence homology that fold into the same 
tertiary structure.926  
Proteins involving different amino acid sequences thus may still fold into the 
same structure and therefore – with the function depending on the structure rather 
than on the amino acid sequence – provide same effects.927 Even substantial varia-
tions between amino acid sequences may not create any difference within the 3-D 
conformation or function of the protein.928 The question thus is whether the use of 
this protein infringes the patent on a structurally related protein that does not bear 
the same amino acid sequence, but has the same functions, because of its identical 3-
D conformation. Similar issues already arose in the context of protein engineering 
decades ago. Here, the question was whether the use of protein variants infringes the 
patent directed to the originally patented protein. This inquiry is a key element in the 
field of protein science. Unless protein claims cover engineered variants, it can be 
relatively simple for a competitor to ‘design around’ a claim merely by generating 
and commercializing one of these variants.929 In order to provide deeper insight into 
the problem, the following section will first briefly illustrate the term of “protein en-
gineering”. As a next step, the question of whether the legal categories developed 
for protein variants are also suitable for proteins performing the same function due 
to the same 3-D structure will be discussed.  
 
925   T292/85 Polypeptide-Expression/Genentech, OJ 1989, 275, 283; BGH, 33 IIC 525 (2002) – 
Snow Removal Blade (Räumschild); GRUR 1972, 704, 705 – Wasser-Aufbereitung; GRUR 
1975, 593, 596 – Mischmaschine. For the American debate, see Sarnoff, Joshua, The Doc-
trine of Equivalents and Claiming the Future after Festo, 14 The Federal Circuit Bar Journal 
2004, 403, as for the European debate see Falck, Kurt von, Zur Äquivalenzprüfung bei im 
Prioritätszeitpunk noch unbekannten Ersatzmitteln, GRUR 2001, 905.  
926   Chapter 2  B III.  
927   Masuoka, Kunihisa, Study on the Ways of Protection of Post-Genome Research Products, 
IIP Bulletin 2002, 84-95, 88.  
928   Holman, Christopher M., Protein similarity score: a simplified version of the blast score as a 
superior alternative to percent identity for claimng genuses of related protein sequences, 21 
Santa Clara Computer & High Tech. L.J. 2004, 55, 58. 
929   Holman, Christopher M., Protein similarity score: a simplified version of the blast score as a 
superior alternative to percent identity for claimng genuses of related protein sequences, 21 
Santa Clara Computer & High Tech. L.J. 2004, 55-98, 60. 
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1. Protein engineering and legal standards for the use of protein variants 
The term “protein engineering” encompasses various activities that aim to create 
novel, non-natively occurring protein structures.930 Such creation may be achieved 
by modifying existing polypeptide chains by combining segments or regions of dif-
ferent proteins, or by creating polypeptide sequences de novo. The most common 
form of protein engineering encompasses efforts to illustrate and quantify the fun-
damental interaction between structure and function, usually in the context of mea-
surement of changes resulting from specific alterations of sequences, as well as stu-
dies of homologous amino acids from engineering. Another form, believed to be the 
“true” protein engineering method, consists of “those experiments in which a protein 
of improved features is confidently synthesized from a design based on well-
understood structure-function relationships”. Advances in recombinant DNA tech-
niques during the 1980s enabled scientists to substantially improve the interactive 
process of modification and measurement.931 Through measurement in a very short 
time frame, protein engineers gained the ability to elucidate the dynamics of struc-
ture-function relationships between primary sequence data and conformational alte-
ration.932 Biologists’ aim is to develop modified proteins with properties superior to 
those existing in nature. The process involves altering the nucleotide sequence of the 
gene such that it encodes a protein with a different amino acid sequence, which in 
turn alters the protein 3-D structure and function. These “second generation” pro-
teins provide various prospects for inventions. For the average protein, a large 
amount of unique variants can be created, each differing from the natural sequence 
by only a single amino acid. In most instances, the modified analogues are function-
ally indistinguishable from the original protein, and the remaining residues are large-
ly biologically inactive or unpredictable for clinical use due to immunogenic side 
effects. However, some cases may be pharmaceutically attractive. Because they are 
unpredictable at the level of amino acid sequence, the disclosure of the polypeptide 
chain does not automatically enable an ordinary skilled person to make potential 
pharmaceutical improvements.933 
An increasing number of new drugs could only be created with the help of mod-
ified proteins. The first approved pharmaceutical drug on the market based on pro-
 
930   Robertson, Dan/Noel, Joseph P., Protein Engineering, San Diego, CA 2004. The book pro-
vides a detailed introduction of the methodology of protein engineering and further demon-
strates different techniques, including computational and laboratory methods.  
931   Basic knowledge of protein engineering also provided in: Sephton, Gregory B., Biotechnol-
ogy: the doctrine of equivalents and infringement of patented proteins, 25 Suffolk University 
Law Review 1991, 1035, 1069. 
932   Kushan, Jeffrey, Protein Patents and the Doctrine of Equivalents: Limits on the Expansion of 
Patent Rights, 6 Berkeley Technology Law Journal 1991, 108, 121f.  
933   Ryan, L. Antony/Brooks, Roger G., Innovation vs. Evasion: Clarifying Patent Rights in 
Second-Generation Genes and Proteins, 17 Berkeley Tech. L.J. 2002, 1265, 1280. 
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tein engineering was Betaseron934, a bacterially produced alteration of beta interfe-
ron that differs from the originally occurring protein by only a single amino acid. 
Other approved drugs based on protein engineering are Eli Lilly’s Humalog (an ana-
log of human insulin), Genentech’s TNK case (an alternated form of human tissue 
plasminogen activator) and Amgens’s Infergen935 (an analog of human alpha interfe-
ron).936 
Bearing great prospects on the one hand, the technique of protein engineering 
may also elevate risks. It raises de novo the problem of patent dependency for pro-
tein and gene inventions. From first sight, dominant patents on unmodified genes or 
proteins should not block those innovative pharmaceuticals. On the other hand, 
scientists are now able to develop proteins that have the same function as the pa-
tented analogues in their competitors’ products.937 This could result in rendering ex-
isting patents almost worthless. Thus, the question of whether patents on recombi-
nant genes and proteins cover second-generation analogs is essential.  
Protein variants must be distinguished from the analyzed subject matters of se-
quence-dissimilar proteins sharing common folds. The former typically share a high 
percentage of sequence similarity938, whereas the latter often do not have any detect-
able sequence similarity.939 Nevertheless, the legal standards developed for in-
fringement by the use of protein variants must also apply a fortiori to sequence-
dissimilar proteins performing the patented function. Sequence-dissimilar proteins 
do not bear any sequence similarity but rather share common folds due to their 3-D 
structure. If the courts apply the strict standards established for infringement by 
mere protein mutants, they are even more obliged to apply this standard for in-
 
934   Betaseron was invented by David Mark, Leo Lin and Shi-Da Yu Lu at Cetus Corporation in 
the early 1980s. See. U.S. Patent No. 4,588,585 (issued May 13, 1986). The new drug based 
on a thin analog was approved by the Food and Drug Administration (FDA) for the treat-
ment of relapsing-remitting multiple sclerosis in 1993. See FDA Press Release, FDA Li-
censes Interferon Beta-1b (July 23, 1993), available at http://www.fda.gov 
/gov/bbs/topics/new00424.html, last checked September 18, 2004. Betaseron is currently 
produced by Chiron Corporation and sold by Berlex Laboratories.  
935   See Humalog (Inslulin lispro Injection) Prescribing information (May 1, 2000), available at 
http://pi.lilly.com/human-prescribing.pdf; TNKase (Tenectephase) Prescribing Information 
(June 2000), available at http://www.gene.com/gene/products/information/pdf/tnkase-
prescribing.pdf, Infergen (Interferon alfacon-1) Prescribing Information (Nov. 30, 1998), 
available at http://208.254.60.143/md/pi/pi.htm., last checked September 18, 2004.  
936   Ryan, L. Antony/Brooks, Roger G., Innovation vs. Evasion: Clarifying Patent Rights in 
Second-Generation Genes and Proteins, 17 Berkeley Tech. L.J. 2002, 1265, 1270.  
937   Ahrer, Karin; Jungbauer, Alois, Chromatographic and electrophoretic characterization of 
protein variants, 841 Journal of Chromatography, Issues 1-2 (2006).  
938   Holman, Christopher M., Protein similarity score: a simplified version of the blast score as a 
superior alternative to percent identity for claiming genuses of related protein sequences, 21 
Santa Clara Computer & High Tech. L.J. 2004, 55, 59. 
939   Friedberg, Iddo/Margalit, Hanah, Persistently conserved positions in structurally similar, 
sequence dissimilar proteins: roles in preserving protein fold and function, 11 Protein 
Science 2002, 350, 350.  
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fringement when it comes to entirely different polypeptide chains that are able to 
perform the patented effect.  
Furthermore, knowledge regarding 3-D protein structure generally has practical 
value in protein engineering. The increasing information on 3-D structural features 
substantially facilitates the production of protein variants. In the past, engineers had 
access solely to primary structure-related information. For decades, prior art had in-
cluded knowledge regarding which amino acid amendments could be made without 
influencing the ultimate effect of the protein. Nevertheless, improved understanding 
of 3-D folding types enables scientists to further classify existing knowledge. With 
the ultimate effect of a protein depending on the tertiary structure, more exact de-
terminations are possible. In order to design and optimize enzymatic function, the 
engineer combines different protein structural features. The increased availability of 
3-D structure knowledge now enables rapid improvement in the field of protein en-
gineering.940  
Therefore, it is possible to arrive at the preliminary conclusion that the standards 
developed for infringement related to protein variants are also suitable for establish-
ing infringement by different proteins with structural similarities. It is, however, 
possible that modifications to existing categories are necessary. The following anal-
ysis will take a critical look at the applicability of protein variant procedure, and 
show in which cases they have to be adjusted. First, literal infringement is consi-
dered. Second, infringement under the doctrine of equivalents will be analyzed.  
2. Literal infringement 
a) Treatment of protein variants in the U.S. 
In the case of the scope of protection of biotechnological inventions, one of the most 
fundamental questions is whether the use of a sequence dissimilar protein sharing 
common folds and function infringes the original protein patent. To answer this 
question one has to start by analyzing what an original patentee must include in his 
claim language in order to protect himself from competitors using the sequence-
dissimilar protein. One form of protection could be to include the protein’s function 
in the claim. Whether this is possible, and how much such an inclusion is interpreted 
as limiting the scope of the patent depends on existing case law related to protein 
inventions. The following paragraphs will examine cases related to protein inven-
tions, consider how protection from “second-generation” analogs941 can be estab-
lished, and derive some basic principles. As a second step, the study will apply the 
principles and particularly consider how protection from “second-generation” ana-
 
940   For advances in 3D protein research and analysis, see Chapter 2 B II and Chapter 2 E II 2.  
941   Ryan, L. Antony/Brooks, Roger G., Innovation vs. Evasion: Clarifying Patent Rights in 
Second-Generation Genes and Proteins, 17 Berkeley Tech. L.J. 2002, 1265, 1265 refers spe-
cifically to the term of “second-generation proteins”.  
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logs can be established. A third step will apply these principles developed in the 
field of protein variants to the case where sequence-dissimilar proteins are used to 
‘invent around’ existing protein patents.  
aa) Claims defining proteins in terms of function 
Previously, claims defining the protein solely by its function have been allowed.942 
Frequently, this was all that was known about the protein, particularly in cases in 
which the DNA sequence encoding for the protein had yet not been disclosed. Func-
tional claims resulted in a broad patent coverage that also included variants perform-
ing desired functions. If the only limitation is function, the claim automatically en-
compasses all variants that carry out such a function. This patent practice has 
changed and currently courts require at least some sort of structural definition or a 
physical characterization that goes beyond mere functional description of the pro-
tein.943 A number of cases deal with the question of how proteins must be described. 
In Genentech v. Wellcome,944Genentech owned a patent on human tissue plasmino-
gen activator protein (t-PA), and on a gene coding for that protein.945 The claim was 
directed to a DNA isolate essentially constituting a DNA sequence encoding t-PA.946 
One of the two potential infringers, Wellcome, used met-t-PA, a product that dif-
fered by a single amino acid from native human t-PA, apparently as a result of a 
 
942   A definition by function apparently continues to be sufficient for antibodies, a sub-category 
of proteins, see Noelle v. Lederman, 355 F.3d 1343, 1349 (Fed. Cir. 2004), (“as long as an 
applicant has disclosed a ‘fully characterized antigen’, either by its structure, formula, 
chemical name, or physical properties, or by depositing the protein in a public depository, 
the applicant can then claim an antibody by its binding affinity to that described antigen.”)  
943   Holman, Christopher M., Protein similarity score: a simplified version of the blast score as a 
superior alternative to percent identity for claimng genuses of related protein sequences, 21 
Santa Clara Computer & High Tech. L.J. 2004, 55-98, 62-68, citing Amgen, Inc. v. Chugai 
Pharmaceutical Co., 927 F.3d 1200 (Fed. Cir. 1991); Ex parte Maizel, 27 U.S.P.Q. 2d (BNA) 
1662 (B. Pat. App. Interferences 1992); Fiers v. Revel, 984 F.2d 1164, 1171 (Fed. Cir. 
1993). 
944   Genentech, Inc. v. Wellcome Foundation, 29 F.3d. 1555 (Fed. Cir. 1994).  
945   Tissue plasminogen activator (tPA), also referred to as ‘clot-busting drug’, is a thrombolyt-
ic agent. It is used for patients having a heart attack or stroke. The drug dissolves blood clots, 
which cause most heart attacks and strokes. A detailed description is available at 
http://www.americanheart.org/presenter.jhtml?identifier=4751, last checked on January 21, 
2008. A good explanation related to the properties of a “human tissue activator“ is also pro-
vided by the CAFC decision itself. Genentech, Inc. v. Wellcome Foundation, 29 F.3d. 1555, 
1557 (“The protein tissue plasmin ogen activator (t-PA) plays an important role in the disso-
lution of fibrin clots in the human body. The body forms such clots typically to breach a rup-
ture in a blood vessel. When they are no longer needed, they are dissolved through the action 
of plasmin, an enzyme which binds to the fibrin and severs the bonds between the fibrin mo-
lecules.  Since plasmin circulates through the blood in an inactive form called plasminogen, 
a mechanism must be provided to activate the plasminogen and convert it to plasmin when a 
clot is targeted for dissolution by the body.  The protein t-PA serves as that mechanism.”) 
946   Genentech, Inc. v. Wellcome Foundation, 29 F.3d 1555, 1558. 
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cloning error. The second competitor, Genetic Institute, utilized a product called 
FE1X, which lacked two of the five domains of the t-PA amino acid sequence and 
had two specific amino acid substitutions.947 
The court held that the question of whether the structurally distinct proteins fall 
within the scope of the claim depends on the meaning of the phrase “human tissue 
plasminogen activator”. Interpreting the claim, the Federal Circuit found that there 
were four possible definitions of the phrase set forth in the specification. First, there 
was a narrow structural definition limited to the amino acid sequence of neutral t-
PA. Furthermore, two broader structural definitions were disclosed that provided 
information of particular regions known to be essential for biological activity. Final-
ly, a functional definition was contributed that covers any protein with the characte-
ristic biological activity.948 The court stated that the first and most narrow definition 
was exclusively suitable for claim construction, since the others “cover an infinite 
number of permutations of natural t-PA”. It held that the specification does not satis-
fy the enablement requirement under Section 112 in terms of the broader definitions. 
Therefore, the court concluded that the phrase “human tissue plasminogen activator” 
means natural t-PA. Since FE1X is not a naturally occurring variant of the full-
length sequence of human t-PA, it is not covered by the patent scope.949   
In Amgen, Inc. v. Chugai Pharmaceutical Co., the claims were directed to a DNA 
sequence encoding a protein having an amino acid sequence “sufficiently duplica-
tive” of erythropoietin to possess ‘‘Epo’s’’ biological property of causing an in-
creased production of red blood cells. 950 The court held one of the claims invalid 
due to a lack of enablement, finding that an endless number of possibilities for 
changing the ‘Epo’ structure existed. In addition, the court concluded that Amgen 
failed to provide sufficient structural information to produce analogs carrying out 
‘Epo’-like activities.951 
In Ex parte Maizel952, the invention involved the amino acid sequence of a B-cell 
growth factor. The claims described a DNA vector encoding a protein consisting of 
the claimed amino acid sequence or a “biologically functional equivalent thereof”.953 
The Board of Patent Appeals held the claims invalid, reasoning that the term “bio-
logical functional equivalent thereof” may cover any conceivable means that brings 
 
947   Genentech, Inc. v. Wellcome Foundation, 29 F.3d 1555, 1557. 
948   Genentech, Inc. v. Wellcome Foundation, 29 F.3d 1555, 1563-1564. 
949   Genentech, Inc. v. Wellcome Foundation, 29 F.3d 1555, 1560. The holdings may be ques-
tionable in light of the Federal Circuits’s en banc holding in Phillips. The Court focused on 
the methodology of claim interpretation and strongly suggested that construing claims nar-
rowly to avoid invalidity should occur only when other means of determining claim scope 
were unavailable. Thus, the Court’s decision in Genentech to adopt the narrow construction, 
limited to the specific amino acid sequence, contrary to the broader generic intent, may not 
be followed in the future, see Phillips v. AWH Corp., 415F.3d 1303, 1313 (Fed. Cir. 2005) 
(en banc). 
950   Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200, 1203 (Fed. Cir. 1991). 
951   Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200, 1217.  
952   Ex parte Maizel, 27 USPQ2d 1662 (P.T.O. Bd.Pat.App. & Int. 1992).  
953   Ex parte Maizel, 27 USPQ2d 1662, 1663.  
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about the desired biological result. The specification did merely disclose a specific 
DNA sequence known to the patentee.954  
In Fiers v. Revel, a claim intended to cover all DNA molecules coding for beta-
interferon.955 The court held that the patent did not meet the written description re-
quirement, because it failed to provide a “precise definition, such as by structure, 
formula, chemical name or physical properties”.956 The above discussed957 decision 
of Regents of the University of California v. Eli Lilly and Co.958 further determined 
the standards for protein claims, reasoning in favor of structural definitions for ami-
no acid sequences. As explained above, the invention involved claims to genes en-
coding mammalian insulin, while the patent description merely disclosed rat insulin 
cDNA. The patent was therefore held to be invalid, because it failed to provide the 
required “separate written description requirement”. The case was distinguished 
from the established practice of determining a broad chemical genus by means of a 
generic formula. The court held that the claims at issue defined the genus by its 
function without describing any functional properties commonly possessed by 
members of the genus that distinguish them from others.959  
 bb) The USPTO Guidelines for Examination of the ‘Written Description Re-
quirement’ 
Despite extensive discussion surrounding the Lilly decision and its reasoning regard-
ing a ‘separate written description requirement’, this case is frequently cited.960 In 
response, the USPTO even changed its general practice, drafting the “Guidelines for 
Examination of Patent Application under the 35 U.S.C. 112, P1 ‘Written Description 
Requirement’”961 and a “Synopsis of Application of Written Description Guidelines” 
(further referred to as “guidelines”)962. The latter apply the standard of a “separate 
written description requirement” to a number of claims involving biotechnological 
 
954   Ex parte Maizel, 27 USPQ2d 1662, 1665. 
955   Fiers v. Revel, 984 .F2d 1164 (Fed. Cir. 1993). 
956   Fiers v. Revel, 984 .F2d 1164, 1171. 
957   Chapter 3 A III 1 c) bb).  
958   Regents of the University of California v. Eli Lilly and Co., 119 F.3d 1559 (Fed. Cir. 1997).  
959   Regents of the University of California v. Eli Lilly and Co., 119 F.3d 1559, 1566. 
960   For example in Capon v. Eshhar, 418 F.3d 1349, 1355 (Fed. Cir. 2005); Moba, B.V. v. Dia-
mond Automation, Inc., 325 F.3d 1306, 1320 (Fed. Cir. 2003); Hoffmann-La Roche, Inc. v. 
Promega Corp., 323 F.3d 1354, 1368 (Fed. Cir. 2003); Amgen Inc. v. Hoechst Marion Rous-
sel, Inc., 314 F.3d 1313, 1331 (Fed.Cir. 2003). 
961   “Guidelines for Examination of Patent Application Under the 35 U.S.C. 112, P1 ‘Written 
Description Requirement’”, 66 Fed. Reg. 1099 (Jan 5, 2001).   
962   United States Patent and Trademark Office, Synopsis of Application of Written Description 
Guidelines, 1997, available at http://www.uspto.gov/web/menu/written.pdf, last checked on 
January 21, 2008. 
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material.963 Although the guidelines must be understood as a mere administrative 
framework, courts frequently rely upon them. In Enzo II,964 the Federal Circuit court 
found that the DNA-related invention had to be rejected under the Written Descrip-
tion Guidelines. The lower district court on remand was appointed to precisely apply 
the USPTO guidelines to the claims.965 In Noelle v. Lederman,966 the CAFC went 
even further, stating that an example in the guidelines directed to a hypothetical an-
tibody claim must be considered as precedent. Relying upon this example, the claim 
at issue was held to be invalid. The court concluded the example to be precedent on 
grounds of that it had been cited in Enzo II, even though Enzo II had only referred to 
the example with regard to the general USPTO written description practice.967  
The guidelines provide information regarding the amount of sequences that must 
be disclosed in order to satisfy the written description requirement. A genus is un-
derstood as a group of species defined by similar sequences. Example 13 of the 
guidelines demonstrates the following claims:  
1. An isolated protein having SEQ ID NO:3 
2. An isolated variant of the protein of Claim 1.968 
Regarding Claim 1 the guidelines determine that “the single disclosed example is 
representative of the claimed genus. In view of pre-existing knowledge, the disclo-
sure is sufficient to show that one of skill in the art would conclude that the appli-
cant was in possession of the claimed genus.” In contrast, Claim 2 fails to meet the 
standard established by the guidelines. They do not allow recitation of a specific se-
quence and to claim it and its functional variants. In this context, it is held that “the 
specification and claim do not indicate what distinguishing attributes are shared by 
the members of the genus”. Thus, it is argued that no structural properties are indi-
cated which distinguish compounds in the genus from others in the protein class.969  
The guidelines further demonstrate that it is possible to claim a genus of protein 
variants sharing similar sequences and common functionality. Applying this prin-
ciple Example 14 of the guidelines represent the following claim:  
 
963   As explained earlier, some of the Judges of the Federal Circuit also apply a “separate written 
description requirement.” For decisisve cases and the debate surrounding these decisions, see 
Chapter 3 A III 1 c). 
964   Enzo Biochem, Inc. v. Gen-Probe Inc., 323 F.3d 956 (Fed. Cir. 2002) (Enzo II)). 
965   Enzo Biochem, Inc. v. Gen-Probe Inc., 323 F.3d 956, 968.  
966   Noelle v. Lederman, 355 F.3d 1343 (Fed. Cir. 2004). 
967   Noelle v. Lederman, 355 F.3d 1343, 1348. 
968   United States Patent and Trademark Office, Synopsis of Application of Written Description 
Guidelines, 1997, 50, available at http://www.uspto.gov/web/menu/written.pdf, last checked 
on January 21, 2008. 
969   United States Patent and Trademark Office, Synopsis of Application of Written Description 
Guidelines, 1997, 51-52, available http://www.uspto.gov/web/menu/written.pdf, last checked 
on January 21, 2008. 
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A protein having SEQ ID NO: 3 and variants thereof that are at least 95% identical to SEQ ID 
NO: 3 and catalyze the reaction of A-B (a functional characteristic of SEQ ID NO: 3.970 
The guidelines explain that “procedures for making variants of SEQ ID NO: 3 which 
have 95 % identity to SEQ ID NO: 3 and retain its activity, are conventional in the 
art”. Further, it is found that “substantial variations” among the members of the ge-
nus do not exist, “since all of the variants must possess the specified catalytic activi-
ty.971  
Subsequent case law, however, questions whether the Court’s decision to adopt 
the narrow construction established in Lilly, namely limited to the specific amino 
acid sequence, should be observed. For example, the CAFC in Capon v. Eshhar, a 
decision that involved chimeric DNA claims, found that the written description re-
quirement of 35 U.S.C. §112 paragraph 1 does not impose a per se rule that the spe-
cification must recite the nucleotide sequence of claimed DNA when that sequence 
is already known in the field.972 The court reasoned that “the law must take cogniz-
ance of the scientific facts” and that the “written description” requirement must be 
applied in the context of the particular invention and the state of the knowledge”.973 
From the Court’s view, “the predictability or unpredictability of the science is rele-
vant to the decision as to how much experimental support is required to adequately 
describe the scope of the invention.”974 The court explained that  
“[T]he “written description” requirement states that the patentee must describe the invention; it 
does not state that every invention must be described in the same way. As each field evolves, 
the balance also evolves between what is known and what is added by each inventive contribu-
tion.”975 
Notwithstanding the decision of Capon v. Eshhar, which will again be addressed in 
the context of defining a protein by its folding type, the law clearly requires more 
than a mere functional definition of proteins. The “percent identity approach” sug-
gested in the guidelines is also conventional U.S. patent granting practice. Large 
numbers of patents have been issued, such as U.S. Patent No. 6,930,085 claiming 
orally administrable peptides that ameliorate symptoms of atherosclerosis. 976 Claim 
2 of this patent, owned by “The Regents of the University of California”, encom-
passes a specific polypeptide wherein said peptide shows greater than approximately 
 
970   United States Patent and Trademark Office, Synopsis of Application of Written Description 
Guidelines, 1997, 53; available at http://www.uspto.gov/web/menu/written.pdf, last checked 
on January 21, 2008. 
971   United States Patent and Trademark Office, Synopsis of Application of Written Description 
Guidelines, 1997, 53-53, available at http://www.uspto.gov/web/menu/written.pdf, last 
checked on January 21, 2008. 
972   Capon v. Eshhar; 418 F.3d 1349, 1358 (Fed. Cir. 2005).  
973   Capon v. Eshhar; 418 F.3d 1349, 1357. 
974   Capon v. Eshhar; 418 F.3d 1349, 1360. 
975   Capon v. Eshhar; 418 F.3d 1349, 1358.  
976   U.S. Patent No. 6,930, “G-type peptides to ameliorate atherosclerosis”, by Fogelman, Alan 
M./Navab, Mohamad, Oakland, CA 2005. 
https://doi.org/10.5771/9783845221441, am 02.12.2021, 20:19:12
Open Access -  - http://www.nomos-elibrary.de/agb
 213 
50% sequence identity with Apolipoprotein J.977 Proteins defined by the percent 
identity method typically recite a “reference sequence” and a specified percent iden-
tity. Thereby, a genus of polypeptide sharing some minimal threshold of sequence 
identity with another is determined. Most patents involving percent identity claims 
will provide some definition of the term “identical”. A typical definition, such as 
provided by the “085 patent” states that percent “identity” refers to sequences or 
subsequences that are the same or have a specified percentage of amino acid resi-
dues that are the same, when compared and aligned for maximum correspondence, 
as measured using a specific sequence comparison algorithm.978  
b) Treatment of protein variants in Germany 
As in the U.S., the German standards developed for protein variants may satisfy the 
treatment of dissimilar proteins bearing structural similarities. In Germany, it is also 
an established practice to read claims to cover protein variants.979 This practice is 
justified by the common knowledge that not every amendment of a provided se-
quence necessarily results in loss of the designated function. There are many known 
proteins in which a sequence variation has either minimal, or no effect at all.980 It is 
known by the prior art that certain amino acid amendments can be made without in-
fluencing the final effect of the protein. Protein variants claims include alleles or de-
rivatives having emerged from amino acid deletion, substitution, insertion, inver-
sion, addition or exchange.981 There are basically four different classes of amino ac-
ids determined by different side chains: (1) non-polar982 and neutral (Alanine, Va-
line, Leucine, Isoleucine, Proline, Phenylalanine, Methionine, Tryptophane), (2) po-
 
977   Apolipoprotein J (apo J) is a protein used in the pathogenesis of Alzheimer; see Glossary of 
The Biotechnology Institute, available at http://www.biotechinstitute.org/what_is/glossary. 
html, last checked on January 21, 2008.  
978   Fogelman, Alan M./Navab, Mohamad, G-type peptides to ameliorate atherosclerosis, Oakl-
and, CA 2005; see also Holman, Christopher M., Protein similarity score: a simplified ver-
sion of the blast score as a superior alternative to percent identity for claimng genuses of re-
lated protein sequences, 21 Santa Clara Computer & High Tech. L.J. 2004, 55-98, 69 citing 
U.S. Patent No. 6,657,047 as another example of a claim defining a protein genus in terms of 
percent identity.  
979   OLG Düsseldorf vom 10.02.2005, I-2 U 80/02, N. Publ. The threshold is what was foreseea-
ble by a person skilled in the art to be covered by the patent claim; in the case of antibodies, 
a skilled person was not able to foresee that recombinantly produced human antibodies were 
included in a claim directed to murine antibodies. 
980   U.S. Patent 6403764 “Insulin-like growth factor-1 protein variants” by Dubaquie, Yves, 
Fielder, Paul J., Lowman, Henry B., CA 2002.   
981   Meyer-Dulheuer, K.-H., Der Schutzbereich von auf Nucleotid- oder Aminosäurensequenzen 
gerichteten biotechnologischen Patenten, GRUR 2000, 179, 180. 
982   Nonpolar refers to covalent bonds in which electron density is symmetrically distributed, see 
The Chemical Glossary, at http://www.allchemicals.info, last checked on January 21, 2008.  
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lar983 and neutral (Glycine, Asparagine, Glutamine, Cysteine, Serine, Threonine and 
Tyrosine), (3) acidic984 and polar (Asparagine, Glutamate), and (4) basic985 and polar 
(Lysine, Arginine, Histidine).986 Due to the similarities within one group, it can be 
predicted that the replacement of one group member (e.g. Leucine through Isoleu-
cine or Valine, the replacement of Asparagine through Glutamate or the replacement 
of Threonine through Serine) results, with a high predictability, in a protein with 
similar effects.987 Thus, the inventor of a novel sequence is entitled to articulate 
claims involving such sequence variants.  
No German cases could be found that deal with the treatment of claims directed 
to protein variants. However, an unpublished decision from the Düsseldorf Court of 
Appeals can provide guidance on their likely treatment.988 In Pro-Urokinase the pa-
tent at issue claimed a thrombolytic with plasminogen activator isolated from urine. 
The urine consisted of urokinase characterized by a certain molecular weight. The 
allegedly infringing embodiment was a pro-enzyme with a single-chain protein 
structure bearing a sequence of 411 amino acids without attached sugar residues de-
rived from a human pharynx carcinoma cell line. The court found that claim 1 con-
sisted of a number of identifying parameters, some of which were of subsidiary im-
portance. The court acknowledged that the allegedly infringing product was “chemi-
cally and in patent-law terms a different product” than the patented product, because 
it lacked a glycoside-sidechain. Nevertheless, the court found that the patent was in-
fringed under the doctrine of equivalents.  The court held that a person skilled in the 
art would have known from the patent specification that any sugar-free high-
molecular single-chain urokinase achieved the same effect as the patented product. 
The court held that the crucial question was whether a person skilled in the art was 
able to understand from the patent disclosure that the allegedly infringing product 
could be used to replace the patented product while achieving the same effect. The 
glycosylation was the only difference between the parameters described in the patent 
claims and the allegedly infringing embodiment. Neither the claim, nor the descrip-
tion, the court found, mentioned that an addition of a sugar molecule was significant. 
The patent description rather disclosed the single-chain nature as key element of the 
product. Therefore, the court concluded, a person skilled in the art would have easily 
recognized the insignificance of the attached sugar. He would either have concluded 
 
983   Polar means a covalent bond with unsymmetrical distribution of electron density, see The 
Chemical Glossary, available at http://www.allchemicals.info, last checked on January 21, 
2008.  
984   Acidic side chains are side chains havinga negative charge under physiological conditions, 
Whitford, David, Proteins: Structure and Function, Chichester, West Sussex, U.K 2005, 25.  
985   Basic refers to proteins with side chains consisting of a ionizable OH group, see The Chemi-
cal Glossary, available at http://www.allchemicals.info, last checked on January 21, 2008. 
986   Whitford, David, Proteins, Structure and Function, Chichester, West Sussex, U.K 2005, 15. 
987   Whitford, David, Proteins, Structure and Function, Chichester, West Sussex, U.K 2005, 24-
25. See also PCT-Application WO93/08298, Soluble Variants of Type I Membrane Proteins, 
and Methods of using them, The Wistar Institute of Anatomy and Biology, 1993.  
988   Düsseldorf, Court of Appeals, 2 U 52/89, N. Publ. 
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that the non-glycosylated protein could be considered thrombolic or derived from 
the claim language that the patented effect could be achieved from different glycosy-
lation patterns.989 
The decision shows that equivalency is determined from the perspective of the 
person skilled in the art. If he understood from the patent disclosure that same ef-
fects could be achieved990 by a means other than the patented means, equivalency is 
constituted. This is typically the case if the structural variation is of no significance 
for the patented effect. As stressed by Lederer, this approach is consistent with the 
three “Improver Questions” established by English House of Lords: 
 “1) Does the variant have a material effect upon the way the invention works? If yes, the va-
riant is outside the claim. If no 2) Would this (i.e. that the variant had no material effect) have 
been obvious at the date of publication of the patent to a reader skilled in the art? If no, the va-
riant is outside the claim. If yes 3) Would the reader skilled in the art nevertheless have un-
derstood from the language of the claim that the patentee intended that strict compliance with 
the primary meaning was an essential requirement of the invention? If yes, the variant is out-
side the claim.”991 
The application of the rules established in the field of chemicals to the issue of pro-
tein variants is justified. On the one hand, the inventor cannot be expected to test all 
structural elements at all possible positions in the molecule before filing a patent 
claim. The rule, on the other hand, that a person skilled in the art must understand 
from the disclosure that the allegedly infringing variant is achieving same effects 
sufficiently copes with the principle of legal certainty.  
 
 c) Application of the principles reliable for protein variants on the use of se-
quence-dissimilar proteins 
Both the European and the U.S. system follow similar approaches with regard to 
protection from the use of protein variants. Under both laws, sequence similarity is 
used as a reference. But is this of any assistance for a patentee who seeks to protect 
himself from competitors using sequence-dissimilar proteins? Many dissimilar-
sequence proteins share common folds without sharing any sequence homology. 
These proteins are not covered by a percent identity approach using the sequence as 
reference. But, how can an inventor broaden his patent coverage to other proteins 
sharing common functions? As explained above, to merely claim the function of the 
protein is no solution, because due to advances in protein research the law does not 
tolerate such a practice.992 A definition based on the protein’s function is conse-
quently not a viable alternative. As discussed in chapter II, the folding type rather 
 
989   OLG Düsseldorf, Pro-Urokinase, N. Publ. 
990   21 IIC 860 (1990) – Epilady United Kingdom II. 
991   Lederer, Franz, Equivalence of chemical product patents, 30 IIC 275, 277 (1999).  
992   See Chapter 4 C IV 2 a) aa); also Amgen, Inc. v. Chugai Pharmaceutical Co., 927 F.3d 1200 
(Fed. Cir. 1991); Ex parte Maizel, 27 U.S.P.Q. 2d (BNA) 1662 (P.T.O. Bd.Pat.App. & Int. 
1992); Fiers v. Revel, 984 F.2d 1164, 1171 (Fed. Cir. 1993).  
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than the sequence dictates the protein’s function.993 Hence, if the protein is defined 
by its folding type, all sequence-dissimilar proteins bearing the same func-
tions/effects are automatically included. The proteins’ definition by folding type 
thus must be considered an alternative approach that appropriately provides protec-
tion from competitive use, and at the same time ensures adequate disclosure to so-
ciety. Claims that follow this approach may either directly define the protein by its 
tertiary structure or include a percent identity that uses the folding type as a refer-
ence. The method used for protection against the competitive use of protein variants 
(percent identity with sequence reference) could thus be modified accordingly. As 
shown above, the USPTO guidelines, Example 13, suggest the following form for 
such claims: 
A protein having [SEQ ID NO: 3] and variants thereof that are at least 95% identical to [SEQ 
ID NO: 3] and catalyze the reaction of A-B (a functional characteristic of SEQ ID NO: 3).994 
To enable the coverage of the folding type, the sequence reference must be replaced 
by a reference to the folding type. Such claim may read as follows:  
A protein having SEQ ID NO: 3 and [a folding type X] and variants thereof that are at least 
95% identical to [a folding type X] and catalyze the reaction of A-B (a functional characteris-
tic of SEQ ID NO: 3) 
The suggested approach (percent identity with 3D folding type reference) warrants 
that advances in prior art accomplished by modern proteomics technologies directed 
to physical structure determination are adequately taken into account. 
d) Analysis of the approach to define a protein by folding type and function 
There might, however, exist certain practical difficulties in claiming a protein by its 
folding type. From a view that uses the 3-D protein folding structure as opposed to 
sequence, the sequence might have a number of advantages. First, an amino acid se-
quence is moderately stable; its form does not change depending on surrounding 
conditions such as temperature, chemical environment, or upon the binding of addi-
tional compounds. Further, it is moderately simple to express a sequence in terms of 
words entailing simple search and comparison of the prior art. Such an expression 
contains the advantage that the prior art can be more easily searched and compared. 
With regard to a 3-D protein structure, by contrast, the surrounding conditions, e.g., 
the temperature or other influencing circumstances, must also be included in the pa-
tent claim. With regard to infringement or validity of a patent, the examination of 
the 3-D folding structure might thus be much less certain compared to sequences. 
With regard to the concrete claim language, defining the “fold” for purposes of 
claiming involves a high level of complexity. While the amino acid is stable, 3-D 
protein conformation obviously fluctuates moderately. Consequently, an inventor 
 
993   Chapter 2 B I 3.  
994   See Chapter 4 C IV 2 a) bb), citing United States Patent and Trademark Office, Synopsis of 
Application of Written Description Guidelines, 1997, 53; available at 
   http://www.uspto.gov/web/menu/written.pdf, last checked on January 21, 2008. 
https://doi.org/10.5771/9783845221441, am 02.12.2021, 20:19:12
Open Access -  - http://www.nomos-elibrary.de/agb
 217 
must include information as to how much a structure could vary from a reported 
structure and still fall within the claim. 
The above cited decision of Capon v. Eshhar995, however, provides some relief to 
inventors, since they do not have to disclose what is already established in the art. 
The court held that nucleotide-by-nucleotide re-analysis is not required when the 
structure of the component DNA segments has already been disclosed and deter-
mined by known methods.996 The court also explained that it is “not necessary that 
every permutation within a generally operable invention” be elucidated in order to 
be effective for an inventor to obtain a generic claim, as long as the effect is suffi-
ciently demonstrated to characterize a generic invention.997 Altogether, the suffi-
ciency of specification support must be determined on a claim-by-claim basis under 
the facts of the particular case. The “predictability or unpredictability of the science 
is relevant for deciding how much experimental support is required to adequately 
describe the scope of an invention”.998  
With regard to the initial question of how a claim can define a protein by its fold-
ing type, this means that a patentee is not required to provide a re-description of 
what is established in the art. Thus, if the specific effect of a surrounding condition 
to a claimed tertiary structure is already known in the art it must not be expressed in 
the patent. If scientists have already reported the extent to which a certain structure 
could vary from other reported structures, it is not necessary to include this informa-
tion in the patent language again. In summary, the more advances in proteomics are 
achieved, the less a patentee is required to disclose in his patent. Consequently, the 
improvement of proteomics technology and its contribution to the state of the art 
will increasingly provide substantial relief to patentees seeking to obtain broad pro-
tein 3D structure claims. 
Another practical difficulty with claiming a protein by its 3-D folding structure 
might, however, exist with regard to the prior art. If a patent defines a protein by a 
certain fold, there might be proteins in the prior art, but whose fold has not yet been 
determined or reported. The question thus emerges whether these prior art proteins 
anticipate the claim, e.g. render the claim invalid. The above-analyzed trilateral stu-
dies clearly indicated that the tertiary folding type can be patented, although corres-
ponding proteins are already disclosed by their primary sequence, as long as the in-
ventor proves that the tertiary folding type is the more reliable parameter than the 
primary sequence.999  
In order to determine whether a protein 3D structure claim is anticipated, the ex-
aminer must be able to distinguish the 3-D structure of prior art proteins from the 
newly claimed protein folding structure. Therefore, it is necessary that the 3-D struc-
 
995   Capon v. Eshhar, 418 F.3d 1349 (Fed. Cir. 2005) 
996   Capon v. Eshhar, 418 F.3d 1349, 1358.  
997   Capon v. Eshhar, 418 F.3d 1349, 1359.  
998   Capon v. Eshhar, 418 F.3d 1349, 1360.  
999   Chapter 3 B II 1 c). 
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ture for these prior art proteins was accurately determined previously. Otherwise, 
there would be no possibility for the examiner to make such a distinction.  
In order to receive a patent to all proteins sharing a common fold, a patent appli-
cant must describe a protein by its function. Therefore, it should be required to iden-
tify key residues in an active site, claim all proteins sharing a certain fold, and indi-
cate the disposition of key functional groups in that structure. 
Besides the practical difficulties that are likely to be manageable for sophisticated 
patent drafters, there seem to be no obstacles that would inherently prevent one from 
using the approach of defining a protein by its tertiary folding stage limited to a spe-
cific function. With regard to the scope of claims, an approach based on fold does 
clearly have some advantages over an approach based on sequence similarity. With 
the law expected to tolerate such claims, patentees should not hesitate to use it.  
3.  Infringement under the doctrine of equivalents 
a) U.S. 
 aa) Methods for determining equivalents 
Rather than seeking broad literal coverage, one might rely on the doctrine of equiva-
lents to expand the claim coverage. This approach must be sharply distinguished 
from the above-described method. An inventor does not literally define a protein by 
its tertiary folding type, but rather solely by its sequence. The coverage towards se-
quence-dissimilar proteins sharing common functions might then be achieved by the 
doctrine of equivalents.1000 The expansion of these rights under the doctrine of equi-
valents raises the question of their equitable nature. The question of expansion pri-
marily depends on which method is applied for establishing equivalents. As set forth 
above, several approaches have been used in the U.S in order to determine equiva-
lents. As a first step, it will be analyzed which of these methods is suitable for cover-
ing inventions involving 3-D protein structures. The analysis will particularly take 
into account the fact that – due to the advances in proteomics – prior art now in-
cludes substantial knowledge regarding protein folding properties and structures in 
 
1000   Ryan, L. Antony/Brooks, Roger G., Innovation vs. Evasion: Clarifying Patent Rights in 
Second-Generation Genes and Proteins, Berkeley Tech. L.J., 17 Berkeley Tech. L.J. 2002, 
1265, 1284. The Federal Circuit applied the doctrine of equivalents to a number of cases in-
volving proteins, see Holman, Christopher M., Protein similarity score: a simplified version 
of the blast score as a superior alternative to percent identity for claimng genuses of related 
protein sequences, 21 Santa Clara Computer & High Tech. L.J. 2004, 55, 61 and the cited 
cases Amgen, Inc. v. Hoechst Marion Roussel, Inc., 314 F.3d 1313 (Fed. Circ. 2003); Ge-
nentech Inc. v. Wellcome Foundation, 29 F.3d 1555 (Fed. Circ. 1994). 
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general.1001 Hence, the emerging question is how those developments influence the 
handling of legal categories such as the doctrine of equivalents.  
i. The “Hypothetical Claim” Analysis 
First, the ‘hypothetical claim’ approach is examined. The question raised in Wilson 
Sporting Goods1002 is whether this hypothetical claim is anticipated by the prior 
art.1003 If anticipation is established, it is improper to permit the patentee to enforce 
the patent under the doctrine of equivalents. If, by contrast, the hypothetical claim is 
patentable in the light of prior art, prior art does not bar the expansion of the claim 
under the doctrine of equivalents.1004 
The method only introduces the framework of a new analytical technique, without 
considering the details of its application.1005 It establishes a limitation of equivalents 
without providing detailed information regarding the exact determination of what is 
considered to be within the limits. The answer to the question of how equivalency is 
limited does not automatically provide information about how it is determined. A 
hypothetical claim will not anticipate the allegation of equivalents, particularly in 
protein science. A structurally similar protein or a protein variant will typically not 
be included in the prior art and thus not be anticipated or rendered obvious by the 
hypothetical claim. In many cases, the competitor using the structurally similar pro-
tein is the first to discover the structural similarity and the resulting effect. The same 
applies for the creator of a protein variant who, in many cases, is the first to modify 
the protein.1006 Hence, the theory does not provide an adequate protection from 
competitors creating analogs or isolating structurally similar proteins with the pur-
pose of copying existing drugs.1007  
A number of authors suggested applying an “expanded hypothetical claim analy-
sis” and to incorporate the requirement of Section 112.1008 Such an approach shall 
 
1001   Whitford, David, Proteins: Structure and Function, Chichester, West Sussex, U.K 2005, 39. 
1002   Wilson Sporting Goods Co. v. David Geoffrey & Associates, 904 F.2d 677 (Fed. Cir. 1990), 
cert. denied, 111 S. Ct. 537 (1990).  
1003   Wilson Sporting Goods Co. V. David Geoffrey & Assocs., 904 F.2d 677, 684 (Fed. Circ. 
1990) (emphasis in original), cert. denied, 498 U.S. 922 (1990); see also K-2 Corp. v. Salo-
mon S.A., 191 F.3d 1356, 1367 (Fed. Cir. 1999).  
1004   Kushan, Jeffrey, Protein Patents and the Doctrine of Equivalents: Limits on the Expansion of 
Patent Rights, 6 Berkeley Technology Law Journal 1991, 108, 131. 
1005   Parker, Hendrik D., Doctrine of Equivalents analysis after Wilson Sporting Goods: The hy-
pothetical claim hydra, 18 AIPLA Quarterly Journal 1990, 262, 274. 
1006   Ryan, L. Antony/Brooks, Roger G., Innovation vs. Evasion: Clarifying Patent Rights in 
Second-Generation Genes and Proteins, 17 Berkeley Tech. L.J. 2002, 1265, 1267. 
1007   Ryan, L. Antony/Brooks, Roger G., Innovation vs. Evasion: Clarifying Patent Rights in 
Second-Generation Genes and Proteins, 17 Berkeley Tech. L.J. 2002, 1265, 1267.  
1008   Sarnoff, Joshua, The Doctrine of Equivalents and Claiming the Future after Festo, 14 The 
Federal Circuit Bar Journal 2004, 403, 447. Although the Federal Circuit has held that the 
hypothetical claim construction is a useful tool, it has yet not required district courts to do 
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not only examine whether the hypothetical claim is anticipated by the prior art, but 
also whether the patent specification provides sufficient information to enable the 
scope of such a claim.1009 This technique is not persuasive, either. First, it conflicts 
with the public dedication rule. According to this rule, subject matter disclosed in 
the specification, but not claimed, is dedicated to the public and thus not suitable for 
determining equivalents. The decisive elements for the interpretation of patent 
claims are the claims themselves. Further, the test shifts the burden of proof for in-
fringement. Usually, the patentee must prove infringement. Applying this principle 
under the doctrine of equivalents means that the patentee must prove that the prior 
art does not bar the asserted equivalents. Under the hypothetical claim analysis, the 
patentee has to prove the validity of the hypothetical claim. According to the statuto-
ry presumption of validity, however, the patentee is usually not obliged to prove the 
validity of the asserted claim. Instead, an asserted infringer carries the burden of 
proving the affirmative defense of invalidity of the asserted claim. If the hypotheti-
cal claim test requires that the patentee must prove the validity of the hypothetical 
claim, the interpretation that the patentee must also prove the validity of the asserted 
claim may be assumed. Introducing another preliminary and subsidiary validity 
analysis with respect to a second claim not actually present is not helpful for an ex-
act examination in trial.1010 Rather than clarifying the analysis of equivalents, the test 
leaves many questions open, in particular regarding the treatment of structurally 
similar proteins or protein variants.   
For all these reasons, the hypothetical claim analysis is not an appropriate method 
for coping with the new challenges arising from advances in protein engineering and 
in the field of proteomic inventions.  
ii. The interchangeability test 
In addition, the ‘insubstantiality of differences test’ will be evaluated. The question 
raised in Graver Tank & Manufacturing Co. v. Linde Air Products Co.1011 was 
“whether persons reasonably skilled in the art would have known of the interchan-
geability of an ingredient not contained in the patent with one that was”.1012 Accord-
 
so; for a more detailed description see Siekman, Michael T., The Expanded Hypothetical 
Claim Test: A Better Test for Infringement for Biotechnology Patents under the Doctrine of 
Equivalents, Boston University Journal of Science and Technology Law 1996, 6-12.  
1009   Ryan, L. Antony/Brooks, Roger G., Innovation vs. Evasion: Clarifying Patent Rights in 
Second-Generation Genes and Proteins, 17 Berkeley Tech. L.J. 2002, 1265, 1287.  
1010   Parker, Hendrik D., Doctrine of Equivalents analysis after Wilson Sporting Goods: The hy-
pothetical claim hydra, 18 AIPLA Quarterly Journal 1990, 262, 275. 
1011   Graver Tank & Manufacturing Co. v. Linde Air Products Co. 339 U.S. 605 (1950). 
1012   Graver Tank & Manufacturing Co. v. Linde Air Products Co. 339 U.S. 605, 609.  
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ing to Hilton Davis1013, this test had to take additional circumstances into account 
than the ‘function-way-result’ test, which was considered to be insufficient.   
As for proteins, the method attempts to determine whether the function of two 
proteins differs. A protein is “interchangeable” if a person skilled in the art is rela-
tively indifferent as to which one he would use. If, on the other hand, the skilled ar-
tesian prefers one protein, particularly due to its biological function, “interchangea-
bility” is denied and equivalents are rejected. This test, however, is not suitable for 
coping with the challenges of modern protein design and drug development. The ap-
proach of distinguishing a protein merely on the level of its end function brings cer-
tain risks. Differences with regard to long term- and side effects may not be taken 
into account since the statement of one skilled in the art may very often not include 
any long-term research. Generally, a precise analysis of a protein cannot be made 
without examining the “way” in which a particular function is performed. 
Protein functions mainly depend on the proteins’ 3-D folding structure. In order 
to distinguish the end function precisely, an accurate understanding of slight differ-
ences within these structures is important. Even though the end function might only 
differ slightly, the concrete binding activity of a particular binding pocket can vary 
greatly. In contrast, the mere comparison of protein function in a biological organ-
ism does not typically take the 3-D structure into account, but focuses on the end 
function. At a time in which protein analyses mainly focus on the disclosure and 
analysis of the tertiary folding structure, this method appears insufficient and impre-
cise.   
iii. The ‘function-way–result’ test 
Next, a closer look is taken at the ‘function-way-result’ test. This method establishes 
a detailed examination of how a particular function is performed by binding activity 
or administering techniques. The accused product infringes if it substantially per-
forms the same function in substantially the same fashion to obtain the same result 
as the existing patent.1014 Thus, the first step is to determine the ‘function’ that cha-
racterizes the patented gene or protein.  
Commentators1015 have complained that the elements of the function-way-result-
test are not suitable for determining the scope of equivalents for biotechnology pa-
tents. First, sources of claim construction might refer both to broader and narrower 
“functions”. Moreover, relying on the patent specification and prior art causes a 
 
1013   Hilton Davis Chem. co. v. Warner-Jenkinson Co., 62 F.3d 1512, 1518-19 (Fed. Cir. 1995) 
(en banc), revised on other grounds, 520 U.S. 17 (1997).  
1014   Sanitary Refrigerator Co. v. Winters, 280 U.S. 30, 42 (1929).  
1015   Takenaka, Toshiko, Doctrine of Equivalents after Hilton Davis: a comparative law analysis, 
22 Rutgers computer and technology law journal 1996, 479-520; Ryan, L. Antony/Brooks, 
Roger G., Innovation vs. Evasion: Clarifying Patent Rights in Second-Generation Genes and 
Proteins, 17 Berkeley Tech. L.J. 2002, 1265. 
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problem of timing. In Warner-Jenkison v. Hilton Davis, the Supreme Court held that 
equivalents must be examined at the time of infringement.1016 If the question of 
“function” is analyzed, any properties of the patented gene or protein disclosed be-
tween the time of invention and the time of infringement are automatically consi-
dered irrelevant.1017 Finally, critics allege that the test is problematic with regard to 
the “way” component. They assert that current scientific understanding of the way in 
which proteins perform their functions is not yet well advanced and often based on 
“trial and error” testing.  
The criticism is not persuasive. According to Section 35 U.S.C. § 112 1, courts 
can only accept the functions that are enabled by the patent specification when they 
interpret claims. Regarding the way a certain function is performed, skilled artisans 
are commonly able to interpret the differences in the function of proteins. Although 
the exact folding structure might not be known, scientists may be familiar with fold-
ing groups, such as protein super families, and be able to determine the family to 
which the given protein belongs. It may also be possible to make statements con-
cerning the amino acid sequences that play a critical role in folding at the tertiary 
level. With current developments in proteomics, whose goal is total disclosure of 3-
D protein structures, difficulties with the ‘function-way-result’ test that may have 
existed in the past have been overcome. With proteomic researchers able to tho-
roughly determine 3-D protein structures, the test is in most cases easy to conduct. 
1018 The method of analyzing the ‘function’, the ‘way’ and the ‘result’ of a protein 
thus leads to a very precise and accurate comparison of the native protein, its engi-
neered analogs and dissimilar proteins with structural similarities. In particular, it is 
even possible to determine slight differences in binding activity and thus indicate 
long-term and side effects. The mode is therefore appropriate, suitable, and suffi-
cient for determining equivalents with regards to inventions involving 3-D protein 
structure. In particular, it is adequate for the determination of whether the patent 
scope covering a protein extends to sequence-differing proteins sharing common 
fold and function.  
bb) The ruling of Genentech v. Wellcome and the doctrine of equivalents 
The above-mentioned1019 decision of Genentech v. Wellcome1020 encompasses a de-
tailed analysis of how the doctrine of equivalents is examined according to the func-
tion-way-result test. The decision is of particular interest because the dissenting opi-
 
1016   Warner-Jenkison v. Hilton Davis, 520 U.S. 17, 19.  
1017   Ryan, L. Antony/Brooks, Roger G., Innovation vs. Evasion: Clarifying Patent Rights in 
Second-Generation Genes and Proteins, 17 Berkeley Tech. L.J. 2002, 1265, 1286.  
1018   Different view: Ryan, L. Antony/Brooks, Roger G., Innovation vs. Evasion: Clarifying Pa-
tent Rights in Second-Generation Genes and Proteins, 17 Berkeley Tech. L.J. 2002, 1265, 
1287. 
1019   Chapter 4 C IV 2a) aa).  
1020   Genentech, Inc. v. Wellcome Foundation, 29 F.3d 1555.  
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nion closely questions the function-way-result test, asserting that it lacks the ability 
to cope with the challenges of protein engineering.1021 In reviewing this major deci-
sion, the arguments used in the dissenting part will be evaluated. Moreover, it will 
be discussed whether they are of any value for the field of proteomic inventions.  
After the examination of literal infringement, the court in Genentech v. Wellcome 
had to decide whether the “human tissue plasminogen activator limitation” appear-
ing in the Genentech patent claims was met by an equivalent element of FE1X, the 
competitor’s protein variant, under the doctrine of equivalents.1022 Reviewing the 
claims, the court emphasized that the ‘way’ or ‘result’ prongs were highly dependent 
on the ‘function’ prong. The first important issue in the context of the “triple-test” of 
equivalency was thus “how broadly one defines the function of human t-PA”.1023 
With the intended function viewed in the context of the patent, the prosecution histo-
ry, and the prior art, the court concluded that the district court had interpreted the 
claim language too broadly. The ‘function’ of human t-Pa, rather, includes a ‘fibrin 
binding’ process. Such a narrow definition of the claim, however, “is devoid of any 
… linking argument showing that FE1X functions in substantially the same way as 
human t-PA or achieves substantially the same result”.1024 Furthermore, the court 
stated that existing testimony on the binding activity of the active centers was only 
vague and speculative. As a consequence of the deletion of the E and F regions in 
the protein variant, the binding affinity of FE1X must be considered to be substan-
tially different from the natural protein.1025 First, the mode of the protein variant’s 
binding is different. Second, the protein variant behaves differently from human t-
PA.1026 The court furthermore relied on the decision of Malta1027acknowledging that 
the state of the science in this area of endeavor is very imprecise. Therefore, Malta 
could not be interpreted as requiring plaintiffs/appellees to prove more specific de-
tails of the binding mechanism to the different properties and structure of FE1X in-
volved in the binding process.1028 Nevertheless, the court could determine that by 
demonstrating that a certain region of the protein structure plays a role in the binding 
function of both the natural and the modified protein, compliance with the ‘triple-
test’ was insufficient. The profound differences in the properties and structure pos-
sessed by each protein would not allow such an interpretation.1029  
In the dissenting opinion,1030 Judge Lourie asserted that the focus on the ‘func-
tion, way-result’ is undue. Especially when the patented material is chemical in na-
 
1021   Krefft, Alexander Richard, Patente auf human-genomische Erfindungen: Rechtslage in 
Deutschland, Europa und den USA, München 2003, 291. 
1022   Genentech, Inc. v. Wellcome Foundation, 29 F.3d 1555, 1568. 
1023   Genentech, Inc. v. Wellcome Foundation, 29 F.3d 1555, 1567. 
1024   Genentech, Inc. v. Wellcome Foundation, 29 F.3d, 1555, 1568. 
1025   Genentech, Inc. v. Wellcome Foundation, 29 F.3d 1555, 1568. 
1026   Genentech, Inc. v. Wellcome Foundation, 29 F.3d, 1555, 1568-69.  
1027   Malta v. Schulmerich, 952 F.2d 1320 (Fed. Cir. 1991).  
1028   Genentech, Inc. v. Wellcome Foundation, 29 F.3d 1555, 1569. 
1029   Genentech, Inc. v. Wellcome Foundation, 29 F.3d 1555, 1569. 
1030   Genentech, Inc. v. Wellcome Foundation, 29 F.3d 1555, 1570.  
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ture, this “limited means of analysis” fails to fully elucidate the issue. Pursuant to his 
view, it is not clearly distinguishable whether the particular characteristics of each 
product are part of the ‘way’-, ‘result’- or ‘function’-prong. It is insufficient to say 
that the ‘triple-test’ determines “how” a substance works instead of what it does. 
The “insubstantially change-test” would rather be the only adequate method for illu-
strating the scope of equivalents. Applying such a method, however, the judge also 
reversed the district court’s decision and chose to deny an infringement under the 
doctrine of equivalents.1031  
 cc) Application of the ‘function-way-result’ test to the issue of sequence-
dissimilar proteins 
How are the principles established in Genentech applied with regard to the initial 
question of whether the use of sequence-dissimilar proteins infringes the patent to 
the native protein? The court in Genentech focused on the question of how much the 
structure of a protein can be altered without amounting to a different “way” of ac-
complishing its function. It concluded that no equivalency was present, reasoning 
that the two patents involved different ways and functions. A sequence dissimilar 
protein can be considered to satisfy the “way” prong of the function-way-result in-
quiry. A protein having a different fold, by contrast, must be considered to accom-
plish the function by a different “way”. As for Genentech’s case reliance on the Mal-
ta decision1032 it cannot be said any more that the state of the art in the area of pro-
tein science remains imprecise.1033 In the post-genomic era, physical methods of de-
termining the 3-D of proteins have been highly improved. Due to advanced proteo-
mic technologies, such as x-ray crystallography or NMR structure determination, 
scientists are now able to determine the structures of many proteins on a precise lev-
el. Considerable research has been performed about protein folding models and 
aligned identical residues in sequence-dissimilar proteins sharing common folds. It 
is thus highly appropriate to require patentees to generate this information.1034 
 
1031   Genentech, Inc. v. Wellcome Foundation, 29 F.3d 1555, 1568. 
1032   Malta v. Schulmerich, 952 F.2d at 1327. 
1033   The consideration of prior art is also required in light of the above-cited Capon v. Eshhar 
case, where the court reasoned that the “law must take cognizance of the scientific facts”, see 
Capon v. Eshhar; 418 F.3d 1349, 1376 (Fed. Cir. 2005). 
1034   The ‘function-way-result’ method had been applied by various other cases, e.g. Hughes Air-
craft Co. v. United States, 86 F.3d 1566, 1584 (Fed. Cir.1996), remanded, 520 U.S. 1183, 
117 S.Ct. 1466, 137 L.Ed.2d 680 (1997), aff'd, 140 F.3d 1470, reh'g denied, 148 F.3d 1384 
(Fed.Cir.1998), cert. denied, 525 U.S. 1177, 119 S.Ct. 1112, 143 L.Ed.2d 108 (1999) (The 
patent at issue involved a method of keeping satellites properly aligned with the sun so to 
keep batteries loaded at any time. Years later the technology was computerized and put on 
the satellite itself. The Federal Circuit ruled that an inventor is not required to predict all fu-
ture developments that enable the practice of his invention and therefore concluded in-
fringement of this “later-arising technology” under the doctrine of equivalents. The conclu-
sion was drawn by analyzing whether both inventions were operated by the same function, 
 
https://doi.org/10.5771/9783845221441, am 02.12.2021, 20:19:12
Open Access -  - http://www.nomos-elibrary.de/agb
 225 
dd) Expansion of the patent coverage to as yet unidentified species 
The initial question has been whether an inventor is able to extend a claim defining 
the protein by sequence and function to sequence-dissimilar proteins sharing com-
mon effects by relying upon the doctrine of equivalents. With these proteins typical-
ly being unknown at the time the patent is issued, it must be asked whether patent 
claims can be interpreted broadly enough to encompass alternative, as yet unidenti-
fied, species. With later-discovered sequence-dissimilar proteins sharing common 
folds and effects representing a new technological means that is able to achieve 
same effects than an earlier patented technological means, it must be asked whether 
a patent involving a disclosed technology equivalently expands to later-arising tech-
nologies. To answer this question, one must precisely consider the legal limitations 
of the doctrine. As explained earlier,1035 reliance upon equivalents is excluded if 
prosecution history estoppel applies. This rule basically states that a patentee cannot 
recapture through equivalents what he has surrendered during patent prosecution.1036  
What is the relevance of this limitation in the context of the initial question, e.g., 
with regard to whether a patentee is able to claim as yet unidentified species bearing 
the same/similar folding type and function? Narrowing amendments are usually 
made in cases in which the patent offices find a claim too broad, e.g., not sufficient-
ly supported by the patent description. Thus, they typically occur in cases in which a 
patentee attempts to claim unidentified species yet unknown at the time the patent 
application is filed.1037 In this respect, it must be asked whether a narrowing 
amendment of protein function claims results in blocking a patentee from equiva-
lently claiming yet undiscovered sequence-dissimilar, and structure-similar proteins. 
The question of whether a patentee may prove equivalents even though he narrowed 
the claim during the application process is of major interest for 3-D protein structure 
related inventions. 1038 As set forth above, the more recent Festo litigation abolished 
the earlier ‘complete bar’ rule and developed the ‘flexible bar’ approach.1039 The de-
 
way and result. The case is considered a landmark for determining that the patent scope may 
encompass subsequent advances in prior art.   
1035   Chapter 4 B I.  
1036   Bergen-Babinecz, Katja/Hinrichs, Nikolaus/Jung, Roland/Kolb, Georg, Zum Schutzbereich 
von US-Patenten: Festo und eine deutsche Sicht, GRURInt. 2003, 487, 490.  
1037   Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., Ltd., 535 U.S. 722 (2002). 
1038   To a certain point, the above-cited Genentech case already anticipated the revised Festo 
standards by demonstrating that a patentee who narrows an originally broad claim to a pro-
tein defined by function during prosecution history is not allowed to extend the patent scope 
beyond what was removed in the application process. The decision shows that a patentee 
cannot rely on the doctrine of equivalents for a scope of protection that encompasses subject 
matter deliberately removed from examination by the PTO during prosecution through nar-
row claiming. Having narrowed the claim during prosecution history, Genentech is not al-
lowed to extend the patent scope beyond what was removed in the application process, see 
Genentech, Inc. v. Wellcome Foundation, 29 F.3d at 1557. 
1039   In particular ‘Festo VIII’ where the Supreme Court disagreed with the ‘complete bar’ rule 
develped by the CAFC, setting forth a ‘flexible bar’ approach (Festo Corp. v. Shoketsu Kin-
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cision of Festo VIII clearly determines when such a rule allows a patentee to claim 
equivalents, despite surrendering of parts of the original scope during prosecu-
tion.1040 According to the Federal Circuit’s complete-bar rule, the first goal of the 
history estoppel is “to hold the inventor to the representations made during the ap-
plication process”.1041 By narrowing the content of a patent application, the patentee 
accepts that the patent does not extend as far as the original claim. The Supreme 
Court, however, held that this does not result in a precise drafting of the claim lan-
guage such that a reliance on equivalency per se becomes unnecessary.1042 The 
Court explains that:   
“[T]he narrowing amendment may demonstrate what the claim is not; but it may still fail to 
capture precisely what the claim is. There is no reason why a narrowing amendment should be 
deemed to relinquish equivalents unforeseeable at the time of the amendment and beyond a 
fair interpretation of what was surrendered. Nor is there any call to foreclose claims of equiva-
lents for aspects of the invention that have only a peripheral relation to the reason the amend-
ment was submitted. The amendment does not show that the inventor suddenly had more fore-
sight in the drafting of claims than an inventor whose application was granted without 
amendments having been submitted.”1043 
The decision clearly explains that a patentee may prove equivalents for elements that 
have been unforeseeable at the time of the amendment. Thus, technology established 
at a later date is equivalently included, whereas previously established techniques 
that were not literally specified are not.1044 The rational behind this finding is that 
patentees should not be punished for their inability to claim later-arising technology. 
In this respect, Judge Rader in Festo explained:  
“[w]ithout a doctrine of equivalents, any claim drafted in current technological terms could be 
easily circumvented after the advent of an advance in technology.”1045  
 
zoku Kogyo Kabushiki Co., 535 U.S. 722 (2002)) and ‘Festo IX’ where the CACFC on re-
mand examined the claims at issue in light of such a ‘flexible bar’ rule (Festo Corp. v. 
Shoketsu Kinzoku Kogyo Kabushiki Co., Ltd., 344 F.3d 1359 (Fed. Cir. 2003)). 
1040   Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722 (2002) (Festo VIII). 
1041   Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722, 724. 
1042   Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722, 738. 
1043   Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722, 738. 
1044   In Chiron Corp. v. Genentech, Inc., the court distinguished between “nascent technology” 
and “future technology”, e.g. “technology that arises after the date of application.”; see at: 
363 F.3d 1247, 1254-1256 (Fed. Cir. 2004). For a profound description of this case see Sar-
noff, Joshua, The Doctrine of Equivalents and Claiming the Future after Festo, 14 The Fed-
eral Circuit Bar Journal 2004, 403, 430.  
1045   Festo VI, 234 F.3d 558, 619 (Fed. Cir. 2000) (Rader, J., concurring in part and dissenting in 
part). See also Festo IX, 344 F.3d ate 1359, 1376-77 (Fed. Cir. 2003) (en banc) (Rader, J., 
concurring) (arguing for the foreseeability standard to avoid disrupting patentees expecta-
tions regarding patent scope during prosecution). Opponents of this view, including Sarnoff 
in the above-cited article, argue that the fact that a patent’s claims may be designed-around 
in the future represents neither a doctrinal rational to extend protection beyond the claimed 
invention nor an indication that such additional protection would be appropriate. Therefore, 
opponents argue that some additional fairness criterion should be required to justify protec-
tion for unclaimed or unclaimable later-arising equivalents; Sarnoff, Joshua, The Doctrine of 
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Hence, narrowing amendments of protein function claims do not impede a patentee 
to rely upon equivalents for yet undiscovered sequence dissimilar proteins that per-
form common functions. Reliance upon equivalents for already known sequence-
dissimilar proteins, by contrast, would be excluded by prosecution history estoppel, 
provided that a patentee had surrendered the scope of claims during the prosecution 
process.  
Another difficulty patentees claiming the folding type of a protein may encounter 
falls under the principle of public dedication. Broad generic references in the written 
description may dedicate the patented subject matter to the public. As explained in I. 
B., the disclosure-dedication rule requires a patentee who discloses specific facts to 
also claim it, and to submit these claims to such a broader subject matter for exami-
nation. Otherwise, disclosed facts are dedicated to the public and may not be recap-
tured by using the doctrine of equivalents.1046 The question emerges as to whether 
generic disclosures in the patent specification, such as the description of a protein 
folding type result in that all members, including the as yet unidentified of this par-
ticular genus are automatically dedicated to the public.  
The decision PSC Computer Products, Inc. v. Foxconn International1047 explains 
that the question of what is dedicated to the public mainly depends upon how specif-
ic a disclosure in a written description must be. The Federal Circuit found that equi-
valents are barred to the extent that persons of ordinary skills in the art would be 
able to “identify the subject matter that had been disclosed and not claimed.”1048 
This means that not only expressly, but also implicitly disclosed subject matter is 
dedicated. With regard to the initial question it has to be asked whether this implies 
a conflict with the doctrine of equivalents protection for later species of proteins 
having similar folding structures. According to the principles of public dedication, 
the answer depends on whether the yet unidentified species is included in the patent 
being claimed. Under the PSC Computer decision, a patent description that implicit-
ly contains information to as yet unidentified species is already sufficient to exclude 
such information from patentability. Consequently, the genus must be disclosed in a 
manner that would suggest the disclaiming of alternative, as yet unidentified species. 
1049  
 
Equivalents and Claiming the Future after Festo, 14 The Federal Circuit Bar Journal 2004, 
403, 452. 
1046   PSC Computer Products, Inc. v. Foxconn International, Inc., 355 F.3d 1353 (Fed. Cir. 2004). 
1047   PSC Computer Prods, Inc. v. Foxconn Intern., Inc., 355 F.3d 1353 (Fed. Cir. 2004). 
1048   PSC Computer Prods, Inc. v. Foxconn Intern., Inc., 355 F.3d 1353, 1360. 
1049   PSC Computer Prods, Inc. v. Foxconn Intern., Inc., 355 F.3d 1353, 1360.  
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b) Germany  
aa) Infringement under the doctrine of equivalents  
How should a claim that is broad enough to cover common structural folds be writ-
ten pursuant to German claim construction rules? In order to establish the decisive 
elements for construction, the principles for equivalent claim construction explained 
in Chapter IV B. 2. must be considered. In addition, a claim must be viewed in light 
of recent case law of the German Federal Supreme court related to the determination 
of equivalents. The decisions of Plastic Pipe1050, Custodiol I1051, Custodiol II1052, 
Cutting Blade I1053 and Cutting Blade II1054 were related to the question of whether 
figures or measurements in a claim allow some degree of approximation (and if so, 
to what degree). As in the U.S., the German Federal Supreme Court explicitly em-
phasized that the principle of legal certainty requires that the semantic content of the 
patent claims establish not only the starting point but also the decisive basis for de-
termining the extent of protection.1055 The following analysis will particularly focus 
on the Cutting Blade decisions. In Cutting Blade I1056 the court stated in this context 
that  
“if an embodiment departing from the essential meaning of the patent claim is to 
be included within the extent of protection, it is not sufficient that (1) it solves the 
problem underlying the invention with modified but objectively equivalent means 
and (2) that the person skilled in the art is able to use his specialist knowledge to 
identify the modified means as having the same effect. Just as the same effect cannot 
be found without focusing on the patent claim, (3) the considerations that the person 
skilled in the art must apply must in addition be focused on the essential meaning of 
the technical teaching protected in the patent claim in such a way that the person 
skilled in the art regards the different embodiment with its modified means as being 
equivalent to the solution in question.”1057  
Hence, an ordinary person skilled in the art has to define the scope beyond the 
wording of the protection based on the claim language. But to what extent is a patent 
used, and infringement established? In order to answer this question, it is necessary 
to first determine the content of patent claims, i.e., the semantic meaning attached to 
the claim language. If the contested embodiment uses the essential meaning of the 
 
1050   BGH, 34 IIC 302 (2003) – Plastic Pipe (Kunstoffrohrteil). 
1051   BGH, GRUR 2002, 523 – Custodiol I. 
1052   BGH, 34 IIC 197 (2003) - Custodiol II. 
1053   BGH, 33 IIC 873 (2002) – Cutting Blade I (Schneidmesser I). 
1054   BGH, GRUR 2002, 519 – Cutting Blade II (Schneidmesser II). 
1055   BGH, 33 IIC 873, 874 (2002) – Cutting Blade I (Schneidmesser I); Meier-Beck, Peter, Aktu-
elle Fragen der Schutzbereichsbestimmung im deutschen und europäischen Patentrecht, 
GRUR 2003, 905, 906. 
1056   As for the factual background, see, Geißler, Bernhard, Noch lebt die Äquivalenzlehre, 
GRURInt 2003, 1, 3.  
1057   BGH, 33 IIC 873, 874 (2002) – Cutting Blade I (Schneidmesser I). 
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patent claim, infringement exists. In order to find that the modified means used in 
the contested embodiment has the same effect for the solution of the problem under-
lying the invention, the skilled person may combine considerations based on the es-
sential meaning of the invention with his particular knowledge.1058  
In determining whether a concrete feature of the contested embodiment is within 
the scope of the patent, the corresponding features of both substances must be ana-
lyzed. An extension of scope to a different means finally depends on whether the 
principle of legal certainty still allows, or requires, such an extension in order to 
provide an appropriate reward for the patent owner for his scientific efforts.1059 Pur-
suant to the principle of legal certainty, it is not sufficient that an embodiment of the 
invention is solely included in the patent description, but not encompassed by the 
semantic meaning of the claims. The inventor who is able to describe essential cha-
racteristics in the description should also be able to draft his patent claims encom-
passing such knowledge.1060 
As set forth in question 3) in Cutting Blade I, the determination of an ordinary 
person skilled in the art must be focused on the essential meaning of the technical 
teaching protected in the patent claim in a way such that a person skilled in the art 
regards the different embodiment with the modified means as being equivalent to the 
solution at issue.1061 Hence, the reasoning of Cutting Blade I not only requires a con-
crete orientation on the semantic meaning of the patent claim, but also gives a closer 
definition of such orientation; the person skilled in the art must be able to predict 
and take into account the contested embodiment. “Being equivalent to the solution at 
issue” is not to be understood technically in a sense of solely obtaining equal effects. 
The term rather refers to the closeness of the skilled person‘s considerations to the 
patent claim, which determines whether the contested embodiment is covered by the 
semantic meaning of the claim language.1062 A contested embodiment is not covered 
if the skilled person’s considerations are completely unrelated to the patent claim 
language. Rather, it is already sufficient that one single embodiment of the variant 
has no relation to the patented characteristics.1063 The German Federal Supreme 
Court applied this rule in Custodiol II.1064 In this decision, the patent claim was di-
rected to a protective solution for the prevention of ischaemic1065 damage to the 
heart and kidneys, and it determined that such solution should contain 10 +/-2 mil-
 
1058   BGH, 33 IIC 873, 874 (2002) – Cutting Blade I (Schneidmesser I). 
1059   Benkard/Scharen, EPÜ, Art. 69, No. 82.  
1060   Benkard/Scharen, EPÜ, Art. 69, No. 84; Meier-Beck, Peter, Aktuelle Fragen der Schutzbe-
reichsbestimmung im deutschen und europäischen Patentrecht, GRUR 2003, 905, 906. 
1061   BGH, 33 IIC 873, 875 (2002) – Cutting Blade  I (Schneidmesser I).  
1062   BGH, 33 IIC 873, 877 (2002) – Cutting Blade I (Schneidmesser I). 
1063   Meier-Beck, Peter, Aktuelle Fragen der Schutzbereichsbestimmung im deutschen und euro-
päischen Patentrecht, GRUR 2003, 905, 908-909. 
1064   BGH, 34 IIC 197 (2003) - Custodiol II.     
1065   Local anemia (insufficient blood supply) results from vasoconstriction, thrombosis or embo-
lism, see Hyper Dictionary, available at http://www.hyperdictionary.com/dictionary/ is-
chaemia, last checked on January 21, 2008.  
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limole of magnesium chloride. The defendant used a protective solution that differed 
from the patented solution by the fact that the solution only contained an amount of 
4 mmol/1 magnesium chloride.1066 The court ruled that the amount of 4 mmol/1 
magnesium chloride instead lacked any relation to what was patented, i.e., to the 
10+/-2 millimole magnesium chloride of the patented subject matter. Hence, the 
contested embodiment did not fall into the patent scope, irrespective of the fact that 
it could be used equally effectively of therapeutic treatment.1067  
The question of whether the skilled persons’ considerations are focused on the es-
sential meaning of the patented teaching in such a fashion that he regards the differ-
ent embodiment with its modified means as being equivalent to the solution in ques-
tion (question 3) shows parallels to the Catnic case1068. The decision handeled down 
by the U.K. House of Lords that dealt with the legal situation in the U.K. at an earli-
er stage offers some observations on the determination of equivalents under English 
law. Although the German question is phrased differently than the British example 
(“[W}hether persons of relevant practical knowledge and experience would under-
stand that strict compliance with a particular descriptive word or phrase was in-
tended by the patentee to be an essential requirement of the invention.”)1069 both ap-
proaches are comparable. Nevertheless, the German law not only determines when 
equivalents per se is excluded, but provides sets the framework for how it must be 
narrowed under certain conditions.1070  
The first question in the Cutting Blade I decision (“whether the allegedly infring-
ing product solves the problem underlying the invention with modified but objec-
tively equivalent means”) resembles the first Catnic question, but is slightly differ-
ent.1071 It is not asked whether a different means “works in the same way” but 
whether it solves the problem underlying the invention by means which have the 
same technical effect.1072 The latter must be identical; even small discrepancies re-
sult in the rejection of equivalents. The decision of whether the variants provide the 
 
1066   BGH, 34 IIC 197, 197 (2003) - Custodiol II.     
1067   BGH, 34 IIC 197, 202-203 (2003) – Custodiol II;  Meier-Beck, Peter, Aktuelle Fragen der 
Schutzbereichsbestimmung im deutschen und europäischen Patentrecht, GRUR 2003, 905, 
910.  
1068   Catnic Components Ltd v Hill & Smith Ltd, [1981] F.S.R. 60 (House of Lords 1980). 
1069   Catnic Components Ltd v Hill & Smith Ltd, [[1981] F.S.R. 60, 61.  
1070   Meier-Beck, Peter, Aktuelle Fragen der Schutzbereichsbestimmung im deutschen und eu-
ropäischen Patentrecht, GRUR 2003, 905, 909; there also exist differences from the protocol 
question; such as that claims are not only considered to be the starting point, but also the de-
cisive basis for determining the extent of protection, see Meier-Beck, Peter, The Scope of 
Patent Protection - The test for Determining Equivalents, 36 IIC 339, 341(2005); different 
view Benkard/Scharen, EPÜ, Art. 69, Nos. 72-75, stating that a distinction between essential 
and non-essential aspects of the claim language is contrary to patent law.  
1071   Meier-Beck, Peter, The Scope of Patent Protection - The test for Determining Equivalents, 
36 IIC 339, 342 (2005).  
1072   Meier-Beck, Peter, The Scope of Patent Protection - The test for Determining Equivalents, 
36 IIC 339, 343 (2005); Kirin-Amgen Inc v. Hoechst Marion Roussel, [2005] R.P.C. 9, 2004 
WL 2330204, No. 75. 
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same effects is based on grounds of the claims. A technical effect is only considered 
to be the same if it describes all the effects that a skilled person understands from the 
claim to be set forth by every single feature and by the mutual connection of all fea-
tures of the claim. Technical effects are understood as the results of the technical 
teaching of the claim.1073 The first question of Cutting Blade I must be read in the 
light of another decision made by the German Federal Supreme Court. In Roasting 
Pots1074, the German court stated that the examination of whether a means is objec-
tively equivalent must also be determined in orientation to the patent claim lan-
guage. The headnote explains that an inquiry is necessary, which considers not only 
the final result of the problem solution to be equally effective, but also all characte-
ristics that are involved in the problem solution process. Thus, the skilled person 
must be able to predict each single element of such a process. With regard to numer-
ic measurements, the application of this rule results in that the person skilled in the 
art must be able to obtain not only equal results by using a modified numeric term, 
but also exactly the same result as is claimed. 1075   
Finally, the second question of the Cutting Blade I decision (“whether the person 
skilled in the art is able to use his specialist knowledge to identify the modified 
means as having the same effect”) is considered. It simply asks whether the person 
skilled in the art is able to find modified means that gives rise to the same effects.1076 
Altogether, the legal treatment of figures and measurements establishes a standard 
for equivalents, which is significantly stricter than earlier applied approaches. 1077 In 
earlier decisions, it had been sufficient for a substance patent to cover equally effec-
tive variants, provided a person skilled in the art could easily have predicted them to 
be equally effective as the original protein by reading the patent as a whole. 
bb) Transfer of the case law related to figures and measurements to the field of 3-D 
protein structures inventions  
Is the recent German case law concerning the doctrine of equivalents applicable to 
protein inventions? Some have complained that infringement under equivalents 
would per se be contradictory to the concept of absolute product protection. Accord-
ing to Benkard/Scharen, the use of the doctrine of equivalents for the extension of 
 
1073   Meier-Beck, Peter, The Scope of Patent Protection - The test for Determining Equivalents, 
36 IIC 339, 343 (2005). 
1074   BGH, 33 IIC 349 (2002) – Roasting Pots (Bratgeschirr). 
1075   Meier-Beck, Peter, Aktuelle Fragen der Schutzbereichsbestimmung im deutschen und euro-
päischen Patentrecht, GRUR 2003, 905, 908. 
1076   BGH, 33 IIC 873, 875 (2002) – Cutting Blade I (Schneidmesser I); Meier-Beck, Peter, Aktu-
elle Fragen der Schutzbereichsbestimmung im deutschen und europäischen Patentrecht, 
GRUR 2003, 905, 908; Busse/Keukenschrijver, PatG, § 14, No. 43. 
1077   Benkard/Scharen, Patentgesetz, § 14 No. 67. Earlier decisions understood figures and mea-
surements as a mere exemplary determination of the claimed technical teaching, see  RGZ 
86, 412, 416; RG GRUR 28, 481.  
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scope of absolute product patents seems impossible. He asserts that abstract, equally 
effective results can only be achieved by identical substances. Yet, no chemical sub-
stance can be equivalent to another chemical substance. 1078 The determination of 
equivalents at least requires one category in which two means/substances are equally 
effective. With substances lacking such category, opponents allege that they cannot 
establish any equivalents.1079  
These arguments, however, are not persuasive in light of European Directive 
98/44/EC, pursuant to which every genetic sequence must indicate its function, e.g., 
the encoded protein and the effect the protein is providing.1080 This principle was 
incorporated into the EPC. Pursuant to Implementing Regulation to the EPC, Rule 
43 (former Rule 29), “the industrial application of a sequence or a partial sequence 
of a gene must be disclosed in the patent application.” 
Accordingly, protein inventions typically disclose a function. They not only indi-
cate the essential properties, which are responsible for certain functions, but also de-
termine the structural features that result in similar or equal groups of protein do-
mains and active centres.  Thus, with such equally effective category being pro-
vided, infringement under the doctrine of equivalents is possible.1081  
But, how are the principles set forth in Cutting Blade I related to the initial ques-
tion of whether a patent can be extended to sequence-dissimilar proteins sharing 
common folds and effects? As reported above, in addition to the requirement that the 
modified means must be objectively equivalent (Cutting Blade-question No. 1) and 
predictable for persons skilled in the art (Cutting Blade-question No. 2), the different 
embodiment that is accomplished with modified means must be equivalent to the 
solution in question (Cutting Blade-question No. 3).1082 With regard to the last, the 
proteins’ underlying biological function is considered a technical effect that is ac-
complished by an equivalent embodiment - the same folding type. This folding type 
must be covered by the semantic meaning of the original patent. Hence, the original 
patent must indicate the characteristic properties, such as core folding residues that 
are responsible for the cause of function. A skilled person must then be able to rely 
upon this information and to classify the folding type to which a claimed protein be-
longs. Due to the provided information, the skilled person must be able to under-
stand which of the disclosed properties are responsible for the biological function. 
Folding types bearing same effects due to the same binding or inhibitor activities are 
 
1078   Benkard/Scharen, Patentgesetz, § 14, No. 55; also, Lederer, Franz, Equivalents of Chemical 
Product Patents, 3 IIC 275, 275 (1999). 
1079   Hirsch, Fritjoff/Hansen, Bernd, Der Schutz von Chemie-Erfindungen, Weinheim, New York, 
Basel, Camebridge, Tokyo 1995, 293.  
1080   Directive 98/44/EC states: “Whereas a mere DNA sequence without indication of a function 
does not contain any technical information and is therefore not a patentable invention.” 
1081   BGH, GRUR 1984, 425 – Bierklärmittel; Lederer, Franz, Equivalents of Chemical Product 
Patents, 30 IIC 275 (1999) or Meyer-Dulheuer, K.-H., Der Schutzbereich von auf Nucleotid- 
oder Aminosäurensequenzen gerichteten biotechnologischen Patenten, GRUR 2000, 179, 
182. 
1082   Chapter 4 C IV 3 b) aa).  
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considered equivalents. If different residues or other decisive folding aspects are re-
sponsible for the same/similar effects or functions, they lack a relationship to the 
original protein and thus do not suffice. In sum, an analysis based on the Cutting 
Blade  inquiry demands a thorough examination that resembles the standards re-
quired by the ‘function-way-result’ method. Both patent law systems are in this con-
text comparable. 
Does the German approach allow that patent claims extend to unforeseeable tech-
nologies under the doctrine of equivalents? Are as yet unidentified tertiary structures 
bearing the same functions/effects as the earlier patented protein encompassed by 
the original patent claim? This question had been already asked with regard to the 
discussed-above U.S. patent law system. Thus, it is necessary to ask whether patent 
claims can be interpreted broadly enough to encompass new technologies achieving 
same effects. Here, much depends on the second Cutting Blade question, asking 
whether a skilled person is able to identify the modified means having the same ef-
fects. As set forth in the introduction, the German Patent law system determines 
equivalents at the time of priority.1083 It follows that new technologies, i.e., yet un-
known means, would not be covered by earlier issued patents, since a person skilled 
in the art at the time of priority is not able to foresee later-arising ways to achieve 
same functions. The German law, however, allows that the skilled person (who was 
able to identify a modified means at the time of priority) relies on his earlier aware-
ness if the identified means in the future is replaced by a new technology that was 
still unknown at the time of priority.1084 Hence, claims are interpreted sufficiently 
broadly to encompass new techniques if the newly developed means replace the ear-
lier means that had been predictable for the person skilled in the art. Insofar the 
German patent law that in principle determines equivalency at the time of priority 
comes to the same conclusion as the U.S. law that evaluates equivalency at the time 
of infringement. A more restrictive approach, however, has been employed in anoth-
er European country. In the already mentioned Amgen v. TKT case, the English 
House of Lords denied equivalents with regard to TKT’s new method for manufac-
turing DNA by gene activation.1085 Amgen used an exogenous DNA sequence 
coding for ‘‘Epo’’ which has been introduced into an host cell, wheras TKT was able 
to achieve the same results by an endogenous DNA sequence coding for ‘‘Epo’’ in a 
human cell into which an exogenous control sequence has been inserted.1086 Amgen 
argued that its claims must be construed in terms sufficiently general to include me-
 
1083   See Chapter 4 B II b); Benkard/Scharen, GPA, § 14 , No. 111.  
1084   Benkard/Scharen, GPA, § 14 , No. 113, 117; Kraßer, Rudolf, Patentrecht: ein Lehr- und 
Handbuch zum deutschen Patent- und Gebrauchsmusterrecht, europäischen und internationa-
len Patentrecht, 5. Aufl., München 2004, 753; Falck, Kurt von, Zur Äquivalenzprüfung bei 
im Prioritätszeitpunk noch unbekannten Ersatzmitteln, GRUR 2001, 905, 907; according to 
Tilmann, Winfried/Dagg, Nicola, EU-Patentrechtsharmonisierung I: Schutzumfang, 2000, 
459, 465, determination of equivalents is made at the time of infringement.  
1085   Kirin-Amgen Inc. and others v Hoechst Marion Roussel Ltd and others, [2005] R.P.C. 9 
(House of Lords 2004). 
1086   For the detailed factual background see Chapter 3 A II 3 b) a). 
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thods unknown at the priority date to cover new technologies for achieving same re-
sults. Thus, the claim should be read as including any DNA sequence, whether ex-
ogenous or endogenous, which expresses ‘Epo’ in consequence of the application to 
the cell of any form of DNA recombinant technology.1087 Lord Hoffman, for the 
House of Lords, denied such an expansion of the words of the claims under the doc-
trine of equivalents. The judge emphasized that “there is no difficulty in principle 
about construing general terms to include embodiments which were unknown at the 
time the [patent] was written”. However, a claim must be properly construed “in a 
way which was sufficiently general to include the new technology”.1088 In this re-
spect, Lord Hoffmann explained: 
“’Purposive construction’ does not mean that one is extending or going beyond the definition 
of the technical matter for which the patentee seeks protection in the claims. The question is 
always what the person skilled in the art would have understood the patentee to be using the 
language of the claim to mean... There will be occasions upon which it will be obvious to the 
skilled man that the patentee must in some respect have departed from conventional use of 
language or included in his description of the invention some element which he did not mean 
to be essential. But one would not expect that to happen very often.”1089 
Thus, the House of Lords precluded any protection of equivalents beyond the “pur-
posive interpretation” of a patented invention. Nevertheless, the rationale demon-
strates that it is not per se impossible to claim yet unknown technologies. In the dis-
pute, Amgen would have been aware that recombinant technologies were develop-
ing rapidly and that new approaches had been achieved in bacterial and yeast cells 
and that their use in mammalian cells was regarded a desired goal. Thus, it would 
have been able to rely upon equivalents if it had drafted claims broadly enough to 
indicate a person skilled in the art that new developments of manufacturing recom-
binant ‘‘Epo’’ were included.1090  
Notwithstanding this general possibility of claiming new technologies, the U.K. 
formulation differs sharply from the U.S. approach. Here, the skilled person can rely 
upon the knowledge that exists at the time of infringement.1091 Consequently, he is 
allowed to consider developments that were yet unknown in the time of priority. The 
U.S. concept is thus significantly broader than the British one. Further developments 
must demonstrate whether other European countries, such as Germany, will follow 
the British example. In the meantime, a high level of uncertainty surrounds the ap-
plication of the doctrine of equivalents for new techniques that achieve the same re-
sults as earlier claimed inventions. With regard to the initial question of the treat-
ment of sequence-dissimilar proteins achieving the same effects as earlier claimed 
 
1087   Kirin-Amgen Inc. and others v Hoechst Marion Roussel Ltd and others [2005] RPC 9, No. 2. 
1088   Kirin-Amgen Inc. and others v Hoechst Marion Roussel Ltd and others [2005] RPC 9, No. 
80 
1089   Kirin-Amgen Inc. and others v Hoechst Marion Roussel Ltd and others [2005] RPC 9, No. 
34.  
1090   Kirin-Amgen Inc. and others v Hoechst Marion Roussel Ltd and others [2005] RPC 9, No. 
78.  
1091   Warner-Jenkinson, 520 U.S. 17, 37.  
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proteins, it is thus still uncertain what courts will demand that patentees include in 
the patent involving the original protein.   
c) Conclusions 
Under the U.S. patent law system, the ‘function-way-result’ method is considered an 
adequate means for determining equivalents. A sequence-dissimilar protein can be 
considered to satisfy the ‘way’-prong of this ‘triple-identity’ – inquiry, while a pro-
tein bearing a different fold must be considered to accomplish the function a differ-
ent ‘way’. It is further appropriate to require patentees to generate precise structural 
information, because the state of the art in protein science has significantly im-
proved due to advanced functional proteomic analysis. In particular, methods capa-
ble of accomplishing in-depth protein structure determination have been developed. 
An expansion of claim coverage to as yet unidentified sequence-dissimilar proteins 
sharing common folding properties and effects is not limited. Prosecution history 
estoppel does not bar patentees. The flexible bar rule allows inventors to claim equi-
valents for elements that have been unforeseeable at the time of the amendment. 
Furthermore, generic disclosure in the patent specification, such as the indication of 
3-D folding characteristics does not automatically result in a dedication of all mem-
bers of the particular genus to the public. It is, however, necessary to disclose the 
genus in a manner that would suggest the disclaimer of alternative, as yet unknown 
species.  
Unlike the U.S. approach, German patent law does not address the question of 
equivalents on a case-by-case basis, although the established and generalized prin-
ciples are derived from case law related to figures and measurements. In sum, these 
principles require a theoretical analysis under Art. 69 EPC to determine whether the 
use of protein variants has the same effect as the patented technical teaching. The 
decisive element of the ‘Cutting Blade-questions’ discussed above is the presence of 
a technical effect that must be identical and predictable for a person skilled in the 
art.1092 The folding type is considered the modified means that is responsible for the 
biological effect, or, in other words, the proteins’ function. A patentee must there-
fore include the properties responsible for the conduct of function, thus binding or 
inhibiting residues. A skilled person must rely upon this information and be able to 
predict which proteins belong to the same folding type due to similar properties that 
cause like/similar folding types. The examination required for the reasons set forth 
above significantly resembles the function-way-result approach conducted under the 
U.S. patent law system.  
Although the German patent law system determines equivalency at the time of 
priority, it allows claims to be equivalently expanded to later-arising technologies, 
 
1092   Meier-Beck, Peter, The Scope of Patent Protection - The test for Determining Equivalents, 
36 IIC 339, 342 (2005); Kirin-Amgen Inc v. Hoechst Marion Roussel, [2005] R.P.C. 9, 2004 
WL 2330204, Section 75. 
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such as yet unidentified sequence-dissimilar proteins bearing the same functions. A 
person skilled in the art must be able to replace the means that had been predictable 
at the priority date by the later-developed new technology. Like in the U.S., the de-
cision upon equivalents is consequently made in light of later disclosed knowledge. 
Despite of the broad German approach, the U.K. in the recent TKT decision em-
ploys a more restrictive method of determining equivalents. The U.K. formulation 
precludes any protection of equivalents that is beyond the “purposive interpreta-
tion”. If this approach is followed by other European countries, the possibility of ex-
panding claims by reliance upon equivalency is significantly narrowed.  
In sum, the above analysis shows that the doctrine of equivalents might clearly be 
available in some cases related to proteins that share common folding types.1093 
Nevertheless, difficulties do arise with regard to the prediction of whether equiva-
lents can be established. In the U.S., the function-way-result method requires paten-
tees to include substantial knowledge regarding the 3-D protein structure into the 
patents. If this information is included in the claim language, narrowing amend-
ments during the application procedure might be necessary. Consequently, prosecu-
tion history estoppel might bar inventors from reliance upon equivalents subject to 
already-known proteins. If the information related to 3-D structure is indicated in the 
patent specification rather than in the claims, patentees risk dedication of their 
knowledge to the public. Then, a reliance upon equivalents is barred by the public-
dedication rule, unless the 3-D structural information for specific proteins, such as 
unidentified ones, is explicitly disclaimed. 
In Germany, the necessary theoretical inquiry derived from the case law related to 
figures and measurements requires the presence of a technical effect. A person 
skilled in the art must then rely upon a step-by-step description in the claim lan-
guage and evaluate whether the potentially infringed embodiment is entirely present 
in the competitive product. The equivalent determination of a tertiary folding type, 
however, introduces a significant level of complexity which may overwhelms courts 
and patent examiners. Consequently, it is difficult to predict to which extend the de-
termination of equivalents regarding protein folds is already understood by the per-
son skilled in the art.1094 Furthermore, the U.K. formulation of equivalents, i.e., the 
requirement to draft claims sufficiently general that persons skilled in the art under-
stand the inclusion of a new technology challenges inventors to foresee what will be 
invented in the future. From this restrictive perspective, and the overall uncertainty 
 
1093   Holman, Christopher M., Protein similarity score: a simplified version of the blast score as a 
superior alternative to percent identity for claiming genuses of related protein sequences, 21 
Santa Clara Computer & High Tech. L.J. 2004, 55, 61.  
1094   Bergen-Babinecz, Katja/Hinrichs, Nikolaus/Jung, Roland/Kolb, Georg, Zum Schutzbereich 
von US-Patenten: Festo und eine deutsche Sicht, GRURInt. 2003, 487, 487 citing Judge Mi-
chel from the CAFC who emphasizes the high level of uncertainty surrounding the doctrine 
of equivalents. 
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surrounding this area of the law, the inventor should, to the extent possible, seek 
broad literal coverage rather then rely upon the doctrine of equivalents.1095  
 V. U.S. Patent No. 5,835,382 “Small Molecule Mimetics of Erythropoietin”1096: 
A characteristic proteomic patent  
A number of cases involving the filing of patents involving protein crystal structure 
determination have been described. Furthermore, the case study illustrated further 
claims related to proteomic research, among them claims to 3-D structural data di-
rected towards the use of structural data in rational drug design. To substantiate the 
results of these concrete claims, it is useful to consider another patent. Specifically, 
the legal treatment of a patent directed to the screening of erythropoietin (‘‘Epo’’) 
mimetics will be reviewed, since it encompasses a number of characteristics typical 
of proteomic inventions.1097 In particular, it demonstrates an indirect way to claim a 
protein defined by its folding type and may also involve screened sequence-
dissimilar proteins consisting of the same folding type as the ‘‘Epo’’ molecule. The 
invention involves a computer-assisted method for identifying molecules that are 
able to bind to the ‘‘Epo’’ receptor. Due to their structural similarity these ‘‘Epo’’ 
‘mimetics’1098 act in the same fashion as ‘‘Epo’’. In particular, they are capable of 
binding to the ‘‘Epo’’ receptor. Since they display the response usually found in 
‘‘Epo’’, the identified compounds emulate the important functions that are otherwise 
performed by the ‘‘Epo’’ molecule, acting as agonists of the ‘‘Epo’’ receptor. The 
claimed method is conducted on grounds of precise structural information obtained 
from x-ray crystallographic methods of the extracellular domain of ‘‘Epo’’ receptor 
linked to a binding peptide (which acts as an ‘‘Epo’’ mimetic). This crystallographic 
data enables the identification of atoms in the peptide mimetic that are significant 
 
1095   Holman, Christopher M., Protein similarity score: a simplified version of the blast score as a 
superior alternative to percent identity for claiming genuses of related protein sequences, 
Holman, Christopher M., Protein similarity score: a simplified version of the blast score as a 
superior alternative to percent identity for claimng genuses of related protein sequences, 21 
Santa Clara Computer & High Tech. L.J. 2004, 55, 61 who recommends not relying on the 
doctrine in order to expand the claim coverage on protein variants.  
1096   Wilson; Ian A./Livnah; Oded/Stura; Enrico A./Johnson; Dana L./Jolliffe; Linda K., Small 
molecule mimetics of erythropoietin, La Jolla 1998. 
1097   Wilson; Ian A./Livnah; Oded/Stura; Enrico A./Johnson; Dana L./Jolliffe; Linda K., Small 
molecule mimetics of erythropoietin, La Jolla 1998, see also Meyers, T. C./Turano, T. 
A./Greenhalgh, D. A./Waller, P. R., Patent protection for protein structures and databases, 7 
Suppl Nature Structural Biology 2000, 950, 951.  
1098   The term “Mimetics” refers to selected chemical structures similar to the three-dimensional 
structure of the subset of atoms of the the ‘EPO’ peptide, see Meyers, T. C./Turano, T. 
A./Greenhalgh, D. A./Waller, P. R., Patent protection for protein structures and databases, 7 
Suppl Nature Structural Biology 2000, 950, 951.  
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for ‘‘Epo’’ receptor binding. This data includes a 3-D array of the important contact 
atoms.1099  
The written description reveals the tertiary structure of the ‘‘Epo’’ receptor and 
discloses the binding properties of potential ‘‘Epo’’ mimetics. It determines that 
other molecules including a portion in which the atoms have a 3-D structure similar 
to some or all of the ‘‘Epo’’ contact atoms are likely to be capable of acting as an 
‘‘Epo’’ mimetic. The description further discloses that a peptide considerably small-
er than the natural ‘‘Epo’’ can act as an agonist and induce an adequate biological 
response. Thereby, it is assumed that the binding peptide forms a substantially 
smaller contact interface than the natural ‘‘Epo’’ with the receptor. The description 
also concludes that the identification of the most crucial residues and functional key 
interactions provides a practical target for drug design.1100  
To get a better sense of what is exactly claimed, it is useful to reproduce excerpts 
of the actual specification. It reads as follows:  
1. A computer-assisted method for identifying potential mimetics of erythropoietin, using a 
programmed computer comprising a processor, a data storage system, an input device, and 
an output device, comprising the steps of:  
 (a) to ... (d) 
2. A computer-assisted method for identifying potential mimetics of erythropoietin, using a 
programmed computer comprising a processor, a data storage system, an input device, and 
an output device, comprising the steps of:  
 (a) to ... (c)  
3. A compound having a chemical structure selected using the method of claim 1, said com-
pound being an ‘Epo’ mimetic.  
4. ...1101 
5. The compound of claim 3 wherein said compound is a peptide.  
6. The compound of claim 5 wherein said peptide has 15 of fewer amino acids. 1102 
The patent includes various aspects that are remarkable in light of the discussion 
above. With regard to the demonstrated invention involving a natural ‘‘Epo’’ prod-
uct, it must be distinguished, because it is not directed to the purification of natural 
‘‘Epo’’, but rather to its replacement through a different protein. The underlying mo-
tivation of the inventors, however, might be similar; both methods may enable drug 
design independent of recombinantly obtained ‘‘Epo’’ molecules. The former me-
thod obtains the ‘‘Epo’’ molecule from urine, plasma or other substances; the latter 
 
1099   Wilson; Ian A./Livnah; Oded/Stura; Enrico A./Johnson; Dana L./Jolliffe; Linda K., Small 
molecule mimetics of erythropoietin, La Jolla 1998. 
1100   Wilson; Ian A./Livnah; Oded/Stura; Enrico A./Johnson; Dana L./Jolliffe; Linda K., Small 
molecule mimetics of erythropoietin, La Jolla 1998. 
1101   Claim 4 referred to non-peptide molecules that are not subject of this analysis.  
1102   Wilson; Ian A./Livnah; Oded/Stura; Enrico A./Johnson; Dana L./Jolliffe; Linda K., Small 
molecule mimetics of erythropoietin, La Jolla 1998.  
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is directed to the identification of ‘Epo’ mimetics that equally perform the natural 
‘‘Epo’’ functions.1103  
As to the question of dependency, it is relevant that the computerized data related 
to the ‘‘Epo’’ receptor has been obtained on grounds of recombinant technologies 
and associated crystallizing methods not encoding ‘‘Epo’’ itself, but rather the 
membrane receptor protein to which ‘‘Epo’’ binds. High relevance is established 
with regard to the question of whether dissimilar proteins bearing structural similari-
ties and function infringe earlier issued patents. From the perspective of inventors 
holding patents to the original ‘‘Epo’’, the claimed ‘‘Epo’’ mimetics might represent 
a case of sequence-dissimilar proteins having equal/similar folding features and 
functions as the native ‘‘Epo’’. It is also worth noting that the question of ‘reach-
through claiming’ is not raised. Potentially screened ‘‘Epo’’ mimetics are precisely 
defined by size and shape. The patent description thus provides sufficient informa-
tion for matching the enablement requirement. 
In terms of scope of protection issues, it is clear that anyone who uses the coordi-
nates to identify structures similar to the specified peptide may be an infringer and 
consequently may be liable for damages and prohibited from using this method to 
find ‘‘Epo’’ mimetics. As for patent dependency and infringement of other patents, 
the following rules can be established. First, the computerized method stimulates the 
‘‘Epo’’ receptor rather than the ‘‘Epo’’ molecule itself. Hence, no patent dependen-
cy exists with regard to inventions involving the natural or the recombinantly ob-
tained ‘‘Epo’’. Second, the structural data referring to the ‘‘Epo’’ receptor relies on 
recombinantly produced molecules and crystallographic analysis. Therefore, patent 
dependency with regard to potential patents covering these crystallizations methods 
is established. Additionally, patents involving the recombinant production of ‘‘Epo’’ 
receptors are infringed. Patents for recombinantly obtained ‘‘Epo’’ molecules are 
not infringed unless the patent owner includes structural knowledge as to the crucial 
binding residues and core interaction features, i.e., atoms. In this event, the patent is 
extended to the ‘‘Epo’’ mimetic molecule determined by this information pursuant 
to the doctrine of equivalents.   
The patent demonstrates the great significance of the above conducted discussion 
on infringement through the use of sequence-dissimilar proteins or other non-
patented molecules. In order to ‘invent around’ existing patents, inventors search for 
proteins that are not yet patented but able to perform similar biological functions. 
Attempts to find alternatives for patented compound occur also in the field of prion 
research. For example, U.S. Patent 5,773,572, entitled “Fragments of prion pro-
teins”, concerns synthetic polypeptides that emulate the 3-D structures of proteins 
involved in mental prion disorders.1104  
 
1103   Wilson; Ian A./Livnah; Oded/Stura; Enrico A./Johnson; Dana L./Jolliffe; Linda K., Small 
molecule mimetics of erythropoietin, La Jolla 1998 
1104   U.S. Patent 5,773,572 “Fragments of prion proteins” by Fishleigh, Robert Vincent/Robson, 
Barry/Mee, Roger Paul, Macclesfield 1998. 
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VI. Use of selective 3-D protein structure parts (Selection inventions) 
1. Relationship to patents covering the entire protein 
With regard to a selection invention, it is primarily the dependency on the patent that 
covers the entire protein that has to be considered. Hence, the patent to the genetic 
sequence is only involved if the entire protein is part of a patented recombinant 
process. A potential claim to a selective part of a protein has already been analyzed 
in the case study above,1105 but shall be introduced again, reading as follows:  
An isolated and purified polypeptide consisting of a portion of protein P starting at one of 
amino acids 214 to 218 and ending at one of amino acids 394 to 401 of protein P as set forth in 
SEQ ID NO: 1.1106   
As introduced above, “selection inventions” claim a narrow range within a broad 
scope disclosed by the prior art. 1107Besides determining the “obviousness” of a 
claim to a selective field of a broader invention, the question of patent dependency is 
a decisive element of selection inventions. For classification of the problem, the 
same principles are applied as those used for the treatment of “improvement inven-
tions”. Developments of improved versions of drugs are not necessarily directed to a 
selective part of the earlier invention, but can also cover additional aspects or the 
broadening of the earlier version. Generally the term “improvement” is used as an 
“umbrella term” and also includes the cases in which one “invents around” an exist-
ing invention, e.g. attempts to advance the existing technique by using different 
compounds or facilities without touching the scope of the existing patent.1108 With 
the high standard of the “obviousness” factor developed in the field of “selection in-
ventions”, the inventive step requirement, however, always includes an improve-
ment over the earlier invention, and the prior art, respectively. Thus, even though 
not all improvements of a drug produce selectivity, each selective invention can be 
considered as improvement. The same protein can be used in an improved manner 
due to the disclosure made with regard to the binding pockets. Generally, patent law 
does not vest in the original patent holder any right to improvements or derivative 
inventions and new patents can be granted for the selective part if all other require-
ments are met. In most cases, the selective patent is “blocked” by the original patent 
holder, meaning that the selection invention cannot be used without a license from 
the original patent holder whose technology has been incorporated into the improved 
 
1105   Chapter 3 B II 2 a).  
1106   European Patent Office, Japan Patent Office, United States Patent and Trademark Office, 
Trilateral Project WM4, Comparative Studies in New Technologies (Biotechnology, Busi-
ness Methods, etc.), Report on Comparative Study on Protein 3-Dimensional (3-D) Structure 
Related Claims, Vienna 2002, 9. 
1107   Chapter 3 B II 2 d).  
1108   Dow, Kenneth J./Quigley, Traci Dreher, Improvements for handling improvement clauses in 
IP licenses: an analytical framework, 20 Santa Clara Computer & High Tech. L.J. 2004, 577, 
580-581. 
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entity.1109 Likewise, the original patent holder is blocked from using the selection 
invention. Hence, at least one of the patent owners needs a license from the other in 
order to use the invention. With the threat of mutual patent blocking, it might be ad-
visable for both patent holders to determine the details of patent use by negotiated 
agreement.1110  
As for a selection invention, concerns and objectives of both the owner of the 
broader, and the owner of the narrow, patent are relatively clear. Typically, the pa-
tentee of a selection invention involving a protein domain is interested in producing 
the protein in a recombinant fashion. Even though his invention may have been de-
veloped without the use of a recombinant process, e.g., by determining the binding 
pockets through protein crystallization or in silico screening methods, in most cases 
a large amount of highly purified proteins is required in order to exercise his inven-
tion. Thus, he needs to license the use of a recombinant process. If the owner of the 
recombinant process is interested in using the improvements of the selective parts, 
cross licensing can be considered. The particular negotiation and defining of im-
provement clauses is generally a difficult task.1111 In the case of a selection inven-
tion, however, it is still relatively easy. As the improvement must consist of the 
properties of a selective part of the earlier invention, the improvement clause has to 
cover all cases in which the use of the improved product was based on selective 
properties or the earlier patented product. 
In the cases in which the improvement is not related to any selective part, but in-
stead to aspects such as other compounds used or protein analogs or variants being 
developed, licensing clauses might create considerable difficulties. The concerns and 
objectives of both parties may be quite divergent. For example, a licensor who de-
veloped a specific product or process and plans to continue the advancement of this 
technology may not wish his improvement to automatically be subsumed within his 
original agreement with the licensee. On the other hand, the licensee might be con-
cerned about the restrictions that are conveyed by the improvement clause, such as 
typically used obligations, regarding the further exploitation of the improvements. 
The definition of the term “improvements” is thus an essential element and existing 
case law still leaves many questions unanswered. In Deering Milliken, the court held 
that a clear definition of what is considered as an improvement requires “clear, deli-
berate, and appropriate language”.1112  
 
1109   Dow, Kenneth J./Quigley, Traci Dreher, Improvements for handling improvement clauses in 
IP licenses: an analytical framework, 20 Santa Clara Computer & High Tech. L.J. 2004, 577, 
581. 
1110   Dow, Kenneth J./Quigley, Traci Dreher, Improvements for handling improvement clauses in 
IP licenses: an analytical framework, 20 Santa Clara Computer & High Tech. L.J. 2004, 577, 
581. 
1111   Brunsvold Brian G./O’Reilley, Dennis P., Drafting Patent License Agreements, 5th ed. 
Washington D.C. 2004, 99.  
1112   Deering-Milliken Research Corp. v. Leesona Corp., 201 F. Supp. 776 (E.D.N.Y. 1962), aff'd 
315 F.2d 475 (2d Cir. 1963).  
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2. The Amgen case   
The importance of improvement clauses and their interpretation is illustrated by the 
Amgen case.1113 Amgen, a newly founded biotechnology firm, owned two promising 
drugs, Epogen and Neupogen. Faced with financial problems, the firm did not have 
sufficient funding to develop the two pharmaceuticals. Due to this pressure, Amgen 
created the following deal with Ortho Pharmaceuticals. In exchange for a much 
needed credit of $ 10 million dollars, Amgen conveyed Ortho exclusive worldwide 
rights to sell ‘‘Epo’’ while retaining its own rights to sell ‘‘Epo’’ for the kidney di-
alysis market in the U.S. The deal proved to be a lifesaver for Amgen, but also made 
the company lose more than two-thirds of the market for its Epogen drug.1114 A 
couple of years later, Amgen developed a new-improved version of “Epo”, a hyper-
glycosylated analog of ‘‘Epo’’ known as NESP. Amgen alleged the drug to have the 
advantage of a three-fold longer half-life than the original ‘‘Epo’’, resulting in less 
frequent dosing.1115 In order to gain access to the lucrative worldwide non-dialysis 
market that was estimated to amount to at least 1.35 billion in 1998, Amgen argued 
that NESP was not covered by the 1985 license agreement with Ortho. Ortho coun-
tered that NESP was an improvement covered by the agreement to which it had ex-
clusive rights outside the dialysis market. The arbitration panel, which took over the 
case, finally decided that Amgen had exclusive rights to NESP and that the new ana-
log could not be considered as an improvement covered by the elaborated license. 
The ruling not only resulted in giving Amgen access to the lucrative market for 
‘‘Epo’’, but also raised Amgen’s shareholder value more than 23%.1116 The case 
helped Amgen to develop into one of the world’s largest biotechnology firms.1117 
3. Applicable law 
With regard to selection inventions, little difference exists between the U.S. and Eu-
rope. As for the European system, the principles applying to a selection invention 
have already been described above.1118 Novelty presupposes that the selected sub-
field is narrow, that it contains sufficient distance to the known range illustrated by 
 
1113   A detailed description of the case can be found in Fürst, Ingeborg, Amgen's NESP victory 
cuts out Johnson & Johnson, 17 Nature Biotechnology 1999, 124, 124; see also Straus, Jo-
seph, Genpatente: rechtliche, ethische, wissenschafts- und entwicklungspolitische Fragen, 
Basel, Frankfurt/Main 1997, 50. 
1114   Dow, Kenneth J. /Quigley, Traci Dreher, Improvements for handling improvement clauses in 
IP licenses: an analytical framework, 20 Santa Clara Computer & High Tech. L.J. 2004, 577, 
578.  
1115   Dow, Kenneth J. /Quigley, Traci Dreher, Improvements for handling improvement clauses in 
IP licenses: an analytical framework, 20 Santa Clara Computer & High Tech. L.J. 2004, 577, 
578.  
1116  Fürst, Ingeborg, Amgen's NESP victory cuts out Johnson & Johnson, 17 Nature Biotechnolo-
gy 1999, 124, 124. 
1117  See Amgens’ home page available at http://www.amgen.com/, last checked on January 21, 
2008.  
1118  Chapter 3 B II 2 d).  
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working examples, that it is not randomly selected, but is the result of a more 
tightly-focused selection and that it provides not only an embodiment of the prior art 
description, but also a further invention.1119 Nonobviousness/inventive step require 
an outstanding effect, property, or use when compared with compounds in the 
known generic invention.1120 Under both systems, European and the U.S., a patent 
involving a selection invention always depends on earlier issued patents covering 
the entire subject. Consequently, the use of a patent to a selective protein part auto-
matically infringes the patent directed to the entire protein.1121  
With regard to general improvement patents, the crucial question is whether the 
skilled person was able to predict the improved technology. This is questionable, if 
the considerations leading the skilled person are based on inventive activity.1122 One 
receives a patent based on inventive activity, provided that all further patentability 
requirements are fulfilled. The scope of protection of earlier issued patents might 
then equivalently expand to the new technology and create dependency. In this 
event, the later-issued patent will depend on the earlier issued patent. The two Ger-
man Federal Supreme Court’s decisions Fixing Device II1123 and Segmentation De-
vice for Trees1124 have provided rulings on the subject. The first impression is that 
both rulings appear contradictory. In Fixing Device II, the court stated that: 
 [t]he scope of protection of a patent can also include such embodiments that make use of the 
protected teaching while also implementing an inventive further realization; it is then a de-
pendent invention.1125 
Headnote No.1 of the decision Segmentation Device for Trees by contrast deter-
mines that: 
“The extent of protection of a patent according to Sec. 14 of the Patent Act 1981 is in any 
event no greater than the extent of protection of a patent according to the previously applicable 
law. It does not comprise equivalent derivations based on an inventive step.”1126 
Hence, any inventive further realization that uses the technical teaching of the pa-
tented invention results in an infringing act, but an equivalent derivation based on 
an inventive step does not. Accordingly, it is of the essence as to whether the con-
tested embodiment uses and further develops the patented invention or whether it is 
 
1119   Blumer, Fritz, Formulierung und Änderung der Patentansprüche im europäischen Patent-
recht, München 1998, 345.  
1120   Blumer, Fritz, Formulierung und Änderung der Patentansprüche im europäischen Patent-
recht, München 1998, 358.  
1121   Meyers, T. C./Turano, T. A./Greenhalgh, D. A./Waller, P. R., Patent protection for protein 
structures and databases, 7 Suppl Nature Structural Biology 2000, 950, 951. The previously 
issued patent to the entire molecule may thus also be referred to as the dominant patent.  
1122   Kraßer, Rudolf, Äquivalenz und Abhängigkeit im Patentrecht, Tübingen 1998, 516, 527. 
1123   BGH, 23 IIC 111(1992) - Fixing Device II (Befestigungsvorrichtung II).  
1124   BGH, 26 IIC 261 (1995) - Segmentation Device for Trees (Zerlegevorrichtung für Baum-
stämme). 
1125   BGH, 23 IIC 111 (1992) - Fixing Device II  (Befestigungsvorrichtung II). 
1126   BGH, 26 IIC 261, 261 (1995) - Segmentation Device for Trees (Zerlegevorrichtung für 
Baumstämme). 
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inventively derived. The invention involved in Fixing Device II, by contrast, only 
involved a further development, since the general concept of the invention was used 
only in a slightly different way.1127 In contrast, Segmentation Device for Trees dealt 
with the question of equivalent derivation based on an inventive step.1128 The court 
emphasized the importance of the principle of legal certainty which de facto results 
in a limitation of the scope of protection. Further developments that have been made 
on grounds of inventive activity of third parties should not be interpreted as having 
been encompassed by the original claim language. The patent owner does not profit 
from the work done by others. 1129 In this respect, the court referred to principles es-
tablished by the German Federal Supreme Court, namely, that no motivation exists 
for society to grant protection to an inventor if he has not provided any specific and 
clearly determined mental activity.1130 Hence, neither the German Patent Act nor 
constitutional principles can justify an extension of the scope of protection to an 
equivalent derivate based on an inventive step that goes further than the patented in-
vention.  
None of these decisions, however, specified how the inventive activity should 
precisely be determined. This missing explanation caused wide-ranging discussions 
in the literature. General interpretations concluded that it is not contradictory to as-
sume the contested embodiment to be inventive and equivalent at the same time. 
With the patenting of the contested embodiment and the infringement of the patent 
not ruling each other out, the mere fact that a patent has been granted for the con-
tested embodiment does not by itself disprove equivalents.1131 
The decision Snow Removal Blade1132, which dealt with the different embodi-
ments of a snow-crawler bar, brought more clarity to this question. Here, the court 
distinguished between two different kinds of properties an invention may contain: 
substituted properties and properties that improve an earlier invention through the 
addition of further elements. In the event that the substituted property exclusively 
establishes inventiveness, equivalents must be denied, since a person skilled in the 
art would not have been able to predict the equal effectiveness.1133 This rule does not 
apply in the event that an invention is improved though the addition of further ele-
ments/characteristics. In such a case, the principles developed in Fixing Device II 
 
1127   BGH 23 IIC 111(1992) - Fixing Device II (Befestigungsvorrichtung II ). 
1128   BGH, 26 IIC 261, 266 (1995) - Segmentation Device for Trees (Zerlegevorrichtung für 
Baumstämme). 
1129   BGH, 26 IIC 261, 266 (1995) - Segmentation Device for Trees (Zerlegevorrichtung für 
Baumstämme). 
1130   BGH, 26 IIC 261, 267 (1995) - Zerlegevorrichtung für Baumstämme (Segementation Device 
For Trees).  
1131   Meier-Beck, Peter, The Latest Issues in German Patent Infringment Proceedings, 32 IIC 505, 
516 (2001). 
1132   BGH, 33 IIC 525 (2002) – Snow Removal Blade (Räumschild). 
1133   BGH, 33 IIC 525, 531 (2002) – Snow Removal Blade (Räumschild). 
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continue to be applicable, which results in the conclusion that the contested embo-
diment falls within the equivalent scope of the earlier granted patent.1134  
The questions of equivalency and improvement exist under U.S. law as well.1135  
In Varco L. P. v. Pason,1136 the question was whether Varco's claim to an automatic 
drilling system covered the electronic drilling system later developed by Pason.1137  
Varco alleged that “it first developed an automatic drilling system that uses multiple 
parameters to regulate the release of the drill string”, which is why its patent also 
covered the electronic system operated by Pason.1138 The Federal Circuit found the 
interpretation of claims by the district court, which had denied infringement, to be 
“unduly restrictive.”1139  The court determined that “because this case seems to 
present an instance of after-arising technology (e.g., improvements on prior innova-
tions), the district court may find it appropriate to consider infringement under the 
doctrine of equivalents.” 1140 
As under German law, a distinction between improvements that add to the initial 
patent claim elements and those that substitute for those elements must be made.1141 
Only the latter raises the above discussed problem as to whether equivalency can be 
found if an ordinary person skilled in the art involves inventive activity in his as-
sumptions. The earlier described Warner-Jenkinson decision avoids the question by 
clearly establishing equivalency as of the date of infringement.1142 If equivalency is 
determined at the time of infringement, the inquiry is made in light of later (post-
 
1134   BGH, 33 IIC 525, 532 (2002) – Snow Removal Blade (Räumschild); Allekotte, Bernd, 
Räumschild - Neuschnee in der Diskussion über Patentverletzung und efinderische Tätigkeit, 
GRUR 2002, 472, 475. 
1135   Varco L. P. v. Pason, 436 F.3d 1368 (Fed. Cir. 2006), citing the following additional cases: 
Am. Hosp. Supply Corp. v. Travenol Labs., Inc., 745 F.2d 1, 9 (Fed. Cir. 1984) (“An appro-
priate range of equivalents may extend to post-invention advances in the art in an appropriate 
case.”);   Hughes Aircraft Co. v. United States, 86 F.3d 1566, 1584 (Fed. Cir. 1996), re-
manded, 520 U.S. 1183, 117 S.Ct. 1466, 137 L.Ed.2d 680 (1997), aff'd, 140 F.3d 1470, reh'g 
denied, 148 F.3d 1384 (Fed. Cir. 1998), cert. denied, 525 U.S. 1177, 119 S.Ct. 1112, 143 
L.Ed.2d 108 (1999) (stating that an inventor is not required to predict all future develop-
ments that enable the practice of his invention);  SuperGuide Corp. v. DirecTV Enter., Inc., 
358 F.3d 870, 880 (Fed.Cir.2004) (quoting SRI Int'l v. Matsushita Elec. Corp. of Am., 775 
F.2d 1107, 1121 (Fed. Cir. 1985) (en banc )) (“The law ‘does not require that an applicant 
describe in his specification every conceivable and possible future embodiment of his inven-
tion.’ ”);  Smithkline Beecham Corp. v. Excel Pharm., Inc., 356 F.3d 1357, 1364 (Fed. Cir. 
2004) (stating that the “quintessential example of an enforceable equivalent” is “after-
arising” technology); Glaxo Wellcome, Inc. v. Impax Lab. Inc., 356 F.3d 1348, 1354 (Fed. 
Cir. 2004) (also concluding that the “quintessential example of an enforceable equivalent” is 
after-arising technology). 
1136   Varco L. P. v. Pason, 436 F.3d 1368 (Fed. Cir. 2006).  
1137   Varco L. P. v. Pason, 436 F.3d 1368, 1372.  
1138   Varco L. P. v. Pason, 436 F.3d 1368, 1370. 
1139   Varco L. P. v. Pason, 436 F.3d 1368, 1376.  
1140   Varco L. P. v. Pason, 436 F.3d 1368, 1376. 
1141   Sarnoff, Joshua, The Doctrine of Equivalents and Claiming the Future after Festo, 14 The 
Federal Circuit Bar Journal 2004, 403, 410.  
1142   Warner-Jenkinson, 520 U.S. 17, 37.  
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issuance) knowledge.1143 Thus, the improvement may be a non-obvious improve-
ment at its time of filing, and yet equivalent in light of later arising knowledge. Later 
arising knowledge might also cause obviousness of the improvement. 
VI. Use of compounds identified through 3-D protein structure screening methods 
The final question to be analyzed is whether the use of compounds obtained through 
an in-silico screening process infringes the patent that was granted to the screening 
process itself. As a first step, a recent case related to compounds that have been 
identified by a patented method and later been imported into the country where the 
existing patent was originated will be presented. Then, several approaches to the 
protection of identified compound will be examined.  
1. Protection as product of patentable process  
Infringement is constituted if identified compounds can be classified as products of a 
patented process.1144 Under Art. 64 paragraph 2 EPC and § 9 paragraph 2 No. 3 
GPA, a patent to a patented process “shall extend to the product directly obtained by 
such process.” German and other European courts distinguish between patents di-
rected to manufacturing processes or working processes.1145 Manufacturing proc-
esses aim to make a physical product, and the patent to the process extends to such a 
product. In contrast, a working process does not result in a product, but is typically 
conducted for the purpose of achieving an abstract result of an action (“abstrakter 
Handlungserfolg”).1146 A product which is obtained directly from a patented process 
is the product with which the process ends.1147 A compound can still be considered 
 
1143   Sarnoff, Joshua, The Doctrine of Equivalents and Claiming the Future after Festo, 14 The 
Federal Circuit Bar Journal 2004, 403, 410.  
1144   Benkard/Jaenstaed, EPŰ, Art. 64, No. 19; also Clark, Vici, Reach-through infringement: 
what are the limits?, 6 Bio-Science Law Review 2000/2001, 249, 250. 
1145   BGH, 11 IIC 236 (1980) – Color Picture Tubes (Farbbildröhre); Benkard/Jaenstaed, EPŰ, 
Art. 64, No. 24; Benkard/Scharen, Patentgesetz, § 9, No. 53. 
1146    Straus, Joseph, Reach-through claims and research tools as recent issues of patent law in: 
Estudios sobre propiedad industrial e intellectual y derecho de la competencia, Curell Suñol, 
M./et al. (Eds.): Grupo Español de la AIPPI, Barcelona, 2005, 921, 928.  
1147   BGH 8 IIC 147 (1995) – Alkylendiamine I; UK Court of Appeal, 11 IIC 591, 591 (1998)  – 
Pioneer Electronics Capital Inc. v. Warner Music Manufacturing Europe (“Under European 
law, a product obtained directly by means of a patented process is the product with which the 
process ends”). A classification of what is considered “directly obtained” is made based on 
two major approaches, namely the “Chrononological approach” (Chronologischer Ansatz) 
and the “Theory of Properties” (Eigenschaftstheorie). See Beier, Friedrich-Karl/Ohly, An-
sgar, Was heißt "unmittelbares Verfahrenserzeugnis"? - Ein Beitrag zur Auslegung des Art. 
64 (2) EPÜ, GRUR Int. 1996, 973. See also Benkard/Scharen, Patentgesetz, § 9, No. 53; 
Benkard/Jaenstaed, EPÜ, Art. 64, 25. 
https://doi.org/10.5771/9783845221441, am 02.12.2021, 20:19:12
Open Access -  - http://www.nomos-elibrary.de/agb
 247 
the direct result of a patented process after having undergone further modifications, 
provided it retained its identity and did not lose its fundamental characteristics. 1148 
With regard to the subject under consideration, in-silico screening processes are 
directed to the finding of potential binding ligands. Such information is used for 
drug design. The actual drug, however, is not made out of the in-silico screening 
process. Without being directed to the manufacture of a physical good, in-silico 
screening processes must be considered mere working processes. The screening 
process does not end with the manufacture of the identified compound, but rather 
with the acquisition of information about the binding properties of such compound. 
Identified compounds do not share the identity of the patented screening operation 
as patented subject matter. In conclusion, patents to in-silico screening methods do 
not provide a patent protection that covers potentially screened compounds.1149 
Thus, uses of identified compounds do not constitute infringement of screening 
process patents.  
2. The Bayer v. Housey Case 
U.S. patent law is also familiar with the extension of a process patent to the product 
which is generated by the process. The Federal Circuit decision Bayer v. Housey1150 
raised the question of whether the importing of knowledge that is disclosed with the 
assistance of a patented process in a foreign country infringes the patented process 
as such.1151 The critical law is Section 35 U.S.C. 271 (g) which lays down that 
“whoever without authority imports into the United States … a product, which is 
made by a process patented in the United States, shall be liable as an infringer”. 1152 
The claim at issue in Bayer/Housey reads as follows:  
1. A method of determining whether a substance is an inhibitor or activator of a protein whose 
production by a cell evokes a responsive change in a phenotypic characteristic other than the 
level of said protein in said cell per se, which comprises (n steps)  
(a) providing a first cell line which produces said protein and exhibits said phenotypic re-
sponse to the protein;   
 
1148   Bruchhausen, Karl, Sind Endprodukte unmittelbare Verfahrensprodukte eines auf die Her-
stellung eines Zwischenproduktes gerichtenten Verfahrens?, GRUR 1979, 743, 744.  
1149   See Pioneer Electronics Capital Inc. v. Warner Music Manufacturing Europe GmbH [1997] 
R.P.C. 757; Wolfram, Markus, 'Reach-Through Claims' and 'Reach-Through licensing' - Wie 
weit kann Patentschutz auf biotechnologische Research Tools reichen?, Mitteilungen der 
deutschen Patentanwälte 2003, 57-64. 
1150   Bayer v. Housey, 340 F.3d 1367-1378 (Fed. Cir. 2003). 
1151   Bayer v. Housey, 340 F.3d 1367, 1371. 
1152   Bayer v. Housey, 340 F.3d 1367, 1371. 
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(b) providing a second cell line which produces the protein at a lower level than the first cell 
line, or does not produces the protein at all, and which exhibits said phenotypic response to the 
protein to a lesser degree or not at all;   
(c) incubating the substance with the first and second cell lines; and  
(d) comparing the phenotypic response of the first cell line to the substance with the phenotyp-
ic response of the second cell line to the substance.1153 
Housey alleged that the knowledge Bayer obtained from the process of the patent as 
such is a product. Bayer argued that “made” means “manufactured” and that infor-
mation is not a manufactured creation.1154 Because of the definition of the term “be-
ing made by a process” was ambiguous, the Court interpreted other provisions of the 
Omnibus Trade and Competitiveness Act of 1988 (which referred to Section 
271(g)), finding several indications that the term “made” had to be understood as 
“manufactured” and applied only to physical goods.1155 Housey asserted that Con-
gress when said “manufactured” in all cases it was referring to manufacturing. Thus, 
when saying “made”, Congress must have intended something else.1156 The Federal 
Circuit was not persuaded, stating that Congress is permitted “to use synonyms in a 
statue”.1157 The court further stated, “Housey’s position suggests an unrealistic level 
of clarity in congressional word selection”1158. Analyzing the legislative history, the 
court came to the same conclusion that “made” is synonymous to “manufactured”. 
The court further reasoned,  
“reading the statue to cover processes other than manufacturing processes could lead to ano-
malous results. The importation of information … cannot be easily controlled. As Bayer points 
out, a person possessing the allegedly infringing information could, under Housey’s interpreta-
tion, possibly infringe by merely entering the country …. Such an illogical result cannot have 
been intended.”1159  
The court found that if the Congress had intended to give the provision a different 
meaning, they had to establish appropriate legislation.1160 The court also considered 
Housey’s assertion that Bayer’s drugs were goods made by its proprietary screening 
methods, holding that the case must be distinguished from Bio-Technology General 
Corp. v. Genentech, where the CAFC had concluded “that a protein made by a host 
organism expressing an inserted plasmid was a product ‘made by’ the patented 
 
1153   Bayer v. Housey, 340 F.3d 1367, 1369.  
1154   Bayer v. Housey, 340 F.3d 1367, 1371. 
1155   See also Liebert, Mary Ann, Information is not physical goods, 22 Biotechnology Law Re-
port 2003, 619-620. 
1156   Bayer v. Housey, 340 F.3d 1367, 1373.  
1157   Tyler v. Cain, 533 U.S. 656, 664 (2001); Bayer v. Housey, 340 F.3d, 1367, 1373.  
1158   Bayer v. Housey, 340 F.3d. 1367, 1373. 
1159   Bayer vs. Housey, 340 F.3d., 1367, 1377; see also Paul v. Davis, 424 U.S. 693, 698-99, 96 
S.Ct. 1155, 47 L.Ed.2d 405 (1976).  
1160   Bayer v. Housey, 340 F.3d 1367, 1376. 
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process for creating the plasmid itself”.1161 By contrast, the court concluded, the pa-
tented process in Bayer is not used in the actual design of the drug. As the lower 
court had noted “processes of identification and generation of data are not steps in 
the manufacture of a final drug product.”1162 Thus, the Court concluded that the 
product of Bayer does not fall under Section 271(g).1163 Infringement under Section 
271(g), the court explained, is limited to the manufacture of physical goods. It does 
not extend to knowledge that is generated by a patented process. Therefore, the 
Court stated that the dismissal of Housey’s claims of infringement of patents cover-
ing methods of screening compounds that have particular characteristics must be af-
firmed.1164 In sum, the reasoning set forth by U.S. courts resembles the situation ex-
isting under the EPC and the GPA.1165 Patents to screening processes do not extend 
to compounds identified by these screening processes.  
VIII. Concluding Remarks 
The foregoing shows that patent owners who often find themselves in an interde-
pendent relationship, are able to balance their interests through cross-licensing 
agreements.1166 This applies with regard to selection inventions where the broad 
 
1161   Bio-Technology General Corp. v. Genentech, Inc., 80 F.3d 1553, 1561 (Fed. cir. 1996); Ba-
yer v. Housey, 340 F.3d, 1367, 1377-1378.  
1162   Bayer AG, 169 F. Supp 2d. at 331; Bayer v. Housey, 340 F.3d 1367. 
1163   Liebert, Mary Ann, Information is not physical goods, 22 Biotechnology Law Report 2003, 
619-620. The Housey patents were rendered invalid in Housey v. AstraZeneca, 366 F.3d. 
1348: Housey sued AstraZeneca alleging infringement of its four patents to screening me-
thods related to protein inhibitors and activators. The district court construed the definition 
of “inhibitor or activator” to include substances that both directly and indirectly affect a pro-
tein of interest. Housey then stipulated that, if this construction were not reversed or mod-
ified on appeal, its patents would be invalid and not infringed. The district court came to a 
final judgment of invalidity and non-infringement. The Federal Circuit held that the claim 
construction of the district court regarding the “inhibitor or activator of a protein” was prop-
erly concluded and thus affirmed the decision. Consequently, the Housey patents were af-
firmed as invalid and not infringed. One judge (Newman) dissented. Housey, 366 F.3d 1348, 
1349.  
1164   Bayer v. Housey, 340 F.3d 1367, 1378.  
1165   Chapter 4 C VII 1.  
1166   Another mechanism by which companies may achieve synergies is the creation of patent 
pools. This practice allows companies practicing related technologies to assign or license 
their patents and establish a “clearing house for patent rights”, Sung, Lawrence M./Pelto, 
Don J., The Biotechnology Patent Landscape in the United States as we enter the New Mil-
lennium, 1 The Journal of World Intellectual Property 1998, 889-901. In exchange for access 
to a patent pool, patentees retain their respective patents and license them non-exclusively to 
others. Licensing is made either directly or through an administrative intermediary created 
for the purpose. Patent pools are subject to close scrutiny for possible anti-trust violations 
and therefore must demonstrate that they have strong ‘pro-competitive’ effects. OECD, Ge-
netic Inventions, Intellectual Property Rights and Licensing Practices, Paris 2002, 66.  
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claim typically dominates selective improvement.1167 With regard to identified com-
pounds, patent owners of the screening method can either try to agree on reach-
through licensing agreements or – a safer method – determine other means, such as 
milestone payments.1168   
A different case arises if the use of 3-D protein structures infringes the patent re-
lated to the underlying genetic information. As the above analysis has shown, this 
occurs provided the protein is obtained recombinantly. As soon as the native protein 
is used, no dependency is established. This result, having been achieved by an appli-
cation of traditional legal standards, seems to establish a strong position for the 
owner of patents related to recombinant technologies. However, the practice of na-
tive protein purification recently has undergone tremendous advances.1169 Hence, 
novel purification systems that enable the receipt of sufficient protein amounts and 
quantities might release inventors from the dependency upon earlier issued recombi-
nant protein patents in the near future. Furthermore, protein research that is based on 
recombinant proteins in many instances will be covered by the research exemption 
in both the U.S. and Europe. 
As for the patents on human gene sequences already issued, it is worth noting that 
the time factor will provide release of a potential blocking danger. The development 
of new drugs based on proteomic related knowledge is a time-consuming process. 
With a patent only providing 20 years of protection (Art. 63(1) EPC), most existing 
patents will expire before the time drugs based on proteomic research begin to be 
commercialized on the market. Until then, the research exemption provided under 
German law1170 will ensure that researchers adequately proceed with their work. 
Advances in the understanding of the complicated patterns of protein folding rais-
es afresh the issue of competitive protein variant use. The awareness that the 3-D 
structure dedicates the function, rather than the sequence, may mobilize competitors 
to use sequence-dissimilar proteins bearing same folds, function and effects. To pro-
tect inventors from such uses, traditional legal standards developed in the field of 
protein variants must be modified. Previously, patentees used percent identity ap-
proaches with the sequence as reference in order to achieve protection from protein 
variants. To expand the patent scope to sequence-dissimilar proteins, the sequence 
reference should be replaced by a reference to the 3-D folding type. In addition, a 
claim to amino acids may be expanded to sequence-dissimilar proteins conducting 
the same functions under the doctrine of equivalents. In the U.S., the ‘triple-identity-
test’ is considered an adequate means for the determination of equivalents. This ap-
proach requires that persons skilled in the art consider a means equivalent by its 
‘function’, its ‘way’ and its ‘result’. Applied to protein 3-D structures, an equal fold-
 
1167   Maynard, John T./Peters, Howard M., Understanding chemical patents: a guide for the in-
ventor, Washington, D.C. 1991, 87; assuming that the selective part is the commercially 
most desirable product. 
1168   See Chapter 3 B III 3 c) aa).  
1169   Chapman, Tim, Protein purification:  Pure but not simple, 434 Nature 2005, 795, 795.  
1170   § 11 Nr. 2 GPA. 
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ing structure satisfies the ‘way-prong’ of the inquiry. A protein bearing a different 
fold, by contrast, is interpreted to conduct a function differently. In Germany, the 
country that is used as example for Europe, established principles require the pres-
ence of a technical effect identical and predictable for a person skilled in the art. The 
folding type is interpreted as  a modified means. A skilled person must rely on all 
information provided by a patent in a step-by-step fashion and be able to predict 
which proteins are members of the same structural type. Due to the legal limitations 
of the doctrine of equivalents and the significant level of complexity required for a 
determination of equivalents, it is, however, not always predictable as to whether 
equivalents can be established or not. With this overall uncertainty, inventors might 
seek broad literal coverage rather than rely upon the doctrine of equivalents.  
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Chapter 5: Summary and Findings 
The aim of this study was to provide a comparative assessment of legal issues at the 
nexus between intellectual property rights and a central area of modern biotechnolo-
gy, proteomics. Specifically, the study discusses the patentability of proteomic pa-
tent claims, and the scope of protection of biotechnological inventions in the post-
genomic, or proteomic, era. The major findings of the analysis can be categorized 
accordingly, i.e., into findings related to patentability, and into results in the area of 
the scope of protection. Moreover, the study of proteomics as an issue for intellec-
tual property rights protection yields some more general results. These will conclude 
this section. 
A. Patentability of Proteomic Patent Claims 
As to the patentability of proteomic inventions, a first set of results is related to pro-
teins defined by structural properties per se. As shown in Chapter 3 B II, both the 
EPO and the USPTO share similar views regarding proteomic claims directed to the 
polypeptide as such. Provided that the polypeptide occurs in various folding types, 
3-D structures can establish unambiguous parameter constellations despite previous 
disclosure of the related amino acid. Consequently, novelty can be established ac-
cording to classical doctrines originating in the field of chemical compounds, such 
as the principle of unambiguous parameter. In this respect, it is important to note 
that the legal treatment of chemical patents does specifically refer to 3-D structures. 
This can be seen in the legal treatment of stereochemistry inventions. Here, novelty 
can only be established through the description of the specific 3-D enantiomere. The 
sole inclusion of racemate mixtures in the patent description does not suffice. 
Hence, 3-D information or data can serve as important parameter during the typical 
application process. 
In the area of crystalline proteins, it is again a principle from the field of chemi-
stry that helps to distinguish between novel proteomic compounds and the prior art. 
Novelty is established by the new physical characteristics of protein crystals. In a 
similar way, claims to selected structural features (such as binding pockets/epitops) 
achieve novelty according to principles developed for selection inventions. In par-
ticular, the selected sub-field must be narrow and sufficiently far removed from the 
known range illustrated by working examples. Moreover, it must not merely be ran-
domly selected, but should be the result of a more tightly focused selection. Finally, 
the selected area should not provide a mere embodiment of the prior art description, 
but, rather, another invention.  
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A second set of results concerns the area of bioinformatics. In this respect, Chap-
ter 3 B III 1 illustrated the controversial issue of the patentability of so-called in-
silico screening methods. The European patent system acknowledges patentability 
and accepts the claim under the requirements for patentable subject matter.1171 In 
contrast, the American patent system rejected related claims, finding that merely 
non-functional, descriptive data was provided, which renders the research results 
obvious. Surprisingly, the U.S. applies stricter standards for patentability than Eu-
rope, even though many critics of intellectual property rights claim that the U.S. sys-
tem sets looser standards.1172 
Based on the application of various general principles, the EPO’s solution proves 
to be more coherent. By contrast, the USPTO’s findings are subject to criticism, 
since they do not consider the patent as a whole, but only its computer-related as-
pects. Such an approach fails to consider the relationship between biological func-
tion and the computerized method. The major question is not whether a known algo-
rithm is fed with new data, but whether the effect of the in vivo biological process 
that is simulated with this algorithm is non-obvious. 1173 While the EPO’s result is 
consistent with general principles, the reasoning behind it requires some substantial 
modifications. In particular, the “further technical effect” required by the EPO 
should not only be derived from software-related aspects, but from the biological 
function the protein performs in vivo.1174  
In sum, the analysis of bioinformatics claims shows that both offices derive their 
solutions from the application of principles that were originally used in the area of 
computer-implemented inventions. However, the nature of proteomic bioinformatics 
requires a more comprehensive analysis of the invention as such that goes beyond 
the aspects of computer implementation. Since the protein’s functions define the 
characteristics of the biological binding process, the former must be considered a 
crucial element of the in-silico method. The computer-based visualization of a bio-
logical function translates and transfers a biological mechanism into virtual space, 
where the (in vivo) technical effect is reproduced in silicio. The patentability re-
quirement of “technical feature” must therefore be derived from the protein’s func-
tion. Such an approach, in turn, is also consistent with what is interpreted as a fur-
ther technical effect by the European Board of Appeals.1175  
A third set of results – demonstrated in Chapter 3 B III 2 - are those involving 
protein data. Like in-silico methods, they are treated under the principles developed 
for computer-implemented inventions. The application of these rules shows that 
claims to mere data lack a further technical effect under the European patent system. 
Similarly, the U.S. patent system considers the claims as abstract ideas, finding that 
 
1171   Chapter 3 B III 1 a) cc) ii. 
1172   Chapter 3 B III 1 a) cc) iii. 
1173   Chapter 3 B III 1 a) cc) iii. 
1174   Chapter 3 B III 1 a) cc) ii. 
1175   Chapter 3 B III 1 a) cc) ii. 
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they establish mere non-functional descriptive material.1176 Both views consistently 
apply well-established principles, and should not be disputed on legal grounds. Nev-
ertheless, scientists could argue that the patent offices do not sufficiently take bio-
physical concepts into account and act in a discriminatory manner. Patent offices 
allow patents on standard chemical formulae which are, in fact, merely 2-D coordi-
nates of molecules combined together with some standard rules of chemical connec-
tivity. The 3-D coordinates of proteins, by contrast, are not deemed to be patentable, 
although they too demonstrate standard rules of chemical connectivity between 
atoms. From a legal perspective, the offices correctly distinguish between computer 
storable data and the established chemical practice of determining compounds by 
means of chemical formula. From a scientist’s perspective, however, it appears that 
distinctions are made regarding the patentability of a molecule depending on the di-
mension in which the coordinates are represented.1177 
A final group of claims – demonstrated in Chapter 3 B III 3 - deals with the po-
tentially large number of innovations that will be directed to identified compounds 
obtained by in-silico screening methods. Patent applicants may seek to cover these 
compounds by drafting reach-through claims. The claim language is specified in a 
way that is broad enough to dominate future compound discoveries that can be used 
for rational drug design. Both offices adopt a similar approach regarding the strategy 
of reach-through claiming. Claims are treated under strict standards and typically 
fail due to a lack of enablement. Hence, inventors should handle the method with 
caution. With strict conditions for both the written description/sufficient disclosure 
requirement and the enablement factor, it may be advisable to use other approaches 
such as milestone payments or reach-through licensing methods. 1178 
To meet the patentability requirements of written description/sufficient disclosure 
and enablement, it is advisable for applicants to disclose theoretical information 
about the size and shape of binding sites of the computerized method and of corres-
ponding compounds. Claims that define identified compounds by size and shape are 
not considered as reach-through claims and are generally allowed by patent offices. 
Inventors, however, must take into account that such claims pose a high risk of be-
ing rendered invalid. If only one prior art ligand has the shape and size demonstrated 
by the claim and therefore would respond to the in-silico protein, the claim lacks 
novelty. With many molecules being reported in prior art, but not defined by size 
and shape, the concrete risk of annihilation of novelty is difficult to foresee.1179 
 
1176   Chapter 3 B III 2 b). 
1177   Chapter 3 B III 3 III 2 c). 
1178   Chapter 3 B III 3 c) bb). 
1179   Chapter 3 B III 3 c) aa), Chapter 3 B IV. 
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B. Scope of Protection 
Long before the term proteomics began to dominate biotechnological research, the 
question of whether the scope of protection of DNA patents would provoke in-
fringements by yet unrealized inventions was discussed extensively. In particular, 
some observers raised concerns regarding whether the design of new gene-based 
pharmaceuticals would be hindered by patented gene sequences. When it became 
clear that the direct applicability of genetic information to medical conditions was 
indeed somewhat limited, these concerns experienced a revival.1180 In what form and 
to what extent do issues of dependency between existing patents on gene sequences 
and other biotechnological inventions arise? What can be said about the likelihood 
of infringement when it comes to gene patents involving the encoded (or recombi-
nantly produced) protein? And how are problems of competitive use dealt with? 
Since proteomics is one of the most important research area in today’s biotechnolo-
gy environment, these questions particularly apply to proteomic inventions. Part C. 
of Chapter IV.  therefore analyzes issues related to patent dependency and infringe-
ment - between gene patents and claims related to the 3-D protein structure, and be-
tween different protein-related claims. 
The results of this analysis can be summarized as follows. First, the use of natu-
rally purified and naturally obtained crystalline proteins does not constitute any in-
fringement.1181 This stands in sharp contrast to recombinantly produced proteins, 
whose 3-D structure inherently falls within the scope of gene patents that declare the 
encoded protein as its function.1182 This discrepancy between recombinant produc-
tion and natural purification/crystallization results from the fact that the patent sys-
tem rewards the inventors of recombinant technologies for their contributions to the 
highly efficient production of large quantities of proteins. Naturally occurring pro-
teins are encoded from non-isolated genes and are not related to the patent covering 
the isolated gene sequence. As long as available purification and separation tech-
niques fail to provide sufficient amounts of high quality proteins, inventors are 
forced to rely upon recombinant technologies. Therefore, issues of patent dependen-
cy cannot be avoided. The temporary limitation of gene patents, however, will pro-
 
1180   One example is the issue of gene therapy. Gene therapy is a technique for correcting defec-
tive genes causing disease development. In most gene therapy treatments, a normal gene is 
inserted into the genome to replace a disease, causing gene. Despite great promises and high 
expectations, the approach has yet not proven succesful in clinical trials. In 1999, gene ther-
apy suffered a major setback with the death of 18-year-old Jesse Gelsinger. This patient died 
shortly after starting the therapy. In 2003, a second child treated in France developed a leu-
kemia-like condition. As a consequence, the FDA placed a temporary halt on all gene thera-
py trials using retroviral vectors in blood stem cells; see Human Genome Project Informa-
tion, available at http://www.ornl.gov/sci/techresources/Hu man_Genome/medicine/ gene-
therapy.shtml; last checked on January 21, 2008. As for the several approaches that may be 
used for correcting genes, see Straus, Joseph, Patenting Human Genes in Europe - Past De-
velopments and Prospects for the Future, 26 IIC 920 (1995). 
1181   Chapter 4 C I; Chapter 4 C III. 
1182   Chapter 4 C II. 
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vide release of a potential blocking danger. Most existing patents to gene sequences 
will expire before the time drugs based on time-consuming proteomic research begin 
to be commercialized on the market.  
Furthermore, problems of the competitive use of protein variants – in particular 
sequence-dissimilar proteins sharing common folds – have been considered.1183 The 
issue is of major importance for several reasons. On a more general level, sequence-
dissimilar proteins can be used to exemplify the question of whether patent claims 
should be interpreted broadly enough to encompass later-arising technologies. More 
specifically, the awareness that the 3-D structure rather than the sequence is the crit-
ical factor in the determination of protein function offers new opportunities to cir-
cumvent and devaluate existing patents. In particular, the effects of previously pa-
tented drugs can become subject to mimicking.1184 This is not only a problem from 
the perspective of current patentees, whose legal rights to protection will be in-
fringed even though they have invested in time- and money-consuming research. It 
will also hamper future research on specific biotechnological structures. The reason 
is that findings related to protein effects may become economically useless as soon 
as they are published. Other firms can cost-effectively (and without running the risk 
of infringement) replicate functions using a dissimilar sequence. Consequently, in-
centives to carry out research on protein effects are weakened. The crucial question 
is thus how patentees can expand their claims to yet unidentified sequence-
dissimilar proteins that bear the same functions as the originally patented proteins. 
Finally, the issue of sequence-dissimilar proteins can be used to ask whether tra-
ditional legal standards developed in the field of protein variants are sufficient to 
deal with problems of competitive use. In this respect, this study showed that the hi-
therto applied practices must be modified in order to guarantee an appropriate scope 
of protection in proteomics. Previously, patentees used a percent identity approach, 
with the sequence as reference parameter. In order to expand the patent scope to se-
quence-dissimilar proteins, the reference to sequence should be replaced by a refer-
ence to the 3-D folding type. Such a procedure would solve a large number of prob-
lems arising from competitive use.1185 
Another possibility that should be clearly distinguished from this approach is to 
expand the coverage of a sequence patent by relying on the doctrine of equiva-
lents.1186  Sequence-dissimilar proteins are then interpreted as later-arising means to 
achieve the already-described effect of the originally patented protein. For the U.S., 
the ‘triple-identity-test’ is considered adequate means for the determination of equi-
valents. This approach requires that persons skilled in the art consider a means 
equivalent by its ‘function’, its ‘way’ and its ‘result’. Applied to protein 3-D struc-
 
1183   Chapter 4 C IV. 
1184   Usually, the problem of patent dependency is not solved through such procedure: the se-
quence-dissimilar proteins must still be obtained recombinantly in order to achieve large 
amounts of highly purified substances, so other genetic patents might be infringed. 
1185   Chapter 4 C IV 2 c).  
1186   Chapter 4 C IV 3 a) dd). 
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tures, an equal folding structure satisfies the ‘way-prong’ of the inquiry. A protein 
bearing a different fold, by contrast, is interpreted as conducting a function in a dif-
ferent ‘way’. As a result, equivalents between sequence-dissimilar structures can be 
established. However, the above-described limitations of the doctrine, such as pros-
ecution history estoppel or the public dedication rule, introduce an element of risk to 
inventors that rely upon equivalency. 
The fact that the doctrine of equivalents is interpreted differently in various coun-
tries adds to this uncertainty. In this respect, the dissimilar treatment in Germany 
and the U.S. is not a major concern. Formally, the U.S. patent law system deter-
mines equivalency at the time of infringement, whereas under the German law the 
time of priority is the decisive factor. However, the German system analyses the 
person skilled in the art’s awareness (of having identified a modified means at the 
time of priority) to ask whether the identified means were substituted/replaced by 
the new technology. Thus, both legal systems evaluate the question of equivalents in 
light of later-arising knowledge. By contrast, the more restrictive approach em-
ployed in the U.K. is substantially different. Here, the House of Lords denied equi-
valency for the new technology of producing proteins by gene activation. If this nar-
row formulation of equivalents precluding any equivalent protection beyond the 
“purposive interpretation,” is accepted by other European countries, the doctrine of 
equivalents will be significantly narrowed. In this respect, inventors would be barred 
from achieving a patent scope corresponding to those granted by U.S. authorities.1187  
While all these aspects do not imply that sequence-dissimilar proteins are neces-
sarily excluded from equivalent protection, they should increase awareness of the 
limitations of related strategies used to broaden the patent scope. Due to the pre-
viously discussed European developments, the ambiguity that might result from le-
gal limitations in the U.S., and the significant level of complexity required for a de-
termination of equivalency, it is not always predictable whether equivalents can be 
established or not. With this overall uncertainty, it is suggested that inventors seek 
broad literal coverage rather than relying upon the doctrine of equivalents. As ex-
plained above,1188 this implies that the alternative - to expand protection by using the 
3-D folding type as reference parameter - should be thoroughly considered.  
Besides the questions arising in the areas of naturally obtained (crystalline) and 
sequence-dissimilar proteins chapter IV analyzes improvement and selection inven-
tions.1189 These two arrangements are especially suited for balancing conflicting in-
terests in the post-genomic era. An important characteristic of many proteomic in-
ventions is that they expand and deepen the knowledge of an already patented sub-
stance. For example, the folding of a sub-area of a protein is described and analyzed 
in a more detailed fashion, which ultimately allows for a more target-oriented drug 
development process. While the previously granted patent may have been too gener-
al to imply a specific medical treatment, it continues to represent an important pre-
 
1187   Chapter 4 C IV 3 c).  
1188   Chapter 4 C IV 2 d. 
1189   Chapter 4 C VI 1.  
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condition for further research. Improvement and selection inventions attenuate the 
resulting tensions between fundamental research and research targeted to specific 
applications. Combined with an intelligent use of cross-licenses, they represent an 
important means of balancing inventors’ interests. Patent systems in the countries 
under consideration acknowledge this, and apply generally the same principles, of-
ten derived from chemical inventions. 
Finally, the scope of protection issues arise in relation to identified com-
pounds.1190 Under both the German and the U.S. patent system, patents for manufac-
turing processes do not cover compounds obtained through screening. Therefore, the 
use of screened compounds does not establish infringement of patented screening 
processes. Under European statutes, a product must be obtained “directly” by means 
of the patented process to be covered by the patent. A product “directly” obtained 
from a patented process is the product with which the process ends. With regard to 
the subject under consideration, the in-silico screening operation is the manufactur-
ing process. The question is thus whether identified compounds should be consid-
ered the direct result of this operation. The screening process, however, does not end 
with the identified compound, but with the database search. Thus, the use of identi-
fied compounds does not establish any infringement. 
In the U.S., the Bayer v. Housey case demonstrated that the issue of identified 
compounds is treated in a similar fashion. The decision dealt with the question of 
whether the import of therapeutical compounds that were disclosed with the assis-
tance of a patented process in a foreign country infringed the patented process as 
such under Section 271 (g) U.S.C. The reasoning of the court indicated that the term 
“made”, as stated in the statue, must be understood as synonymous with “manufac-
tured”. Further, the patented screening process is not used in the actual design of the 
drug, because processes of identification and generation of data are not steps in the 
manufacture of a final drug product. For these reasons, the use of screened and im-
ported compounds does not violate Section 271(g) as long as it is limited to the 
manufacture of physical goods and does not extend to knowledge that is generated 
by a patented process.1191 
C. General Findings 
New technologies always raise doubts about whether the patent system is suited for 
the fostering their advancement without creating excessive inefficiencies. From the 
preceding analysis, it should be clear that in the case of proteomics, traditional pa-
tent categories are often sufficient for coping with the challenges of the new tech-
nology. Thus, one of the more general results of this study is that proteomics as a 
subject matter of patent law should be considered as the continuation of classical 
protein research, which itself has assumed many legal concepts from the area of 
 
1190   Chapter 4 C VII.  
1191   Chapter 4 C VII 2.  
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chemical patents. These are combined with principles from other biotechnological 
fields and from the area of computer-implemented inventions to form the new set of 
principles that govern the IP treatment of the new technology.  
The general set of rules and procedures that has developed during recent decades 
thus seems to be capable of adapting to the changing set of linguistic constructs that 
characterize modern scientific and economic processes. In fact, one of the most im-
portant yardsticks for a modern patent system seems to be whether it is flexible 
enough to deal with the very dynamic development of new research areas (in this 
study, genomics, post-genomics, proteomics, bioinformatics), each characterized by 
its own “language” of scientific communication. As shown in chapters III and IV, 
the application of existing principles does yield sensible solutions for dealing with 
issues of patentability and scope of protection in the area of proteomics. 
Adequate principles, however, are only part of a successful application to a new 
technology. The study at hand also shows that the institutional framework of the pa-
tent system can and does react in a surprisingly flexible fashion to new types of in-
ventions, and changes the way a scientific field is perceived. In the five years since 
the completion of the human genome project, the idea that one gene encodes one 
protein has been replaced by a dynamic view of cell physiology and biochemistry. 
Shortly thereafter, the focus of the resulting new field of proteomics itself changed 
markedly. It became clear that the 3-D structure of proteins is one of the major de-
terminants of a protein’s function, and perhaps the single most important one. Thus, 
within a very short period of time, the state of the art itself has experienced several 
structural breaks. As shown in chapter III, patent offices have quickly adapted to 
every new development, even in an anticipatory manner. Aided by the general prin-
ciples that were laid down by legislative bodies and courts, they have succeeded in 
changing the focus whenever the biotechnological complex changed. It is worth not-
ing that this flexibility was not hampered, but rather facilitated, by the existence of 
traditional patent categories. 
With regard to proteomics, however, the patent system faces more serious and 
fundamental challenges than mere adoption to new linguistic constructs and to new 
research fields. Just as any invention that is likely to have spillover effects in terms 
of further innovation, the patentability of biotechnological compounds forces the pa-
tent system to strike a reasonable balance between open access and exclusivity. The 
tension between these two principles surfaces at various stages of this inquiry, a core 
topic of which is the multiple dimensions that determine the breadth and scope of a 
patent claim. Broad patents that cover a wide range of known and unknown protein 
characteristics and functions lead to strong ex ante incentives to invest in research 
and development. By contrast, narrow patents that preserve the incentives to explore 
spillovers and new aspects of a known compound are desirable ex post, as the eco-
nomic benefits of newly discovered structural properties accrue to downstream in-
ventors.1192 
 
1192   The economic problems that arise due to conflicts between ex ante and ex post efficiency in 
the area of cumulative inventions (i.e., inventions that build upon each other) is extensively 
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This tension between ex ante and ex post optima dominates many debates in the 
area of IP protection in general, and biotechnological patents in particular.1193 Did 
(broad) gene patents hinder further research? How did the patent system react when 
it became clear that knowledge about a protein’s structure may prove to be much 
more important to the development of medical treatments than knowledge about the 
encoding gene, at least in the foreseeable future? How does it deal with the fact that 
scientific developments often lead to a change in perceptions as to what should be 
patented, and how broad the scope of a patent should be? Since it represents one of 
the major technologies in the post-genomic era, proteomics is a very good test case 
to answer these questions. Its study may deliver important insights into the mechan-
isms which the patent system provides and its flexibility in dealing with novel is-
sues.   
When dealing with issues of ex post and ex ante optimality, it should not be unde-
restimated that governments faced with such fundamental trade-offs are in danger of 
suffering from problems of dynamic inconsistency.1194 It would be socially optimal 
to credibly promise a strong and broad protection of IP rights (to encourage R&D 
investment, for example, to facilitate the identification of the genome) and to break 
this promise as soon as research has delivered the result (to facilitate and boost re-
search on new technologies having more direct applications or a higher short-run 
success probability, like proteomics). The resulting credibility problem can only be 
solved by establishing a reputation for strong IP protection. At the same time, how-
ever, this emphasis on ex ante optimality has to be balanced with institutional me-
chanisms that provide enough flexibility to react to new technological developments 
and challenges.1195  
From the analysis above, it seems that the patent system has developed intelligent 
solutions combining a broad scope of protection with flexible means of reducing the 
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ex post cost of such solutions. For example, those observers who feared that gene 
patents may create monopoly positions, punishing the downstream inventors of the 
post-genomic era (i.e. , those who invent on the basis and around genetic informa-
tion to deliver medical applications), should recognize that the existing institutional 
framework offers a number of mechanisms that attenuate such problems. Besides the 
use of cross-licensing, the practice of granting research exemptions, though still hot-
ly debated in the U.S., offers a relatively new but effective means for guaranteeing 
the free flow of scientific information and the advancement of fundamental research. 
Moreover, the concept of “non-obviousness”, “inventive step” or “Erfindungshöhe” 
impedes excessively aggressive patenting strategies by limiting patentability to re-
search efforts that provide a significant benefit to society. In the genomic era, this 
was exemplified when the widespread patenting of ESTs was prevented. In the pro-
teomic era, a number of bioinformatics inventions are already under close scrutiny 
as to whether they are obvious. 
Recapitulating, those who criticize intellectual-property-right protection from an 
economic perspective, argue that “it has become increasingly clear that excessively 
strong or poorly formulated intellectual property rights may actually impede innova-
tion”. In particular, they claim that “sorting out the relative contribution [of different 
ideas] to the outcome … can be nearly impossible”.1196 However, these critics 
should recognize that the patent system has developed a number of principles that 
are capable of balancing the interest of multiple parties without having to define the 
exact contribution of single participants in the scientific process. Since its establish-
ment, the patent system’s primary occupation has been to deal with innovations. It is 
therefore not surprising that the legal principles that have developed over a long pe-
riod of time are an adequate means for protecting current innovators without ham-
pering innovators in fields that have yet to be defined and explored. In this respect, 
the field of proteomics, though still in its early stages, is an inspiring example. 
 
1196  Stiglitz, Joseph E., Intellectual-property rights and wrongs, Daily Times (Pakistan) 2005. 
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